



# 31<sup>ST</sup> ECNP CONGRESS

**6-9 OCTOBER 2018**

**BARCELONA**


*The future of CNS treatments*

## PROGRAMME




**ECNP** *neuroscience  
applied*


LEVEL P0



LEVEL P1



LEVEL M2



# SOCIAL MEDIA

AT THE ECNP CONGRESS

For informational updates and news flashes during the congress, find us on Facebook and follow us on Twitter.

 @ECNPtweets

 myECNP

#ECNP2018

Floor plans	1
Welcome	8
<hr/>	
<b>SCIENTIFIC PROGRAMME</b>	
Types of sessions	10
Poster information	13
<hr/>	
<b>SATURDAY</b>	
Overview	19
Sessions	20
Keynote session	25
<hr/>	
<b>SUNDAY</b>	
Overview	26
Sessions	28
Posters	42
<hr/>	
<b>MONDAY</b>	
Overview	130
Sessions	132
Posters	144
<hr/>	
<b>TUESDAY</b>	
Overview	232
Sessions	234
<hr/>	
<b>INDUSTRY</b>	
Introduction	244
List of partners	245
Industry sessions	257
Sessions Saturday	260
Sessions Sunday	265
Sessions Monday	270
Exhibition	
List of exhibitors	275
Floor plan exhibition	276
<hr/>	
<b>INFORMATION</b>	
<b>Congress information</b>	
Opening hours	280
Accreditation	282
For members	284
For junior scientists	285
Congress committees	287
ECNP Meetings around the congress	290
Info A-Z	291
<b>ECNP general</b>	
Projects and initiatives	296
Membership	298
<b>Contact</b>	300

Dear Colleagues,

A year has passed and here we are once again at our 31st ECNP Congress with new and innovative ideas that represent our mission and our vision. Another great opportunity for anyone interested in translational neuroscience to share information and ideas, foster collaboration, receive training, and much more, all part of an excellent scientific programme that keeps improving over the years thanks to your feedback.

This year we are thrilled to have secured six top plenary lecturers from around the world and from different fields, including three prestigious prize winners. Next to this, we are especially looking forward to a stimulatory and highly timely keynote session by Gareth Leng on food choice and obesity.

Overall, we have modernised and refreshed the congress by implementing more opportunities for discussion. Next to the brainstorming sessions, there are also debates, panel discussions and interactive sessions.

We have a large number of symposia focussing on treatment and drug discovery (S.04, S.07, S.09, S.15), and on the neuroscience underpinning that (S.10, S.13, S.14, S.22). New session formats have also been added to the programme, like the 'ECNP-inspired' and 'New medications' sessions.

The last few years our top paper sessions have been proven to be immensely popular. Six top paper sessions are planned, in which the presenters will highlight the most important and cutting-edge papers in their field.

For junior scientists visiting the congress we have engaging activities lined up as well. A great opportunity to interact with other congress participants are the poster sessions. We have eight junior scientists presenting in the new findings symposium (S.14). Also, the career development sessions are of special interest for junior people. And don't miss our yearly highlight, the 'Science-on-the-Rocks' evening, with an interactive touch by means of a real pubquiz!

The last – but maybe the most important – innovation this year is that we kick off a 'Love your brain' campaign, focusing on many different activities and behaviours that are good for brain health. We are organising a 5km race in Barcelona called 'Run with the President'. Everyone is welcome: runners, walkers, and families. Next to this, you can attend a yoga session, enjoy the healthy food and snacks at the lunches and coffee breaks and do some active offline brain training at the ECNP Plaza. Join in the (healthy) fun!

I hope you enjoy our meeting in this wonderful and cosmopolitan city of Barcelona.

Bienvenidos! Benvinguts!



Celso Arango  
*President*



Astrid Linthorst  
*Chair Scientific Programme  
Committee*



## TYPES OF SESSIONS

ECNP offers a variety of sessions designed to appeal to a wide range of congress participants. Please find below an overview of the sessions that will be held at the 31<sup>st</sup> ECNP Congress.

*In alphabetical order*

### Brainstorming sessions (BS)

Small focused interaction sessions organised by ECNP members on a topic of their choice. The organiser of the session and a second expert in that specific field of interest will initiate the discussion.

### Campfire sessions (CA)

Experimental, informal and highly interactive sessions, held in a campfire circle. Two sessions will be held simultaneously on Sunday, Monday and Tuesday (09.00-09.45) in the 'Bubble'. The facilitator of the session will introduce a topic in five minutes and then drive the discussion further among the participants.

### Career development sessions (CD)

These training sessions each feature a leading expert in the field. The expert is specifically invited to share with you his/her wealth of knowledge and experience. The topics are especially interesting for junior scientists, but sessions are open to all participants. Career development sessions are held daily during the lunch.

### ECNP patient sessions

A special session dedicated to addressing patient issues and topics relevant to patient care and families. This year's topic: social media and suicidal behaviour.

### Industry sessions

#### Satellite symposia (C)

These scientifically oriented sessions (1 hour 30 minutes) are organised by and with educational financial support from industry. The programmes have been reviewed for balance and rigour by the Scientific Programme Committee and are accredited for European CME.

#### Expert science exchange sessions (CE)

The expert science exchange session (1 hour) provides the opportunity for focused, scientifically driven engagement between industry and participants. Each session has a limited capacity of 80 participants and admittance is given on a first-come-first-served basis. The sessions are organised and financially supported by industry.

### Keynote session (KL)

The keynote lecture features a world-renowned speaker who is especially invited to present on a topic of interest that should appeal to all congress participants. The keynote session this year is by **Gareth Leng**, professor of Experimental Physiology at the University of Edinburgh, United Kingdom. He will be talking about **'The neuroscience of food choice and obesity'**. It will take place on **Saturday 6 October 2018, followed by the welcome reception.**

### Nomenclature session (NS)

A lunchtime session on Sunday, specially dedicated to the classification of psychotropic drugs by means of the Neuroscience-based Nomenclature. The topic is 'Why and how psychotropic nomenclature was changed: presenting the NbN app – focus on the paediatric'.

### Plenary lectures (PL)

The plenary lectures are presented by internationally eminent scientists. Six plenary lectures are scheduled, one of which will be held by **Marion Leboyer, 2018 ECNP Neuropsychopharmacology Award winner**. This year, Brain Prize and Anna Monika Award winners **Peter Dayan and Eero Castrén** will also give a plenary lecture. The other lectures are given by Joseph Dalmau, Tracy L. Bale and Patricia Conrod.

### Poster Jam (J)

In the Poster Jam, twelve poster presenters with a high scoring abstract will present their data in three minutes. The Poster Jam will have three parallel sessions with four presenters each. Every session will be on a different topic and at the end, there is time for questions. The Poster Jams will be held on Sunday and Monday (10.45-11.10) in The Circle.

### Poster sessions (P and EP)

Poster sessions are held Sunday (12.00-14.00) and Monday (16.30-18.30) in the poster area. On Monday there will be drinks during the poster session. All posters are presented on poster boards (P) and/or via e-poster (EP) terminals. During the poster sessions there will be a poster award ceremony.

### Parallel sessions

Five parallel sessions are scheduled daily in the morning and in the afternoon (on Saturday only in the afternoon). The parallel sessions are divided into symposia (S), alternative sessions (S) and educational update sessions (E).

**Symposia (S)**

In each regular symposium, four speakers present on a specific topic. Each speaker gets 25 minutes to present, leaving 10 minutes for questions and discussion.

**New Findings symposium (S)**

The eight speakers of this New Findings symposium are selected from the poster presenters at the ECNP Workshop for Junior Scientists in Europe, which is held every year in March in Nice, France.

**Alternative sessions (S)**

This year, we have alternative sessions with new formats where a hot topic or important new area is shared in an interactive way. We will have, for example, a panel discussion and a debate to discuss important topics.

**Regulatory spotlight session (S)**

A special regulatory dialogue session with the European Medicines Agency (EMA). Designed for open and active engagement amongst EMA stakeholders, the session promises to be an excellent opportunity for scientific and regulatory exchange.

**Educational update sessions (E)**

The educational update sessions focus on a continuous dialogue between the participants and the presenters. Different angles of a topic are discussed and state-of-the-art summaries are provided, with emphasis on new information relevant for clinical practice. A 'key pad' system is used to make the sessions more interactive.

**Top paper sessions (TP)**

During six 30-minute top paper sessions speakers will discuss four papers published in the past 12 months, which they consider clinically most important and cutting-edge in their discipline. These sessions are a great way to get up to speed with the latest developments in six different disciplines.

**Welcome reception**

Following the Keynote session on Saturday, participants are invited to the welcome reception held at the congress venue where a drink and a small bite will be served.

**Poster information**

Posters and e-posters can be viewed in three different ways:

**• E-poster bar (exhibition area)**

All e-posters are on display here. Posters with numbers starting with a 'P' have a corresponding paper poster. Poster numbers starting with 'EP' are only available as e-posters.

**• The Circle (poster area)**

Permanent display of *e-poster only* presentations (EP). If you would like to meet a poster presenter in person to discuss an e-poster, you can contact the presenter online via the e-poster service.

**• Poster boards (poster area)**

Display of paper posters. P.001-P.393 are presented on Sunday, P.501-P.893 on Monday.

**Activities related to the posters**

Sunday	Activity
<b>10.40-11.15</b> Poster area	<b>Poster viewing</b> Posters can already be viewed, but it is not mandatory for poster presenters to be at their poster.
<b>10.45-11.10</b> The Circle	<b>Poster Jam</b> Twelve poster presenters with a high scoring abstract will present their data in three minutes.
<b>12.00-13.00</b> Poster area	<b>Poster session</b> All posters are presented on poster boards and/or via e-poster terminals.
<b>13.50-14.00</b> The Circle	<b>Poster Award ceremony</b> For outstanding posters of the highest scientific caliber.
<b>14.50-15.00</b> The Circle	<b>Travel Award ceremony</b> The best abstracts by junior scientists in Europe, accepted for publication and presentation



Monday	Activity
<b>10.45-11.15</b> Poster area	<b>Poster viewing</b> Posters can already be viewed, but it is not mandatory for poster presenters to be at their poster.
<b>10.45-11.10</b> The Circle	<b>Poster Jam</b> Twelve poster presenters with a high scoring abstract will present their data in three minutes.
<b>14.20-14.40</b> The Circle	<b>Travel Award ceremony</b> The best abstracts by junior scientists in Europe, accepted for publication and presentation
<b>16.30-18.30</b> Poster area	<b>Poster session &amp; drinks</b> All posters are presented on poster boards and/or via e-poster terminals.
<b>18.00-18.10</b> The Circle	<b>Poster Award ceremony</b> For outstanding posters of the highest scientific caliber.

### How do I find the poster I want to see?

You can use the following tools to find a specific poster or e-poster:

#### E-poster bar:

The e-poster bar contains 10 small terminals with all the available e-posters. You can browse, or look for a specific poster (search by number, keyword, author). You also have the option to contact the presenting author.

#### ECNP App / Congress information terminals:

Open the 31st ECNP Congress event.

If you would like to see all posters related to one topic, please select the button 'poster topics' on the home screen.



For a specific search:

- Select the 'search' button on the home screen and search by author, keyword, or (part of) the title.
- Select 'posters' to get a list of all posters related to your search.

#### Website:

Visit <https://2018.ecnp.eu/programme/>, choose Sunday or Monday and select the tab 'poster session'. Here you find a list of all posters and e-posters.

Another way is to use the 'search abstract' function within the programme (in the grey bar).

#### All (e-)posters are grouped by the topics below:

Addiction - Disorder  
 ADHD - Disorder  
 Animal models - Method  
 Anxiety - Disorder  
 Autism / ASD - Disorder  
 Biochemistry - Method  
 Biostatistics and computational method  
 Dementia / neuro degeneration - Disorder  
 Eating disorder  
 E-health - Intervention  
 Epidemiology and big data - Method  
 Epilepsy - Disorder  
 Genetic and molecular approaches - Method  
 Healthy brain  
 History/philosophy/ethics - Method  
 Immunology - Method  
 Impulsive and compulsive disorder  
 Intellectual disability disorder  
 Lifestyle and nutrition - Intervention  
 Mood and bipolar disorder  
 Movement disorder  
 Neuroimaging - Method  
 Neuro-inflammatory disorder  
 Neuromodulation - Intervention  
 Neurophysiology/EEG - Method  
 Neuropsychology - Method  
 Pain and headache  
 Personality disorder  
 Pharmacology - Method  
 Pharmacology - Intervention  
 Post-mortem / pathology - Method  
 Prevention / course alteration - Intervention  
 Psychotherapy - Intervention  
 Psychotic disorder  
 Sexual disorder  
 Sleep disorder  
 Stress related disorder  
 Stroke  
 Systems biology - Method

A complete list of (e-)posters, sorted by number, is also available in the final programme booklet.

# IT'S ALL ABOUT HEALTHIER BRAINS

ECNP's reason for being is to advance the science of the brain, in order to facilitate better treatments, so that we can improve human brain health.

## RUN WITH THE PRESIDENT

*It's a run, not a race*

ECNP president Celso Arango will lead a recreational run through Barcelona. All congress participants – of whatever sporting level – are invited to join.

Monday, 07.00-08.00

Registration via <https://2018.ecnp.eu>




## BRAIN FOOD



A balanced diet is important for your brain. In a special session Alejandro Arias-Vásquez will present New Brain Nutrition, an H2020 project to investigate how diet and lifestyle influence our health, brain function, and behaviour. Joining him, celebrity chef Sebastian Lege will show how good science can be turned into good food.

During the congress we'll have healthier snacks on hand like fruit, nuts, muesli bars, and salads for lunch.



Brain health also means the prevention of illness and the encouragement of active, healthy and brain-friendly lifestyles that optimise brain function and resilience.

This year we have a range of sessions on nutrition and neuroscience, starting with our keynote speaker **Gareth Leng**, UK.

To complement the scientific programme, we've also launched a series of activities to put brain health at the centre of the ECNP Congress.

## YOGA

*Start your day in a relaxed way.*


Every morning we have a mindful wake-up session with yoga instructor Lezanne Swart ([ujuyoga.com](http://ujuyoga.com)).

Sunday, Monday and Tuesday,

07.45-08.45, Room 120

For all levels

*Max. 25 participants per session, first come first served.*



## RECHARGE ZONE

The ECNP Plaza has always been a place to relax, refresh and recharge. But now we're adding a new dimension with sudoku and brain puzzlers for a gentle mental workout.





Available for Apple and Android

- 12.30-14.00 SATELLITE SYMPOSIA** (industry sessions)
- C.01 Can increased focus on patient perspectives improve outcomes in the treatment of schizophrenia? **Room 115**
- C.02 Functional recovery in depression: are we doing the right thing for the treatment of depression? **Room 117**

- 14.00-14.45 ECNP PATIENT SESSION**
- ES.01 Social media and suicidal behaviour – patients, clinicians and researchers' perspectives **Room 113**

- 15.00-16.30 SATELLITE SYMPOSIA** (industry sessions)
- C.03 Living with schizophrenia: how to add quality and years to patients' lives **Room 112**
- C.04 Mechanisms underlying clinical manifestations of treatment resistance in schizophrenia **Room 114**
- C.05 From conventional antidepressant efficacy to real-world effectiveness **Room 117**

**16.30-16.50 COFFEE BREAK** Level P1

- 16.50-18.30 SCIENTIFIC SYMPOSIA**
- S.01 Stress-induced neuroinflammation and its role in neuropsychiatric disorders **Room 117**
- S.02 The use of neuroimaging to improve drug development in mood disorders **Room 112**
- S.03 How alcohol changes the brain: epigenetic and functional reprogramming in addiction **Room 113**
- S.04 ECNP New Frontiers symposium – A neurodevelopmental approach to drug discovery for brain disorders **Room 114**
- E.01 Treatment of resistant obsessive compulsive disorder **Room 115**

- 18.45-20.00 KEYNOTE SESSION**
- KL.01 The neuroscience of food choice and obesity **Room 112**

- 20.00-21.00 WELCOME RECEPTION**  
Banquet hall

**UPDATED PROGRAMME:**

<https://2018.ecnp.eu/> ECNP app / congress info terminals

**ES.01 | ECNP PATIENT SESSION**

14.00-14.45 | Room 113

**Social media and suicidal behaviour – patients, clinicians and researchers' perspectives**

Chair: Katharina Domschke, Germany  
 Gil Zalsman, Israel

**ES.01.01 | 14.00**

Clinician's perspective  
 Gil Zalsman, Israel

**ES.01.02 | 14.12**

Researcher's perspective  
 Merike Sisask, Estonia

**ES.01.03 | 14.24**

Patient's perspective  
 Helen Bennett, United Kingdom

**ES.01.04 | 14.36**

Conclusion and general discussion

**COFFEE BREAK**

16.30-16.50 | Level P1

**S.01 | SYMPOSIUM**

16.50-18.30 | Room 117

**Stress-induced neuroinflammation and its role in neuropsychiatric disorders**

Chairs: Yvonne Nolan, Ireland  
 Eric Wohleb, USA

**S.01.01 | 16.50**

Neuroimmune systems in the neurobiology of affective disorders  
 Eric Wohleb, USA

**S.01.02 | 17.15**

The interplay between early-life stress and neuroinflammation on structure and function of the brain throughout life  
 Aniko Korosi, The Netherlands

**S.01.03 | 17.40**

Role of dietary lipids in the regulation of neuroinflammatory processes and associated mood and cognitive disorders  
 Sophie Laye, France

**S.01.04 | 18.05**

Inflammation and hippocampal neurogenesis – exercise as a mood and cognitive modulator  
 Yvonne Nolan, Ireland

**UPDATED PROGRAMME:**

<https://2018.ecnp.eu/> / ECNP app / congress info terminals

**S.02 | SYMPOSIUM**

16.50-18.30 | Room 112

**The use of neuroimaging to improve drug development in mood disorders**

Chairs: *Kamilla Miskowiak, Denmark*  
*Martin Paulus, USA*

**S.02.01 | 16.50**

Neuroimaging and computational approaches to make individual-level treatment predictions  
*Martin Paulus, USA*

**S.02.02 | 17.15**

The application of functional neuroimaging in drug development  
*Pradeep Nathan, United Kingdom*

**S.02.03 | 17.40**

Change in neural response to emotional information as an early predictor of clinical response to SSRI treatment in depression  
*Beata Godlewska, United Kingdom*

**S.02.04 | 18.05**

Neuronal underpinnings of pro-cognitive change in mood disorders  
*Kamilla Miskowiak, Denmark*

**S.03 | SYMPOSIUM**

16.50-18.30 | Room 113

**How alcohol changes the brain: epigenetic and functional reprogramming in addiction**

Chairs: *Markus Heilig, Sweden*  
*Jan M. van Ree, The Netherlands*

**S.03.01 | 16.50**

Epigenetic dysregulation in the mPFC regulates alcohol-associated behaviours  
*Estelle Barbier, Sweden*

**S.03.02 | 17.15**

Alcohol-induced epigenetic dysregulation in the nucleus accumbens promotes pro-inflammatory signaling  
*Claes Wahlestedt, USA*

**S.03.03 | 17.40**

Long-term dysregulation of dopaminergic and opioid transmission in alcohol dependence  
*Anita Hansson, Germany*

**S.03.04 | 18.05**

Dysregulation of synaptic spine formation as a mechanism for structural plasticity in alcohol addiction  
*Dorit Ron, USA*

For industry sessions, please see the 'Industry' tab in this booklet.

**S.04 | SYMPOSIUM**

16.50-18.30 | Room 114

**ECNP New Frontiers symposium –  
A neurodevelopmental approach to drug  
discovery for brain disorders***Chair: Gerard R. Dawson, United Kingdom***S.04.01 | 16.50**How genetics might inform drug discovery  
in neurodevelopmental disorders  
*t.b.a.***S.04.02 | 17.15**What we have learnt from clinical trials in fragile X  
syndrome  
*Sébastien Jacquemont, Canada***S.04.03 | 17.40**How international consortia can advance biomarker  
discovery and clinical trial development for  
neurodevelopmental disorders  
*Declan G. Murphy, United Kingdom***S.04.04 | 18.05**A regulatory perspective to clinical trials and indications  
in neurodevelopmental disorders  
*Tiffany Farchione, USA***E.01 | EDUCATIONAL UPDATE SESSION**

16.50-18.30 | Room 115

**Treatment of resistant obsessive compulsive  
disorder***Moderator: Naomi Fineberg, United Kingdom***E.01.01 | 16.55**Pharmacological treatment of resistant OCD  
*Eric Hollander, USA***E.01.02 | 17.40**Somatic treatments for resistant OCD  
*Eileen M. Joyce, United Kingdom***KL.01 | KEYNOTE SESSION**

18.45-20.00 | Room 112

*Chair: Celso Arango, Spain***GARETH LENG**

UNITED KINGDOM

**The neuroscience of food  
choice and obesity****WELCOME RECEPTION**

20.00-21.00 | Banquet hall

Participants are invited to the welcome reception  
to meet and interact with colleagues. A drink and  
a small bite will be served.**UPDATED PROGRAMME:**<https://2018.ecnp.eu/> / ECNP app / congress info terminals

**07.45-08.45 BRAINSTORMING SESSIONS**

- BS.01 The potentials and limitations of personalised induced pluripotent stem cell (iPSC) models in neuropsychiatry **Room 122**
- BS.02 Youth mental health: new opportunities for preventing mental disorders? **Room 123**
- BS.03 Pharmacogenetic testing in psychiatric patients: are we ready for clinical application? **Room 124**

**09.00-10.00 EXPERT SCIENCE EXCHANGE** (industry session)

- CE.01 Nonadherence with antipsychotics: a vexing problem **Room 118**

**09.00-17.00 EXHIBITION****09.00-10.40 SCIENTIFIC SYMPOSIA**

- S.05 The role of molecular co-modulators in psychiatric, neurodegenerative and metabolic diseases **Room 113**
- S.06 The gut-brain connection in psychiatry **Room 112**
- S.07 Deep brain stimulation for neuropsychiatric and neurological disorders **Room 114**
- S.08 Progress in drug development – new medications and clinical trials **Room 117**
- E.02 EPA educational session – Skating on thin ice: management of clozapine-intolerant and refractory schizophrenia patients **Room 115**

**09.00-09.45 CAMPFIRE SESSIONS**

- CA.01 How to transform my idea into a H2020 proposal **The Bubble**
- CA.02 Scientific basis of mindfulness and meditation **The Bubble**

**10.00-11.00 EXPERT SCIENCE EXCHANGE** (industry session)

- CE.02 Glutamate and major depression **Room 120**

**10.40-11.15 COFFEE BREAK / POSTER VIEWING**  
Poster area and exhibition**10.45-11.10 POSTER JAM**

- J.01 Mood and bipolar disorders **The Circle 1**
- J.02 Animal models **The Circle 2**
- J.03 Anxiety and stress related disorders **The Circle 3**

**11.15-12.00 PLENARY LECTURE**

- PL.01 ECNP Neuropsychopharmacology Award lecture – On the road to precision medicine in psychiatry **Room 112**

**12.00-14.00 LUNCH** Poster area and exhibition**12.00-14.00 POSTER SESSION** Poster area**12.00-14.00 NOMENCLATURE SESSION**

- NS.01 E-based naming of psychotropics – second edition of Neuroscience based Nomenclature (NbN) and first edition of Child and Adolescent NbN (NbN-ca) **Room 115**

**12.10-12.40 CAREER DEVELOPMENT SESSION**

- CD.01 Improve your chances of manuscript acceptance and publication **The Bubble**

**13.20-13.50 AWARD CEREMONY**

- NP.01 Prize for the best publication of negative results in preclinical neuroscience **The Bubble**

**13.20-13.50 TOP PAPER SESSIONS**

- TP.01 Highlights in addiction **Room 113**
- TP.02 Highlights in dementia **Room 114**

**13.50-14.00 POSTER AWARD CEREMONY** The Circle**14.00-14.45 PLENARY LECTURE** Brain Prize lecture

- PL.02 Computational psychiatry **Room 112**

**14.45-15.00 COFFEE BREAK** Poster area and exhibition**14.50-15.00 TRAVEL AWARD CEREMONY** The Circle**15.00-16.00 EXPERT SCIENCE EXCHANGE** (industry session)

- CE.06 When is the right time to change to another antidepressant treatment? **Room 118**

**15.00-16.40 SCIENTIFIC SYMPOSIA**

- S.09 Innovative approaches towards a better and personalised therapy of depression **Room 112**
- S.10 Understanding the biology of aggression: what can we learn from the brain of young people? **Room 113**
- S.11 Abnormal thalamo-cortical circuits in schizophrenia: a central core for perception, cognitive, and sleep deficits **Room 114**
- S.12 INTERACTIVE DISCUSSION – How can both patients and research benefit from digital technology? **Room 117**
- E.03 PTSD in an age of mass migration and asylum **Room 115**

**16.00-17.00 EXPERT SCIENCE EXCHANGE** (industry session)

- CE.07 What are the clinical and functional benefits of early use of long acting injectable antipsychotics in severe mental disorders? **Room 120**

**17.15-18.45 SATELLITE SYMPOSIA** (industry sessions)

- C.06 Current and future management of major depressive disorder: challenges and perspectives **Room 112**
- C.07 Integrating patients' expectations into the management of their depression **Room 113**
- C.08 Comorbid adult ADHD in psychiatric patients: are we missing it? **Room 114**
- C.09 Schizophrenia in 2018: symptoms, treatments, metabolics and cognition across lifespan **Room 115**

**19.00-22.00 FACULTY RECEPTION** (by invitation only)

**BS.01 | BRAINSTORMING SESSION**

07.45-08.45 | Room 122

**The potentials and limitations of personalised induced pluripotent stem cell (iPSC) models in neuropsychiatry***Chair: Majja Castren, Finland**Experts: Edna Grünblatt, Switzerland  
Olaf Schröder, Germany***BS.02 | BRAINSTORMING SESSION**

07.45-08.45 | Room 123

**Youth mental health: new opportunities for preventing mental disorders?***Chair: Christine Freitag, Germany**Experts: Therese van Amelsvoort, The Netherlands  
Paolo Fusar-Poli, United Kingdom***BS.03 | BRAINSTORMING SESSION**

07.45-08.45 | Room 124

**Pharmacogenetic testing in psychiatric patients: are we ready for clinical application?***Chairs: Andreas Menke, Germany  
Raz Gross, Israel**Experts: Revital Amiaz, Israel  
Eva J. Brandl, Germany***S.05 | SYMPOSIUM**

09.00-10.40 | Room 113

**The role of molecular co-modulators in psychiatric, neurodegenerative and metabolic diseases***Chairs: Hermona Soreq, Israel  
Marco Prado, Canada***S.05.01 | 09.00**

Single nucleotide polymorphisms co-modulating anxiety and metabolic disorders

*Hermona Soreq, Israel***S.05.02 | 09.25**

The role of microRNAs in stress response regulation and stress-linked psychopathologies

*Alon Chen, Germany***S.05.03 | 09.50**

Epigenetic alterations associated with parental trauma and PTSD

*Amy Lehrner, USA***S.05.04 | 10.15**

RNA processing impairments in neurodegeneration syndromes

*Marco Prado, Canada*



**S.06 | SYMPOSIUM**

09.00-10.40 | Room 112

**The gut-brain connection in psychiatry**

Chairs: *Gregor Hasler, Switzerland*  
*Roger Adan, The Netherlands*

**S.06.01 | 09.00**

Feeding the microbiota-gut-brain axis – diet, microbiome and neuropsychiatry  
*John F. Cryan, Ireland*

**S.06.02 | 09.25**

Gut-immune-brain axis in autism  
*Marion Leboyer, France*

**S.06.03 | 09.50**

Gut-hormone-brain axis in addiction  
*Elisabeth Jerlhag, Sweden*

**S.06.04 | 10.15**

The role of nutrition in depression  
*Undine Lang, Switzerland*

**S.07 | SYMPOSIUM**

09.00-10.40 | Room 114

**Deep brain stimulation for neuropsychiatric and neurological disorders**

Chair: *Jens Kuhn, Germany*

**S.07.01 | 09.00**

Deep brain stimulation for obsessive-compulsive disorder  
*Sina Kohl, United Kingdom*

**S.07.02 | 09.25**

Deep brain stimulation for Tourette's syndrome  
*Juan Carlos Baldermann, Germany*

**S.07.03 | 09.50**

Deep brain stimulation for addiction  
*Judy Luigjes, The Netherlands*

**S.07.04 | 10.15**

Deep brain stimulation for dementia  
*Jens Kuhn, Germany*

**S.08 | ALTERNATIVE SESSION**

09.00-10.40 | Room 117

**Progress in drug development – new medications and clinical trials**

Chair: *Arne Mørk, Denmark*  
*Mark Weiser, Israel*

**S.08.01 | 09.05**

Development of brexanolone iv, a GABA-A receptor positive allosteric modulator, for postpartum depression  
*Christine Clemson, USA*

**S.08.02 | 09.20**

Esketamine nasal spray combined with an oral antidepressant for relapse prevention in treatment-resistant depression: results of a double-blind, randomized withdrawal, multicenter study (SUSTAIN-1)  
*Ella Daly, USA*

**S.08.03 | 09.35**

A randomized, double-blind, parallel-group, placebo- and active-controlled study to evaluate the efficacy and safety of MIN-117 in patients with major depressive disorder  
*Remy Luthringer, France*

**S.08.04 | 09.50**

Preclinical and clinical findings suggest that evenamide improves symptoms in patients with schizophrenia through glutamatergic modulation  
*Ravi Anand, Switzerland*

**S.08.05 | 10.05**

Cariprazine, the new broad spectrum antipsychotic: clinical data of schizophrenia, bipolar mania, bipolar depression and major depression studies  
*Agota Barabassy, Hungary*

**S.08.06 | 10.20**

MDMA-assisted psychotherapy for PTSD: a promising novel experimental treatment moving into phase 3 trials with FDA breakthrough therapy designation  
*Michael Mithoefer, USA*

**E.02 | EDUCATIONAL UPDATE SESSION**

09.00-10.40 | Room 115

**EPA educational session – Skating on thin ice: management of clozapine-intolerant and refractory schizophrenia patients***Moderator: Silvana Galderisi, Italy***E.02.01 | 09.05**

Needs of patients with treatment resistant schizophrenia – can mobile phone applications help?  
*Illuminada Corripio, Spain*

**E.02.02 | 09.50**

Treatment options for clozapine-intolerant and refractory schizophrenia patients  
*Istvan Bitter, Hungary*

**CA.01 | CAMPFIRE SESSION**

09.00-09.45 | The Bubble

**How to transform my idea into a H2020 proposal***Expert: Ameli Schwalber, Germany***CA.02 | CAMPFIRE SESSION**

09.00-09.45 | The Bubble

**Scientific basis of mindfulness and meditation***Expert: t.b.a.***COFFEE BREAK**

10.40-11.15 | Poster area and exhibition

**POSTER VIEWING**

10.40-11.15 | Poster area

Posters that are on display can already be viewed during this time. It is not mandatory for poster presenters to be at their poster, the official poster session will start at 12.00.  
See pages 42-128 for details.

**J.01 | POSTER JAM**

10.45-11.10 | The Circle 1

**Mood and bipolar disorders***Moderator: Henricus G. Ruhé, The Netherlands***J.02 | POSTER JAM**

10.45-11.10 | The Circle 2

**Animal models***Moderator: David Slattery, Germany***J.03 | POSTER JAM**

10.45-11.10 | The Circle 3

**Anxiety and stress related disorders***Moderator: Raymond Mongeau, France*

**PL.01 | PLENARY LECTURE**

11.15-12.00 | Room 112

*Chair: Gitte Moos Knudsen, Denmark***ECNP Neuropsychopharmacology Award lecture**

Presentation of the award to Marion Leboyer  
by ECNP President-Elect Gitte Moos Knudsen.



**MARION LEBOYER**  
FRANCE

**On the road to precision  
medicine in psychiatry**

**LUNCH**

12.00 -14.00 | Poster area and exhibition

**POSTER SESSION**

12.00-14.00 | Poster area

Poster presenters will be available at their paper  
poster for further explanation and discussion.  
See pages 42-128 for details.

**NS.01 | NOMENCLATURE  
SESSION**

12.00-14.00 | Room 115



**E-based naming of psychotropics – second  
edition of Neuroscience based Nomenclature  
(NbN) and first edition of Child and  
Adolescent NbN (NbN-ca)**

*Chair: Joseph Zohar, Israel***NS.01.01 | 12.05**

Bridging the gap – child and adolescent edition  
of NbN (NbN-ca)

*Celso Arango, Spain***NS.01.02 | 12.20**

New drugs and new concepts in the second edition  
of NbN

*Stephen M. Stahl, USA***NS.01.03 | 12.35**

NbN and WHO classification – the pros and the cons

*David Nutt, United Kingdom***NS.01.04 | 12.50**

New layer in NbN: drug-drug interactions

*Sue Wilson, United Kingdom***NS.01.05 | 13.05**

E-based nomenclature in your pocket – how does  
the NbN app work

*Joseph Zohar, Israel***NS.01.06 | 13.20**

NbN as an educational tool – the experience we  
have gained so far

*Pierre Blier, Canada***13.35**

Q&amp;A and discussion

**CD.01 | CAREER DEVELOPMENT SESSION**

12.10-12.40 | The Bubble

**Improve your chances of manuscript acceptance and publication**Chair: *Laura Airas, Finland*Presenter: *Christine Wayman, United Kingdom***NP.01 | AWARD CEREMONY**

13.20-13.50 | The Bubble

**Prize for the best publication of negative results in preclinical neuroscience**Chairs: *Anton Y. Bespalov, Germany**Thomas Steckler, Belgium***TP.01 | TOP PAPER SESSION**

13.20-13.50 | Room 113

**Highlights in addiction**Chair: *Louk Vanderschuren, The Netherlands*Presenter: *Rainer Spanagel, Germany***TP.02 | TOP PAPER SESSION**

13.20-13.50 | Room 114

**Highlights in dementia**Chair: *Anne Eckert, Switzerland*Presenter: *Paul John Lucassen, The Netherlands***AWARD CEREMONY**

13.50-14.00 | The Circle

Presentation ECNP Poster Awards

**PL.02 | PLENARY LECTURE**

14.00-14.45 | Room 112

**Brain Prize lecture**Chair: *Joop van Gerven, The Netherlands***PETER DAYAN**  
UNITED KINGDOM**Computational psychiatry****COFFEE BREAK**

14.45-15.00 | Poster area and exhibition

**AWARD CEREMONY**

14.50-15.00 | The Circle

Presentation ECNP Travel Awards

**S.09 | SYMPOSIUM**

15.00-16.40 | Room 112

**Innovative approaches towards a better and personalised therapy of depression**Chair: *Catherine Harmer, United Kingdom***S.09.01 | 15.00**

Early prediction of SSRI-treatment outcome using an internet-based medical device – the first results from the PReDicT study

*Michael Browning, United Kingdom***S.09.02 | 15.25**

Neuropsychological and neuroimaging markers for recurrence of major depressive disorder

*Henricus G. Ruhé, The Netherlands*

**S.09.03 | 15.50**

Better prediction of outcomes in depression – what kind of societal impact can we expect?

*Judit Simon, Austria*

**S.09.04 | 16.15**

Using affective neuroscience to address predicted barriers to depression treatment response

*Greg J. Siegle, USA*

**S.10 | SYMPOSIUM**

15.00-16.40 | Room 113

**Understanding the biology of aggression: what can we learn from the brain of young people?**

Chair: *Barbara Franke, The Netherlands*

**S.10.01 | 15.00**

The neurobiology of aggression – defining the brain circuits for subtypes of aggressive behaviour

*James Blair, USA*

**S.10.02 | 15.25**

A population-based study of childhood aggression as a predictor of antisocial personality in young adults

*Jaakko Kaprio, Finland*

**S.10.03 | 15.50**

Basal and reactive neuroendocrinology in adolescent conduct disorder in females

*Christine Freitag, Germany*

**S.10.04 | 16.15**

Poor empathy and abnormal aggression in mice as a model for human psychopathology

*Simone Macri, Italy*

**S.11 | SYMPOSIUM**

15.00-16.40 | Room 114

**Abnormal thalamo-cortical circuits in schizophrenia: a central core for perception, cognitive, and sleep deficits**

Chairs: *Pascal Steullet, Switzerland*  
*Judith Pratt, United Kingdom*

**S.11.01 | 15.00**

The importance of the thalamic reticular nucleus in disrupted thalamocortical connectivity in rodent models of schizophrenia risk factors

*Judith Pratt, United Kingdom*

**S.11.02 | 15.25**

Reduced sleep spindles in schizophrenia – a treatable endophenotype that links risk genes to impaired cognition?

*Dara Manoach, USA*

**S.11.03 | 15.50**

Hypothalamic modulation of thalamic reticular nucleus activity controls arousal and consciousness

*Carolina Gutierrez Herrera, Switzerland*

**S.11.04 | 16.15**

Similar anomalies in the thalamic reticular nucleus of a mice model of redox dysregulation and of schizophrenia patients

*Pascal Steullet, Switzerland*

For industry sessions, please see the 'Industry' tab in this booklet.

**S.12 | ALTERNATIVE SESSION**

15.00-16.40 | Room 117

**INTERACTIVE DISCUSSION****How can both patients and research benefit from digital technology?***Moderator: Guy Goodwin, United Kingdom*

Introduction by the moderator

**S.12.01 | 15.05**Passive remote behavioural monitoring in PRISM, an Innovative Medicine Initiative project  
*Martien Kas, The Netherlands***S.12.02 | 15.15**Online mood tracking and psychoeducation  
*Kate Saunders, United Kingdom***S.12.03 | 15.25**Using mHealth to diagnose and predict psychiatric disorders  
*Ulrich Ebner-Priemer, Germany***15.35**

Table discussions

**15.45**

Tables give feedback to moderator

**S.12.04 | 15.50**The industry perspective  
*Vaibhav Narayan, USA***S.12.05 | 16.00**The patient-caregiver interaction perspective  
*Lior Carmi, Israel***S.12.06 | 16.10**

T.b.a.

**16.20**

Table discussions

**16.30**

Tables give feedback to moderator

**16.35**

Closing

**E.03 | EDUCATIONAL UPDATE SESSION**

15.00-16.40 | Room 115

**PTSD in an age of mass migration and asylum***Moderator: Jonathan Bisson, United Kingdom***E.03.01 | 15.05**Mental health in refugees and asylum seekers  
*Malek Bajbouj, Germany***E.03.02 | 15.50**Treatment of trauma-affected refugees  
*Jessica Carlsson Lohmann, Denmark***UPDATED PROGRAMME:**<https://2018.ecnp.eu/> / ECNP app / congress info terminals

## P.001

**Randomized, double-blind study of flexibly-dosed intranasal esketamine plus oral antidepressant vs. active control in treatment-resistant depression**

V. Popova\*, E.J. Daly, M. Trivedi, K. Cooper, R. Lane, P. Lim, C. Mazzucco, D. Hough, M.E. Thase, R.C. Shelton, P. Molero, E. Vieta, M. Bajbouj, H. Manji, W.C. Drevets, J.B. Singh (Belgium)

Mood and bipolar disorder; Pharmacology - Intervention

## P.002

**Suicide and other causes of death among patients admitted to hospital following attempted suicide: a 10-year follow-up study**

A. Fernandez-Quintana\*, J. Alberdi-Sudupe, F. Iglesias-Gil-de-Bernabé, S. Lantes-Louzao, S. Gómez-Pardiñas, F. Cordido-Carballido (Spain)

Mood and bipolar disorder; Personality disorder; Epidemiology and big data - Method

## P.003

**Volumetric increases in reward circuit correlated with improvement of anticipatory anhedonia in depressive patients after electroconvulsive therapy**

M. Cano Català\*, E. Lee, C. Soriano-Mas, J.A. Camprodon (Spain)

Mood and bipolar disorder; Neuroimaging - Method; Neuromodulation - Intervention

## P.004

**Characterization and prodromal symptoms in early-onset bipolar spectrum disorder**

G. Salazar de Pablo\*, D. Guinart, C. Moreno, C. Arango, C.U. Correll (Spain)

Mood and bipolar disorder; Prevention / course alteration

## P.005

**Lithium therapy in bipolar disorder is associated with higher in-vivo cortical neurite density**

S. Sarrazin\*, C. Poupon, A. Teillac, J.F. Mangin, M. Polosan, P. Favre, C. Laidi, M.A. D'Albis, M. Leboyer, P.M. Lledo, C. Henry, J. Houenou (France)

Mood and bipolar disorder; Neuroimaging - Method; Pharmacology - Intervention

## P.006

**Outcome and predictors of remission in manic patients treated with oral antipsychotics and/or mood stabilizers: a prospective observational study**

M. Barbuti\*, G. Maccariello, G. Vannucchi, A. De Bartolomeis, A. Fagiolini, G. Maina, G. Perugi (Italy)

Mood and bipolar disorder; Pharmacology - Intervention

## P.007

**Peripheral insulin-like growth factor and glutamate-related antibodies in bipolar disorder and lithium prophylaxis**

E. Ferensztajn\*, M. Kaczmarek, M. Wójcicka, E. Kaufman-Szukalska, S. Dziuda,

A. Remlinger-Molenda, A. Szeliga-Neymann, M. Michalak, J. Losy, J.K. Rybakowski (Poland)

Mood and bipolar disorder; Immunology - Method

## P.008

**ADRA2A and ADRA2C gene expression in post-mortem brain is differentially upregulated in subjects with major depressive disorder and schizophrenia**

G. Rivero\*, C. Muguruza, V. Corzo, J.J. Meana, L.F. Callado (Spain)

Mood and bipolar disorder; Psychotic disorder; Post-mortem / pathology - Method

## P.009

**Changes in diagnostics of depression among Family physicians in Latvia following education course of National Research Programme BIOMEDICINE 2014-2017**

E. Rancans\*, A. Kivite, J. Vrublevska, R. Ivanovs (Latvia)

Mood and bipolar disorder; Prevention / course alteration

## P.010

**Affective lability as a mixed symptom: investigating its association with mood reactivity during a major depressive episode**

N. Verdolini\*, G. Menculini, G. Perugi, A. Murru, L. Samalin, J. Angst, J.M. Azorin, C.L. Bowden, S. Mosolov, A.H. Young, M. Barbuti, D. Popovic, E. Vieta, I. Pacchiarotti (Spain)

Mood and bipolar disorder; Prevention / course alteration; Pharmacology - Intervention

## P.011

**5-HT<sub>2A</sub> receptor- and M1 muscarinic acetylcholine receptor-mediated Galpha(q) signalling in patients with psychiatric disorders**

*Y. Odagaki\*, M. Kinoshita, T. Ota, J.J. Meana, L.F. Callado, J.A. Garcia-Sevilla (Japan)*

Mood and bipolar disorder; Psychotic disorder

## P.012

**Long-term safety of esketamine nasal spray plus oral antidepressant in patients with treatment-resistant depression: SUSTAIN-2 phase 3 study**

*E. Wajs\*, A. Leah, R. Morrison, E. Daly, R. Lane, P. Lim, R. Holder, G. Sanacora, A.H. Young, S. Kasper, A.H. Sulaiman, C.T. Li, J.W. Paik, H. Manji, D. Hough, W. Drevets, J. Singh (Belgium)*

Mood and bipolar disorder; Pharmacology - Intervention

## P.013

**Vortioxetine versus venlafaxine for major depressive disorder: a meta-analysis and systematic review**

*B. Maneeton\*, N. Maneeton, P. Woottiluk, A. Oonarom, P. Wiriyacosol (Thailand)*

Mood and bipolar disorder; Pharmacology - Intervention; Pharmacology - Method

## P.014

**Biological changes in a pharmacologically-induced depression model confirm the role of estrogen sensitivity in perinatal depression**

*D. Mehta, M. Rex-Haffner, H.B. Søndergaard, A. Pinborg, E. Binder, V.G. Frokjaer\* (Denmark)*

Mood and bipolar disorder; Genetic & molecular approaches - Method; Neuroimaging - Method

## P.015

**Perspective of personalised drug treatment in depression**

*M. Ising\*, S. Scheuer, P. Belcredi, M. Uhr, F. Holsboer (Germany)*

Mood and bipolar disorder; Stress related disorder

## P.016

**The protective effects of cognitive reserve in major depressive disorder**

*M. Serra-Blasco\*, M. Vicent-Gil, G. Navarra-Ventura, E. Aguilar, X. Goldberg, S. Crivillés, S. Acebillo, D. Palao, M.J. Portella, N. Cardoner (Spain)*

Mood and bipolar disorder; Neuropsychology - Method

## P.017

**The prototypical hallucinogen LSD suppresses rat dorsal raphe serotonergic neuronal activity through 5-HT<sub>1A</sub> and 5-HT<sub>2B</sub> receptors**

*S. Delcourte\*, R. Rovera, O. Dkhissi-Benyahya, A. Etiévant, N. Haddjeri (France)*

Mood and bipolar disorder; Animal models - Method; Pharmacology - Intervention

## P.018

**Major depressive disorder – understanding the patient journey**

*B.T. Baune\* (Australia)*

Mood and bipolar disorder; Healthy brain; Prevention / course alteration

## P.019

**The use of light to potentiate antidepressant medication: preclinical evidence**

*S. Delcourte\*, R. Rovera, H.M. Cooper, C. Coutanson, O. Dkhissi-Benyahya, N. Haddjeri (France)*

Mood and bipolar disorder; Animal models - Method; Pharmacology - Intervention

## P.020

**Alterations in the expression and activity of STEP in the mouse brain induced by genetically defined obesity and lipopolysaccharide (LPS) administration**

*E. Kulikova\*, N. Khotskin, E. Bazhenova, V. Sergiyenko, D. Fursenko, I. Sorokin, I. Kolotygin, A. Khotskina, A. Kulikov (Russia)*

Mood and bipolar disorder; Neuro-inflammatory disorder; Genetic & molecular approaches - Method

## P.021

**Affective disorders and high familial risk of affective disorders associate with aberrant intestinal microbiota**

*M. Vinberg\*, N. Ottesen, I. Meluken, N. Sørensen, O. Pedersen, L. Kessing, K. Miskowiak (Denmark)*

Mood and bipolar disorder; Prevention / course alteration

## P.022

**Long-term functioning outcomes are predicted by cognitive symptoms in working patients with major depressive disorder: results from the AtWoRC study**

*P. Chokka, J. Bougie, J. Proulx, A.H. Tvistholm, A. Ettrup\* (Denmark)*

Mood and bipolar disorder; Pharmacology - Intervention



## P.023

**Gender related issues in patients with bipolar disorder: correlates with clinical variables and therapeutic approaches**

M.E.M. Vismara\*, B. Grancini, V. De Carlo, C. Arici, G. Ciriigliaro, L. Cremaschi, A.C. Altamura, B. Dell'osso (Italy)

Mood and bipolar disorder; Pharmacology - Method

## P.024

**Interaction between BDNF Val66Met gene polymorphism and peripheral BDNF levels on memory function in bipolar disorder compared to normal population**

Y.H. Chang\*, T.Y. Wang, C.C. Huang, H. Hua-Yuan, R.B. Lu (Taiwan)

Mood and bipolar disorder; Genetic & molecular approaches - Method

## P.025

**Thalami shape differences in elderly depressed suicide attempters**

J.A. Betrand, G. Devenyi, K. Greenway\*, G. Turecki, M. Chakravarty, S. Richard-Devantoy (Canada)

Mood and bipolar disorder; Neuroimaging - Method

## P.026

**Association study of polymorphisms within inflammatory genes and treatment resistant depression**

M. Draganov\*, M.J. Arranz, J. De Diego-Adeliño, M. Jubero, D. Puigdemont, E. Alvarez, M.J. Portella (Spain)

Mood and bipolar disorder; Genetic & molecular approaches - Method; Neuro-inflammatory disorder

## P.027

**Comparison of systemic inflammation between psychotic and non-psychotic hospitalizations in acute episodes of bipolar disorder**

N. Karamustafalioglu\*, G. Celikel, A. Kara, E. Celik, C. Kilic, S. Yalcin, I. Ozonder, P. Celikkiran, T. Kalelioglu (Turkey)

Mood and bipolar disorder; Immunology - Method

## P.028

**Treatment of mixed states using intravenous sodium valproate: efficacy and tolerability**

A. Santucci\*, G. Amodeo, A. Fagiolini, A. Goracci (Italy)

Mood and bipolar disorder; Pharmacology - Intervention

## P.029

**Estrogen regulates local protein synthesis in the female hippocampus**

P. Raval\*, J. Mukherjee, K.J. Sellers, H. Creeney, R.R.R. Duarte, S.J. Moss, N.J. Brandon, D.P. Srivastava (United Kingdom)

Mood and bipolar disorder; Pharmacology - Method; Biochemistry - Method

## P.030

**Health-related quality of life in a Phase 2, randomized, placebo-controlled trial of the GABA(A) R modulator SAGE-217 in major depressive disorder**

V. Bonthapally\*, H. Gunduz-Bruce, C. Silber, A. Rothschild, R. Riesenberger, A. Sankoh, H. Li, E. Li, E. Suthoff, C. Zorumski, D. Rubinow, S. Paul, J. Jonas, J. Doherty, S. Kanes (USA)

Mood and bipolar disorder; Pharmacology - Intervention

## P.031

**High risk for suicide is associated with T-cell abnormalities in patients with major depressive disorder**

C. Schiweck\*, H. Drexhage, S. Claes, E. Vrieze (Belgium)

Mood and bipolar disorder; Immunology - Method; Neuro-inflammatory disorder

## P.032

**SAGE-217 in major depressive disorder: a multicenter, randomized, double-blind, Phase 2 placebo-controlled trial**

H. Gunduz-Bruce\*, C. Silber, A. Rothschild, R. Riesenberger, A. Sankoh, H. Li, E. Li, C. Zorumski, D. Rubinow, S. Paul, J. Jonas, J. Doherty, S. Kanes (USA)

Mood and bipolar disorder; Pharmacology - Intervention

## P.033

**Cognitive symptoms in depression and clinical outcomes in a 6-month non-interventional, prospective study of antidepressant treatment in China**

G. Wang, C.X. Wang, K.H.X. Tan, S. Luo\* (China)

Mood and bipolar disorder; Prevention / course alteration

## P.034

**Clinical predictors of treatment resistant depression: replication results from the European multicenter study**

A. Kautzky\*, M. Dold, L. Bartova, M. Spies, G.S. Kranz, D. Souery, S. Montgomery, J. Mendlewicz, J. Zohar, C. Fabbri, A. Serretti, R. Lanzenberger, D. Dikeos, D. Rujescu, S. Kasper (Austria)

Mood and bipolar disorder; Biostatistics & computational method

## P.035

**The interaction between inflammation and neural plasticity controls the efficacy of serotonergic antidepressants**

S. Poggini\*, M.T. Golia, S. Alboni, A. Viglione, F. Abdallah, N. Ciano Albanese, V. Malpassuti, S. Garofalo, G. Millor, C. Limatola, L. Maggi, I. Branchi (Italy)

Mood and bipolar disorder; Neuro-inflammatory disorder; Stress related disorder

## P.036

**Brexanolone iv, a GABA-A receptor modulator, in postpartum depression: pooled analysis of HAM-D sub-items**

S. Meltzer-Brody, H. Colquhoun, R. Riesenberger, C.N. Epperson, K. Deligiannidis, D. Rubinow, H. Li, C. Clemson\*, S. Kaner (USA)

Mood and bipolar disorder; Pharmacology - Intervention

## P.037

**Mu dependent effects of buprenorphine in combination with samidorphan on immobility behavior in Wistar Kyoto rats**

K.L. Smith, D.R. Deaver, R.L. Dean III, J.I. Cunningham, C. Sanchez\*, D.J. Eyerman (USA)

Mood and bipolar disorder; Pharmacology - Intervention; Animal models - Method

## P.038

**Exosomal microRNAs and microRNA dysregulation in bipolar disorder**

D. Ceylan\*, T. Şan, U. Tüfekçi, Ş. Genç, A. Özerdem (Turkey)

Mood and bipolar disorder; Genetic & molecular approaches - Method; Neuro-inflammatory disorder

## P.039

**Diet quality, dietary inflammatory index and body composition as predictors of N-acetylcysteine and mitochondrial agents efficacy in bipolar disorder**

M. Ashton\*, O.M. Dean, W. Marx, M. Mohebi, M. Berk, G.S. Malhi, C. Ng, S.M. Cotton, S. Dodd, J. Sarris, M. Hopwood, C. Voigt, K. Faye-Chauhan, Y. Kim, S.R. Dash, F.N. Jacka, N. Shivappa, J. Herbert, A. Turner (Australia)

Mood and bipolar disorder; Lifestyle and nutrition - Intervention

## P.040

**Repetitive transcranial magnetic stimulation combined with antidepressants for major depressive disorder: a meta-analysis and systematic review**

B. Maneeton\*, N. Maneeton, P. Woottiluk, A. Oonaron (Thailand)

Mood and bipolar disorder; Pharmacology - Intervention; Neuromodulation - Intervention

## P.041

**Identification of a panel of microRNAs as peripheral biomarkers of lithium response in bipolar patients**

C. Mora\*, B. Etain, N. Cattane, N. Lopizzo, L. Arrigoni, C.M. Claire, B. Frank, A. Cattaneo (Italy)

Mood and bipolar disorder; Genetic & molecular approaches - Method

## P.042

**Group psychoeducation in the treatment of unipolar depression - multicentric randomized controlled trial**

A. Dzibur Kulenovic\* (Bosnia and Herzegovina)

Mood and bipolar disorder; Psychotherapy - Intervention

## P.043

**The impact of neurocognition on emotional intelligence in euthymic patients with bipolar disorder**

C. Varo\*, E. Jiménez, B. Solé, C.M. Bonnín, C. Torrent, E. Valls, G. Lahera, A. Martínez-Arán, E. Vieta, M. Reinares (Spain)

Mood and bipolar disorder; Neuropsychology - Method

## P.044

**Sex-specific association between the cortisol awakening response and obsessive-compulsive symptoms in a non-clinical population**

*C.S. Melia\*, V. Soria, N. Salvat-Pujol, Á. Cabezas, R. Nadal, M. Urretavizcaya, L. Ortega, J.A. Monreal, J.M. Crespo, P. Alonso, E. Vilella, D. Palao, J.M. Menchón, J. Labad (Spain)*  
 Impulsive and compulsive disorder; Neuropsychology - Method; Biochemistry – Method

## P.045

**Peripheral blood SIRT1 mRNA levels in depression and treatment with electroconvulsive therapy**

*C. McGrory\*, K. Ryan, E. Kolshus, M. Finnegan, D. McLoughlin (Ireland)*  
 Mood and bipolar disorder; Genetic & molecular approaches - Method

## P.046

**Effectiveness of auditory closed-loop stimulation during sleep on depression**

*K. Danilenko\*, E. Koblelev, S.V. Yarosh, G.R. Khazankin, L.I. Aftanas (Russia)*  
 Mood and bipolar disorder; Neuromodulation - Intervention

## P.047

**Genetic risk and psychiatric disorders predict psychotic like experiences in two longitudinal cohorts: offspring of bipolar vs offspring of controls**

*I. Mendez\*, B. Birmaher, D. Axelson, F. Castro (Spain)*  
 Mood and bipolar disorder; Psychotic disorder

## P.048

**Predictors of the subjective-objective cognition discrepancy in unipolar disorder**

*J.Z. Petersen\*, R.J. Porter, K.W. Miskowiak (Denmark)*  
 Mood and bipolar disorder; Neuropsychology - Method

## P.049

**Antidepressant effect of ketamine in chronic unpredictable mild stress model: involvement of nod-like protein inflammasome driven pathway**

*F. Aricioglu\*, C. Yalcinkaya, C. Sahin Ozkartal, E. Tuzun, C. Kucukali, C. Kandemir, S. Sirvanci, T. Utkan (Turkey)*  
 Mood and bipolar disorder; Neuro-inflammatory disorder; Pharmacology - Intervention

## P.050

**Diagnostic change in a multicenter first-psychotic episode cohort: identifying baseline factors associated with conversion to bipolar disorder.**

*E. Salagre\*, J. Pinzon, B. Cabrera, G. Mezquida, M. Bioque, M. Parellada, J. Saiz-Ruiz, E. Vieta, M. Bernardo, I. Grande (Spain)*  
 Mood and bipolar disorder; Prevention / course alteration; Psychotic disorder

## P.051

**Agreement between clinician-centred and patient-centred depressive symptoms scales**

*S. Arostegui\*, B. Santos, E. González-Fraile, C. Sanz-Arzuaga, L. Intxauspe, J. Ballesteros (Spain)*  
 Mood and bipolar disorder; Neuropsychology - Method

## P.052

**The differential role of depressive and manic symptoms in predicting functioning outcome in major depression: a BRIDGE-Mix-II post-hoc analysis**

*G. Anmella\*, N. Verdolini, I. Pacchiarotti, A. Aedo, J. Angst, J.M. Azorin, C.L. Bowden, S. Mosolov, L. Samalin, D. Popovic, A.H. Young, G. Perugi, E. Vieta, A. Murru (Spain)*  
 Mood and bipolar disorder; Prevention / course alteration

## P.053

**Predominant polarity in bipolar I and II disorders: a five-year follow-up study**

*S. Pallaskorpi\*, K. Suominen, T. Rosenström, P. Arvilommi, O. Mantere, H. Valtonen, S. Leppämäki, A. García-Estela, I. Grande, F. Colom, E. Vieta, E. Isometsä (Finland)*  
 Mood and bipolar disorder; Personality disorder

## P.054

**Depression and heart failure: preliminary findings from the deus ex machina study**

*E. Moreira\*, S. Martins, L.F. Azevedo, J. Silva-Cardoso, L. Fernandes (Portugal)*  
 Mood and bipolar disorder; Sleep disorder; Anxiety - Disorder

## P.055

**Evaluation of the recurrence rates after the first manic episode: one year follow-up study**

*V. Erbasan\*, M. Aydin, Y. Selvi, K. Altınbaş (Turkey)*  
 Mood and bipolar disorder; Pharmacology - Intervention; Prevention / course alteration

**P.056****Repeated subanesthetic administration of ketamine maintains an increase in dopamine neurotransmission: an electrophysiological study in rat brain***C.M. Iro, M. El Mansari, P. Blier\* (Canada)*

Mood and bipolar disorder; Pharmacology - Method

**P.057****Predicting depression severity: the role of socio-cognitive variables***F. Caetano\*, S. Carvalho, C. Silva (Portugal)*

Mood and bipolar disorder; Pharmacology - Intervention; Neuropsychology - Method

**P.058****CSF butyrylcholinesterase and acetylcholinesterase activity and their relationship to pro-inflammatory cytokines in late-life major depression***N. Pomara\*, D. Bruno, J. Nierenberg, C. Reichert, M. Fu, H. Zetterberg, K. Blennow (USA)*

Mood and bipolar disorder; Neuro-inflammatory disorder

**P.059****The gut microbiome and linkage to brain function in patients with bipolar depression: a preliminary study***S. Hu\*, Q. Lu, J. Lai, T. Huang, Y. Xu (China)*

Mood and bipolar disorder; Neuro-inflammatory disorder; Pharmacology - Intervention

**P.060****Relations between pharmacokinetic parameters of carbamazepine and therapeutic response in bipolar patients***B.N. Saguem\*, A. Braham, C. Chbili, S. Ben Nasr, S. Saguem, B. Ben Hadj Ali (Tunisian Republic)*

Mood and bipolar disorder; Pharmacology - Intervention

**P.061****Neuro-retinal changes and its correlations with visual disturbances in patients with bipolar disorder***M.J. Rodrigo\*, E. Vilades, E. Orduna, G. Larrea, M. Satue, J. Garcia-Campayo, M. Navarro-Gil, E. Garcia-Martin (Spain)*

Mood and bipolar disorder; Neuroimaging - Method; Dementia &amp; neuro degeneration - Disorder

**P.062****Dynamic change of gut microbiota characteristics following quetiapine treatment in patients with bipolar depression***S. Hu\*, A. Li, T. Huang, J. Lai, Q. Lu, J. Lu, S. Lu, D. Wang, Y. Xu (China)*

Mood and bipolar disorder; Genetic &amp; molecular approaches - Method

**P.063****Hypothalamic-pituitary-adrenal axis functioning in remitted, manic and depressed bipolar patients compared to controls***A. Giurgiuc\*, V. Matei, A. Crasan, R. Grigoras, D. Cozman, S. Schipor, A. Caragheorgheopol, E. Postolache, A. Rosca (Romania)*

Mood and bipolar disorder; Prevention / course alteration

**P.064****Polygenic risk: predicting depressive symptoms in clinical and epidemiological cohorts of adolescents***T. Halldorsdottir\*, C. Piechaczek, V. Pehl, P. Wagenbuechler, A.P.S. De Matos, D. Czamara, M. Rex-Haffner, E.Ö. Arnarson, W.E. Craighead, G. Schulte-Körne, E.B. Binder (Germany)*

Mood and bipolar disorder; Genetic &amp; molecular approaches - Method; Prevention / course alteration

**P.065****Bipolar disorder may increase the risk of caesarean section***E. Sole Roige\*, A. Roca, B. Sureda, A. Torres, E. Roda, E. Vieta, L. Garcia- Esteve (Spain)*

Mood and bipolar disorder; Lifestyle and nutrition - Intervention; Stress related disorder

**P.066****Do all depressive patients show the same cognitive profile? A Cluster analysis***M. Vicent-Gil\*, M.J. Portella, M. Serra-Blasco, G. Navarra-Ventura, E. Aguilar, X. Goldberg, I. Figueroa, L. Ros, D.J. Palao, N. Cardoner (Spain)*

Mood and bipolar disorder; Neuropsychology - Method

## P.067

**Childhood maltreatment, cortisol awakening response, cognitive performance and major depressive disorder: association with disability perception**

*N. Salvat-Pujol\**, J. Labad, M. Urretavizcaya, A. De Arriba-Arnau, A. Ferrer, J.M. Crespo, C. Soriano-Mas, J.M. Menchón, V. Soria (Spain)  
Mood and bipolar disorder; Neuropsychology - Method

## P.068

**Low dose of cholecalciferol induces antidepressant-like effect in the middle aged ovariectomized female rats treated with 17 $\beta$ -estradiol**

*J. Fedotova\**, S. Pivina (Russia)  
Mood and bipolar disorder; Pharmacology - Intervention; Animal models - Method

## P.069

**Gender differences in subjective cognition in adults with major depressive disorder: are they related to depression severity and objective cognition?**

*G. Navarra Ventura\**, M. Serra-Blasco, M. Vicent-Gil, E. Aguilar, X. Goldberg, S. Fernandez-Gonzalo, R. Coronas, J.A. Monreal, D. Palao, N. Cardoner (Spain)  
Mood and bipolar disorder; Neuropsychology - Method

## P.070

**Efficacy and safety/tolerability of atypical antipsychotics in the treatment of bipolar depression: a systematic review and network meta-analysis**

*K. Hagi\**, T. Nosaka, A. Pikalov, A. Loebel, C. Correll (Japan)  
Mood and bipolar disorder; Pharmacology - Intervention

## P.071

**Clozapine as a mood stabilizer in the treatment of rapid cycling bipolar affective disorder**

*C. Akkaya\**, M.O. Kılınçel (Turkey)  
Mood and bipolar disorder; Pharmacology - Intervention

## P.072

**Chronic co-treatment of NS398 (COX-2 inhibitor) with MTEP changes strategy of mice in Barnes Maze, through membrane resistance variation**

*K. Stachowicz\**, B. Bobula, M. Kusek, K. Tokarski, M. Sowa-Kućma, P. Misztak, P. Pańczyszyn-Trzewik, A. Piłc (Poland)  
Mood and bipolar disorder; Stress related disorder

## P.073

**Clinical characteristics associated with benzodiazepines' use in mood, anxiety and psychotic spectrum disorders**

*V. De Carlo\**, B. Grancini, M. Vismara, C. Arici, G. Cirnigliaro, A.C. Altamura, B. Dell'Osso (Italy)  
Mood and bipolar disorder; Pharmacology - Intervention; Psychotic disorder

## P.074

**Indirect evidence of endophenotypic nature of depressive rumination: results of MTHFD1L and HTR2A genes**

*N. Eszlari\**, X. Gonda, P. Petschner, D. Baksa, J.F.W. Deakin, G. Bagdy, G. Juhasz (Hungary)  
Mood and bipolar disorder; Genetic & molecular approaches - Method

## P.075

**Use of parenteral trazodone in bipolar disorder**

*C. Amendola\**, C. Crapanzano, M. Ballerio, S. Bolognesi, A. Goracci, A. Fagiolini (Italy)  
Mood and bipolar disorder; Pharmacology - Method

## P.076

**Esketamine nasal spray combined with an oral antidepressant for relapse prevention in treatment-resistant depression: results of a double-blind, randomized withdrawal, multicenter study (sustain-1)**

*E.J. Daly, M. Trivedi, A. Janik\**, H. Li, Y. Zhang, X. Li, R. Lane, A.R. Duca, D. Hough, M.E. Thase, J. Zajecka, A. Winokur, I. Divacka, A. Fagiolini, W.J. Cubala, I. Bitter, P. Blier, R.C. Shelton, P. Molero, H. Manji, W.C. Drevets, J.B. Singh (USA)  
Mood and bipolar disorder; Pharmacology - Intervention;

## P.077

**Therapeutic drug level measurement in breast milk**

*S. Kittel-Schneider\**, K. Preis, A. Menke, S. Unterecker, J. Deckert, A. Reif (Germany)  
Mood and bipolar disorder; Anxiety - Disorder; Pharmacology - Method

## P.078

**Mania induced by antidepressant withdrawal – case report and review**

*R. Barranha\**, J. Felgueiras, H.C. Pinto (Portugal)  
Mood and bipolar disorder; Pharmacology - Intervention

P.079

**Cannabis use in first hospitalisation for manic episode: relations to sociodemographic and clinical characteristics***E. Nieto\*, C. Isern, S. Biel, M. Khatib (Spain)*

Mood and bipolar disorder; Addiction - Disorder

P.080

**Association study of methylenetetrahydrofolate reductase genetic polymorphism C677T with extrapyramidal side effects of antipsychotic treatment***T. Zhilyaeva\*, A. Marina, A. Sergeeva, A. Blagonravova, G. Mazo (Russia)*

Psychotic disorder; Genetic &amp; molecular approaches - Method; Lifestyle and nutrition - Intervention

P.081

**Cardiovascular abnormalities in patients with psychosis treated with long-acting injectable antipsychotics: a comparative study***R. Bálint\*, L. Dehelean, M. Andor, M. Manea, A.M. Romoşan, I. Papavă, R.Ş. Romoşan, M. Tomescu (Romania)*

Psychotic disorder; Pharmacology - Intervention; Prevention / course alteration

P.082

**First episode of schizophrenia: potential biomarkers of pharmacotherapy efficacy***M. Uzbekov\*, V. Brilliantova, S. Shikhov, N. Smolina, T. Syrejšchikova, G. Dobretsov, N. Maximova (Russia)*

Psychotic disorder; Biochemistry - Method; Pharmacology - Intervention

P.083

**Theory of mind impairment in early onset schizophrenia correlates with deficits in intrinsic functional connectivity***D. Ilzarbe Simorte\*, E. De la Serna, I. Baeza, M. Rosa, O. Puig, A. Calvo, J. Castro-Fornieles, G. Sugranyes (Spain)*

Psychotic disorder; Neuroimaging - Method; Neuropsychology - Method

P.084

**Clinical results of the use of the highest approved dose of monthly paliperidone palmitate: PICTURE sub-analysis study***M. Vega\*, S. Arqués, R. Vázquez-Noguerol, B. Nebot Tarazona, B. Herrera, M. García Dorado (Spain)*

Psychotic disorder; Pharmacology - Intervention

P.085

**Cortical dopamine is essential for the hallucinogenic effect of 3,4-methylenedioxypyrovalerone (MDPV) demonstrated by enhanced EEG activity in rats***I.M. Shokry\*, J.J. Callanan, R. Tao (St. Kitts and Nevis, Federation of)*

Psychotic disorder; Addiction - Disorder

P.086

**Antipsychotics in adolescents at ultra-high risk of psychosis: findings from the “Reggio Emilia At-Risk Mental States” project***G. Galli\*, L. Pelizza, M. Poletti, S. Azzali, F. Paterlini, S. Garlassi, I. Scazza, L.R. Chiri, F. Fontana, V. Barbanti Silva, R. Favazzo, M. Fabiani, L. Pensierini, L. Cioncolini, E. Semrov, A. Raballo (Italy)*

Psychotic disorder; Pharmacology - Intervention

P.087

**Effects of childhood maltreatment on cognition and emotional processing in schizophrenia***S. Won\*, S.W. Lee, H.D. Rim, J. Woo (South-Korea)*

Psychotic disorder; Neuropsychology - Method

P.088

**Improvement of negative symptoms in schizophrenia with paliperidone palmitate: 1-month versus 3-month long-acting injectables***M. Mathews, S. Gopal, A. Singh, J. Gogate, E. Kim, K. Pungor\* (Germany)*

Psychotic disorder; Pharmacology - Intervention

P.089

**The role of side effects, treatment related automatic thoughts and treatment adherence on subjective well-being under antipsychotic treatment***S. Batmaz\*, Ö.A. Yüncü, N. Sevil, B. Erkek Manisalı (Turkey)*

Psychotic disorder; Pharmacology - Intervention; Mood and bipolar disorder

P.090

**Factors that be associated with social function in recovered schizophrenia patients***R. Igata\*, H. Hikaru, H. Takashi, K. Asuka, A. Kiyokazu, K. Yuki, T. Hirota, B. Hiroki, Y. Reiji (Japan)*

Psychotic disorder; Pharmacology - Method

**P.091****Microglial immunophenotype in post-mortem schizophrenia brains**

*T. Tofani\**, *G. Buckland*, *L.J. De Picker*, *J.A.R. Nicoll*,  
*D. Boche (Italy)*

Psychotic disorder; Neuro-inflammatory disorder;  
Post-mortem / pathology - Method

**P.092****Neuropsychological characteristics of children and adolescent offspring of patients diagnosed with schizophrenia or bipolar disorder.**

*E. De la Serna\**, *G. Sugranyes*, *D. Moreno*, *S. Romero*,  
*C. Moreno*, *E. Rodriguez-Toscano*, *I. Baeza-Peretegaz*,  
*J. Castro-Fonieles (Spain)*

Psychotic disorder; Neuropsychology - Method

**P.093****Age at first episode modulates progressive cortical thinning in individuals with psychosis**

*L. Pina-Camacho\**, *K. Martínez*, *J. Santonja*,  
*C.M. Diaz-Caneja*, *C. Arango*, *M. Bernardo*, *J. Janssen*,  
*M. Parellada (Spain)*

Psychotic disorder; Neuroimaging - Method

**P.094****GPR52 agonists represent a novel approach to treat unmet medical need in schizophrenia**

*A.J. Grottick*, *B. Grayson*, *G. Podda*, *N. Idris*, *J.C. Neill*,  
*S. Hobson\* (Germany)*

Psychotic disorder; Pharmacology - Intervention;  
Prevention / course alteration

**P.095****Mobile therapeutic attention for treatment-resistant schizophrenia: a prospective multicenter feasibility study in patients, caregivers and clinicians**

*A. Alonso Solís\**, *E. Grasa*, *K. Rubinstein*, *A. Caspi*,  
*K. Farkas*, *Z. Unoka*, *J. Usall*, *S. Marco*, *J. Seppälä*,  
*E. Jääskeläinen*, *C. Almazán*, *J. Caro Mendivelso*,  
*A. Triantafyllou*, *P. Kokkinakis*, *S. Van Der Graaf*,  
*C. Jewell*, *J. Berdún*, *E. Reixac*, *I. Corripio (Spain)*

Psychotic disorder; E-health - Intervention

**P.096****Which subjectively perceived side-effects occur the most in high-dose clozapine use?**

*I. Ristic\**, *D. Ignjatovic-Ristic*, *D. Cohen*, *J. Jovic (Serbia)*

Psychotic disorder; Pharmacology - Method

**P.097****Hippocampal structural alterations and neurocognitive performance in the bipolar-schizophrenic spectrum**

*T. Toffanin\**, *A. Miola*, *B. Salvati*, *C. Idotta*, *G. Pigato*,  
*H. Follador*, *N. Martino*, *A. Baratto*, *N. Scupola*,  
*G.I. Perini (Italy)*

Psychotic disorder; Neuroimaging - Method

**P.098****Cognitive function, social functioning and quality of life in first-episode psychosis: a 1-year longitudinal study**

*M. Okruashvili\**, *M. Roinishvili*, *T. Gamkrelidze*,  
*M.H. Herzog*, *E. Ckonja (Georgia)*

Psychotic disorder; Neuropsychology - Method

**P.099****Association between self-reported sleep quality and verbal learning in early stage clinically-stable schizophrenia outpatients**

*F. Dal Santo\**, *M.P. García-Portilla*, *L. González-Blanco*,  
*J. Rodríguez-Revuelta*, *L. García-Álvarez*, *L. De la Fuente-Tomás*,  
*Á. Velasco*, *I. Abad*, *C. Iglesias*, *P. Sáiz*,  
*J. Bobes (Spain)*

Psychotic disorder; Sleep disorder; Neuropsychology - Method

**P.100****Effects of perinatal cannabis exposure on transcriptional regulation of dopamine receptor d2 and cannabinoid receptor 1 in rats at adulthood**

*M. Di Bartolomeo\**, *T. Stark*, *M. Pucci*, *F. Drago*,  
*M. Kuchař*, *M. Mauro*, *M. Vincenzo*, *D. Claudio (Italy)*

Psychotic disorder; Addiction - Disorder; Lifestyle and nutrition - Intervention

**P.101****White matter structural connectivity abnormalities in subjects with deficit schizophrenia: a diffusion tensor imaging study**

*G.M. Giordano\**, *M. Quarantelli*, *A. Mucci*, *A. Prinster*,  
*A. Soricelli*, *A. Amodio*, *A. Vignapiano*, *A. Nicita*,  
*P. Bucci*, *S. Galderisi (Italy)*

Psychotic disorder; Neuroimaging - Method

**P.102****Relationship between antipsychotic compliance and malondialdehyde in acute and stabilized paranoid schizophrenia**

*E. Díaz- Mesa\**, A. Morera-Fumero, M. Alcantara-Gutierrez, L. Navarro-Morejon, R. Calles-Marban, P. Abreu-Gonzalez, M.D.R. Cejas-Mendez, L. Fernandez-Lopez, M. Henry-Benitez (Spain)  
Psychotic disorder; Neuro-inflammatory disorder

**P.103****The role of intrathecal rheumatological antibodies in patients with schizophreniform disorders: possible biomarkers for brain involvement?**

*D. Endres\**, N. Venhoff, D. Tang, U. Salzer, T. Hottenrott, O. Stich, R. Dersch, L. Tebartz van Elst (Germany)  
Psychotic disorder; Neuro-inflammatory disorder

**P.104****Is attenuated abstract thinking a marker of high risk for psychosis? A study of cognition in patients with psychosis and their siblings**

*V. Voracková\**, P. Knytl, P. Šustová, A. Dorazilová, J. Juraj, A. Cvrčková, P. Mohr, M. Rodriguez (Czech Republic)  
Psychotic disorder; Neuropsychology - Method; Prevention / course alteration

**P.105****Analysis of antipsychotic therapy in outpatients diagnosed with the first episode of schizophrenia**

*E. Chumakov\**, Y. Ashenbrenner, N. Petrova (Russia)  
Psychotic disorder; Pharmacology - Intervention

**P.106****Prevalence of psychotic-like experiences in healthy adolescents: preliminary data and educational program for high schools**

*A. Dorazilova\**, A. Šebela, A. Cvrčková, V. Voráčková, J. Jonáš, P. Švancer, P. Knytl, P. Mohr, M. Rodriguez (Czech Republic)  
Psychotic disorder; Prevention / course alteration

**P.107****Expression of CB1-5HT2A receptor heteromers in olfactory neuroepithelium-derived cells in schizophrenia: clinical and neuropsychological correlates**

*D. Guinart\**, E. Moreno, A. Cuenca-Royo, L. Galindo, C. Fernandez, E.J. Perez, E. Menoyo, J. Garcia, P. Salgado, C.U. Correll, R. De la Torre, V. Perez, P. Robledo (Spain)  
Psychotic disorder; Genetic & molecular approaches - Method; Neuropsychology - Method

**P.108****Apolipoprotein serum levels related to metabolic side effects in patients with schizophrenia**

*S.A. Ivanova\**, A.S. Boiko, I.A. Mednova, E.G. Kornetova, A.J.M. Loonen (Russia)  
Psychotic disorder; Pharmacology - Intervention; Biochemistry - Method

**P.109****Predictors of weight change after long-term treatment with brexpiprazole in schizophrenia**

*M.K. Josiassen\**, A.H. Tvistholm, C. Weiss, S.R. Meehan, M. Hobart, R.A. Baker (Denmark)  
Psychotic disorder; Pharmacology - Intervention

**P.110****Tardive dyskinesia in schizophrenia: gene polymorphisms of muscarinic and adrenergic receptors**

*A.S. Boiko\**, I. Pozhidaev, A. Semke, B. Wilffert, S.A. Ivanova, A.J.M. Loonen (Russia)  
Psychotic disorder; Movement disorder; Genetic & molecular approaches - Method

**P.111****Visual hallucinations and lifetime use of HPPD-related drugs: results from a large online survey**

*M. Linszen\**, H. Kleijer, I. Sommer (The Netherlands)  
Psychotic disorder; Epidemiology and big data - Method

**P.112****Avolition and microstructural brain abnormalities in Schizophrenia: reduced fractional anisotropy in pathways connecting amygdala and insular cortex**

*A. Amodio\**, M. Quarantelli, A. Mucci, A. Prinster, A. Soricelli, A. Vignapiano, G.M. Giordano, A. Nicita, P. Bucci, S. Galderisi (Italy)  
Psychotic disorder; Neuroimaging - Method



**P.113****Four year follow-up of offspring of schizophrenia and bipolar patients: measures of brain morphology and their relationship with emerging psychosis.**

*G. Sugranyes\*, E. De la Serna, J.C. Pariente, D. Ilzarbe, S. Romero, V. Sanchez-Gistau, D.M. Moreno, I. Baeza, J. Castro-Fornieles (Spain)*

Psychotic disorder; Neuroimaging - Method; Mood and bipolar disorder

**P.114****Neurobiology of sensorimotor gating deficits in the Roman rat strains: studies of c-Fos expression and COMT activity**

*C. Tapias-Espinosa\*, C. Río-Álamos, A. Sánchez-González, T. Cañete, I. Oliveras, D. Sampedro-Viana, M.D.M. Castillo-Ruiz, E.M. Tunbridge, A. Tobeña, A. Fernández-Teruel (Spain)*

Psychotic disorder; Animal models - Method; Genetic & molecular approaches - Method

**P.115****Predictors of response in treatment-resistant schizophrenia – a meta-analysis**

*A. Seppälä\*, J. Pylvänäinen, J. Miettunen, M. Isohanni, I. Corripio, H. Koponen, J. Seppälä, E. Jääskeläinen (Finland)*

Psychotic disorder; Prevention / course alteration

**P.116****Clozapine augmented with amisulpride in treatment-resistant schizophrenia**

*G. Sulejmanpasic\*, S. Bise (Bosnia and Herzegovina)*

Psychotic disorder; Pharmacology - Intervention

**P.117****Gender differences in clinical and sociodemographic characteristics in first episode psychosis patients**

*L. Berze\*, E. Rancans, K. Slikova, K. Pavlovs, S. Kikuste (Latvia)*

Psychotic disorder; Prevention / course alteration

**P.118****Facial emotion recognition in schizophrenia spectrum disorders – how polypharmacy impacts processing speed**

*S. Jerotic\*, S. Andric Petrovic, I. Ristic, Z. Pavlovic, M. Mihaljevic, N.P. Maric (Serbia)*

Psychotic disorder; Neuropsychology - Method; Pharmacology - Intervention

**P.119****Genetic variants implicated in the pathogenesis of delusional disorder: a systematic review of evidence-to-date**

*A. Gonzalez Rodriguez\*, F. Estrada, J.A. Monreal, D. Palao, J. Labad (Spain)*

Psychotic disorder; Genetic & molecular approaches - Method

**P.120****BDNF levels and cognitive impairment in schizophrenia: a meta-analysis**

*E. Bora\* (Turkey)*

Psychotic disorder; Biochemistry - Method

**P.121****Psychological sex, sexual response, attachment styles and sexual quality of life in patients diagnosed with schizophrenia - preliminary findings**

*J. Stusiński, M. Lew-Starowicz\* (Poland)*

Psychotic disorder; Sexual disorder

**P.122****Implicit and explicit bodily emotions and social functioning in schizophrenia**

*M. Hajdúk\*, H. Klein, C. Springfield, E. Bass, A. Pinkham (Slovak Republic)*

Psychotic disorder; Neuropsychology - Method

**P.123****The effects of ligands of the alpha7 nicotinic acetylcholine receptors on memory and social behaviour in the neurodevelopmental model of schizophrenia**

*A. Potasiewicz\*, M. Holuj, P. Popik, N. Agnieszka (Poland)*

Psychotic disorder; Pharmacology - Intervention

## P.124

**Imbalance in the deployment of neural resources during visual working memory encoding in schizophrenia as a possible intermediate phenotype**

M. Stäblein\*, V. Oertel-Knöchel, H. Storchak, D. Ghinea, D. Kraft, C. Knöchel, A. Reif (Germany)

Psychotic disorder; Neuroimaging - Method; Neuropsychology - Method

## P.125

**Antidepressant-like effect of (R,S)- sulforaphane (an activator of Nrf2) in the olfactory bulbectomy model in mice**

P. Pańczyszyn-Trzewik\*, M. Sowa-Kućma, K. Stachowicz, P. Misztak, G. Nowak (Poland)

Psychotic disorder; Animal models - Method; Neuro-inflammatory disorder

## P.126

**Patterns of mentalisation and empathy as possible predictors of violence in schizophrenia**

Z. Kristof, S. Kresznerits, M. Olah, A. Gyollai, K. Lukacs-Miszler, T. Halmaj, K.N. Fountoulakis, T. Tenyi, P. Dome, X. Gonda\* (Hungary)

Psychotic disorder; Prevention / course alteration

## P.127

**Relation between early-onset psychosis and formal thought disorder in schizophrenia**

S. Altinok, K. Alptekin\*, H. Ulas, B. Yalincetin, B. Degirmencioglu, B.B. Akdede (Turkey)

Psychotic disorder; Prevention / course alteration; Epidemiology and big data - Method

## P.128

**Premorbid social functioning and depressive symptoms predict internalized stigma in stable schizophrenia**

A. Hofer\*, B. Frajo-Apor, G. Kemmler, S. Pardeller, F. Wartelsteiner, W.W. Fleischhacker (Austria)

Psychotic disorder; Prevention / course alteration

## P.129

**Pituitary volume alterations and clinical correlates in unmedicated patients with schizophrenia**

D. Raveendranathan\*, J. Narayanaswamy, V. Shivakumar, G. Venkatasubramanian (India)

Psychotic disorder; Neuroimaging - Method

## P.130

**Dopamine supersensitivity psychosis: pharmacological mechanisms**

B. Almeida\* (Portugal)

Psychotic disorder; Pharmacology - Intervention

## P.131

**Machine learning analysis of differential effects of neuroleptic treatment and clinical improvement in first-episode schizophrenia**

A. Korda\*, C. Schmidt-Kraepelin, R. Bottlender, M. Jäger, C. Gaser, M. Reiser, N. Koutsouleris, E.M. Meisenzahl (Germany)

Psychotic disorder; Neuroimaging - Method; Healthy brain

## P.132

**Clinical and genetic determinants of serum brain-derived neurotrophic factor (BDNF) levels in psychotic patients: a longitudinal prospective study**

M. Manchia\*, L. Deriu, M. Tusconi, D. Primavera, E. Caboni, N. Iaselli, D. Sundas, R. Collu, M. Scherma, D. Congiu, A. Squassina, W. Fratta, P. Fadda, B. Carpiniello (Italy)

Psychotic disorder; Genetic & molecular approaches - Method

## P.133

**Fluctuations in hallucinatory experiences within a day in relation to dopamine D2 receptor blockade with antipsychotics in patients with schizophrenia**

T. Koizumi\*, R.R. Bies, T. Suzuki, B.G. Pollock, M. Mimura, H. Uchida (Japan)

Psychotic disorder; Pharmacology - Method

## P.134

**Testosterone, luteinizing hormone levels and methylation status in men with hypersexual disorders**

A. Chatzittofis\*, A. Boström, K. Öberg, J. Flanagan, H. Schiöth, S. Arver, J. Jokinen (Sweden)

Sexual disorder; Genetic & molecular approaches - Method

## P.135

**Sexual dysfunctions in psychiatric patients: the roles of mental disorders and pharmacotherapy**

L. Signorini\*, L. Del Matto, A. Goracci, A. Fagiolini (Italy)

Sexual disorder; Pharmacology - Intervention

## P.136

**Testosterone levels and sexual function in drug-naïve first – episode nonaffective psychosis patients compared with healthy controls**

*N. Del Cacho Ortega\*, D. Cuadras, R. Vila-Badía, A. Butjosa, M. Dolz, M. Kaplan, M.J. Rodriguez, G. Profep, J. Usall (Spain)*

Sexual disorder; Psychotic disorder

## P.137

**Hoarding symptoms in adults with attention deficit/hyperactivity disorder: a role for inattention**

*S. Morein\*, C. White, S. Chamberlain (United Kingdom)*

ADHD - Disorder; Impulsive and compulsive disorder

## P.138

**Rapid cycling in bipolar disorder: clinical characterisation and association with attention deficit hyperactivity disorder**

*A. Aedo\*, A. Murru, R. Sánchez, I. Grande, E. Vieta, J. Undurraga (Spain)*

ADHD - Disorder; Mood and bipolar disorder

## P.139

**Development of the child personality and mental health screening questionnaire, second version in Korea**

*J.W. Hwang\*, D.H. Ahn, Y.J. Lee (South-Korea)*

ADHD - Disorder; Anxiety - Disorder; Autism / ASD - Disorder

## P.140

**Effects of dopamine level on object recognition and formation of cognitive maps in rats**

*N. Kurzina, A. Volnova\*, I. Aristova, R. Gainetdinov (Russia)*

ADHD - Disorder; Animal models - Method

## P.141

**Norepinephrine transporter methylation profile and association with symptoms of ADHD and in vivo NET expression as measured by PET**

*H. Sigurdardottir\*, G.S. Kranz, C. Rami-Mark, G.M. James, T. Vanicek, G. Gryglewski, N. Berroteran-Infante, A. Kautzky, M. Hienert, T. Traub-Weidinger, M. Mitterhauser, W. Wadsak, A. Hartmann, M. Hacker, D. Rujescu, S. Kasper, R. Lanzenberger (Austria)*

ADHD - Disorder; Genetic & molecular approaches - Method; Neuroimaging - Method

## P.142

**Domain specific alterations in cognitive conflicts and adjustments after sleep deprivation related to subclinical ADHD-symptoms**

*O. Floros\*, J. Axelsson, R. Almeida, L. Tigerström, M. Lekander, T. Sundelin, P. Petrovic (Sweden)*

ADHD - Disorder; Sleep disorder

## P.143

**Pharmacological treatment of ADHD: an evidence map using minerva database, a new tool for clinical psychopharmacology research**

*X. Castells\*, R. Cunill (Spain)*

ADHD - Disorder; Pharmacology - Intervention; Pharmacology - Method

## P.144

**Aripiprazole in acute treatment of children and adolescents with autism spectrum disorders: a systematic review and meta-analysis**

*N. Maneeton\*, B. Maneeton, S. Puthisri, S. Suttajit, S. Likhitsathian, M. Srisurapanont (Thailand)*

Autism / ASD - Disorder; Pharmacology - Intervention

## P.145

**Cognitive-behavioral therapy in high-functioning autism spectrum disorder adults: a longitudinal observational study**

*S. Marini\*, T. D'Ambrogio, B. Paola, G. Sorge (Italy)*

Autism / ASD - Disorder; Psychotherapy - Intervention

## P.146

**Autism and psychosis-proneness trait expressions interactively modulate superior temporal glutamatergic and GABAergic neurotransmitter concentrations**

*T. Ford\*, A. Abu-Akel, L. Downey, D. Crewther (Australia)*

Autism / ASD - Disorder; Psychotic disorder; Neuroimaging - Method

## P.147

**Psychiatric comorbidities in high functioning autism: polygenic overlap with major depression and attention deficit hyperactivity disorder.**

*J. González-Peñas\*, A. García-Alcon, M.J. Penzol, P. Hernández, J. Costas, M. Parellada (Spain)*

Autism / ASD - Disorder; Genetic & molecular approaches - Method; Biostatistics & computational method

P.148

**Augmented activity-dependent responses of neural progenitors in fragile X syndrome***M. Castren\*, S. Achuta (Finland)*

Autism / ASD - Disorder; Intellectual disability disorder

P.149

**Grik4 over-expression underlies altered synaptic gain and enhances basal activation of amygdala circuits.***V. Arora\*, M. Isabel Aller, J. Lerma (Spain)*

Autism / ASD - Disorder; Anxiety - Disorder; Animal models - Method

P.150

**Cerebral amyloid deposition and subjective memory complaints***J.W. Kim\* (South-Korea)*

Dementia &amp; neuro degeneration - Disorder; Neuroimaging - Method

P.151

**The effects of repetitive low-dose ketamine administration on emotional memory processes in mice***M. Erdiñç, E. Uyar\*, İ. Kelle, H. Akkoç, L. Erdiñç, Y. Nergiz, U. Şeker (Turkey)*

Dementia &amp; neuro degeneration - Disorder; Mood and bipolar disorder

P.151

**The effects of repetitive low-dose ketamine administration on emotional memory processes in mice***M. Erdiñç, E. Uyar\*, İ. Kelle, H. Akkoç, L. Erdiñç, Y. Nergiz, U. Şeker (Turkey)*

Dementia &amp; neuro degeneration - Disorder; Mood and bipolar disorder

P.152

**Pro-cognitive effects of a AHN-208, 5-HT6 receptor antagonist, in the novel object recognition test in rats***M. Krawczyk\*, A. Hogendorf, A. Hogendorf, M. Matłoka, K. Dubiel, R. Moszczyński-Pętkowski, J. Pieczykolan, A.J. Bojarski, P. Zajdel, P. Popik (Poland)*

Dementia &amp; neuro degeneration - Disorder; Animal models - Method

P.153

**Behavioural effects of overexpression of nerve growth factor in the hippocampus of rats with degeneration of septal cholinergic neurons***M. Zaichenko\*, Y. Dobryakova, A. Bolshakov, M. Stepanichev, V. Markevich (Russia)*

Dementia &amp; neuro degeneration - Disorder; Neuromodulation - Intervention

P.154

**Psychotropic drugs and behavioural and psychological symptoms in nursing homes: are the best approaches being used?***A.R. Ferreira\*, M.R. Simões, J. Guedes, L. Fernandes (Portugal)*

Dementia &amp; neuro degeneration - Disorder; Pharmacology - Intervention

P.155

**Cholesterol regulates the expression and activity of amyloid beta-degrading enzymes***C. De Dios\*, I. Bartolessis, V. Roca-Agujetas, A. Colell (Spain)*

Dementia &amp; neuro degeneration - Disorder; Biochemistry - Method; Animal models - Method

P.156

**Ability of swept-source optical coherence tomography to detect retinal and choroidal changes in patients with Parkinson disease***E. Orduna Hospital\*, M.J. Rodrigo, E. Vilades, G. Larrea, M. Satue, E. Garcia-Martin (Spain)*

Dementia &amp; neuro degeneration - Disorder; Neuroimaging - Method

P.157

**Hippocampal neurogenesis, nigral dopaminergic neurons and behavior in aging C57Bl/6 mice: the effects of alpha-synuclein amyloidogenic fibrils***O. Solovieva\*, A.M. Ratmirov, M.A. Gruden, V.V. Sherstnev (Russia)*

Dementia &amp; neuro degeneration - Disorder; Animal models - Method

**P.158****Psychopharmacological treatment in elderly patients referred to a consultation-liaison psychiatry service**

*E. Monteagudo\**, *R. Sánchez-González*, *L. Pintor-Pérez*,  
*P. Calvo-litomi*, *A. Rodríguez-Urrutía*,  
*S. Herranz-Villanueva*, *B. Barra-Cañas* (Spain)  
Dementia & neuro degeneration - Disorder;  
Pharmacology - Intervention; Prevention / course  
alteration

**P.159****Linear measurement of the nucleus basalis of Meynert in Alzheimer's disease and mild cognitive impairment**

*K. Jethwa\**, *P. Dhillon*, *D. Auer* (United Kingdom)  
Dementia & neuro degeneration - Disorder;  
Neuroimaging - Method

**P.160****Dimethyl fumarate affects spleen lymphocyte production of interleukin 10 in streptozotocin-induced model of Alzheimer's disease in rats**

*G. Świątek\**, *J. Dunacka*, *M. Wyroślak*, *M. Gratek*, *J. Marchewka*,  
*I. Majkutewicz*, *B. Grambecka*, *W. Glac*, *D. Wrona* (Poland)  
Dementia & neuro degeneration - Disorder; Immunology  
- Method; Animal models - Method

**P.161****Cigarette smoking and vascular dementia in rats: relationships with oxidative stress**

*T. Utkan\**, *Y. Yazir*, *G. Gacar*, *S.S. Gocmez*, *T. Demirtaş Şahin*,  
*O. Baris* (Turkey)  
Dementia & neuro degeneration - Disorder;  
Neuropsychology - Method

**P.162****Evaluation of trazodone and quetiapine in patients with Alzheimer's type dementia and sleep disturbance**

*B. Petrescu\** (Romania)  
Dementia & neuro degeneration - Disorder; Sleep  
disorder; Pharmacology - Intervention

**P.163****The behavioral and psychological symptoms of dementia in Down syndrome (BPSD-DS) scale: comprehensive assessment of psychopathology in Down syndrome**

*A.D. Dekker\**, *P.P. De Deyn* (The Netherlands)  
Dementia & neuro degeneration - Disorder; Intellectual  
disability disorder

**P.164****An investigation of the locus coeruleus in Alzheimer's disease using neuromelanin-sensitive magnetic resonance imaging**

*R. Hou\**, *R. Ollington*, *E. Lewis*, *C. Everitt*, *C. Holmes*,  
*A. Darekar* (United Kingdom)  
Dementia & neuro degeneration - Disorder;  
Neuroimaging - Method

**P.165****Implication of nigral dopaminergic lesion and repeated L-DOPA exposure in non-motor symptoms of Parkinson's disease**

*S. Loiodice\**, *H. Wing Young*, *B. Rion*, *B. Méot*,  
*P. Montagne*, *A.S. Denibaud*, *R. Viel*, *C. Drieu La Rochelle* (France)  
Dementia & neuro degeneration - Disorder; Animal  
models - Method

**P.166****Fronto-temporal dementia and mania: the problem of the differential diagnosis**

*M. Jesus\**, *C. Cagigal*, *T. Silva*, *V. Martins* (Portugal)  
Dementia & neuro degeneration - Disorder; Mood and  
bipolar disorder

**P.167****The effect of atypical antipsychotic drugs on the neurotrophic factors gene expression in the MPTP model of Parkinson's disease**

*A. Tsybko\**, *T. Ilchibaeva*, *N. Khotskin*, *V. Naumenko*,  
*N. Popova* (Russia)  
Movement disorder; Pharmacology - Method

P.168

**Brain-derived neurotrophic factor modulates neuronal network structure and dynamics in striatal cultures: Implications for Huntington's disease**

*E. Rodríguez-Urgellés\**, *S. Fernández-García*,  
*J.G. Orlandi*, *G. García-Díaz Barriga*, *M.J. Rodríguez*,  
*J. Soriano*, *J. Alberch*, *M. Masana* (Spain)  
Movement disorder; System biology - Method; Dementia  
& neurodegeneration - Disorder

P.169

**Microstructural changes in white and grey matter related to apathy, depression and anxiety in de novo Parkinson's disease patients**

*S. Prange\**, *E. Metereau*, *A. Maillat*, *E. Lhommée*,  
*H. Klinger*, *P. Pellissier*, *D. Ibarrola*, *R.A. Heckemann*,  
*E. Broussolle*, *A. Castrioto*, *L. Tremblay*, *V. Sgambato*,  
*P. Krack*, *S. Thobois* (France)  
Movement disorder; Neuroimaging - Method; Mood and  
bipolar disorder

P.170

**Handwriting patterns as measures of motor symptoms in patients with severe mental disorders**

*J.I. Aznarte\**, *M.F. Soriano*, *Y. Crespo*, *S. Iglesias-Parro*,  
*A.J. Ibáñez-Molina* (Spain)  
Movement disorder; Psychotic disorder

P.171

**Impulsivity in Huntington's disease: impaired decision-making and motor disinhibition**

*D. Mclauchlan\**, *D. Linden*, *A. Rosser* (United Kingdom)  
Movement disorder; Impulsive and compulsive disorder

P.172

**Chronic inflammation in hepatitis C patients is associated with increased perceived stress and abnormal connectivity between insula and basal ganglia**

*G. Oriolo\**, *R. Navines*, *L. Blanco*, *D. Martín-Hernández*,  
*Z. Mariño*, *M. Caverio*, *R. Sola*, *L. Capuron*, *J.C. Leza*,  
*J. Pujol*, *X. Forn*, *R. Martín-Santos* (Spain)  
Neuro-inflammatory disorder; Mood and bipolar  
disorder; Neuroimaging - Method

P.173

**Prevalence and association between a high-sensitivity CRP and psychiatric diagnostic groups in gender separated sample**

*Y. Sakai\**, *S. Reitan* (Japan)  
Neuro-inflammatory disorder; Epidemiology and big data  
- Method

P.174

**Longitudinal C-reactive protein (CRP) population sub-groups as predictors of depression: findings from the ALSPAC birth cohort**

*E.F. Osimo\**, *J. Stochl*, *G.M. Khandaker* (United Kingdom)  
Neuro-inflammatory disorder; Mood and bipolar disorder

P.175

**Alzheimer disease drug huperzine A has an impact on immunity in laboratory mice**

*M. Pohanka\** (Czech Republic)  
Neuro-inflammatory disorder; Immunology - Method;  
Dementia & neurodegeneration - Disorder

P.176

**The impact of coping strategies on depression, anxiety, quality of life and disease activity in Behçet's disease**

*I.M. Atay\**, *I. Erturan* (Turkey)  
Neuro-inflammatory disorder; Psychotherapy -  
Intervention

P.177

**Identification of gut microbiota signature in Alzheimer's disease: possible role in influencing peripheral inflammation**

*N. Lopizzo\**, *S. Provasi*, *M. Marizzoni*, *L. Borruso*,  
*P. Andryszak*, *G.B. Frisoni*, *A. Cattaneo* (Italy)  
Neuro-inflammatory disorder; Dementia & neuro  
degeneration - Disorder

P.178

**Do cognitive deficits play a role in treatment-resistant depression? Characterizing resistance from cognitive perspective**

*C. López-Solà\**, *M. Serra-Blasco*, *M. Vicent-Gil*,  
*G. Navarra-Ventura*, *E. Aguilar*, *M. Guinovart*,  
*J.A. Monreal*, *D.J. Palao*, *N. Cardoner* (Spain)  
Mood and bipolar disorder; Pharmacology - Intervention

## P.179

**The effect of pentadecapeptide BPC 157 on ischemic/reperfusion injuries in rat brain***J. Vukojević\* (Croatia)*

Stroke; Pharmacology - Intervention; Animal models - Method

## P.180

**Relationship of alcohol and/or cannabis use in the last year and the severity of the Internet gaming disorder symptoms***C. Evren\*, E. Dalbudak, M. Topcu, N. Kutlu, B. Evren (Turkey)*

Addiction - Disorder; ADHD - Disorder; Personality disorder

## P.181

**Calcium in the brain: A dose-dependent manner?***R. Schuster\*, P. Bach, A. Koopmann, S. Vollstaedt-Klein, R. Spanagel, F. Kiefer (Germany)*

Addiction - Disorder; Pharmacology - Intervention

## P.182

**Effects of CYP2D6 genetic polymorphisms on the efficacy and safety of fluvoxamine in patients with depressive disorder and alcohol use disorder***M. Zastrozhin\*, E. Grishina, K. Ryzhikova, A. Sorokin, L. Savchenko, E. Bryun, D. Sychev (Russia)*

Addiction - Disorder; Genetic &amp; molecular approaches - Method; Pharmacology - Method

## P.183

**Suicidal intentionality among deaths due to acute reaction after drug consumption: a five-year follow-up study***A. Fernandez-Quintana\*, D. Miguel-Arias, A.M. Bermejo-Barrera, C. Pereiro-Gómez, M.J. Tabernero-Duque (Spain)*

Addiction - Disorder; Post-mortem / pathology - Method; Epidemiology and big data - Method

## P.184

**Possible involvement of chemokine ligands in addictive drugs-induced conditioned place preference in mice***S. Kishioka\*, F. Saika, N. Kiguchi, D. Kobayashi, S. Matsuzaki (Japan)*

Addiction - Disorder; Neuro-inflammatory disorder

## P.185

**Endocannabinoid signaling of homeostatic status modulates connectivity in the brain's reward system***A. Verdejo-Garcia\*, C. Martin-Perez, L. Forcano, A. Pastor, E. Christensen, Z. Andrews, R. De la Torre (Australia)*

Addiction - Disorder; Eating disorder; Neuroimaging - Method

## P.186

**Cytoprotective and antioxidant effects of lithium pyruvate in peripheral blood mononuclear cells of patients with alcoholism***I. Losenkov\*, E.V. Plotnikov, E.V. Epimakhova (Russia)*

Addiction - Disorder; Pharmacology - Intervention

## P.187

**Subjects affected by a substance use disorder with or without a comorbid mental disorder: looking for differential factors***G. Mateu-Codina\*, F. Fonseca-Casals, M. Gratacos-Mayora, R. Martin-Santos, R. Sauras-Quetcuti, A. Farre-Martinez, L. Diaz-Digon, C. Castillo-Buenaventura, M. Torrens-Melich (Spain)*

Addiction - Disorder; Genetic &amp; molecular approaches - Method

## P.188

**Genetic risk score for affective dysregulation associated with cocaine severity, impulsivity, emotion recognition deficits and striatum volumes***A. Verdejo-Garcia\*, N. Albein-Urios, V. Lorenzetti, B. Gutierrez (Australia)*

Addiction - Disorder; Neuropsychology - Method; Genetic &amp; molecular approaches - Method

## P.189

**Pregabalin reduces smoking and drinking in alcohol dependent subjects***E. Krupitsky\*, K. Rybakova, E. Skurat, A. Mikhailov, N. Neznanov (Russia)*

Addiction - Disorder; Pharmacology - Intervention; Prevention / course alteration

## P.190

**Subliminal cue reactivity in amphetamine dependence***J. Guterstam\*, N. Jayaram-Lindström, J. Berrebi, P. Petrovic, M. Ingvar, P. Fransson, J. Franck (Sweden)*

Addiction - Disorder; Neuroimaging - Method

P.191

**The novel psychoactive phenethylamine 4-fluoroamphetamine produces a mild psychedelic state without affecting creative thinking**

*K. Kuypers\**, *E.B. De Sousa Fernandes Perna*, *E.L. Theunissen*, *S.W. Toennes*, *N.L. Mason*, *N.R.P.W. Hutten*, *J.G. Ramaekers* (*The Netherlands*)  
Addiction - Disorder; Pharmacology - Intervention

P.192

**Neuroglial damage markers in alcohol and substance dependence**

*A.D. Yalçın\**, *U. Tural* (*Turkey*)  
Addiction - Disorder; Biochemistry - Method

P.193

**Curcumin attenuates methamphetamine-induced conditioned place preference via an inhibition of CC chemokine ligand 2 expression**

*F. Saika\**, *N. Kiguchi*, *D. Kobayashi*, *S. Matsuzaki*, *S. Kishioka* (*Japan*)  
Addiction - Disorder; Animal models - Method

P.194

**Consumption of MDMA: a survey in the French male homosexual population**

*A. Laurin*, *R. Courcieras*, *M. Marinescu\**, *Y. Bescond* (*France*)  
Addiction - Disorder; Prevention / course alteration; Lifestyle and nutrition - Intervention

P.195

**Experimental study of endogenous dipeptide Cyclo-L-prolylglycine in aspects of opioid addiction and analgesia in rodents**

*M. Konstantinopolsky\**, *T. Gudasheva*, *L. Kolik* (*Russia*)  
Addiction - Disorder; Animal models - Method

P.196

**Differential plasma chemokines profile in dual depression - the role of tumor necrosis factor alpha (TNF-alpha) and stromal cell-factor one (SDF-1)**

*M. Barrera Conde\**, *J.I. Mestre-Pinto*, *N. García Marchena*, *J. Pavón*, *M. Farre*, *F. Rodríguez de Fonseca*, *M. Torrens*, *C. Castillo*, *J.A. Mateus*, *E. Papaseit*, *C. Pérez-Mañá*, *R. Rodríguez Minguela*, *P. Rossi*, *C. Tamarit*, *G. Vallecillo*, *D. Martínez* (*Spain*)  
Addiction - Disorder; Mood and bipolar disorder; Neuro-inflammatory disorder

P.197

**Influence of alcohol and acetaldehyde on human psychomotor functions: findings from the alcohol clamping in healthy young population**

*F. Ueno\**, *H. Uchida*, *S. Hara*, *S. Matsushita*, *S. Higuchi* (*Japan*)  
Addiction - Disorder; Neuropsychology - Method; Healthy brain

P.198

**The neuroanatomy of cannabis use: does gender matter? Findings from the ENIGMA addiction working group**

*M.G. Rossetti\**, *S. Mackey*, *P. Patalay*, *A. Batalla*, *M. Bellani*, *Y.Y. Chye*, *P. Conrod*, *J. Cousijn*, *H. Garavan*, *N. Solowij*, *C. Suo*, *P.M. Thompson*, *M. Yucel*, *P. Brambilla*, *V. Lorenzetti* (*Italy*)  
Addiction - Disorder; Neuroimaging - Method

P.199

**Experimental analysis of development of compulsive behavioural disorders due to intravenous fentanyl self-administration**

*N. Chkhikvishvili\**, *T. Naneishvili*, *M. Dashniani*, *M. Burjanadze* (*Georgia*)  
Addiction - Disorder; Animal models - Method

P.200

**The effect of Ecstasy/MDMA use on psychiatric symptoms in recreational users**

*O. Zwalf*, *T. Ford\**, *A. Hayley*, *C. Stough*, *L. Downey* (*Australia*)  
Addiction - Disorder; Pharmacology - Method; Healthy brain

P.201

**Cocaine-induced persistent alterations of the activity of the amygdala-insula pathway after long abstinence**

*A. Salin\**, *V. Lardeux*, *M. Solinas*, *P. Belujon* (*France*)  
Addiction - Disorder; Neurophysiology / EEG - Method

P.202

**Effects of a novel G protein-biased opioid, PZM21, on nociceptive and addiction-like behavior in mice**

*L. Kudla\**, *U. Skupio*, *L. Wiktorowska*, *R. Bugno*, *A. Bojarski*, *K. Golembiowska*, *R. Przewlocki* (*Poland*)  
Addiction - Disorder; Pharmacology - Method; Animal models - Method



**P.203****Noradrenergic modulation of stopping impulsivity in cocaine use disorder**

*R. Rodrigues\**, *S. Morein-Zamir*, *C. Meng*, *H. Ziauddeen*, *E. Fernandez-Egea*, *R. Regenthal*, *B.J. Sahakian*, *E.T. Bullmore*, *T.W. Robbins*, *K.D. Ersche (United Kingdom)*  
Addiction - Disorder; Impulsive and compulsive disorder; Pharmacology - Intervention

**P.204****Impact of acute and repeated administration of cocaine on expression of proteins involved in the cerebral metabolism of cholesterol**

*J. AlSebaaly\**, *L. Rabbaa Khabbaz*, *E. Dugast*, *M. Solinas*, *N. Thiriet (France)*  
Addiction - Disorder; Animal models - Method

**P.205****Characteristics and prevalence of problematic internet use in public rehab centers**

*F. Mucci\**, *D. Marazziti*, *L. Dell'Osso*, *S. Baroni (Italy)*  
Addiction - Disorder; E-health - Intervention

**P.206****Identification of a novel trace amine-associated receptor 1 agonist with in vivo activity**

*M. Dorofeikova\**, *A. Gerasimov*, *A. Lukin*, *I. Sukhanov*, *M. Krasavin*, *R.R. Gainetdinov (Russia)*  
Addiction - Disorder; Pharmacology - Intervention

**P.207****Altered brain network functioning in cigarette smokers**

*I.H. Park\**, *J.I. Kim*, *K. Seon-Wan (South-Korea)*  
Addiction - Disorder; Neuroimaging - Method

**P.208****Novel electrocardiogram markers for prediction of arrhythmia and sudden cardiac death in synthetic cannabinoid users**

*Y.H. Balcioglu\**, *S.S. Kirliglu*, *F. Oncu*, *N. Karamustafalioglu (Turkey)*  
Addiction - Disorder; Prevention / course alteration

**P.209****Deconstructing appetitive learning in cocaine addiction using hierarchical Bayesian modelling**

*T.V. Lim\**, *R.N. Cardinal*, *P.S. Jones*, *T.W. Robbins*, *K.D. Ersche (United Kingdom)*  
Addiction - Disorder; Biostatistics & computational method; Impulsive and compulsive disorder

**P.210****Brain activation changes to acute citalopram is influenced by trait anxiety**

*A.E. Édes\**, *S. McKie*, *B. Deakin*, *B. Gyorgy*, *G. Juhasz (Hungary)*  
Anxiety - Disorder; Neuroimaging - Method; Pharmacology - Method

**P.211****Associations of plasma leptin to clinical manifestations in female patients with panic disorder**

*V. Masdrakis\**, *C. Papageorgiou*, *M. Markianos (Greece)*  
Anxiety - Disorder; Biochemistry - Method

**P.212****Sex and age related differences in allostatic load index in patients with general anxiety disorder treated with alprazolam**

*C. Soria*, *C. Remedi*, *A. Pastore*, *L. D'Alessio\**, *E. Roldan (Argentina)*  
Anxiety - Disorder; Pharmacology - Intervention; Stress related disorder

**P.213****Differential patterns of brain activation between obsessive-compulsive and hoarding disorders during motor inhibition and cognitive flexibility**

*M. Suñol\**, *I. Martínez-Zalacain*, *M. Picó-Pérez*, *C. López-Solà*, *E. Real*, *M.À. Fullana*, *J. Pujol*, *N. Cardoner*, *J.M. Menchón*, *P. Alonso*, *C. Soriano-Mas (Spain)*  
Anxiety - Disorder; Impulsive and compulsive disorder; Neuroimaging - Method

## P.214

**Amygdalar hyperactivation in response to safety signal in anxiety trait and generalised anxiety disorder**

*D. Porta Casteràs\**, X. Goldberg, E. Via, I. Martínez-Zalacain, M.A. Fullana, J. Pujol, J. Menchón, D. Palao, C. Soriano-Mas, B. Harrison, N. Cardoner (Spain)  
Anxiety - Disorder; Neuroimaging - Method

## P.215

**Lithium chloride treatment increases serotonergic gene expression in the midbrain raphe nuclei of male mice in the chronic social defeat stress model**

*A. Galyamina\**, D. Smagin, I. Kovalenko, I. Belozertseva, N. Tamkovich, N. Kudryavtseva (Russia)  
Anxiety - Disorder; Pharmacology - Intervention; Stress related disorder

## P.216

**Effects of acute and chronic treatment of STEP inhibitor, TC-2153, on the nervous system and behaviour of zebrafish (*Danio rerio*)**

*A. Kulikov\**, N. Sinyakova, E. Kulikova, N. Evglevsky, I. Kolotygin, K. Volcho, N. Salakhutdinov, V. Kulikov, A. Romaschenko, M. Moshkin (Russia)  
Anxiety - Disorder; Animal models - Method; Pharmacology - Intervention

## P.217

**Involvement of serotonergic system and AMPA receptors in antidepressant-like effects of low-dose ketamine administration in mice**

*M. Erdinç\**, E. Uyar\*, İ. Kelle, H. Akkoç, L. Erdinç (Turkey)  
Anxiety - Disorder; Mood and bipolar disorder

## P.218

**5-HT7 receptor-mediated modulation of synaptic transmission in the mice basolateral amygdala**

*J.E. Sowa\**, M. Kusek, M. Siwiec, G. Hess, K. Tokarski (Poland)  
Anxiety - Disorder; Neurophysiology / EEG - Method

## P.219

**Involvement of 5 $\alpha$ -reductase and ATP-sensitive potassium channels in behavioral effects of pyrazolopyridine derivative GIZH-72 in mice**

*N. Kudryashov\**, K. Kasabov, T. Kalinina, A. Shimshirt, A. Volkova, A. Kurshin, Z. Lyudmila, T. Voronina (Russia)  
Anxiety - Disorder; Stress related disorder; Pharmacology - Intervention

## P.220

**Amygdala and periaqueductal gray involvement in the anxiety- and panic-modulating effects caused by serotonergic activation of dorsal raphe subnuclei**

*H. Zangrossi Jr.\**, M. Matthiesen, L. Mendes, E. Fortaleza (Brazil)  
Anxiety - Disorder; Stress related disorder

## P.221

**Dapagliflozin attenuates anxiolytic-like behavior of rats in open field test**

*R. Keles\**, A.N. Hazar-Yavuz, S. Yildiz, M. Cam, G. Sener (Turkey)  
Anxiety - Disorder; Animal models - Method; Pharmacology - Intervention

## P.222

**The impact of intimate partner violence on psychiatric disorders and severity of pain among female patients with fibromyalgia**

*N. Gündüz\**, E. Erzincan, A. Polat (Turkey)  
Anxiety - Disorder; Pain and headache; Stress related disorder

## P.223

**Serotonin transporter gene hypermethylation – an epigenetic footprint of depressive symptomatology in panic disorder?**

*C. Ziegler\**, L. Kollert, M. Schiele, M. Mahr, A. Gajewska, C. Schartner, K.P. Lesch, J. Deckert, K. Domschke (Germany)  
Anxiety - Disorder; Genetic & molecular approaches - Method

## P.224

**Monoamine Oxidase A (MAOA) methylation in acrophobia: an epigenetic correlate of therapy response?**

*M. Schiele\**, C. Ziegler, L. Kollert, A. Katzorke, D. Gromer, P. Pauli, J. Deckert, M. Herrmann, K. Domschke (Germany)  
Anxiety - Disorder; Psychotherapy - Intervention; Genetic & molecular approaches - Method

**P.225****Rapid anxiolytic effects of 5-HT4 receptor agonist involves prefrontal cortex-brainstem neural circuit recruitment**

*C. Faye\*, R. Hen, B.P. Guiard, C.A. Denny, A.M. Gardier, I. Mendez-David, D.J. David (France)*

Anxiety - Disorder; Animal models - Method; Pharmacology - Intervention

**P.226****An equation based on mice behaviour at the adult age predicts lifespan**

*I. Martínez de Toda Cabeza\*, C. Vida, M. De la Fuente (Spain)*

Anxiety - Disorder; Animal models - Method

**P.227****Effects of sibutramine on intracellular calcium stores: recommendations for drug development studies in binge eating disorder**

*F. Alyu Tekeş\*, S. Değirmenci, B. Turan, Y. Öztürk (Turkey)*

Eating disorder; Pharmacology - Intervention; Pharmacology - Method

**P.228****The effects of relaxin-3 knock down neurons on body weight and food intake in female rats**

*C. De Avila Dal'bo\*, S. Ma, A. Gundlach, E. Timofeeva, C. Cifani (Canada)*

Eating disorder; Stress related disorder; Anxiety - Disorder

**P.229****White matter microstructure in anorexia nervosa**

*A. Phillipou\*, S. Carruthers, M. Di Biase, A. Zalesky, L. Abel, D. Castle, C. Gurvich, S. Rossell (Australia)*

Eating disorder; Neuroimaging - Method

**P.230****Cortical thickness in subjects twenty years after diagnosis of anorexia nervosa during adolescence**

*I. Flamarique\*, E. De la Serna, A. Calvo, J. Pariente, S. Andrés-Perpiña, M.T. Plana, S. Romero, M. Gárriz, N. Bargalló, J. Castro-Fornieles (Spain)*

Eating disorder; Neuroimaging - Method

**P.231****Brain functional connectivity correlates of negative and positive urgency in obesity: fitting treatments to individuals**

*R. Miranda-Olivos\*, C. Soriano-Mas, V.L. Raquel, J. Verdejo-Román, J.F. Navas, C. Martín-Pérez, J.M. Menchón, A. Verdejo-García, O. Contreras-Rodríguez (Spain)*

Eating disorder; Neuroimaging - Method

**P.232****Tracking the ventral striatum temporal response during social feedback in anorexia nervosa**

*S. Membrives\*, E. Via, M. López-Solà, F. Fernández-Aranda, I. Sánchez, I. Martínez-Zalacaín, D.J. Palao, J. Pujol, C.G. Davey, B.J. Harrison, J.M. Menchón, C. Soriano-Mas, N. Cardoner (Spain)*

Eating disorder; Neuroimaging - Method

**P.233****Neural correlates of altered emotion regulation in obesity**

*T. Steward, M. Picó Pérez\*, G. Mestre-Bach, I. Martínez-Zalacaín, M. Suñol, N. Vilarrasa, A. García-Ruiz-de-Gordejuela, S. Jiménez-Murcia, J.M. Menchón, C. Soriano-Mas, F. Fernández-Aranda (Spain)*

Eating disorder; Neuroimaging - Method

**P.234****Prevalence of female athlete triad in Bulgaria**

*P. Chumpalova-Tumbeva\*, V. Valtchev, M. Stoimenova-Popova, L. Tumbev, I. Veleva, K. Stoychev, P. Popov (Bulgaria)*

Eating disorder; Epidemiology and big data - Method

**P.235****Eating attitudes in medical students**

*E. Camcı\*, M. Badilli, N. Uslan, M. Guvercin, G. Gultekin (Turkey)*

Eating disorder; Anxiety - Disorder; Lifestyle and nutrition - Intervention

**P.236****Environmental enrichment exerts anxiolytic and panicolytic-like responses and decreases the activation of serotonergic neurons in the dorsal raphe**

*D. Abreu Lopes\*, J.S. De Andrade, B.A. Rosario, R. Conte, I.C. Céspedes, M.B. Viana (Brazil)*

Stress related disorder; Anxiety - Disorder; Animal models - Method

## P.237

**Ketamine improves depressive symptoms caused by stress and induces c-Fos expression in the brain resembling some effects of stress**

*N. Dygalo\**, *U.S. Drozd*, *T.S. Kalinina*, *E.V. Sukhareva*, *V.V. Bulygina*, *G.T. Shishkina*, *D.A. Lanshakov* (Russia)  
Stress related disorder; Pharmacology - Intervention; Animal models - Method

## P.238

**The 5-HT7 receptor antagonist SB 269970 reverses prenatal stress-induced changes in synaptic transmission in the rat dorsal raphe nucleus**

*J. Sowa\**, *G. Hess* (Poland)  
Stress related disorder; Mood and bipolar disorder

## P.239

**P2X7 receptors are involved in stress-related behaviours and antidepressant effect**

*D.E. Ribeiro\**, *L.A. Stanquini*, *C. Biojone*, *P.C. Casarotto*, *B. Elfving*, *H.K. Müller*, *G. Wegener*, *S.R.L. Joca* (Brazil)  
Stress related disorder; Animal models - Method

## P.240

**Psychopharmacological intervention in patients with adjustment disorder referred to a consultation-liaison psychiatry service over a 10-year-period**

*R. Sánchez González\**, *A. Rodríguez Urrutia*, *E. Monteagudo Gimeno*, *S. Herranz Villanueva*, *L. Pintor Pérez* (Spain)  
Stress related disorder; Pharmacology - Intervention; Anxiety - Disorder

## P.241

**Disturbances in the glucose metabolism in the brain: the role of stress and high-fat diet**

*K. Glombik\**, *J. Detka*, *A. Kurek*, *B. Budziszewska* (Poland)  
Stress related disorder; Animal models - Method; Lifestyle and nutrition - Intervention

## P.242

**Increased neurogenesis in the rostral hippocampus in the rat is associated with anhedonia induced by chronic mild unpredictable stress**

*N. Lazareva\**, *V. Aniol*, *M. Stepanichev*, *A. Manolova*, *N. Gulyaeva* (Russia)  
Stress related disorder; Animal models - Method; Mood and bipolar disorder

## P.243

**Individual variability of synaptic depression in the hippocampus of young male and female rats after neonatal pro-inflammatory stress**

*I. Kudryashova\**, *A. Manolova*, *M. Stepanichev*, *N. Gulyaeva* (Russia)  
Stress related disorder; Neuro-inflammatory disorder; Animal models - Method

## P.244

**Effects of ketamine and tiagabine in mice exposed to single prolonged stress protocol, a mouse model of posttraumatic stress disorder**

*N. Malikowska\**, *K. Sałat*, *P. Popik* (Poland)  
Stress related disorder; Anxiety - Disorder; Mood and bipolar disorder

## P.245

**Early and late-life stress and longitudinal telomere length in old twins**

*L. Gerritsen\**, *S. Hagg*, *C. Reynolds*, *N. Pedersen* (The Netherlands)  
Stress related disorder; Epidemiology and big data - Method

## P.246

**Psychiatric symptoms depend on tinnitus-related characteristics and clinical variables in tinnitus patients**

*J.J. Kim\**, *S.H. Kim*, *J.S. Yi*, *J.E. Jeong*, *S.N. Park* (South-Korea)  
Stress related disorder; Anxiety - Disorder

## P.247

**A study on irritable bowel syndrome (IBS) in mental health professionals and the psychosocial factors affecting this**

*S.H. Jang\**, *W.M. Bahk*, *J.W. Hong*, *S.Y. Lee* (South-Korea)  
Stress related disorder; Anxiety - Disorder; Lifestyle and nutrition - Intervention

## P.248

**The veterans experience, depression, and quality of life in elderly patients of a Korean veteran's hospital**

*S.W. Kim\**, *H.C. Kim* (South-Korea)  
Stress related disorder; Mood and bipolar disorder

## P.249

**Effects of acute mGluR7 PAM on changes in short-time plasticity and mGluR7 levels after chronic treatment with mGluR5 antagonist and COX-2 inhibitor**

*B. Bobula\*, K. Tokarski, M. Sowa-Kućma, P. Misztak, A. Pilc, K. Stachowicz (Poland)*

Stress related disorder; Anxiety - Disorder; Mood and bipolar disorder

## P.250

**TpH2 expression after neonatal dexamethasone treatment and acute or chronic stress in adulthood**

*T. Kalinina\*, E. Sukhareva, D. Lanshakov, V. Bulygina, N. Dygalo (Russia)*

Stress related disorder; Animal models - Method; Pharmacology - Intervention

## P.251

**Neuropeptide y promoter polymorphisms and childhood trauma effects on anxiety sensitivity in a South African adolescent population**

*R. Sinnerton\*, L. Martin, L. Van der Merwe, S. Hemmings, S. Seedat (United Kingdom)*

Stress related disorder; Anxiety - Disorder; Genetic & molecular approaches - Method

## P.252

**Transcutaneous vagus nerve stimulation facilitates invigoration of effort**

*C. Burrasch\*, M.P. Neuser, V. Teckentrup, M. Walter, N.B. Kroemer (Germany)*

Lifestyle and nutrition - Intervention; Neuromodulation - Intervention; Eating disorder

## P.253

**Effects of intermittent fasting on autonomic nervous system, locomotor and exploratory activity, anxiety level, pain threshold and body weight in rats**

*I. Dzhumaniazova\*, E. Khirazova, A. Bayzhumanov (Russia)*

Lifestyle and nutrition - Intervention; Animal models - Method

## P.254

**Comprehensive assessment of physical fitness in patients with depression**

*A. Jasińska - Mikołajczyk\*, K. Drews, K. Domaszewska, F. Rybakowski (Poland)*

Lifestyle and nutrition - Intervention; Mood and bipolar disorder

## P.255

**Long term effects of high fat diet given early in life in prenatally stressed rats: role of the inflammatory response**

*M. Mazzelli\*, N. Cattane, C. Mora, V. Begni, A. Berry, F. Cirulli, M.A. Riva, A. Cattaneo (Italy)*

Lifestyle and nutrition - Intervention; Animal models - Method; Stress related disorder

## P.256

**The impact of raw milk consumption on gastrointestinal bowel and skin complaints in immune depressed adults**

*T. Baars, C. Berge, J. Garssen, J. Verster\* (The Netherlands)*

Lifestyle and nutrition - Intervention; Healthy brain

## P.257

**LSD increases social adaptation to opinions similar to one's own**

*K. Preller\*, L. Schilbach, P. Dürler, T. Pokorny, F.X. Vollenweider (Switzerland)*

Neuromodulation - Intervention; Pharmacology - Intervention; Neuroimaging - Method

## P.258

**Low-Field Magnetic Stimulation (LFMS) decreases cuprizone-induced cognitive impairment and brain pathology in mice**

*Y. Zhang\*, O. Adebisi, Z. Wei, A. Mooshekhian, D. Truong, C. Lavoie, J. Cohen, Z. Zhang, F. Wang, R. Bowen, X.M. Li (Canada)*

Neuromodulation - Intervention; Animal models - Method; Neuro-inflammatory disorder

## P.259

**Insulin, insulin secretagogue and glucagon-like peptide differentially modulate neuronal activity in the prefrontal cortex and dopaminergic systems**

*B. Gronier\*, A. Omoloye (United Kingdom)*

Neuromodulation - Intervention; System biology - Method; Pharmacology - Method

## P.260

**Postictal orientation time factors in electroconvulsive therapy**

*A. De Arriba Arnau\*, A. Dalmau, V. Soria, N. Salvat-Pujol, M. González Águila, C. Rodríguez Angulo, M. Carmona Román, J.M. Menchón, M. Urretavizcaya (Spain)*

Neuromodulation - Intervention; Mood and bipolar disorder

## P.261

**Repetitive transcranial magnetic stimulation (rTMS) versus antidepressants as an add-on treatment for depression in schizophrenia**

*N. Maslenikov\*, E. Tsukarzi, S. Mosolov (Russia)*  
Neuromodulation - Intervention; Psychotic disorder;  
Mood and bipolar disorder

## P.262

**Combination of electroconvulsive therapy and clozapine in patients with treatment-resistant schizophrenia**

*I.W. Chung\*, T. Youn, J.K. Choi, H.Y. Jung, J.H. Kim, C.H. Han, Y.S. Kim (South-Korea)*  
Neuromodulation - Intervention; Pharmacology - Intervention; Psychotic disorder

## P.263

**Serotonin2B receptors exert a GABA-mediated inhibitory control on dorsal raphe nucleus serotonin neuron activity: a microdialysis study in the rat**

*U. Spampinato\*, A. Cathala, C. Devroye, J.M. Revest, F. Artigas (France)*  
Pharmacology - Intervention; Psychotic disorder;  
Addiction - Disorder

## P.264

**Individual differences in impulsivity moderate L-DOPA effects on value-based decision-making**

*J. Petzold\*, A. Kienast, Y. Lee, S. Pooseh, T. Goschke, M.N. Smolka (Germany)*  
Pharmacology - Intervention; Healthy brain;  
Neuropsychology - Method

## P.265

**Functional outcome in patients with major depressive disorder treated by agomelatine 25-50 mg as compared to placebo**

*S.H. Kennedy, R. Heun, A.S. Avedisova, A. Ahokas, V. Olivier, F. Picarel-Blanchot\*, C. De Bodinat (France)*  
Pharmacology - Intervention; Mood and bipolar disorder

## P.266

**Sex hormones mediate the behavioral and neurochemical response to d-amphetamine: A [11C]-(+)-PHNO study in healthy female subjects**

*A. Weidenauer\*, U. Sauerzopf, M. Bauer, L. Bartova, L. Nics, C. Philippe, S. Pfaff, V. Pichler, M. Mitterhauser, W. Wadsak, R. Lanzenberger, S. Kasper, N. Praschak-Rieder, M. Willeit (Austria)*  
Pharmacology - Intervention; Psychotic disorder;  
Addiction - Disorder

## P.267

**Role of the psychiatric clinical pharmacist on quality of life in elderly patients with mental health problems**

*M. Stuhec\*, N. Bratovič (Slovenia)*  
Pharmacology - Intervention; Dementia & neuro degeneration - Disorder; Mood and bipolar disorder

## P.268

**Isoalantolactone amino derivatives as potential neuroprotectors**

*M. Neganova\*, E. Dubrovskaya, S. Afanasieva, E. Shevtsova, S. Klochkov (Russia)*  
Pharmacology - Intervention; Biochemistry - Method;  
Dementia & neuro degeneration - Disorder

## P.269

**The ampakine CX717 has a rapid, but short-lasting antidepressant-like activity in the rat**

*M. Gordillo-Salas, J. Ren, J.J. Greer, A. Adell\* (Spain)*  
Pharmacology - Intervention; Mood and bipolar disorder

## P.270

**Salmeterol, a selective and long-lasting  $\beta_2$  adrenergic agonist, promotes adult hippocampal neuroplasticity**

*V. Bortolotto, H. Bondi, B. Cuccurazzu, M. Rinaldi, P.L. Canonico, M. Grilli\* (Italy)*  
Pharmacology - Intervention; Mood and bipolar disorder

## P.271

**Pridopidine reverses phencyclidine-induced memory impairment**

*K. Sahlholm\*, M. Valle-León, V. Fernández-Dueñas, F. Ciruela (Sweden)*  
Pharmacology - Intervention; Dementia & neuro degeneration - Disorder; Animal models - Method

P.272

**Stable schizophrenia patients switched to paliperidone palmitate 3-monthly formulation in real life: functioning and resource use**

*P. García-Portilla\**, *P.M. Llorca*, *G. Maina*, *V.P. Bozikas*, *H. Devrimci-Ozguven*, *S.W. Kim*, *P. Bergmans*, *I. Usankova*, *P. Cherubin*, *K. Pungor* (Germany)  
Pharmacology - Intervention; Psychotic disorder

P.273

**Descriptive study about the use of asenapine in an acute psychiatric unit along 2017**

*I. González Gil\**, *R. Sánchez*, *O. Ferrandez*, *A.M. Rodríguez*, *M. Roldán*, *J.J. Fuentes*, *M.P. Frings*, *M.T. Campillo*, *G. Hurtado* (Spain)  
Pharmacology - Intervention; Mood and bipolar disorder

P.274

**Improved insight in first episode schizophrenic outpatients switching from oral to long-acting injectable aripiprazole: a cohort study**

*M.C. Spano\**, *G. Di Iorio*, *M. Lorusso*, *L. Carlucci*, *A. Miuli*, *G. Martinotti*, *M. Di Giannantonio* (Italy)  
Pharmacology - Intervention; Psychotic disorder

P.275

**Intramuscular and intravenous trazodone for the treatment of agitation**

*C. Crapanzano\**, *M. Ballerio*, *S. Bolognesi*, *A. Goracci*, *A. Fagiolini* (Italy)  
Pharmacology - Intervention; Mood and bipolar disorder

P.276

**Efficacy of lurasidone versus placebo in schizophrenia: a systematic review and meta-analysis of randomized controlled studies**

*T. Nosaka*, *K. Hagi\**, *A. Pikalov*, *A. Loebel* (Japan)  
Pharmacology - Intervention; Psychotic disorder

P.277

**Efficacy of cannabinoid system in anterior cingulate cortex on effort-based decision making mediates partly via change in levels of p-CREB and p-GSK3**

*Z. Fatahivanani\**, *A. Haghparast*, *A. Zeinaddini-Meymand*, *F. Khodaghali* (Iran)  
Pharmacology - Intervention; Animal models - Method

P.278

**Association of EEG abnormalities and plasma clozapine levels in patients with major psychotic disorders**

*I.W. Chung\**, *T. Youn*, *H.S. Kim*, *Y.S. Kim* (South-Korea)  
Pharmacology - Intervention; Psychotic disorder

P.279

**Regulation of dopamine release by nociceptin in rat striatum**

*M. Choi\**, *B. Kim* (South-Korea)  
Pharmacology - Intervention; Mood and bipolar disorder

P.280

**IPR-166: a potent and selective prolyl oligopeptidase inhibitor ameliorates cognitive symptoms associated to schizophrenia after oral administration**

*R. Prades\**, *E. Munarriz-Cuezva*, *L. Urigüen*, *J.J. Meana*, *T. Tarragó* (Spain)  
Pharmacology - Intervention; Intellectual disability disorder; Psychotic disorder

P.281

**Clozapine in treatment resistant obsessive-compulsive disorder: a case series**

*P.F. Laurenzi\**, *C. Crapanzano*, *A. Fagiolini* (Italy)  
Pharmacology - Intervention; Anxiety - Disorder; Psychotic disorder

P.282

**Sustained functional recovery and symptomatic remission after maintenance treatment with aripiprazole once-monthly in patients with bipolar I disorder**

*E. Vieta*, *R.A. Baker*, *J. Madera\**, *P. Zhang*, *P. Such*, *J. Calabrese* (USA)  
Pharmacology - Intervention; Mood and bipolar disorder

P.283

**LB-102, a potential schizophrenia treatment, displays polypharmacology as a racemate – S enantiomer binds D2 and D3 and R binds 5-HT7**

*A. Vaino\**, *Z. Prensky*, *M. Hixon*, *V. Grattan* (USA)  
Pharmacology - Intervention; Psychotic disorder

P.284

**Adherence to antidepressant therapies in patients with depressive disorders attending an outpatient in a clinic public mental health hospital Colombia**

*J. Restrepo, G. Martínez, L. Martínez, M. Rodríguez, J. Gaviria, A. Urrego, J. Ospina, N. Morales\*, F. Hernández, S. Ochoa (Colombia)*

Psychotherapy - Intervention; Pharmacology - Method; Pharmacology - Intervention

P.285

**Effects of mindfulness-based interventions on biomarkers in psychiatric disorders: a systematic review**

*D. Ikuse\*, K. Sanada, M. Ota, H. Suzuki, A. Hirata, A. Yoshizawa, M. Jesús, M.M.P. Demarzo, A. Iwanami, G.C. Javier (Japan)*

Psychotherapy - Intervention; Psychotic disorder; Neuromodulation - Intervention

P.286

**Baseline neurofunctional predictors of improvement in self-harming behaviors in adolescents before and after group therapy**

*S. Romero\*, P. Santamarina-Perez, I. Mendez, S.M. Leslie, M. Picado, E. Font, E. Moreno, E. Martinez, A. Morer, M.M. Packer, M.K. Singh (Spain)*

Psychotherapy - Intervention; Neuroimaging - Method

P.287

**Acute stress effect on hypothalamus BDNF expression, monoamines levels and adrenal catecholamines in mouse lines differed by 5-HT1A receptor function**

*E. Kondaurova\*, Y. Antonov, A. Pershina, E. Bazhenova, D. Bazovkina, N. Popova (Russia)*

Animal models - Method; Stress related disorder; Biochemistry - Method

P.288

**Differential effects on neurotransmission and behavior in mouse models overexpressing human wild-type or mutated  $\alpha$ -synuclein or mutated LRRK2 protein**

*R. Pavia-Collado\*, D. Alarcón-Arís, V. Còppola, E. Ruiz-Bronchal, R. Revilla, M. Andrés, F. Artigas, A. Bortolozzi (Spain)*

Animal models - Method; Movement disorder

P.289

**Effects of prenatal exposure to methylazoxymethanol acetate on juvenile social play behavior and ultrasonic communication in male and female rats**

*M. Holuj\*, A. Potasiewicz, M. Wojcik, A. Nikiforuk, P. Popik (Poland)*

Animal models - Method; Psychotic disorder

P.290

**Region-specific increases in the expression of translocator protein 18kDa (TSPO) after chronic exposure to haloperidol in naïve adult rats**

*M.C. Cotel, E. Lenartowicz, S. Natesan, M. Dadabhoy, A. Vernon\* (United Kingdom)*

Animal models - Method; Pharmacology - Intervention; Psychotic disorder

P.291

**Yokukansan, a traditional herbal preparation, increases the protein kinase B signaling in aged mice and 5XFAD mouse model of Alzheimer's disease**

*E. Morkovin\*, R. Kaushik, J. Schneeberg, A. Confettura, M. Kreutz, O. Senkov, A. Dityatev (Russia)*

Animal models - Method; Dementia & neuro degeneration - Disorder

P.292

**The add-on of 5-HT6 antagonist, but not agonist, to haloperidol treatment improves MK-801-induced memory deficits in rats**

*A. Partyka\*, J. Rychtyk, M. Jastrzębska-Więsek, K. Mysłowska, A. Wesołowska (Poland)*

Animal models - Method; Pharmacology - Intervention; Psychotic disorder

P.293

**Recognition memory impairment and neuronal degeneration induced by intracerebroventricular or intrahippocampal administration of okadaic acid**

*M. Chighladze\*, G. Beselia, M. Burjanadze, M. Dashniani (Georgia)*

Animal models - Method; Dementia & neuro degeneration - Disorder



**P.294****Investigation of the effects of pregabalin on the cognitive performances in laboratory animals**

*B.R. Buca\**, *L. Mititelu-Tartau*, *A. Creteanu*, *A. Panainte*, *G. Popa (Romania)*

Animal models - Method; Anxiety - Disorder; Sleep disorder

**P.295****Effects of acute forced swimming on the expression of BDNF, TRKB and PSA-NCAM in the hippocampus of the Roman high- and low-avoidance rats**

*M.P. Serra*, *L. Poddighe*, *M. Boi*, *F. Sanna\**, *M.A. Piludu*, *M.G. Corda*, *O. Giorgi*, *M. Quartu (Italy)*

Animal models - Method; Anxiety - Disorder; Mood and bipolar disorder

**P.296****Knock-down of G protein-coupled receptor 88 in the striatum reduces psychiatric deficits in a rat non-motor model of Parkinson's disease**

*B. Galet\**, *M. Ingallinesi*, *J. Pegon*, *N. Faucon Biguet*, *A. Do Thi*, *R. Meloni (France)*

Animal models - Method; Dementia & neuro degeneration - Disorder; Genetic & molecular approaches - Method

**P.297****Peripubertal treatment with cannabidiol reverses behavioral alterations in  $\Delta 9$ -THC animal model of schizophrenia**

*T. Stark\**, *G. Giurdanella*, *V. Pekarik*, *M. Kuchar*, *Z. Babinska*, *J. Ruda-Kucerova*, *S. Salomone*, *R. Mechoulam*, *F. Drago*, *A. Sulcova*, *V. Micale (Czech Republic)*

Animal models - Method; Psychotic disorder; Pharmacology - Intervention

**P.298****Lack of microglial Interleukin-6 ameliorates the brain's response to traumatic brain injury**

*P. Sanchis\**, *J. Vizueta*, *M. Giralt*, *J. Hidalgo (Spain)*

Animal models - Method; Neuro-inflammatory disorder; Stroke

**P.299****Is the alternative splicing factor Rbfox1 associated with aggressive behaviour in mouse models?**

*A. O'Leary\**, *E. Candemir*, *F. Freudenberg*, *A. Reif*, *D.A. Slattery (Germany)*

Animal models - Method; Genetic & molecular approaches - Method

**P.300****Behavioural profile of DAT-KO rats: water escape test and forced swim test**

*M. Tur\**, *I. Belozertseva (Russia)*

Animal models - Method; Stress related disorder; Genetic & molecular approaches - Method

**P.301****Effect of agmatine on impairment of hippocampal neurogenesis and neuroinflammation in streptozotocin-induced diabetes in rats**

*H. Zortul\**, *F. Aricioglu*, *G. Hafez*, *Y. Yazir*, *T. Utkan (Turkey)*

Animal models - Method; Neuro-inflammatory disorder; Pharmacology - Intervention

**P.302****Evaluation of effects of the TAAR1 partial agonist RO5263397 on executive cognitive functions**

*I. Sukhanov\**, *A. Dorotenko*, *N. Bortnikov*, *M. Tur*, *A. Dolgorukova*, *M. Dorofeikova*, *I.V. Belozertseva*, *R.R. Gainetdinov (Russia)*

Animal models - Method; Impulsive and compulsive disorder; Pharmacology - Intervention

**P.303****Dapagliflozin attenuates depressive-like behavior of male rats in the forced swim test**

*M.E. Cam\**, *A.N. Hazar-Yavuz*, *S. Yildiz*, *R. Keles*, *B. Ertas*, *L. Kabasakal (Turkey)*

Animal models - Method; Mood and bipolar disorder; Pharmacology - Intervention

**P.304****A PPAR-alpha agonist gemfibrozil ameliorates cognitive and memory impairments in a sporadic Alzheimer's disease rat model**

*S. Yildiz\**, *M.E. Cam*, *R. Keles*, *A.N. Hazar-Yavuz*, *L. Kabasakal (Turkey)*

Animal models - Method; Dementia & neuro degeneration - Disorder; Pharmacology - Intervention

**P.305****Two distinct mechanisms for synaptic vesicle clustering in vertebrate axons***E. Sopova\*, O. Shupliakov (Russia)*

Animal models - Method; Neuroimaging - Method

**P.306****Effects of adipokinetic hormone/red pigment-concentrating hormone family of peptides on MK-801 induced schizophrenia models in rats***O. Mutlu\*, T. Páleníček, N. Pinterová, K. Šíchová, J. Horáček, K. Holubová, C. Höschl, A. Stuchlík, F. Erden, K. Valeš (Turkey)*

Animal models - Method; Pharmacology - Method; Psychotic disorder

**P.307****Toll like receptor pre-stimulation with lipopolysaccharide, monophosphoryl lipid a and pam3cys attenuates seizure activity in a pilocarpine rat model***M. Hosseinzadeh\*, H. Gholami pour-badie, F. Motamedi (Iran)*

Animal models - Method; Epilepsy - Disorder

**P.308****Effects of frovatriptan and almotriptan on locomotor activity in female rats with experimental model of migraine***K. Saracheva\*, L. Vasileva, D. Getova (Bulgaria)*

Animal models - Method; Pain and headache

**P.309****Analyzing test batteries in animal models of psychopathology with MANOVA: one possible approach to increase external validity***Y. Stukalin\*, H. Einat (Israel)*

Animal models - Method; Mood and bipolar disorder; Biostatistics &amp; computational method

**P.310****Characterization of the neonatal phencyclidine and post-weaning social isolation dual-hit model of schizophrenia-like behavior in the rat***A.M. Hamieh\*, E. Sable, A.M. Hernier, V. Castagne (France)*

Animal models - Method; Psychotic disorder

**P.311****Cholinergic influence in brain pathology and cognition***B. Kolisnyk, M. Al-Onaizi, M.A.M. Prado, V. Prado\* (Canada)*

Animal models - Method; Dementia &amp; neuro degeneration - Disorder; Genetic &amp; molecular approaches - Method

**P.312****Effects of two anti-parkinsonian drugs on learning and memory processes in rats***A. Mihaylova\*, H. Zlatanova, I. Kostadinov, D. Delev, N. Doncheva (Bulgaria)*

Animal models - Method; Dementia &amp; neuro degeneration - Disorder

**P.313****Protective effects of vildagliptin against cognitive impairments and oxidative stress induced by insulin resistance in rat***S. Reyhani-Rad\*, K. Dadashzadeh, J. Mahmoudi, S. Sadigh-Eteghad, R. Badalzadeh (Iran)*

Animal models - Method; Pharmacology - Intervention; Lifestyle and nutrition - Intervention

**P.314****Individual variability in mice in a test-retest protocol of the forced swim test and the amphetamine-induced hyperactivity test***M. Kazavchinsky\*, A. Lan, A. Dafna, H. Einat (Israel)*

Animal models - Method; Mood and bipolar disorder

**P.315****Activation of the alpha4 beta2 nicotinic acetylcholine receptor facilitates set-shifting performance in rats***A. Nikiforuk\*, A. Potasiewicz, H. Arias, P. Popik (Poland)*

Animal models - Method; Pharmacology - Method; Pharmacology - Intervention

**P.316****Ketamine in a model of depression resistant to tricyclic antidepressants***V. Pesic\*, A. Dobrosavljević, D. Stanić, B. Batinić, B. Plečaš (Serbia)*

Animal models - Method; Pharmacology - Method; Mood and bipolar disorder

P.317

**Antidepressant effect of adipokinetic hormone/red pigment-concentrating hormone family of peptides in olfactory bulbectomy model of rats**

*O. Mutlu\**, *L. Kleteckova*, *J. Horáček*, *K. Holubová*,  
*T. Páleníček*, *G. Ulak*, *C. Höschl*, *K. Valeš* (Turkey)  
Animal models - Method; Pharmacology - Method; Mood and bipolar disorder

P.318

**Different effects of adipokinetic hormone/red pigment-concentrating hormone family of peptides in posttraumatic stress disorder model of rats**

*O. Mutlu\**, *C. Cerit*, *N. Pinterová*, *J. Horáček*, *F. Akar*,  
*T. Páleníček*, *C. Höschl*, *K. Valeš* (Turkey)  
Animal models - Method; Stress related disorder;  
Pharmacology - Method

P.319

**Researching the effects of witnessing trauma in rats**

*A. Coskun\**, *S. Candansayar*, *H. Bolay Belen*,  
*A. Donmez*, *O. Gulbahar*, *N. Coskun* (Turkey)  
Animal models - Method; Anxiety - Disorder

P.320

**A gene expression study of the glutamate-nitric oxide pathway in schizophrenia**

*M. Kinoshita\**, *E. Candemir*, *S. Kittel-Schneider*, *A. Reif*,  
*F. Freudenberg* (Germany)  
Genetic & molecular approaches - Method;  
Post-mortem / pathology - Method; Psychotic disorder

P.321

**Photoperiodic responses of behavior and the brain monoamines in obese AY/a and wild-type a/a mice**

*E. Bazhenova\**, *N. Khotskin*, *I. Sorokin*, *D. Fursenko*,  
*A. Kulikov* (Russia)  
Genetic & molecular approaches - Method; Animal models - Method; Mood and bipolar disorder

P.322

**Level of DNA methylation in BDNF gene is significantly decreased in anorexia nervosa**

*G. Maussion*, *J. Clarke*, *P. Gorwood*, *N. Ramoz\** (France)  
Genetic & molecular approaches - Method; Eating disorder

P.323

**Stress variables and methylation of the DDR1 gene in early intervention psychotic patients**

*E. Vilella\**, *L. Moreno*, *A. Lluch*, *C. Miró*, *P. Mulet*,  
*I. Renovell*, *V. Sánchez-Gistau* (Spain)  
Genetic & molecular approaches - Method; Psychotic disorder

P.324

**Involvement of serotonin2A (5-HT2A) receptor and terminal fragment of chromosome 13 in the development of hypothermia in lipopolysaccharide (LPS)-treated mice**

*I. Voronova\**, *G. Khramova*, *D. Bazovkina*, *A. Kulikov*  
(Russia)  
Genetic & molecular approaches - Method;  
Pharmacology - Intervention; Animal models - Method

P.325

**Over-expression and pattern disruption of exon II HTR2A spliced transcript isoforms in drug-naïve schizophrenic peripheral blood lymphocytes**

*M. Belinskaia\**, *A.M. Zobotina*, *A.S. Zhuravlev*,  
*M.N. Grunina*, *R.F. Nasyrova*, *A.E. Taraskina* (Russia)  
Genetic & molecular approaches - Method; Psychotic disorder

P.326

**The influence of the serotonin transporter gene 5-HTTLPR polymorphism on suicidal behavior: a meta-analysis**

*G. Fanelli\**, *A. Serretti* (Italy)  
Genetic & molecular approaches - Method; Prevention / course alteration

P.327

**Risk for antipsychotic-induced extrapyramidal symptoms: a focus on monoamine receptors on peripheral blood lymphocytes**

*A. Zobotina\**, *M.N. Grunina*, *R.F. Nasyrova*,  
*M.M. Pchelina*, *E.E. Ershov*, *E.M. Krupitsky*,  
*A.E. Taraskina* (Russia)  
Genetic & molecular approaches - Method; Neuro-inflammatory disorder; Psychotic disorder

**P.328****The role of microRNA (miRNA) in the etiology of bipolar disorder**

A. Caldiroli\*, A. Terrasi, S. Grassi, G.S. Carnevali, F. Mucci, P. Colapietro, V. Vaira, S. Tabano, M. Miozzo, A.C. Altamura, M. Buoli (Italy)

Genetic & molecular approaches - Method; Mood and bipolar disorder; Psychotic disorder

**P.329****Collapsin response mediator protein-4 gene variant as a risk factor for schizophrenia**

S. Atshemyan\*, A. Arakelyan, R. Zakharyan (Armenia, Rep. of)

Genetic & molecular approaches - Method; Neuropsychology - Method; Psychotic disorder

**P.330****From pre-hypertension to brain decline: detectable changes in the neuro-immune and vascular biomarker continuum as a molecular predictor in humans**

M. Gruden, A. Ratmirov\*, V. Sherstnev (Russia)

Biochemistry - Method; Stroke; Immunology - Method

**P.331****Modulation of neurosecretion by levetiracetam and approaches for its multistep analysis**

L. Kasatkina\*, E. Sturm, A. Heinemann, I. Triakash (Ukraine)

Biochemistry - Method; Animal models - Method; Neuromodulation - Intervention

**P.332****Decreased peripheral magnesium levels in depression: a systematic review and meta-analysis**

H.Y. Jung\*, W. Hahm, K.S. Na (South-Korea)

Biochemistry - Method; Mood and bipolar disorder

**P.333****Real time oxidative stress markers of patients with post-stroke depression: an electron paramagnetic resonance study**

D. Komsiyyska\*, G. Nikolova, Y. Petkov, Y. Karamalakova, T. Manolova, V. Gadjeva (Bulgaria)

Biochemistry - Method; Healthy brain

**P.334****Pharmacologically diverse antidepressant drugs disrupt the interaction of neurotrophic factor receptor TRKB and endocytic adaptor protein complex AP-2**

S.M. Fred\*, L. Laukkanen, L. Vesa, A. Lesnikova, H. Göös, M. Varjosalo, T. Rantamäki, P.C. Casarotto, E. Castrén (Finland)

Biochemistry - Method; Pharmacology - Method; Genetic & molecular approaches - Method

**P.335****Effect of mood on serum osmolarity: a comparison between manic, depressive and mixed states of bipolar disorder**

E. Celik\*, G. Celikel, T. Kalelioglu, N. Karamustafalioglu, A. Genc, M. Emul (Turkey)

Biochemistry - Method; Mood and bipolar disorder

**P.336****Cloninger's temperament dimensions and longitudinal alcohol use in early mid-life: a Northern Finland birth cohort 1966 study**

D. Vladimirov\*, S. Niemelä, S. Keinänen-Kiukaanniemi,

L. Ala-Mursula, J. Auvinen, M. Timonen, J. Miettunen (Finland)

Epidemiology and big data - Method; Addiction - Disorder

**P.337****Low-molecular mimetic of BDNF loop 2 protected neurons against oxidative stress via the TrkB and MAPK/Erk activation**

I. Logvinov\*, T.A. Antipova, A.V. Tarasiuk, S.V. Kruglov, T.A. Gudasheva, S.B. Seredenin (Russia)

Biochemistry - Method; Pharmacology - Method

**P.338****Admixture analysis for clozapine plasma level monitoring to optimize treatment response**

V. De Luca\*, H. Takeuchi, C. Borlido, V. Powell, L. Burton, J. Song, J. Lundy, G. Remington (Canada)

Biostatistics & computational method; Psychotic disorder

**P.339****Coordinate based meta analysis of voxel based morphometry studies does not show evidence of specific grey matter loss in posttraumatic stress disorder**

C. Tench, R. Tanasescu, K. Jethwa\*, C. Constantinescu (United Kingdom)

Biostatistics & computational method; Neuroimaging - Method

**P.340****The role of effortful control in performing an executive attention task**

*P. Ossola\*, C. De Panfilis, K.B. Meehan, N.M. Cain, A. Soliani, M. Ferrari, G. Schito, I. Generali, C. Antonucci, C. Marchesi (Italy)*

Biostatistics & computational method; Neuropsychology - Method

**P.341****Association between mental health status and bone mineral density: analysis of the 2008-2010 Korea national health and nutrition examination survey**

*C. Hahn\* (South-Korea)*

Epidemiology and big data - Method; Lifestyle and nutrition - Intervention

**P.342****Correlation between specific component of mental health condition and psychological well-being of Filipino older people**

*P.P. Espinosa\* (Philippines)*

Epidemiology and big data - Method; Anxiety - Disorder; Sleep disorder

**P.343****Long-acting injectable antipsychotics in a mental health unit: pre and post-treatment analysis**

*B. Mata Sáenz\*, I. Díaz-Quero, L. Asensio-Aguerrí, E. Segura-Escobar, C. Rodríguez Gómez-Carreño, E. Lopez-Lavela, V. Muñoz-Martinez, L. Nuevo-Fernandez (Spain)*

Epidemiology and big data - Method; Pharmacology - Method

**P.344****Contributing factors in the comorbidity of depression and pain: a Bayesian approach**

*G. Juhasz\*, P. Petschner, G. Bagdy, B. Deakin, P. Antal, G. Hullam (Hungary)*

Epidemiology and big data - Method; Mood and bipolar disorder; Pain and headache

**P.345****Prescribing psychotropic medications for children and adolescents by young psychiatrists attending the ECNP School of Neuropsychopharmacology**

*D. Stevanovic\*, C. Moreno, A. Zuddas, P. Santosh (Serbia)*

Epidemiology and big data - Method; Pharmacology - Method

**P.346****The relationship between sleep disturbance and depressive symptoms among Korean university students: moderating effect of the positive psychology**

*S.H. Kim\*, S.H. Park, I.H. Choo, S.G. Kim, H.J. Yoon (South-Korea)*

Epidemiology and big data - Method; Sleep disorder; Mood and bipolar disorder

**P.347****Antidepressants and cataract: a disproportionality analysis of the FAERS database**

*S. Siafis\*, D. Spachos, G. Papazisis (Greece)*

Epidemiology and big data - Method; Pharmacology - Method

**P.348****Association of treatment response with obesity and other metabolic risk factors in adults with depressive disorders: results from a the CRESCEND study**

*T.Y. Jun\* (South-Korea)*

Epidemiology and big data - Method; Mood and bipolar disorder

**P.349****Sexual regional dimorphism of post-adolescent and middle age brain maturation**

*A. Pignoni\*, E. Maggioni, B. Crespo-Facorro, I. Nenadic, F. Benedetti, C. Gaser, H. Sauer, R. Roiz-Santiañez, S. Poletti, M.G. Rossetti, M. Bellani, C. Perlini, M. Ruggeri, V.A. Diwadkar, P. Brambilla (Italy)*

Healthy brain; Neuroimaging - Method; Epidemiology and big data - Method

**P.350****Extroverts have increased resting state brain functional connectivity than introverts**

*C. Park\*, S. Youn, D. Ko, Y. Choi, Y.W. Shin (South-Korea)*

Healthy brain; Neuroimaging - Method

**P.351****Inhibition of ERK 1/2 rescues the decay of long-term potentiation in the dentate gyrus in vivo: implication on Alzheimer's disease**

*C. Süer\*, M. Yousef, S. Delibas, E. Babur (Turkey)*

Healthy brain; Neurophysiology / EEG - Method; Pharmacology - Method

**P.352****New structural formations of the cerebellar dentate nucleus and their use in stereotactic navigation in neurosurgical practice***D. Shyian\* (Ukraine)*

Healthy brain; Neuroimaging - Method

**P.353****Neuromorphological peculiarities of the inferior medullary velum of the fourth ventricle (nucleus of the inferior medullary velum)***D. Shyian\* (Ukraine)*

Healthy brain; Neuroimaging - Method

**P.354****The effects of maternal diet on adaptive changes in the brain melanocortin 4 receptors in female offspring***K. Mudlaff\*, D. Gawliński, M. Filip (Poland)*

Healthy brain; Lifestyle and nutrition - Intervention

**P.355****Aggressiveness and violence in psychiatric outpatients: a clinical or a social paradigm***G. Cinnigliaro\*, B. Dell'Osso, M.C. Mauri (Italy)*

Healthy brain; Psychotic disorder

**P.356****Emotional - affective and cognitive dysfunctions in patients with diabetes mellitus type 1***N. Ruzhdiy Shimkina\*, K. Ruzhdii (Russia)*

Healthy brain; Prevention / course alteration; Intellectual disability disorder

**P.357****Development of the immune status questionnaire (ISQ)***A. Van de Loo\*, L.J.F. Wilod Versprille, M. Mackus, A.D. Kraneveld, J. Garssen, J.C. Verster (The Netherlands)*

Immunology - Method; Epidemiology and big data - Method

**P.358****Serum immunological parameters as markers of remission quality in schizophrenia***G. Kostyuk, A. Galkina\*, O. Karpenko, A. Golubev (Russia)*

Immunology - Method; Psychotic disorder

**P.359****Studying the features proteins of serum in patients with schizophrenia***E. Dmitrieva\*, L. Smirnova, A. Seregin, L. Anastasija, K. Elena, S. Arkadij, I. Svetlana (Russia)*

Immunology - Method; Psychotic disorder; Genetic &amp; molecular approaches - Method

**P.360****A network of structural gray matter covariance is associated with a proxy of cortical myelin***F. Beyer\*, S. Kharabian Masouleh, H.L. Schaare, A. Villringer, A.V. Witte (Germany)*

Neuroimaging - Method; Epidemiology and big data - Method; Healthy brain

**P.361****Segmentation of hippocampal subfields and nuclei of the amygdala with major depressive disorder and healthy controls – preliminary findings***T. Vanicek\*, R. Seiger, G. Gryglewski, A. Kautzky, K. Manfred, M. Godbersen, L. Rischka, G.M. James, L. Silberbauer, P. Michenthaler, G.S. Kranz, A. Hahn, D. Winkler, S. Kasper, R. Lanzenberger (Austria)*

Neuroimaging - Method; Mood and bipolar disorder

**P.362****Antipsychotic discontinuation in first episode psychosis: a prospective study using [18F]DOPA and [11C]raclopride PET***S. Kim, S. Shin, E. Kim\* (South-Korea)*

Neuroimaging - Method; Psychotic disorder

**P.363****Psilocybin occupancy of brain serotonin 2A receptors correlates with psilocin levels and subjective experience: a [11C]Cimbi-36 PET study in humans***M.K. Madsen, D. Burmester, D.S. Stenbæk, S. Kristiansen, A. Dyssegaard, S. Lehel, K. Linnet, S.S. Johansen, C. Svarer, B. Ozenne, D. Erritzøe, P.M. Fisher\*, G.M. Knudsen (Denmark)*

Neuroimaging - Method; Neuromodulation - Intervention; Pharmacology - Intervention

P.364

**Cortical surface area abnormalities in young adolescents at ultra-high risk who later develop psychosis**

S. Madero Gómez\*, A. Fortea, P. Van Eindhoven, J.C. Pariente, A. Calvo, A. Batalla, E. De la Serna, D. Ilzarbe, M. Dolz, I. Baeza, G. Sugranyes (Spain)  
Neuroimaging - Method; Psychotic disorder

P.365

**The neuroanatomical pattern of sex and gender in cis/transgender individuals revealed by machine learning-based pattern recognition with NeuroMiner**

P. Baldinger\*, M.F. Urquijo Castro, R. Seiger, G.S. Kranz, M. Spies, U. Kaufmann, C. Windischberger, S. Kasper, P. Falkai, N. Koutsouleris, R. Lanzenberger (Austria)  
Neuroimaging - Method; Biostatistics & computational method; Healthy brain

P.366

**Psilocybin induces aberrant prediction error processing for tactile mismatch responses**

P. Dürler\* (Switzerland)  
Neuroimaging - Method; Pharmacology - Intervention; Psychotic disorder

P.367

**Quantitative assessment of gray matter changes in patients with schizophrenia by MRI approach**

D. Parshukova\*, L. Smirnova, A. Seregin, V. Dubrovskaya, E. Kornetova, V. Yarnykh, A. Semke, S. Ivanova (Russia)  
Neuroimaging - Method; Psychotic disorder

P.368

**Dynamics of ketamine-related resting state functional connectivity changes in healthy controls**

M. Spies\*, M. Klöbl, A. Höflich, G.S. Kranz, T. Vanicek, A. Hahn, D. Winkler, S. Kasper, R. Lanzenberger (Austria)  
Neuroimaging - Method; Mood and bipolar disorder; Pharmacology - Intervention

P.369

**Effects of sexual orientation in homo- and heterosexual men and women on brain structures.**

M. Votinov\*, K.S. Goerlich, E. Smith, U. Habel (Germany)  
Neuroimaging - Method; Sexual disorder; Healthy brain

P.370

**Peripapillar choroidal changes in patients with multiple sclerosis**

M.J. Rodrigo\*, E. Vilades, E. Orduna, G. Larrea, L. Jarauta, M. Satue, E. Garcia-Martin (Spain)  
Neuroimaging - Method; Neuro-inflammatory disorder; Dementia & neuro degeneration - Disorder

P.371

**Ability of swept-source optical coherence tomography to detect retinal changes in patients with bipolar disorder**

E. Orduna Hospital\*, M.J. Rodrigo, E. Vilades, G. Larrea, M. Satue, E. Garcia-Martin (Spain)  
Neuroimaging - Method; Personality disorder

P.372

**Intrinsic functional and structural connectivity of emotion regulation networks in obsessive-compulsive disorder**

M. Picó Pérez\*, J. Ipser, P. Taylor, P. Alonso, C. López-Solà, E. Real, C. Segalàs, A. Roos, J.M. Menchón, D.J. Stein, C. Soriano-Mas (Spain)  
Neuroimaging - Method; Anxiety - Disorder; Impulsive and compulsive disorder

P.373

**Dopamine modulates belief updating but not surprise in the midbrain and ventral striatum**

M. Nour\*, T. Dahoun, P. Schwartenbeck, R. Adams, T. FitzGerald, C. Coello, M. Wall, R. Dolan, O. Howes (United Kingdom)  
Neuroimaging - Method; Psychotic disorder; Healthy brain

P.374

**Susceptibility weighted imaging (SWI) enhanced phase sensitive inversion recovery T1 weighted imaging of the nucleus basalis of Meynert at 7T**

K. Jethwa\*, K. Aphiwatthanasumet, M. Ali, O. Mougín, P. Gowland, D. Auer (United Kingdom)  
Neuroimaging - Method; Dementia & neuro degeneration - Disorder; Neuromodulation - Intervention

P.375

**Cognitive Reserve Assessment Scale in Health (CRASH): the reliability and validity**

S. Amoretti\*, B. Cabrera, M. Garriga, C. Torrent, E. Vieta, M. Bernardo (Spain)  
Neuropsychology - Method; Psychotic disorder

P.376

**Differences in cognitive impairment between psychiatric patients and dementia patients in a Greek hospital with the use of MoCA**

*G. Lyrakos\*, V. Spinaris, M. Tsironi (Greece)*

Neuropsychology - Method; Dementia & neuro degeneration - Disorder

P.377

**Reliability and validity of a behavioral test battery for longitudinal assessment of neuropsychological functions in rats**

*I. Bondi\*, C. Canestrelli, M. Lenoir, F. Noble (France)*

Neuropsychology - Method; Addiction - Disorder

P.378

**Early detection of cognitive impairment in patients with chronic diseases in a Greek hospital**

*G. Lyrakos\*, E. Aslani, V. Spinaris, M. Tzouvala, M. Drosou-Servou, C. Iatrou, M. Tsironi (Greece)*

Neuropsychology - Method; Biostatistics & computational method

P.379

**Experimental researches regarding the influence of serotonin on psycho-motor abilities and spontaneous behaviour in rats**

*B.R. Buca\*, G. Popa, M. Bogdan, L. Pavel, L. Mititelu-Tartau (Romania)*

Neuropsychology - Method; Animal models - Method; Movement disorder

P.380

**Pilot study of neurocognitive functioning and health-related quality of life in coronary artery disease patients**

*J. Burkauskas\*, A. Bunevicius, N.A. Fineberg, J. Brozaitiene, N. Kazukauskienė, N. Mickuviene (Lithuania)*

Neuropsychology - Method; Dementia & neuro degeneration - Disorder

P.381

**A feasibility, acceptability and validation study of the Italian Version of a new cognitive remediation program for psychotic patients – CIRCuiTS**

*D. Palumbo, A. Mucci, G.M. Giordano\*, D. Pietrafesa, C. Aiello, A. Vignapiano, S. Galderisi (Italy)*

Neuropsychology - Method; Healthy brain; Psychotic disorder

P.382

**Cholesterol-dependent effect of antidepressants on activation BDNF receptor (TRKB)**

*P. Casarotto\*, S.M. Fred, C. Biojone, M. Girysh, T. Rog, I. Vattulainen, E. Castrén (Brazil)*

Pharmacology - Method; Animal models - Method; Biochemistry - Method

P.383

**Interaction of valproic acid and antidepressants on clozapine metabolism in affective patients**

*D. Marazziti\*, L. Palego, F. Mucci, S. Baroni, L. Dell'Osso (Italy)*

Pharmacology - Method; Mood and bipolar disorder

P.384

**Decreased ribosomal protein S6 phosphorylation in post-mortem prefrontal cortex of subjects with schizophrenia: effects of antipsychotic treatment**

*L.F. Callado\*, I. Ibarra-Lecue, R. Diez-Alarcia, J.J. Meana, L. Urigüen (Spain)*

Pharmacology - Method; Post-mortem / pathology - Method; Psychotic disorder

P.385

**Effect of aerobic training and lacosamide treatment on the expression of the neurotrophic factor BDNF in rat hippocampus**

*M. Shishmanova\*, K. Georgieva, Y. Koeva, D. Terzieva, Z. Peychev (Bulgaria)*

Pharmacology - Method; Post-mortem / pathology - Method; Prevention / course alteration

P.386

**Norepinephrine transporter occupancy of venlafaxine in patients with major depressive disorder using positron emission tomography and [18F]FMeNER-D2**

*R. Arakawa, P. Stenkrone, A. Takano, J. Svensson, M. Andersson, S. Nag, Y. Asami, C. Halldin, J. Lundberg\* (Sweden)*

Pharmacology - Method; Neuroimaging - Method; Mood and bipolar disorder



## P.387

**A novel Dclk1 transcript is selectively induced by drugs acting on serotonin signalling**

*M. Zygmunt\**, *D. Hoinkis*, *J. Hajto*, *M. Piechota*,  
*J. Rodriguez Parkitna*, *M. Korostyński (Poland)*

Pharmacology - Method; Genetic & molecular approaches - Method

## P.388

**Human cerebral 5-HT<sub>2A</sub> receptor labelling with [18F]altanserin, [3H]LSD, and [3H]M100907. Relevance of radiotracer intrinsic activity**

*R. Diez-Alarcia\**, *C. Muguruza*, *G. Rivero*, *A. García-Bea*,  
*L.F. Callado*, *A. Martín*, *J. Llop*, *J.J. Meana (Spain)*

Post-mortem / pathology - Method; Pharmacology - Method

## P.389

**Serotonin 2A receptors in the postmortem prefrontal cortex of suicide victims: the relevance of controlling confounding variables**

*C. Muguruza\**, *J.L. Palomo-Ruiz*, *B. Morentin*,  
*L.F. Callado*, *J. González-Maeso*, *J.J. Meana (Spain)*

Post-mortem / pathology - Method; Pharmacology - Method; Psychotic disorder

## P.390

**Histone acetylation and methylation at ADRA2A gene promoter in postmortem prefrontal cortex of subjects with schizophrenia**

*I. Brocos Mosquera\**, *G. Rivero*, *B. Morentin*, *J.J. Meana*,  
*L.F. Callado (Spain)*

Post-mortem / pathology - Method; Psychotic disorder

## P.391

**Low brain-derived neurotrophic factor levels in post-mortem brains is associated with sub-syndromic neuropsychiatric symptoms**

*P.V. Nunes\**, *C.F. Nascimento*, *H.K. Kim*, *A. Andreazza*,  
*H.P. Brentani*, *C.K. Suemoto*, *R.E.P. Leite*,  
*R.E.D.L. Ferretti-Rebustini*, *C.A. Pasqualucci*, *R. Nitrini*,  
*L.T. Grinberg*, *L.T. Young*, *W. Jacob-Filho*, *B. Lafer (Brazil)*

Post-mortem / pathology - Method; Dementia & neuro degeneration - Disorder; Mood and bipolar disorder

## P.392

**High prevalence and correlates of Vitamin D deficiency in a sample of 290 psychiatric inpatients**

*I. Baldini\**, *A. Cuomo*, *A. Santucci*, *L. Del Matto*,  
*S. Desantis*, *E. Federico*, *M. Olivola*, *F. Salvaro*,  
*A. Goracci*, *A. Fagiolini (Italy)*

System biology - Method; Biochemistry - Method; Pharmacology - Method

## P.393

**Clinical characteristics of adults with neuro-developmental disorder: a medical records survey**

*T. Nishio\**, *H. Ohta*, *Y. Nakamura*, *S. Toki*, *K. Sanada*,  
*N. Kato*, *A. Iwanami (Japan)*

Autism / ASD - Disorder; ADHD - Disorder

## EP.1000

**Biological therapies for Alzheimer Dementia – the current status of clinical research and future trends**

*D. Vasile\**, *O. Vasiliu*, *A.G. Mangalagiu*, *B.M. Petrescu*,  
*C. Tudor*, *C.A. Candea*, *D. Ungureanu (Romania)*

Dementia & neuro degeneration - Disorder; Immunology - Method; Pharmacology - Method

## EP.1001

**Pharmacological management of internet gaming disorder – a systematic literature review**

*D. Vasile\**, *O. Vasiliu*, *D.G. Vasiliu*, *F. Vasile (Romania)*

Addiction - Disorder; Impulsive and compulsive disorder; Pharmacology - Intervention

## EP.1002

**Pharmacological management of late-onset schizophrenia – a case series**

*O. Vasiliu*, *D. Vasile*, *A.G. Mangalagiu*, *M.B. Petrescu\*\**,  
*C.A. Candea*, *C. Tudor*, *A.F. Fainarea*, *M.C. Patrascu*,  
*E.A. Morariu*, *A.M. Badic*, *R.E. Manolache*,  
*I.A. Alexandru (Romania)*

Psychotic disorder; Pharmacology - Intervention; Addiction - Disorder

## EP.1003

**Combined pharmacological treatment for alcohol dependence – review of current evidence and new study project**

*O. Vasiliu*, *D. Vasile*, *M.B. Petrescu\*\**, *A.G. Mangalagiu*,  
*C.A. Candea*, *A.F. Fainarea*, *M.C. Patrascu*, *E.A. Morariu*,  
*A.M. Badic*, *R.E. Manolache*, *I.A. Alexandru (Romania)*

Pharmacology - Intervention; Addiction - Disorder; Pharmacology - Method

**EP.1004****ENACT: Investigating the efficacy and mechanisms of action of N-acetylcysteine as an adjunctive treatment for first episode psychosis**

*S. Dodd\**, *A. Ratheesh*, *B. O'Donoghue*, *S. Wood*, *K. Allott*, *C. Bartholomeusz*, *C. Bortolasci*, *P. McGorry*, *M. Berk*, *A. Chanen*, *K. Walder*, *P. Amminger*, *O. Dean*, *A. Watson*, *K. Filia*, *S. Cotton (Australia)*

Psychotic disorder; Pharmacology - Intervention

**EP.1005****Student concerns about their gambling and other high risk behaviors in Romania**

*I.R. Lupu\**, *L. Viorel (Romania)*

Addiction - Disorder; Prevention / course alteration

**EP.1006****Retigabine attenuates the effects of dopamine and quinpirole on smooth muscle strips in vitro**

*E. Apostolova\**, *P. Zagorchev*, *V. Kokova*, *L. Peychev (Bulgaria)*

Neuromodulation - Intervention; Animal models - Method

**EP.1007****Evaluation of male patients diagnosed with fibromyalgia syndrome in terms of depression and characteristics**

*C. Tuz\* (Turkey)*

Pain and headache; Biostatistics & computational method

**EP.1008****Psychiatric comorbidities and psychopharmacological treatment in a sample of patients with drug-resistant epilepsy**

*E. Monteagudo\**, *R. Sánchez-González*, *A. Rodríguez-Urrutia*, *S. Herranz-Villanueva*, *L. Pintor-Pérez (Spain)*

Epilepsy - Disorder; Pharmacology - Intervention; Neuropsychology - Method

**EP.1009****The first-episode psychosis: treatment and outcome**

*O. Kukhianidze\**, *N. Okribelashvili (Georgia)*

Psychotic disorder; Pharmacology - Method; Pharmacology - Intervention

**EP.1010****Neurotrophins are regulators of dopamine transporters in peripheral lymphocytes in patients with schizophrenia**

*D. Rodrigues-Amorim*, *C. Rodriguez-Jamardo*, *T. Rivera-Baltanás*, *M. Iglesias-Martínez-Almeida*, *E. De Las Heras*, *D. Facal*, *M. Gandoy*, *J.M. Cancela*, *R. Agís-Balboa*, *J.M. Olivares*, *C. Spuch\* (Spain)*

Neuro-inflammatory disorder; Psychotic disorder; System biology - Method

**EP.1011****Right hippocampus atrophy is independently associated with Alzheimer's disease patients with psychosis**

*Y.I. Chung\**, *K. Lee*, *Y.M. Lee*, *J.M. Park*, *B.D. Lee*, *E. Moon*, *H.J. Jeong*, *S.Y. Kim*, *J.H. Kim (South-Korea)*

Dementia & neuro degeneration - Disorder; Neuroimaging - Method; Psychotic disorder

**EP.1012****The prevalence and the risk factors of dementia among a community sample of an Anatolian city province**

*H.M. Basar\**, *I.A. Senturk (Turkey)*

Dementia & neuro degeneration - Disorder; Epidemiology and big data - Method

**EP.1013****P300 parameters for differential diagnostics of the main etiological types of mild neurocognitive disorders and assessment of treatment effectiveness**

*O. Troian\**, *O. Levada*, *N. Cherednichenko (Ukraine)*

Dementia & neuro degeneration - Disorder; Neurophysiology / EEG - Method

**EP.1014****Efficacy of the new antipsychotic cariprazine on negative and cognitive symptoms: a role for D3 receptors**

*F. Calabrese*, *\*M.A. Riva*, *G. Racagni (Italy)*

\*Pharmacology - Intervention; Psychotic disorder

**EP.1015****Imaging of extracellular nano vesicles exosomes in addiction and psychiatry**

A.H. Mazumder\*, M.A. Rushdy, A. Samoylenko, G. Bart, A. Zhyvolozhnyi, J. Veijola, V. Kiviniemi, S. Vainio (Finland)

Genetic & molecular approaches - Method; Addiction - Disorder; Neuroimaging - Method

**EP.1016****Incretin's neuroprotective effect- A case report of a patient with Alzheimer's disease in which cognitive function was improved by once weekly GLP-1**

I. Shimizu\*, Y. Ono, R. Nakajima, T. Nagao (Japan)

Dementia & neuro degeneration - Disorder;

Pharmacology - Method

**EP.1017****Forensic psychiatry – scenario in the largest security ward in Portugal: psychotic disorder**

T. Carvalhão\*, P. Jorge, J. Santos, P. Batalim (Portugal)

Intellectual disability disorder; Psychotic disorder;

Pharmacology - Intervention

**EP.1018****Comparing emotional intelligence between patients with bipolar disorder and healthy controls**

S.Y. Kuo\*, Y.H. Chang, P.S. Chen, H.Y. Lane, T.Y. Wang, R.B. Lu (Taiwan)

Mood and bipolar disorder; Neuropsychology - Method

**EP.1019****Therapeutic switch from paliperidone palmitate 1-month (PP1M) to paliperidone palmitate 3-month (PP3M) in patients with schizophrenia**

V. Mancini\*, S. Gargarella, G. Baroni, G. Sepede,

M.C. Spano, C. Montemitro, S. Marini, M. Alessandrini,

M. Di Giannantonio (Italy)

Psychotic disorder; Pharmacology - Intervention

**EP.1020****The role of affective temperaments on the symptomatological and functional outcome of mania: a 194 bipolar I patients naturalistic study**

G. Maccariello\*, M. Barbuti, D. Cesari, G. Vannucchi,

A. De Bartolomeis, A. Fagiolini, G. Maina, G. Perugi (Italy)

Mood and bipolar disorder; Pharmacology - Intervention

**EP.1021****Vitamin D and depression: which relationship?**

P. Barata\*, J.C. Melo, T. Maia (Portugal)

Mood and bipolar disorder; Healthy brain; Prevention / course alteration

**EP.1022****A review on monitoring metabolic side effects of second-generation antipsychotics**

P. Barata\*, R. Serrano, J.C. Melo, T. Maia (Portugal)

Pharmacology - Intervention; Pharmacology - Method

**EP.1023****Functioning of stable schizophrenia patients receiving antipsychotics: a comparison of typical lai, atypical lai and atypical oral antipsychotics**

F.L. Azhar\*, J.S. Gill, A.H. Sulaiman (Malaysia)

Psychotic disorder; Pharmacology - Method

**EP.1024****Sex matters: Differences in structure, function, transcription and translation of microglia from male and female brains**

S.A. Wolf\* (Germany)

Healthy brain; Autism / ASD - Disorder

**EP.1025****The effects extreme low intermittent electromagnetic field on neuroendocrine communication**

Z. Molnar\*, A. László, L. Rácz, A. Serester, K. Sepp,

P. Hausinger, M. Gálfi, M. Radács (Hungary)

System biology - Method; Animal models - Method

**EP.1026****Prenatal N-acetyl-cysteine prevents offsprings' metabolic and emotional dysfunction in a mouse model of maternal obesity**

F. Cirulli\*, V. Bellisario, P. Panetta, C. Raggi,

M.C. Magnifico, M. Arese, A. Berry (Italy)

Lifestyle and nutrition - Intervention; Healthy brain;

Animal models - Method

**EP.1027****Clinical challenges in the approach and manage of psychosis and epilepsy**

P. Barata\*, R. Serrano, J.C. Melo, T. Maia (Portugal)

Epilepsy - Disorder; Psychotic disorder; Pharmacology - Intervention

## EP.1028

**BIO-Young: Smartphone-based biomarkers in adolescents with unipolar disorder and bipolar disorder, their healthy siblings and healthy controls**

*S. Melbye\*, M. Faurholt-Jepsen, M. Frost, J. Bardram, L. Vedel Kessing (Denmark)*

Mood and bipolar disorder; E-health - Intervention

## EP.1029

**Analysis of suicide behaviours in patients with an autism spectrum disorders in an inpatient unit**

*B. Mata Sáenz\*, V. Muñoz-Martinez, L. Asensio-Aguerri, L. Nuevo-Fernández, P. Baos-Sendarrubias, C. Rodríguez Gómez-Carreño, L. Beato-Fernandez (Spain)*

Epidemiology and big data - Method; Autism / ASD - Disorder

## EP.1030

**Analysis of the factors that influence the prevalence of injectable treatment in a sample of patients with severe mental disorders**

*B. Mata Sáenz\*, I. Diaz-Quero, A.J. Ramírez-García, F. García-Lazaro, I. Morales-Saenz (Spain)*

Epidemiology and big data - Method; Pharmacology - Method

## EP.1031

**Safety and tolerability of lurasidone versus placebo in schizophrenia: a systematic review and meta-analysis of randomized controlled studies**

*T. Nosaka, K. Hagi\*, A. Pikalov, A. Loebel (Japan)*

Pharmacology - Intervention; Psychotic disorder

## EP.1032

**Effect of antipsychotics on cognition in patients with schizophrenia: a systematic review and meta-analysis of randomized controlled trials**

*K. Hagi\*, T. Nosaka, A. Pikalov, A. Loebel (Japan)*

Pharmacology - Intervention; Psychotic disorder

## EP.1033

**Psychiatric admission increases body weight**

*J.S. Noh\*, M.Y. Park (South-Korea)*

Lifestyle and nutrition - Intervention; Prevention / course alteration

## EP.1034

**Factors associated with medication adherence among bipolar outpatients**

*S.H. Kim\*, H.C. Youn, J.J. Kim, J.S. Yi (South-Korea)*

Mood and bipolar disorder; Pharmacology - Intervention

## EP.1035

**Blood-brain barrier integrity during the first episode of mania: long-term clinical implications**

*M. Martínez-Cengotitabengoa\*, C. Bermudez-Ampudia, P. Lopez, S. García, K. Mac Dowell, M.J. Diaz-Gutierrez, A. González-Pinto (Spain)*

Neuro-inflammatory disorder; Mood and bipolar disorder

## EP.1036

**Update of analysis of referrals from primary care: a 28-month study**

*I. Diaz-Quero\*, B. Mata-Saenz, L. Nuevo-Fernandez, L. Asensio-Aguerri, V. Muñoz-Martinez, E. Segura-Escobar, C. Rodriguez-Gomez-Carreño, L. Beato-Fernandez (Spain)*

Epidemiology and big data - Method; Prevention / course alteration

## EP.1037

**Analysis of comorbid psychopathology in adolescents with suicidal attempts or suicidal ideation in a childhood and adolescent unit**

*I. Diaz-Quero\*, V. Muñoz-Martinez, B. Mata-Saenz, P. Baos-Sendarrubias, E. Segura-Escobar, C. Rodriguez-Gomez-Carreño, L. Nuevo-Fernandez, L. Asensio-Aguerri, L. Beato-Fernandez (Spain)*

Epidemiology and big data - Method; Prevention / course alteration

## EP.1038

**Globulin test in acute psychotic patients**

*V. Videnova\*, N. Manusheva, B. Stefanovski, V. Isjanovski, S. Pejkovska-Dimovska, O. Dimova (Macedonia)*

Psychotic disorder; Biochemistry - Method

## EP.1039

**A combination of plant extracts in the treatment of anxiety and depressive-like behavior of rats exposed to chronic mild stress**

*I. Kandilarov\*, H. Zlatanova, M. Georgieva-Kotetarova, I. Kostadinova, M. Katsarova, S. Dimitrova, L. Lukanov (Bulgaria)*

Stress related disorder; Animal models - Method; Pharmacology - Intervention

## EP.1040

**Ketamine as an adjunctive therapy for major depression - a randomised controlled pilot trial: The KARMA-Dep Trial (NCT03256162)**

*B. Gallagher\*, M. Finnegan, C. Slattery, M. Foley, G. Gusciute, E. Doody, D. McLoughlin (Ireland)*

Mood and bipolar disorder; Pharmacology - Intervention

## EP.1041

**Antipsychotic adverse effects in Malaysian schizophrenic patients: a comparison of typical LAI, atypical LAI and atypical oral antipsychotics**

*F.L. Azhar\*, J.S. Gill, A.H. Sulaiman (Malaysia)*

Psychotic disorder; Pharmacology - Method

## EP.1042

**Dual Disorder as the initial presentation of CADASIL: a case report**

*C. Cagigal\*, M. Jesus, C. Silva (Portugal)*

Dementia & neuro degeneration - Disorder; Addiction - Disorder

## EP.1043

**Challenges in treatment of bipolar affective disorder in comorbidity with obsessive-compulsive symptoms**

*M.E. Pereira\*, C. Spínola (Portugal)*

Impulsive and compulsive disorder; Mood and bipolar disorder; Pharmacology - Intervention

## EP.1044

**Linear and volumetric measurement of the nucleus basalis of Meynert in psychotic disorders**

*K. Jethwa\*, P. Liddle (United Kingdom)*

Neuroimaging - Method; Psychotic disorder

## EP.1045

**Structural neuroimaging findings in Alzheimer's disease: coordinate based random effect size meta-analyses of voxel-based morphometry studies**

*K. Jethwa\*, C. Tench (United Kingdom)*

Dementia & neuro degeneration - Disorder; Biostatistics & computational method; Neuroimaging - Method

## EP.1046

**Utility of pre-supplementary motor area anodal high definition transcranial direct current stimulation for treatment resistant OCD**

*J. Narayanaswamy\*, V. Shivakumar, V. Holebasavanahalli T, G. Venkatasubramanian, Y.C.J. Reddy (India)*

Neuromodulation - Intervention; Anxiety - Disorder

## EP.1047

**Patients' and doctors' views on shared decision making in the use of antidepressants for depression**

*S. Zaini, M.A. Said\*, A.H. Sulaiman, H.A.M. Bharathy, C.G. Ng, H. Zaman Huri, J.S. Gill, S.H. Shamsudin (Malaysia)*

Mood and bipolar disorder; Pharmacology - Method

## EP.1048

**Co-morbid anxiety disorders in outpatients with schizophrenia: prevalence and relationship to functionality and quality of life**

*J.S. Gill\*, A.H. Sulaiman, M.A. Said, W.J. Lee (Malaysia)*

Psychotic disorder; Anxiety - Disorder

## EP.1049

**Association among technology use, geriatric depression, wellbeing and social anticipation in elderly**

*C.Y. Lee\*, Y.D. Huang, S.N. Jiang, Y.H. Chang, Y.H. Hung, S.C. Ching, M.Y. Hsiao, Y.R. Hsu (Taiwan)*

Healthy brain; Dementia & neuro degeneration - Disorder

## EP.1050

**First-episode affective psychosis: what makes them different?**

*N. Fernandes\*, M. Martins, I. Fernandes (Portugal)*

Psychotic disorder; Mood and bipolar disorder

## EP.1051

**Novel interactive eye tracking game for training attention in children with attention deficit and hyperactivity disorder**

*A. García Baos\*, T. D'Amelio, P. Collins, E. Liddle, H. Super (Spain)*

ADHD - Disorder; Autism / ASD - Disorder

## EP.1052

**Assessment of the family burden associated with severe mental illness in Azerbaijan**

*J. Ismayilova\* (Azerbaijan)*

Lifestyle and nutrition - Intervention; Psychotic disorder

## EP.1053

**A post hoc analysis from 3 randomized studies comparing relapse in patients with schizophrenia treated with 3 different paliperidone formulations**

*M. Mathews, S. Gopal, A. Singh, I. Nuamah, A.M. Quinn, K. Pungor\*, W. Tan, B. Soares, E. Kim, A. Savitz (Germany)*  
Psychotic disorder; Prevention / course alteration

## EP.1054

**Dimethyl fumarate affects spleen lymphocyte production of interleukin 6 in streptozotocin induced model of Alzheimer's disease in rats**

*J. Dunacka\*, J. Marchewka, M. Wyroślak, M. Gratek, G. Świętek, I. Majkutewicz, B. Grembecka, W. Glac, D. Wrona (Poland)*  
Dementia & neuro degeneration - Disorder; Immunology - Method; Animal models - Method

## EP.1055

**The efficacy of oculomotor training in patients with schizophrenia**

*M. Skuhareuskaya\*, I. Obyedkov, N. Shpak, O. Portnova, T. Skuhareuskaya, P. Buslauski (Belarus)*  
Psychotic disorder; Prevention / course alteration; Neurophysiology / EEG - Method

## EP.1056

**Lurasidone for the treatment of adults with schizophrenia: practical guidance and consensus recommendations**

*A. Javed\*, H. Arthur, L. Curtis, L. Hansen, S. Pappa (United Kingdom)*  
Psychotic disorder; Pharmacology - Intervention

## EP.1057

**Adiponectin and resistin in depression: correlation with clinical and biochemical factors**

*M. Malewska\*, A. Permoda-Osip, F. Rybakowski, J. Rybakowski (Poland)*  
Lifestyle and nutrition - Intervention; Mood and bipolar disorder; Prevention / course alteration

## EP.1058

**Concordance toward the expectation for medication among the patients of depressive, bipolar disorders and psychotic disorders**

*H.R. Song\*, H.S. Kim, B.W. Nam (South-Korea)*  
Pharmacology - Intervention; Mood and bipolar disorder; Psychotic disorder

## EP.1059

**The use of vortioxetine in patients with depression and cognitive disorders**

*G. Provenzano\*, S. Provenzano, M. Conte (Italy)*  
Dementia & neuro degeneration - Disorder; Pharmacology - Intervention

## EP.1060

**Screening with the Korean version of the mood disorder questionnaire for bipolar disorders in adolescents: Korean validity and reliability study**

*S.H. Shim\*, H.Y. Jung, S.W. Hahn, J.C. Yang (South-Korea)*  
Mood and bipolar disorder; Neuropsychology - Method

## EP.1061

**Psychiatric problems in patients with pneumothorax**

*K.S. Lee\*, J.H. Kim (South-Korea)*  
Stress related disorder; Anxiety - Disorder

## EP.1062

**Olanzapine in somatic symptom disorder**

*M. Chioccioli\*, C. Crapanzano, A. Politano, B. Beccarini Crescenzi, A. Fagiolini (Italy)*  
Pharmacology - Intervention; Healthy brain

## EP.1063

**Effects of sildenafil on depressive-like behaviors associated with cigarette smoking in rats**

*Y. Yazir\*, T. Utkan, G. Gacar, C. Ozer, T. Demirtaş Şahin, S.S. Gocmez (Turkey)*  
Mood and bipolar disorder; Pharmacology - Method

## EP.1064

**The effect of fabomotizole under 'Open Field' stress on sigma-1 receptor's intracellular translocation in brains of inbred BALB/c and B6 mice**

*E. Abramova\*, M. Voronin, R. Kurbanov, S. Seredenin (Russia)*  
Anxiety - Disorder; Pharmacology - Method; Stress related disorder

## EP.1065

**Do really lithium increase the prevalence of psoriasis in bipolar disorder?**

*L. Ros\*, I. Figueroa, S. Crivillés, E. Aguilar, E. Patró, J.D. Barbero, N. Cardoner, X. Labad, J.A. Monreal, D. Palao, J. Cobo (Spain)*  
Mood and bipolar disorder; Pharmacology - Method

## EP.1066

**Efficacy of THN201, a new combination between mefloquine and donepezil low-dose, on neurocognitive disorders linked to Alzheimer's disease**

*M. Droguerre\*, A. Duchêne, J. Meunier, F. Mouthon, M. Charvériat (France)*

Dementia & neuro degeneration - Disorder;  
Pharmacology - Intervention

## EP.1067

**Serotonergic antidepressants as maintenance therapy in anxious depression**

*M. Uzbekov\*, N. Maximova (Russia)*

Anxiety - Disorder; Pharmacology - Intervention;  
Prevention / course alteration

## EP.1068

**Major offenders, not criminally responsible due to psychiatric disorder - comparing violence risk between hospital and prison detained subjects**

*H. Prata Ribeiro\*, A. Ponte, M. Duarte, B. Lourenço, S. Bernardes, A. Molodynski, S. Alves, F. Vieira (Portugal)*

History / philosophy / ethics - Method; Psychotic disorder

## EP.1069

**Relationship between cognitive remediation and atypical antipsychotics in negative syndrome of schizophrenia**

*F. Franza\*, G. Del Buono, P. Ferdinando, G. Aldi, G. Tavormina, B. Solomita (Italy)*

Psychotic disorder; Pharmacology - Intervention

## EP.1070

**Psychiatry manifestations during hormonal replacement treatment in salt-wasting adrenal congenital hyperplasia: a case report**

*M. Valverde Barea\*, S. Jiménez Fernández, G. Ruiz Martínez, I. Martínez Reyes, M.I. Rodríguez Natal (Spain)*

Intellectual disability disorder; Impulsive and compulsive disorder; Genetic & molecular approaches - Method

## EP.1071

**Genes involved in neurodevelopment, neuroplasticity, and bipolar disorder: CACNA1C, CHRNA1, and MAPK1**

*T.Y. Jun\* (South-Korea)*

Genetic & molecular approaches - Method; Mood and bipolar disorder

## EP.1072

**The role of astrocytes in the early-life stress induced programming of the brain**

*M. Abbink\*, E.F.G. Naninck, K. Yam, P.J. Lucassen, A. Korosi (The Netherlands)*

Lifestyle and nutrition - Intervention; Stress related disorder; Neuro-inflammatory disorder

## EP.1073

**Mobbing, workplace bullying and psychological pain (case report)**

*S. Arsova\*, S. Bajraktarov, N. Manusheva (Macedonia)*

Stress related disorder; Anxiety - Disorder

## EP.1074

**Anxiety and depression levels and quality of life during the follow-up period after lung cancer surgery: a preliminary study**

*D. Ozden Omaygenc, U. Ozer\*, O. Isgorucu (Turkey)*

Prevention / course alteration; Anxiety - Disorder

## EP.1075

**Psychiatric comorbidity in patients with posttraumatic stress disorder and enduring personality change after catastrophic experience**

*L. Bradic\*, D. Begic, I. Lokmic-Pekic, A. Hrnjica, M. Ahmic (Bosnia and Herzegovina)*

Stress related disorder; Addiction - Disorder; Mood and bipolar disorder

## EP.1076

**Sociodemographic characteristics and clinical variables as predictors for rehospitalisation in psychiatric hospital**

*I. Lokmic-Pekic, L. Bradic\*, A. Hrnjica, R. Softic, S. Nejra, D. Begic (Bosnia and Herzegovina)*

Psychotic disorder; Addiction - Disorder

## EP.1077

**The role of parenting style and adult attachment for eating disorder: systematic review and meta-analysis**

*H.Y. Jung\*, W. Hahm, K.S. Na (South-Korea)*

Eating disorder; Lifestyle and nutrition - Intervention

## EP.1078

**Aripiprazole monotherapy from acute to long acting therapy**

*F. Chimenz\*, N. Gambardella (Italy)*

Pharmacology - Method; Pharmacology - Intervention

## EP.1079

**Influencing behaviour via the microbiome: the effect of OM-85 bacterial extract in neurodevelopmental disorders**

S. Dam\*, J. Szopinska, C. Belzer, J. Buitelaar, A. Arias-Vasquez, J. Glennon (The Netherlands)  
Autism / ASD - Disorder; Animal models - Method; ADHD - Disorder

## EP.1080

**Mouse model of depression and anxiety in females**

I. Kovalenko\*, G. Vishnivetskaya, D. Smagin, M. Marenina, D. Avgustinovich, N. Kudryavtseva (Russia)  
Animal models - Method; Stress related disorder

## EP.1081

**Relationship of glutamatergic and autistic gene expression in the hippocampus of male mice with disturbances of social behaviour**

I. Kovalenko\*, A. Galyamina, D. Smagin, K. Baranov, N. Kudryavtseva (Russia)  
Autism / ASD - Disorder; Stress related disorder

## EP.1082

**Competence of agitated patients to make reasonable decisions into their treatment**

B. Pacciardi\*, A. Calcedo, A. Gracia (Italy)  
History / philosophy / ethics - Method; Mood and bipolar disorder; Pharmacology - Intervention

## EP.1083

**Structural and metabolic cerebral alterations between elderly bipolar disorder and behavioral variant frontotemporal dementia: a pilot MRI-PET study**

G.M. Mandolini\*, G. Delvecchio, A. Arighi, C. Prunas, A.M. Pietrobboni, G. Marotta, C. Cinnante, F.M. Triulzi, D. Galimberti, E. Scarpini, A.C. Altamura, P. Brambilla (Italy)  
Neuroimaging - Method; Mood and bipolar disorder; Dementia & neuro degeneration - Disorder

## EP.1084

**Use of clozapine in self-harm**

C. Taddeucci\*, M.A. Trusso, A. Goracci, A. Fagiolini (Italy)  
Pharmacology - Intervention; Impulsive and compulsive disorder

## EP.1085

**Dose- and time-dependent effects of biperiden on memory performance**

S. Caldenhove\*, L. Borghans, J. Ramaekers, A. Sambeth, A. Blokland (The Netherlands)  
Healthy brain; Neurophysiology / EEG - Method; Neuropsychology - Method

## EP.1086

**The complex association between the antioxidant defense system and clinical status in early psychosis**

S. García Fernández\*, S. Alberich, M. Martínez-Cengotitabengoa, C. Arango, J. Castro-Fornieles, M. Parellada, I. Baeza, C. Moreno, J.A. Micó, E. Berrocoso, M. Graell, S. Otero, T. Simal, A. González-Pinto (Spain)  
System biology - Method; Psychotic disorder

## EP.1087

**Treatment emergent adverse effect measures adapted for the Romanian language: a pilot study**

M. Muntean\*, S. Andronic, D.C. Matees, A. Moraru, L.C. Pantelimon, C. Suru, V.R. Enatescu (Romania)  
Psychotic disorder; Psychotherapy - Intervention

## EP.1088

**Anxiolytic-like effect of chlorogenic acid, gallic acid and ferulic acid in olfactory bulbectomized rats**

S. Valcheva-Kuzmanova\*, M. Todorova, I. Belcheva, S. Belcheva, R. Tashev (Bulgaria)  
Animal models - Method; Pharmacology - Method; Anxiety - Disorder

## EP.1089

**Persistent hiccups induced by fluoxetine and sertraline - a case report**

D.C.L. Teo\*, C.S. Lim, E.K.M. Wuan, S.N. Tan (Singapore)  
Pharmacology - Intervention; Anxiety - Disorder; Mood and bipolar disorder

## EP.1090

**Comparison of dose dependent subjective alcohol intoxication effects (predicted, real and recalled) in healthy volunteers**

J. Mateus, P. Diaz-Pellicer\*, C. Pérez-Mañá, K. Langorh, F. Fonseca, M. Torrens, M. Farré, R. De la Torre (Spain)  
Lifestyle and nutrition - Intervention; Pharmacology - Intervention; Neuropsychology - Method



## EP.1091

**The effect of chronic neonatal injection of arginine vasopressin (6-9) on the social behaviour of rats***A. Selezneva\* (Russia)*

Neuromodulation - Intervention; Neuropsychology - Method; Biostatistics &amp; computational method

## EP.1092

**Influence of original structural analogue AVP (6-9) Ac-D-MPRG on exploratory activity and level of anxiety of white rats***A. Stakhanova\*, O. Voskresenskaya, A. Kamensky, V. Golubovich (Russia)*

Animal models - Method; Pharmacology - Intervention

## EP.1093

**Cardiovascular disease and depression: biological correlations***P. Barata\*, J.C. Melo, T. Maia (Portugal)*

Mood and bipolar disorder; Neuro-inflammatory disorder; Stress related disorder

## EP.1094

**Inhaled loxapine in the management of acute agitation: an open-label study***E. Bonnard\*, M.O. Krebs, F. Rivollier (France)*

Pharmacology - Intervention; Psychotic disorder; Mood and bipolar disorder

## EP.1095

**Sleep quality may moderate the impairment of neuropsychological performance in patients with bipolar disorder***Y.R. Hsu\*, Y.H. Chang, T.Y. Wang, P.S. Chen, C.L. Huang, C. Hao-Wen, R.B. Lu (Taiwan)*

Mood and bipolar disorder; Neuropsychology - Method

## EP.1096

**Psychiatry manifestations of yuan-harel-lupski syndrome: a case report***S. Jimenez Fernández, M. Valverde Barea\*, M.P. Vargas Melero, I. Martínez Reyes, I. Rodríguez Natal (Spain)*

Autism / ASD - Disorder; Genetic &amp; molecular approaches - Method; Impulsive and compulsive disorder

## EP.1097

**Reducing the rate and duration of ReADMISsions among patients with unipolar disorder using smartphone-based monitoring and treatment: the RADMIS trial***M. Tønning\*, M. Faurholt-Jepsen, M. Frost, K. Martiny, N. Tuxen, N. Rosenberg, J. Busk, O. Winther, J.E. Bardram, L.V. Kessing (Denmark)*

E-health - Intervention; Mood and bipolar disorder

## EP.1098

**Prolactin, flupenthixol decanoate and first episode schizophrenia – clinical and laboratory correlates***M. Retief\*, L. Asmal, B. Chiliza, L. Phahladira, R. Emsley (South Africa)*

Psychotic disorder; Biochemistry - Method

## EP.1099

**Alcohol withdrawal syndrome and delirium tremens in inpatient care: a clinical epidemiological study***I. Kovács\*, C.S. Kovács, B.A. Lázár, A. Bajsz, J. Daróczy, D. Lakatos, I. Demeter, Z. Demetrovics, J. Kálmán, Z. Janka, B. Andó (Hungary)*

Addiction - Disorder; Epidemiology and big data - Method

## EP.1100

**How does alexithymia affects psychological and physical symptoms in patients with non-cardiac-atypical chest***S. Jang\* (South-Korea)*

Anxiety - Disorder; Pain and headache

## EP.1101

**Polytherapy versus monotherapy in the treatment of first episode of psychosis***A. Hrnjica\*, S. Bise, R. Šetić, I. Lokmić- Pekić,**B. Kurtović, Š. Šarkić- Bedak (Bosnia and Herzegovina)*

Psychotic disorder; Pharmacology - Method

## EP.1102

**Metacognitive awareness of medical students declined during the first three years of study***M. Tatić\*, M. Simonović (Serbia)*

Neuropsychology - Method; Epidemiology and big data - Method

## EP.1103

### Potential neuroprotective activity of alkaloid securinine derivatives

*S. Klochkov\*, M. Neganova, E. Shevtsova, S. Pukhov, E. Dubrovskaya (Russia)*

Biochemistry - Method; Dementia & neuro degeneration - Disorder; Pharmacology - Intervention

## EP.1104

### Effects of temperament and personality, defenses, and psychological characteristics on major depressive disorder

*B.H. Koo\*, W.S. Seo, H.M. Sung, E.J. Cheon, H.G. Kim, Y.J. Lee, W.S. Choi, M.S. Keum, S.H. Jo, J.H. Choi, J.W. Kim, N.Y. Kong, S. Koo, B.R. Kim (South-Korea)*

Mood and bipolar disorder; Stress related disorder

## EP.1105

### Antenatal depressive symptoms and associated risk factors among Korean pregnant women

*S.J. Baek\*, S.Y. Kwon, E.Y. Seo, J. Nam, C.H. Lee, K.S. Choi (South-Korea)*

Mood and bipolar disorder; Prevention / course alteration

## EP.1106

### Depression on neuro-oncology

*M.F.G. Martins\*, M. Maldaum, C.L. Lancellotti (Brazil)*

Epidemiology and big data - Method; Mood and bipolar disorder; Prevention / course alteration

## ECNP MEMBERSHIP

Join – and support – one of the leading scientific associations promoting brain research and the interests of brain researchers in Europe.

### Benefits related to the ECNP Congress

- Significantly reduced registration fees for the ECNP Congress.
- Exclusive access to the Members' and Faculty lounge at the ECNP Congress.
- ECNP members can bring one junior scientist to the ECNP Congress for € 100.
- The possibility to host a brainstorming session at the next congress.

### Access to the latest information and research

- Free online subscription to the ECNP journal *European Neuropsychopharmacology*.
- Ability to join an ECNP Network.
- Ability to participate in an ECNP-ISCTM working group.
- Access to the ECNP members' website.
- Access to a member directory ('find a member'), to connect to a wide network of ECNP members.

### More opportunities

- Input into ECNP policy, by means of voting at the General Assembly (ordinary members only).
- Serve on an ECNP committee and help shape ECNP's future.
- Apply for an invitation to the ACNP Annual Meeting.

For more information, go to  
[www.ecnp.eu/membership](http://www.ecnp.eu/membership)

**07.45-08.45 BRAINSTORMING SESSIONS**

- BS.04 Improving translation of preclinical research to the treatment of substance use disorders **Room 122**
- BS.05 Do we have biomarkers available for schizophrenia? **Room 123**
- BS.06 Why, when and how should clinicians assess cognition in their patients with mood disorders? **Room 124**

**09.00-10.00 EXPERT SCIENCE EXCHANGE (industry session)**

- CE.03 Pathways to recovery: matching symptoms with brain circuits for personalised treatment of major depressive disorder **Room 118**

**09.00-17.00 EXHIBITION**

**09.00-10.40 SCIENTIFIC SYMPOSIA**

- S.13 Thinking mental health outside of the brain box: the interplay between mind, body and environment **Room 112**
- S.14 New findings in applied neuroscience **Room 113**
- S.15 Towards personalised treatment of bipolar disorder: searching for predictors of lithium-response and suicidality in patients **Room 114**
- S.16 PANEL DISCUSSION – More same than different? The state of evidence for shared etiologies across psychiatric disorders **Room 117**
- E.04 Transcranial Magnetic Stimulation (TMS): from benchmark to bedside **Room 115**

**09.00-09.45 CAMPFIRE SESSIONS**

- CA.03 The PRISM project: precision medicine comes to neurosymptomatics **The Bubble**
- CA.04 Mental health promotion **The Bubble**

**10.40-11.15 COFFEE BREAK & POSTER VIEWING**

Poster area and exhibition

**10.45-11.10 POSTER JAM**

- J.04 Psychotic disorders **The Circle 1**
- J.05 Addiction **The Circle 2**
- J.06 Pharmacology **The Circle 3**

**11.15-12.00 PLENARY LECTURE**

- PL.03 Anna Monika Award lecture – Neurotrophic factors and neuronal plasticity in antidepressant drug responses **Room 112**

**12.00-13.30 LUNCH** Poster area and exhibition

**12.10-12.40 CAREER DEVELOPMENT SESSION**

- CD.02 Research and mass media in a 'post-truth' world: future challenges and career opportunities **The Bubble**

**12.10-12.40 TOP PAPER SESSIONS**

- TP.03 Highlights in psychotic disorders **Room 113**
- TP.04 Highlights in child and adolescent disorders **Room 114**

**12.15-13.15 GENERAL ASSEMBLY OF ECNP MEMBERS**

Room 115



**13.30-14.15 PLENARY LECTURE**

- PL.04 Brain Prize lecture – Pathogenesis of autoimmune disease and the role of autoimmunity in psychiatric disease **Room 112**

**14.15-14.45 COFFEE BREAK** Poster area and exhibition

**14.20-14.40 TRAVEL AWARD CEREMONY** The Circle

**14.45-15.45 EXPERT SCIENCE EXCHANGE (industry session)**

- CE.04 Discovering ADHD in adults **Room 118**

**14.45-16.25 SCIENTIFIC SYMPOSIA**

- S.17 The effects of cannabis on mental health: who is vulnerable and who is resilient? **Room 113**
- S.18 Big data and machine learning in psychiatry: technological breakthroughs for the clinic of the future **Room 112**
- S.19 Targeting brain energy metabolism to understand and treat mood psychopathologies **Room 114**
- S.20 ECNP-INSPIRED – From psychedelics to fish on bikes: learning from the unusual **Room 117**
- E.05 Which diagnosis, which treatments in infant psychiatry **Room 115**

**15.45-16.45 EXPERT SCIENCE EXCHANGE (industry session)**

- CE.05 Discovering ADHD in adults **Room 118**

**16.30-18.30 POSTER SESSION & DRINKS** Poster area

**17.15-18.45 SATELLITE SYMPOSIA (industry sessions)**

- C.10 New trends in schizophrenia research and therapeutic practices **Room 112**
- C.11 Mild cognitive impairment (MCI): age-associated burden or treatable disease? **Room 113**
- C.12 Functional recovery in major depressive disorder in the age of personalised medicine **Room 114**
- C.13 Dopamine D2 partial agonists in the treatment of schizophrenia – finding the right balance **Room 115**

**18.00-18.10 POSTER AWARD CEREMONY** The Circle

**20.30-23.00 SCIENCE-ON-THE-ROCKS**

**BS.04 | BRAINSTORMING SESSION**

07.45-08.45 | Room 122

**Improving translation of preclinical research to the treatment of substance use disorders**Chairs: *Jaanus Harro, Estonia*Experts: *Louk Vanderschuren, The Netherlands*  
*Anton Y. Bespalov, Germany***BS.05 | BRAINSTORMING SESSION**

07.45-08.45 | Room 123

**Do we have biomarkers available for schizophrenia?**Chair: *Michael Davidson, Israel*Experts: *Dan Rujescu, Germany*  
*Florence Thibaut, France***BS.06 | BRAINSTORMING SESSION**

07.45-08.45 | Room 124

**Why, when and how should clinicians assess cognition in their patients with mood disorders?**Chair: *Kerstin Jessica von Plessen, Switzerland*Experts: *Kamilla Miskowiak, Denmark*  
*Eduard Vieta, Spain***S.13 | SYMPOSIUM**

09.00-10.40 | Room 112

**Thinking mental health outside of the brain box: the interplay between mind, body and environment**Chairs: *Igor Branchi, Italy*  
*Andreas Meyer-Lindenberg, Germany***S.13.01 | 09.00**Brain energy metabolism regulates vulnerability to stress  
*Carmen Sandi, Switzerland***S.13.02 | 09.25**Drug by environment interaction in antidepressant treatment: SSRIs amplify the influence of the living conditions on mood  
*Igor Branchi, Italy***S.13.03 | 09.50**Diet and physical activity impact on mood disorder vulnerability and course  
*Brenda Penninx, The Netherlands***S.13.04 | 10.15**Brain mechanisms of environmental risk for schizophrenia  
*Andreas Meyer-Lindenberg, Germany***S.14 | NEW FINDINGS SYMPOSIUM**

09.00-10.40 | Room 113

**New findings in applied neuroscience**Chair: *Raymond Mongeau, France***S.14.01 | 09.04**Involvement of the GluN2C subunit in the psychotomimetic effects of ketamine and other GluN receptor antagonists  
*Mireia Tarrés-Gatius, Spain***S.14.02 | 09.16**Distinctive neural response towards certain and conditional monetary loss in adolescents with attentiondeficit/hyperactivity disorder  
*Jeroen Van Dessel, Belgium***S.14.03 | 09.28**The diminishing role of testosterone on emotional control during adolescence  
*Anna Tyborowska, The Netherlands***S.14.04 | 09.40**Unraveling real-life influences on city dwellers mental health via GPS-triggered electronic diaries and neuroscience  
*Markus Reichert, Germany*

**S.14.05 | 09.52**

Optical activation of TrkB receptors in Parvalbumin interneurons reopens critical periods in the adult visual cortex  
*Frederike Winkel, Finland*

**S.14.06 | 10.04**

Differential long-lasting behavioural and molecular effects of microbiota perturbations during the adolescent period in mice  
*Christine Fülling, Ireland*

**S.14.07 | 10.16**

Cellular substrate of developmental hypofrontality in a mouse model of mental disorders  
*Jastyn Pöppl, Germany*

**S.14.08 | 10.28**

Epigenetic aging in major depressive disorder  
*Laura Han, The Netherlands*

**S.15 | SYMPOSIUM**

09.00-10.40 | Room 114

**Towards personalised treatment of bipolar disorder: searching for predictors of lithium-response and suicidality in patients**

Chair: *Frank Bellivier, France*

**S.15.01 | 09.00**

Barriers to optimising benefits of lithium treatment – reliability and utility of response scales, and clinical strategies to close the efficacy-effectiveness gap  
*Jan Scott, United Kingdom*

**S.15.02 | 09.25**

Non-genetic predictors of lithium response in bipolar disorder  
*Frank Bellivier, France*

**S.15.03 | 09.50**

Suicidal behaviour in bipolar disorder – the role of genetics and early adverse environment  
*Barbara Arias, Spain*

**S.15.04 | 10.15**

Genome wide association studies for patients with bipolar disorders – ConLiGen research  
*Thomas G. Schulze, Germany*

**S.16 | ALTERNATIVE SESSION**

09.00-10.40 | Room 117

**PANEL DISCUSSION – More same than different? The state of evidence for shared etiologies across psychiatric disorders**

Moderators: *Mark Weiser, Israel*  
*Hilleke Hulshoff Pol, The Netherlands*

Introduction by the moderators

**S.16.01 | 09.05**

Epidemiology of shared genetic risk across psychiatric disorders  
*Mark Weiser, Israel*

**S.16.02 | 09.20**

Schizophrenia and the neurodevelopmental continuum; new support from genomics  
*Michael J. Owen, United Kingdom*

**S.16.03 | 09.35**

The baseline and longitudinal course of cognition across 3 major psychiatric disorders  
*Abraham Reichenberg, USA*

**S.16.04 | 09.50**

Structural brain abnormalities and psychopathology with increased familial risk for psychosis  
*Hilleke Hulshoff Pol, The Netherlands*

**10.05**

Panel discussion

For industry sessions, please see the 'Industry' tab in this booklet.

**E.04 | EDUCATIONAL UPDATE SESSION**

09.00-10.40 | Room 115

**Transcranial Magnetic Stimulation (TMS):  
from benchmark to bedside***Moderator: Stefano Pallanti, Italy***E.04.01 | 09.05**TMS: general principles and physiological mechanisms  
*Joan Camprodon, USA***E.04.02 | 09.50**TMS and neuroplasticity  
*Martijn Figeer, The Netherlands***CA.03 | CAMPFIRE SESSION**

09.00-09.45 | The Bubble

**The PRISM project: precision medicine comes  
to neurosymptomatics***Experts: Martien Kas, The Netherlands  
Hugh M. Marston, United Kingdom***CA.04 | CAMPFIRE SESSION**

09.00-09.45 | The Bubble

**Mental health promotion***Experts: Stefan Borgwardt, Switzerland***COFFEE BREAK**

10.40-11.15 | Poster area and exhibition

**POSTER VIEWING**

10.40-11.15 | Poster area

Posters that are on display can already be viewed during this time. It is not mandatory for poster presenters to be at their poster, the official poster session will start at 16.30.  
See pages 144-228 for details.

**J.04 | POSTER JAM**

10.45-11.10 | The Circle 1

**Psychotic disorders***Moderator: Iria Grande, Spain***J.05 | POSTER JAM**

10.45-11.10 | The Circle 2

**Addiction***Moderator: t.b.a.***J.06 | POSTER JAM**

10.45-11.10 | The Circle 3

**Pharmacology***Moderator: t.b.a.***PL.03 | PLENARY LECTURE**

11.15-12.00 | Room 112

**Anna Monika Award lecture***Chair: Elisabeth Binder, Germany***EERO CASTRÉN**  
FINLAND**Neurotrophic factors  
and neuronal plasticity  
in antidepressant drug  
responses****LUNCH**

12.00-13.30 | Poster area and exhibition

**CD.02 | CAREER DEVELOPMENT SESSION**

12.10-12.40 | The Bubble

**Research and mass media in a 'post-truth' world: future challenges and career opportunities**Chair: *Emma Robinson, United Kingdom*Presenter: *Thomas Parkhill, Italy***TP.03 | TOP PAPER SESSION**

12.10-12.40 | Room 113

**Highlights in psychotic disorders**Chair: *Kim Q. Do, Switzerland*Presenter: *Florence Thibaut, France***TP.04 | TOP PAPER SESSION**

12.10-12.40 | Room 114

**Highlights in child and adolescent disorders**Chair: *Mara Parellada, Spain*Presenter: *Josefina Castro-Fornieles, Spain***GENERAL ASSEMBLY OF ECNP MEMBERS**

12.15-13.15 | Room 115

**PL.04 | PLENARY LECTURE**

13.30-14.15 | Room 112

**Brain Prize lecture**Chair: *Michelle Roche, Ireland***JOSEP DALMAU**

USA

**Pathogenesis of autoimmune disease and the role of autoimmunity in psychiatric disease****COFFEE BREAK**

14.15-14.45 | Poster area and exhibition

**AWARD CEREMONY**

14.20-14.40 | The Circle

Presentation ECNP Travel Awards

**S.17 | SYMPOSIUM**

14.45-16.25 | Room 113

**The effects of cannabis on mental health: who is vulnerable and who is resilient?**Chairs: *Valerie Curran, United Kingdom**Alexandra Eva Sulcová, Czech Republic***S.17.01 | 14.45**

How do different cannabinoids in cannabis influence vulnerability to mental health problems?

*Valerie Curran, United Kingdom***S.17.02 | 15.10**

What determines an individual's vulnerability to cannabis dependence?

*Peggy van der Pol, The Netherlands*

**S.17.03 | 15.35**

Vulnerability to psychosis: the role of genetics and insights from studies on cannabinoid-induced acute persistent psychosis (CIAPP)  
*Deepak Cyril D'Souza, USA*

**S.17.04 | 16.00**

Effects of cannabis on the adolescent brain  
*Joanna Jacobus, USA*

**S.18 | SYMPOSIUM**

14.45-16.25 | Room 112

**Big data and machine learning in psychiatry: technological breakthroughs for the clinic of the future**

Chairs: *Tim Hahn, Germany*  
*Susan Whitfield-Gabrieli, United Kingdom*

**S.18.01 | 14.45**

Imaging epidemiology: big data for precision medicine  
*Christian Beckmann, The Netherlands*

**S.18.02 | 15.10**

Machine learning technology for neuroimaging in psychiatry  
*Janaina Mourao-Miranda, United Kingdom*

**S.18.03 | 15.35**

From group-based inference to personalised medicine – large-scale clinical datasets for biomarker discovery  
*Susan Whitfield-Gabrieli, United Kingdom*

**S.18.04 | 16.00**

Deep learning for personalised medicine  
*Tim Hahn, Germany*

**UPDATED PROGRAMME:**

<https://2018.ecnp.eu/> / ECNP app / congress info terminals

**S.19 | SYMPOSIUM**

14.45-16.25 | Room 114

**Targeting brain energy metabolism to understand and treat mood psychopathologies**

Chairs: *Christopher R. Pryce, Switzerland*  
*Marco Andrea Riva, Italy*

**S.19.01 | 14.45**

Brain energy metabolism and its disruption  
*Pierre J. Magistretti, Switzerland*

**S.19.02 | 15.10**

Molecular imaging of brain oxygen metabolism and mitochondrial function  
*Alessandro Colasanti, United Kingdom*

**S.19.03 | 15.35**

Stress, brain mitochondria and psychiatric disorders  
*Freddy Jeanneteau, France*

**S.19.04 | 16.00**

Mouse models for stress- and inflammation-induced changes in energy metabolism  
*Christopher R. Pryce, Switzerland*

**S.20 | ALTERNATIVE SESSION**

14.45-16.25 | Room 117

**ECNP-INSPIRED – From psychedelics to fish on bikes: learning from the unusual**

Short inspirational talks

Chair: *Astrid C.E. Linthorst, United Kingdom*

Introduction by the chair

**S.20.01 | 14.50**

Psychiatry without ethics is like fish riding bicycles  
*Damiaan Denys, The Netherlands*

**S.20.02 | 15.10**

Time to open up your mind to psychedelics in psychiatry?  
*David Nutt, United Kingdom*



## MONDAY SESSIONS

### S.20.03 | 15.30

Enhancing cognition in patients with psychiatric disorders and in healthy people

*Barbara J. Sahakian, United Kingdom*

### S.20.04 | 15.50

The biology of insomnia: the forgotten yet second-most common mental disorder

*Eus J.W. van Someren, The Netherlands*

### S.20.05 | 16.10

Genomics: finally a path towards new drugs in psychiatry

*Stephan Ripke, USA*

## E.05 | EDUCATIONAL UPDATE SESSION

14.45-16.25 | Room 115

### Which diagnosis, which treatments in infant psychiatry

*Moderator: Kai von Klitzing, Germany*

#### E.05.01 | 14.50

The formulation of psychopathology in infancy through the lens of the Diagnostic Classification DC:0-5

*Miri Keren, Israel*

#### E.05.02 | 15.35

Treatment approaches for psychopathology in infancy

*Kaija Puura, Finland*

## POSTER SESSION & DRINKS

16.30-18.30 | Poster area

## AWARD CEREMONY

18.00-18.10 | The Circle

Presentation ECNP Poster Awards



For industry sessions, please see the 'Industry' tab in this booklet.

# European Neuropsychopharmacology

## Neuroscience Applied



## Journal benefits

- Free online access for subscribers and ECNP members
- Easy online submission via Journal website ([ees.elsevier.com/neuropsychopharmacol](http://ees.elsevier.com/neuropsychopharmacol))
- Mobile optimised website for easy viewing

[www.europeanneuropsychopharmacology.com](http://www.europeanneuropsychopharmacology.com)

@els\_psychiatry

[facebook.com/elsevierpsychiatry](https://facebook.com/elsevierpsychiatry)

**ECNP**  
neuroscience applied

ELSEVIER

P.500

**Visfatin levels in patients with and without metabolic syndrome in cases of bipolar depression**

*P. Osip, A. Permoda-Osip\*, M. Dmitrzak-Węglarz, J. Rybakowski, F. Rybakowski (Poland)*

Mood and bipolar disorder; Pharmacology - Intervention

P.501

**Dysregulation of the nitric oxide pathway as a risk factor for increased cardiovascular risk in patients with major depression**

*J.M. Le Melleo\* (Canada)*

Mood and bipolar disorder; Neuropsychology - Method

P.502

**Clinical audit: TAILOR - Target Antidepressant Initiation choice to unLock positive patient Outcomes and Response**

*J. Hopwood\* (Australia)*

Mood and bipolar disorder; Pharmacology - Intervention

P.503

**Association of polymorphic variants of genes of kinase signaling pathways with atypical depression**

*N. Vyalova\*, I. Losenkov, G. Simutkin, S. Ivanova (Russia)*

Mood and bipolar disorder; Genetic & molecular approaches - Method

P.504

**Increased oxidative stress in the frontal cortex of suicide victims is associated with changes in NMDA receptor, AMPK activity and magnesium level.**

*M. Sowa-Kućma\*, P. Panczyszyn-Trzewik, P. Misztak, G. Nowak (Poland)*

Mood and bipolar disorder; Post-mortem / pathology - Method; Stress related disorder

P.505

**Evaluation of suicide attempt by using medicines and chemicals**

*G. Kavak\* (Turkey)*

Mood and bipolar disorder; Personality disorder; Psychotic disorder

P.506

**Impact of sleep quality on cognitive performance and heterogeneity of depression in patients with major depressive disorder (MDD)**

*E. Berdzenishvili\*, M. Okruashvili, M. Roinishvili, T. Gamyreliдзе, E. Chkonia (Georgia)*

Mood and bipolar disorder; Sleep disorder

P.507

**Relationship between remission and recovery from a depressive episode and 5HTR2A gene polymorphisms in a child and adolescent sample**

*A. Blazquez Hinojosa\*, P. Gassó, N. Rodríguez, D. Boloc, T. Torres, S. Mas, A. Lafuente, L. Lázaro (Spain)*

Mood and bipolar disorder; Genetic & molecular approaches - Method

P.508

**The relation between interhemispheric microstructural deficits and illness course in bipolar disorder**

*R. Queissner\*, S. Seiler, A. Birner, M. Tschernegg, R. Pilz, N. Dalkner, S. Bengesser, M. Platzer,*

*F. Fellendorf, C. Hamm, A. Maget, J. Wagner-Skacel, B. Reininghaus, E. Reininghaus (Austria)*

Mood and bipolar disorder; Neuroimaging - Method

P.509

**Academic and social functioning in early life epochs in schizophrenia patients and first-degree unaffected relatives**

*Bucci, P. Mucci, A.\* Rossi, A. Rocca, P. Bertolino, A. Galderisi, S. Maj, M. (Italy)*

Psychotic disorder; Neuropsychology - Method

P.510

**Lithium versus quetiapine and aripiprazole: real-world comparative effectiveness on bipolar disorder patients**

*V. Fricchione Parise\*, L. Addeo, R. Laezza, R. Di Benedetto, E. De Vivo, P. Bianco (Italy)*

Mood and bipolar disorder; Pharmacology - Intervention; Prevention / course alteration

P.511

**Objective quantification of psychomotor dynamics during pharmacological treatment of unipolar depression**

*S. Haralanov, P. Terziyanova\*, E. Haralanova, R. Dimitrov, D. Bogdanova, E. Milushev, G. Dzhupanov (Bulgaria)*

Mood and bipolar disorder; Pharmacology - Intervention

P.512

**ONO-2910640, a potent TRPC4/5 inhibitor, produced rapid-onset antidepressant-like effect in mice**

*A. Kishi\*, T. Niwa, S. Ueno, T. Kitajima, S. Katsumata (Japan)*

Mood and bipolar disorder; Pharmacology - Intervention; Stress related disorder

**P.513****Inflammatory cytokines and BDNF levels are correlated with different states of bipolar disorder, but not with anxiety comorbidities**

*T.Y. Wang\*, Y.H. Chang, P.W. Li, P.S. Chen, R.B. Lu (Taiwan)*

Mood and bipolar disorder; Anxiety - Disorder; Immunology - Method

**P.514****The antidepressant effects of a multimodal intervention including agomelatine correlate with circadian phase advance in youths with depression**

*R. Robillard, J. Carpenter\*, K.L. Feilds, D. Hermens, D. White, S. Naismith, D. Bartlett, B. Whitwell, J. Southan, E. Scott, I. Hickie (Australia)*

Mood and bipolar disorder; Sleep disorder; Pharmacology - Intervention

**P.515****Cognitive impairment in treatment-resistant depression: are there any differences between objective and subjective deficits?**

*M. Guinovart Julian\*, M. Vicent Gil, M. Serra Blasco, G. Navarra Ventura, D.J. Palao Vidal, N. Cardoner Alvarez (Spain)*

Mood and bipolar disorder; Neuropsychology - Method; Prevention / course alteration

**P.516****Large-scale serum biomarker profiling in patients with bipolar disorder**

*E. Pålsson\*, J. Jakobsson, A. Isgren, C. Sellgren, C.J. Ekman, J. Holmén-Larsson, M. Landén (Sweden)*

Mood and bipolar disorder; Biochemistry - Method; System biology - Method

**P.517****Genes of neurotrophic factors and responsiveness to antidepressive psychopharmacotherapy in patients with depressive disorders**

*L. Levchuk\*, I. Losenkov, I. Pozhidaev, D. Osmanova, G. Simutkin, N. Bokhan, A. Loonen, S. Ivanova (Russia)*

Mood and bipolar disorder; Genetic & molecular approaches - Method; Pharmacology - Intervention

**P.518****Personality disorder comorbidity and rehospitalization rates in bipolar disorder: a cohort study**

*Y. Goren, A. Krivoy, S. Gur, A. Weizman, E. Hochman\* (Israel)*

Mood and bipolar disorder; Personality disorder

**P.519****Memantine produces antidepressant effect through the enhancement of hippocampal neurogenesis in olfactory bulbectomized mice**

*O. Nakagawasai\*, K. Takahashi, W. Nemoto, T. Odaira, W. Sakuma, Y. Arai, T. Tadano, K. Tan-No (Japan)*

Mood and bipolar disorder; Animal models - Method

**P.520****Samidorphan attenuates the effects of buprenorphine in rat models evaluating abuse potential**

*J.I. Cunningham\*, N.N. Burke, M.S. Todtenkopf, D.P. Finn, M. Roche, J.P. Kelly, D.J. Eyerman, C. Sanchez (USA)*

Mood and bipolar disorder; Addiction - Disorder; Pharmacology - Intervention

**P.521****Polypharmacy in psychiatry: unwanted side effects and inflammatory response system – a naturalistic study of 195 patients under treatment**

*H.H. Stassen\*, S. Bachmann, R. Bridler, K. Cattapan, D. Herzig, K. Höppner, A. Schneeberger, E. Seifritz, A. Wirth, M. Weisbrod (Switzerland)*

Mood and bipolar disorder; Pharmacology - Method; Neuro-inflammatory disorder

**P.522****Effects of trazodone on firing rate of serotonergic neurons in dorsal raphe rat brain slices**

*F. Bonfiglio\*, A. Montalbano, B. Mlinar, P. Lorenzo, M. Magnani, B. Garrone, R. Corradetti (Italy)*

Mood and bipolar disorder; Pharmacology - Intervention; Pharmacology - Method

**P.523****Ketamine rapidly stimulates local protein synthesis in primary neuronal cultures**

*H. Creaney\*, P. Raval, D.P. Srivastava, A.C. Vernon (United Kingdom)*

Mood and bipolar disorder; Pharmacology - Method; Biochemistry - Method

**P.524****Thirty-year cardiovascular risk in patients with newly diagnosed bipolar disorder and their healthy first-degree relatives**

*K. Coello\*, H. Kjærstad, S. Stanislaus, S. Melbye, M. Fauerholt-Jepsen, K. Miskowiak, M. Vinberg, L.V. Kessing, K. Munkholm (Denmark)*

Mood and bipolar disorder; Stroke

**P.525****Is the effect of fluoxetine on plasticity related to serotonin transporter or tropomyosin-related receptor kinase B?**

*M.J.F. Levy\*, F. Boulle, M.B. Emerit, H.W. Steinbusch, D. Van den Hove, G. Kenis, L. Lanfumey (France)*

Mood and bipolar disorder; Genetic & molecular approaches - Method

**P.526****Paternal transmission of vulnerability to high fat diet-induced metabolic and neurobehavioural impairments**

*S. Manta\*, B. Coutens, S. Tummasorn, J. Zemdegs, C. Moro, X. Fioramonti, N. Chattipakorn, S.C. Chattipakorn, C. Rampon, B.P. Guiard (France)*

Mood and bipolar disorder; Lifestyle and nutrition - Intervention

**P.527****Baseline characteristics of suicidal ideators and suicide attempters; comparisons between hospital based and community based cohorts**

*S.J. Rhee\*, C.H.K. Park, J.W. Lee, S.Y. Lee, J. Moon, D.W. Jeon, S.H. Shim, S.J. Cho, S.G. Kim, J. Lee, J.W. Paik, M.H. Kim, S. Kim, J.H. Park, S. You, H.J. Jeon, Y.M. Ahn, Y.S. Choi (South-Korea)*

Mood and bipolar disorder; Epidemiology and big data - Method

**P.528****Hypersomnia as an objective clinical biomarker and prognostic indicator in depressed patients: a post-hoc analysis from the BRIDGE-II- MIX Study**

*A. Murru\*, G. Guiso, M. Barbuti, N. Verdolini, L. Samalin, J.M. Azorin, J. Angst, C.L. Bowden, M. Sergey, A. Young, D. Popovic, M. Valdes, G. Perugi, E. Vieta, I. Pacchiarotti (Spain)*

Mood and bipolar disorder; Sleep disorder

**P.529****Cognitive functioning in patients treated with electroconvulsive therapy**

*L. Kalisova\*, M. Kubinova, J. Michalec, K. Madlova, J. Albrecht, J. Raboch (Czech Republic)*

Mood and bipolar disorder; Psychotic disorder

**P.530****Affective temperaments, bipolarity, perceived stress and the severity of post-traumatic stress syndrome in patients with prostate cancer**

*K. Machalska\*, A. Turek, A.A. Chrobak, A. Czech, Ł. Bełch, M. Siwek, P. Chłosta, D. Dudek (Poland)*

Mood and bipolar disorder; Stress related disorder

**P.531****Zinc levels in depressed patients: results from a meta-analysis**

*S. Jiménez Fernández, M. Valverde Barea\*, I. Martínez Reyes, M.I. Rodríguez Natal (Spain)*

Mood and bipolar disorder; System biology - Method; Neuromodulation - Intervention

**P.532****Psychomotor symptoms in major depressive episode are related to bipolarity. A pooled analysis of the BRIDGE and BRIDGE-II-MIX cohorts**

*C. Mainardi\*, I. Pacchiarotti, N. Verdolini, M. Barbuti, G. Maccariello, J. Angst, J.M. Azorin, C.L. Bowden, S. Mosolov, A.H. Young, E. Vieta, G. Perugi (Italy)*

Mood and bipolar disorder; Movement disorder

**P.533****Efficacy and safety of esketamine nasal spray plus an oral antidepressant in elderly patients with treatment-resistant depression**

*R. Ochs-Ross\*, E. Daly, Y. Zhang, R. Lane, P. Lim, K. Foster, D. Hough, H. Manji, W. Drevets, G. Sanacora, C. Adler, R. McShane, R. Gaillard, J. Singh (USA)*

Mood and bipolar disorder; Pharmacology - Intervention

**P.534****Emotion recognition and its connection to the marital status of patients with bipolar affective disorder**

*I.A. Ravis\*, M.M. Minciuna, I. Papava, Z. Popovici, A.C. Bredicean (Romania)*

Mood and bipolar disorder; Prevention / course alteration

**P.535****Social support deficit and depression treatment outcomes in patients with acute coronary syndrome: findings from the EsDEPACS study***J.S. Yoon\*, J.W. Kim (South-Korea)*

Mood and bipolar disorder; Pharmacology - Intervention

**P.536****Clinical outcome after stop continuation and maintenance electroconvulsive therapy: a longitudinal retrospective study***P. Serra\*, E. Martínez-Amorós, L. Urraca, X. Goldeberg, D.J. Palao, N. Cardoner (Spain)*

Mood and bipolar disorder; Neuromodulation - Intervention

**P.537****Biomarkers in cerebrospinal fluid of patients with bipolar disorder versus healthy individuals: a systematic review***U. Knorr\*, A.H. Simonsen, H. Zetterberg, K. Blennow, S.G. Hasselbalch, L.V. Kessing (Denmark)*

Mood and bipolar disorder; System biology - Method

**P.538****Lithium treatment and cancer incidence in bipolar disorder – a large nationwide Swedish register study***L. Martinsson\*, J. Westman, J. Hällgren, U. Ösby, L. Backlund (Sweden)*

Mood and bipolar disorder; Pharmacology - Intervention

**P.539****Relationship between melatonergic and thyroid systems in depression***F. Duval\*, M.C. Mokrani, A. Erb, G. Felix, C. Calleja, V. Raverot, P. Pévet (France)*

Mood and bipolar disorder; System biology - Method

**P.540****Associations between cognitive symptoms and functional outcomes in Chinese patients with depression in a 6-month non-interventional, prospective study***T.M. Si, L.N. Wang, K.H.X. Tan, S. Luo\* (China)*

Mood and bipolar disorder; Prevention / course alteration

**P.541****Thyroid axis activity and dopamine function in major depression***F. Duval\*, M.C. Mokrani, A. Erb, F. Gonzalez, C. Calleja (France)*

Mood and bipolar disorder; System biology - Method

**P.542****Escitalopram in acute treatment of children and adolescents with major depressive disorders: a meta-analysis and systematic review***N. Maneeton\*, B. Maneeton, S. Puthisri, P. Woottiluk (Thailand)*

Mood and bipolar disorder; Pharmacology - Intervention; Pharmacology - Method

**P.543****Serotonergic antidepressants amplify the influence of the living condition on mood in depressed patients enrolled in the STAR\*D study***A. Viglione\*, S. Poggini, V.C. Malpassuti, F. Chiarotti, A. Giuliani, I. Branchi (Italy)*

Mood and bipolar disorder; Epidemiology and big data - Method

**P.544****A genome-wide association study of treatment-resistant depression and meta-analysis with STAR\*D***C. Fabbri\*, S. Kasper, A. Kautzky, J. Zohar, D. Souery, S. Montgomery, D. Albani, I. Raimondi, D. Dikeos, D. Rujescu, J. Mendlewicz, A. Serretti (Italy)*

Mood and bipolar disorder; Pharmacology - Intervention; Genetic &amp; molecular approaches - Method

**P.545****The early antidepressant-like effect of deep brain stimulation: patterns of activity and their modulation by analgesics***L. Perez-Caballero\*, M.L. Soto-Montenegro, M. Hidalgo-Figueroa, M. Casquero-Veiga, J.A. Mico, M. Desco, E. Berrocoso (Spain)*

Mood and bipolar disorder; Animal models - Method

**P.546****Adherence to medication and physical activity in older people with diabetes: the association with depression***R. Mendes, S. Martins\*, L. Fernandes (Portugal)*

Mood and bipolar disorder; Pharmacology - Method

P.547

**Antipsychotic in the treatment of acute mania: a retrospective study at centro hospitalar psiquiátrico de lisboa***S. Nascimento\*, J. Aguiar, I. Caldas, C. Pereira, M. Nascimento, A. Nobre (Portugal)*

Mood and bipolar disorder; Psychotic disorder

P.548

**Effect of lurasidone on cognition in children and adolescents with bipolar depression: interim analysis of a 2-year open-label extension study***K.E. Burdick, R. Goldman, M. Tocco\*, L. Deng, A. Loebel (USA)*

Mood and bipolar disorder; Pharmacology - Intervention

P.549

**Efficacy of long-term treatment with lurasidone in children and adolescents with bipolar depression: interim analysis of a 2-year open-label study***M.P. DelBello, R. Goldman\*, M. Tocco, A. Pikalov, L. Deng, A. Loebel (USA)*

Mood and bipolar disorder; Pharmacology - Intervention

P.550

**Safety of long-term treatment with lurasidone in children and adolescents with bipolar depression: interim analysis of a 2-year extension study***M.P. DelBello, R. Goldman, M. Tocco, A. Pikalov\*, L. Deng, A. Loebel (USA)*

Mood and bipolar disorder; Pharmacology - Intervention

P.551

**Hippocampal FGF-antisense overexpression increase depression-like behaviour in the rat***B. Uzay\*, H. Karatas-Kursun, M. Yemisci, T. Dalkara, E. Eren-Kocak (Turkey)*

Mood and bipolar disorder; Anxiety - Disorder; Stress related disorder

P.552

**The utility of early detection of postpartum depression***F. Salvaro\*, L. Del Matto, I. Baldini, S. Desantis, E. Federico, M. Olivola, A. Goracci, S. Bolognesi, A. Fagiolini (Italy)*

Mood and bipolar disorder; Prevention / course alteration

P.553

**Lithium versus valproate: prescribing profile of mood stabilisers for bipolar disorder in an acute care unit***J. Aguiar\*, M. Nascimento, I. Caldas, C. Pereira, S. Nascimento (Portugal)*

Mood and bipolar disorder; Pharmacology - Intervention

P.554

**Bipolar disorder and seasonality pattern in a sample of Portuguese patients***I. Caldas\*, C. Pereira, J. Aguiar, M. Nascimento, S. Nascimento (Portugal)*

Mood and bipolar disorder; Epidemiology and big data - Method

P.555

**Childhood trauma dependent anxious depression sensitizes HPA axis function***D. Lehrieder, J. Fietz, C. Leistner, C. Wurst, S. Stonawski, K. Lechner, Y. Busch, J. Deckert, K. Domschke, A. Menke\* (Germany)*

Mood and bipolar disorder; Stress related disorder

P.556

**Risk factors for suicide in bipolar disorder: a cohort study of 12,850 patients***C. Hansson\*, E. Joas, E. Pålsson, K. Hawton, B. Runesson, M. Landén (Sweden)*

Mood and bipolar disorder; Epidemiology and big data - Method

P.557

**50-kHz ultrasonic vocalizations increase after sleep deprivation as mania-like elevated mood in rats: effects of lithium***R. Andreatini\*, E. Wendler, C.P. De Souza, A.P.S. Dornellas, L.E. Dos Santos, S.T. Ferreira, J.C. Galduróz, M. Wöhr, R.K. Schwarting (Brazil)*

Mood and bipolar disorder; Pharmacology - Method

P.558

**Serum orexin A and oxytocin levels and their relationships with attachment and childhood trauma in patients with depression***S. Ozsoy\*, D.S. Erdem, U. Abdulrezzak, M. Basturk (Turkey)*

Mood and bipolar disorder; Neuropsychology - Method

P.559

**Suicide mortality and use of psychotropic drugs in patients hospitalized due to bipolar disorder: a Finnish nationwide cohort study**

*M. Lähteenvuo\**, *D. Antolin Concha*, *A. Tanskanen*, *H. Taipale*, *J. Tiihonen* (Finland)

Mood and bipolar disorder; Epidemiology and big data - Method

P.560

**Agomelatine in depressed patients with comorbid anxiety: subgroup-analysis of the VIVALDI-studies**

*G. Laux\**, *B. Barthel* (Germany)

Mood and bipolar disorder; Pharmacology - Intervention

P.561

**Emotion recognition in major depressed patients: evidence of lack of relationship with suicidal behavior**

*A. Velasco\**, *F. Dal Santo*, *J. Rodriguez-Revuelta*, *I. Abad*, *L. De la Fuente-Tomás*, *L. González-Blanco*, *L. García-Álvarez*, *A. Fernández-Peláez*, *M.P. García-Portilla*, *J. Bobes*, *P.A. Saiz* (Spain)

Mood and bipolar disorder; Neuropsychology - Method

P.562

**A new GSK-3 $\beta$  inhibitor with in vivo activity in models of mood disorders**

*B. Garrone\**, *A. Reggiani*, *V. Capurro*, *M. Lanfranco*, *M. Summa*, *F.P. Di Giorgio*, *S. Tongiani* (Italy)

Mood and bipolar disorder; Animal models - Method

P.563

**Single nucleotide polymorphisms (SNPs) implicated in determining predominant polarity in bipolar disorder**

*D. Popovic\**, *Y. Stukalina*, *M. Hagin*, *M. Shugol*, *M. Mosheva*, *O. Sentissi*, *C. Fabbri*, *D. Soery*, *A. Serretti* (Israel)

Mood and bipolar disorder; Genetic & molecular approaches - Method

P.564

**Oxidative stress and inflammation markers are associated to severity of depressive disorders**

*Y. Sánchez\**, *I. Leal*, *P. López* (Spain)

Mood and bipolar disorder; Neuro-inflammatory disorder

P.565

**Relationship between perceived low sleep quality and depression in a Korean elderly population**

*S.H. Koh\**, *K.J. Chang*, *C.H. Hong* (South-Korea)

Mood and bipolar disorder; Sleep disorder

P.566

**The effect of early life stress on theory of mind performance in patients with major depressive disorder**

*N. Németh*, *B. Czéh*, *T. Tényi*, *M. Simon\** (Hungary)

Mood and bipolar disorder; Neuropsychology - Method

P.568

**Changes in salivary aldosterone concentrations in patients with major depressive disorder**

*L. Izakova\**, *N. Hlavacova*, *V. Segeda*, *M. Kralova*, *D. Jezova* (Slovak Republic)

Mood and bipolar disorder; Biochemistry - Method

P.569

**Hormones, Emotional processing and prepartum Attachment in Pregnant women with Affective Disorders (HEAPAD)**

*A. Bjertrup\**, *M.B. Jensen*, *M.S. Schjødt*, *A. Kjærbye-Thygesen*, *M.S. Væver*, *R.L. Mikkelsen*, *M. Moszkowicz*, *V.G. Frøkjær*, *M. Vinberg*, *L.V. Kessing*, *K.W. Miskowiak* (Denmark)

Mood and bipolar disorder; Neuropsychology - Method

P.570

**Is olfactory memory a marker of depression? Differences between bipolar and unipolar disorders**

*F. Kazour\**, *S. Richa*, *W. Elhage*, *B. Atanasova* (Lebanon)

Mood and bipolar disorder; Neuropsychology - Method

P.571

**Relationship between implicit motor learning and neurological soft signs in schizophrenia and bipolar disorder**

*A. Tereszko\**, *A. Chrobak*, *K. Siuda-Krzywicka*, *Z. Sołtys*, *M. Siwek*, *D. Dudek* (Poland)

Mood and bipolar disorder; Movement disorder

UPDATED PROGRAMME:

<https://2018.ecnp.eu/> ECNP app / congress info terminals

**P.572**

**A case report of rapid anti-suicidal and robust antidepressant effects of ketamine in post-psychotic depression**

*L. Bartova\**, *K. Papageorgiou*, *I. Milenkovic*, *M. Dold*, *A. Weidenauer*, *M. Willeit*, *D. Winkler*, *S. Kasper (Austria)*  
Mood and bipolar disorder; Pharmacology - Intervention; Psychotic disorder

**P.573**

**Child maltreatment predicting more severe psychiatric and biological phenotype among adolescent patients with depressive symptoms**

*M. Mitkovic-Voncina\**, *S. Lestarevic*, *M. Pejovic-Milovancevic*, *J. Radosavljev-Kircanski*, *M. Kalanj*, *D. Lecic-Tosevski (Serbia)*  
Mood and bipolar disorder; Stress related disorder; Neuro-inflammatory disorder

**P.574**

**Augmentation of pharmacotherapy by sleep deprivation with sleep phase advance in treatment-resistant depression: changes of cortisol, IL-10, and IL-1 $\beta$**

*E. Dopierala\**, *E. Ferencztajn-Rochowiak*, *A. Jasińska-Mikołajczyk*, *M. Chłopocka-Woźniak*, *J. Rybakowski (Poland)*  
Mood and bipolar disorder; Pharmacology - Intervention

**P.575**

**Predictors of sexual impairment at 6months after a manic episode: A post-hoc analysis of the MANACOR study**

*L. Al Chaal\**, *A. Aedo*, *M. Reinares*, *I. Grande*, *C. González*, *G. Anmella*, *C. Del Mar Bonnin*, *M. Mur*, *C. Sáez*, *E. Nieto*, *A.L. Montejo*, *E. Vieta*, *A. Murru (Spain)*  
Mood and bipolar disorder; Sexual disorder

**P.576**

**Predictors of response to electroconvulsive therapy: a new role for tissue-type plasminogen activator and plasminogen activator inhibitor 1**

*N. Moschny\**, *A. Neyazi*, *H. Maier*, *K. Jahn*, *A. Khan*, *M. Bajouj*, *S. Bleich*, *H. Frieling (Germany)*  
Mood and bipolar disorder; Stress related disorder

**P.577**

**Evening chronotype mediates the association between early life stress and emotional dysregulation in bipolar disorder**

*D. Caruso\**, *I. Masci*, *F.L. Paolilli*, *G. Cipollone*, *B. Tripodi*, *M. Novi*, *U. Moretto*, *L. Palagini (Italy)*  
Mood and bipolar disorder; Sleep disorder; Stress related disorder

**P.578**

**Concurrent benzodiazepines undermine the antidepressant effect of ketamine**

*V. Andrashko\**, *T. Novak*, *J. Horacek*, *M. Klirava*, *M. Brunovsky (Czech Republic)*  
Mood and bipolar disorder; Pharmacology - Intervention

**P.579**

**Interactions between oxytocin receptor gene methylation and callous-unemotional traits impact socioaffective brain systems in conduct-disordered youth**

*M. Aghajani\**, *E. Klapwijk*, *O. Colins*, *C. Ziegler*, *K. Domschke*, *R. Vermeiren*, *N. Van der Wee (The Netherlands)*  
Personality disorder; Neuroimaging - Method; Genetic & molecular approaches - Method

**P.580**

**Risk factors for intergenerational child maltreatment: the role of temperament**

*M. Mitkovic-Voncina\**, *M. Pejovic-Milovancevic*, *V. Mandic-Maravic*, *D. Lecic-Tosevski (Serbia)*  
Personality disorder; Stress related disorder

**P.581**

**Social cognition and functional connectivity in borderline personality disorder**

*X. Duque Alarcon\** (Mexico)  
Personality disorder; Neuroimaging - Method

**P.582**

**Brain metabolites and the relation with cognition and psychotic symptoms in medication-free psychosis and controls: a pharmacological magnetic resonance spectroscopy study**

*C. Vingerhoets\**, *G. Bakker*, *M. Van der Pluijm*, *O. Bloemen*, *L. Reneman*, *M. Caan*, *J. Booij*, *T. Van amelsvoort (The Netherlands)*  
Psychotic disorder; Neuroimaging - Method



**P.583****Muscarinic M1 receptor signalling underlying cognition in psychotic disorders**

*C. Vingerhoets\*, G. Bakker, B. Sahakian, O. Bloemen, M. Caan, J. Booij, T. Van Amelsvoort (The Netherlands)*  
Psychotic disorder; Neuroimaging - Method

**P.584****Objective equilibrium quantification of individual locomotor behaviour as a translational pharmacodynamic biomarker in schizophrenia**

*S. Haralanov, G. Dzhupanov\*, P. Terziivanova, E. Milushev, E. Haralanova (Bulgaria)*  
Psychotic disorder; Pharmacology - Intervention

**P.585****c-Fos expression response to olanzapine, amisulpride, quetiapine, and aripiprazole in the rat forebrain and effect of a mild stress preconditioning**

*J. Pecenak\*, R. Koprdoва, J. Bundzikova, A. Kiss (Slovak Republic)*  
Psychotic disorder; Pharmacology - Intervention; Animal models - Method

**P.586****Samidorphan mitigates olanzapine-induced weight gain and metabolic dysfunction in rats and nonhuman primates**

*J.I. Cunningham\*, D.J. Eyerman, M.S. Todtenkopf, R.L. Dean, M. Knopp, D.R. Deaver, C. Sanchez, M. Namchuk (USA)*  
Psychotic disorder; Mood and bipolar disorder; Pharmacology - Intervention

**P.587****Deep brain stimulation in treatment resistant schizophrenia: PET changes post-stimulation**

*A. Roldán\*, S. Sarró, M. Rabella, F. Sampedro, A. Alonso-Solís, E.M. Grasa, M.J. Portella, V. Pérez, E. Álvarez, J. Molet, R. Rodríguez, P. McKenna, E. Pomarol-Clotet, I. Corripio (Spain)*  
Psychotic disorder; Neuromodulation - Intervention; Neuroimaging - Method

**UPDATED PROGRAMME:**

<https://2018.ecnp.eu/> / ECNP app / congress info terminals

**P.588****Altered DNA methylation of the oxytocin receptor gene is associated with susceptibility to psychosis and anhedonia-asociality in females**

*M. Bang\*, S.J. Kim, K.R. Kim, S.Y. Lee, J.Y. Park, E. Lee, J.I. Kang, S.K. An (South-Korea)*  
Psychotic disorder; Genetic & molecular approaches - Method; Neuroimaging - Method

**P.589****Blood lactate elevation during the lactate stress test supports systemic mitochondrial dysfunction in schizophrenia**

*A. Valiente Palleja\*, G. Muntané, H. Torrell, Y. Alonso, E. Vilella, L. Martorell (Spain)*  
Psychotic disorder; Biochemistry - Method; System biology - Method

**P.590****The effects of antipsychotics on cingulate morphology and synaptic density in psychosis: a translational approach**

*D. Burrows\*, A.C. Vernon, O.D. Howes (United Kingdom)*  
Psychotic disorder; Animal models - Method

**P.591****The importance of early initiation of antipsychotic treatment and maintenance of good therapeutic adherence in schizophrenia**

*A. Szalontay\*, D. Radu, A. Bolos, I. Untu (Romania)*  
Psychotic disorder; Pharmacology - Method

**P.592****Cariprazine, a selective dopamine D3 receptor partial agonist with unique features to treat schizophrenia negative and cognitive symptoms**

*I. Laszlovszky\*, A. Barabassy, B. Kiss, B. Szatmári, N. Adham, W. Earley, G. Németh (Hungary)*  
Psychotic disorder; Neuroimaging - Method; Pharmacology - Intervention

**P.593****Treatment approach "Robin" for adolescents at high risk for developing a psychotic disorder: therapy modules enhanced by a smartphone application**

*N. Traber-Walker\*, M. Gerstenberg, S. Metzler, S. Walitza, M. Franscini (Switzerland)*  
Psychotic disorder; Psychotherapy - Intervention

P.594

**Molecular linking of influenza infection to cellular pathology of protein misassembly: the case of disrupted-in-schizophrenia 1 (DISC1)**

R. Marreiros\*, I. Prikulis, A. Müller-Schiffmann,  
A.R. Moreira, S. Sahu, I. Soloviev, S. Selvarajah,  
V. Lingappa, C. Korth (Germany)

Psychotic disorder; Dementia & neuro degeneration -  
Disorder

P.595

**Understanding gaps in perception surrounding long-acting injectable antipsychotic use within the forensic system**

R. Kronfli\*, T. Trussler (Canada)

Psychotic disorder; Pharmacology - Method;  
Pharmacology - Intervention

P.596

**Social stigma towards people with mental disorders among the psychiatrists, general practitioners and young doctors(interns).**

K. KANDRATSENIA\* (Belarus)

Psychotic disorder; Prevention / course alteration

P.597

**Converging evidence linking reinforcement learning deficits in schizophrenia to impairments in the representation of expected value**

D. Hernaus\*, J. Gold, J. Waltz, M. Frank (The  
Netherlands)

Psychotic disorder; Biostatistics & computational method

P.598

**Early age at onset of psychotic symptoms**

V. Verdino\*, A. Goracci, S. Bolognesi, A. Di Muro,  
F. Pieraccini, A. Fagiolini (Italy)

Psychotic disorder; Prevention / course alteration

P.599

**Cognitive effects of second-generation antipsychotic polypharmacy in stabilized patients with schizophrenia**

D.Y. Park\*, H. Song, J. Choi, S.H. Kang, J.I. Lee,  
W.H. Lee (South-Korea)

Psychotic disorder; Pharmacology - Intervention

P.600

**Low doses of palmitate of paliperidone 1-monthly (paliperidone palmitate 1-monthly): results of real clinical practice**

J.A. Campos\*, L. Docasar, A.M. Seoane (Spain)

Psychotic disorder; Pharmacology - Intervention

P.601

**Neuroactive steroids as endophenotypes of psychotic disorder: preliminary data**

P. Knytl\*, V. Voráčková, S. Čerešňáková, P. Mohr (Czech  
Republic)

Psychotic disorder; Genetic & molecular approaches -  
Method; Prevention / course alteration

P.602

**Functional brain correlates of negative symptoms in schizophrenia assessed using a novel executive paradigm**

A. Santo-Angles\*, P. Fuentes-Claramonte, M. Lechón,  
I. Argila, A. Nieto, P. Salgado-Pineda, A. Albacete,  
M. Martín, S. Aguilar, N. Ramiro, F. Portillo, C. Sarri,  
L. Salo, C. Bosque, M.L. Torres, S. Sarro, R. Salvador,  
P.J. McKenna, E. Pomarol-Clotet (Spain)

Psychotic disorder; Healthy brain; Neuroimaging -  
Method

P.603

**Agmatine attenuated sensorimotor gating deficit in schizophrenia model in rats: combination of neonatal MK-801 and isolation rearing**

G. Unal, F. Aricioglu\*, H. Zortul, O. Dilek (Turkey)

Psychotic disorder; Animal models - Method;  
Pharmacology - Intervention

P.604

**Exploring the brain correlates of ideas of reference with a virtual reality paradigm in fMRI**

P. Fuentes-Claramonte\*, A. Santo-Angles, M. Lechón,  
I. Argila-Plaza, A. Nieto-Martinez, P. Salgado-Pineda,  
A. Albacete, M. Martín, S. Aguilar, N. Ramiro, F. Portillo,  
C. Sarri, L. Salo, C. Bosque, P. Rodrigues, L. Torres,  
S. Sarró, R. Salvador, P.J. McKenna, E. Pomarol-Clotet  
(Spain)

Psychotic disorder; Neuroimaging - Method

**P.605****The risk prediction of development of neuroleptic hyperprolactinemia based on genetic markers**

*D. Osmanova\*, M. Freidin, O. Fedorenko, A. Loonen, S. Ivanova (Russia)*

Psychotic disorder; Genetic & molecular approaches - Method; Psychotherapy - Intervention

**P.606****CDC42 rs2473317 polymorphism is associated with schizophrenia: A case-control study in the Armenian population**

*A. Stepanyan\*, H. Ghazaryan, S. Atshemyan, R. Zakharyan, A. Khoyetsyan (Armenia, Rep. of)*

Psychotic disorder; Genetic & molecular approaches - Method

**P.607****The study of dopamine receptor genes in patients with schizophrenia**

*I. Pozhidaev\*, D. Osmanova, O. Fedorenko, N. Vyalova, A. Semke, B. Wilffert, A. Loonen, S. Ivanova (Russia)*

Psychotic disorder; Genetic & molecular approaches - Method; Psychotherapy - Intervention

**P.608****The role of the duration of untreated psychosis in cognitive deficit in schizophrenia – preliminary results**

*J. Jonáš\*, A. Dorazilová, V. Voráčková, A. Cvrčková, P. Šustová, M. Hájková, M. Rodriguez (Czech Republic)*

Psychotic disorder; Neuropsychology - Method

**P.609****Symptomatology and metabolic markers in persons using antipsychotics for non-psychotic disorders in the northern Finland birth cohort 1966**

*E. Jääskeläinen, M. Haapea, I. Haataja, J. Ruohomäki, J. Miettunen (Finland)*

Pharmacology - Intervention; Anxiety - Disorder; Mood and bipolar disorder

**P.610****Association between executive functions at first episode of psychosis and the later development of prefrontal cortical thinning and negative symptoms**

*G. Tronchin\*, T.N. Akudjedu, S. McInerney, C. Scanlon, J. Kenney, J. McFarland, H. Anderson-Schmidt, D.M. Cannon, B. Hallahan, C. McDonald (Ireland)*

Psychotic disorder; Neuroimaging - Method; Neuropsychology - Method

**P.611****The effect of early life stress on human dopamine receptor D2 (DRD2) and parvalbumin (PVALB) promoter methylation and the association with cognition**

*K. Klaus\*, H.F. Fachim, G.P. Reynolds, K. Pennington (United Kingdom)*

Psychotic disorder; Genetic & molecular approaches - Method

**P.612****Functional mode of action of ASP5736, a selective 5-HT5A receptor antagonist for treatment of cognitive dysfunction in schizophrenia**

*T.H. Svensson\*, M. Yamazaki, N. Yamamoto, J. Yarimizu, M. Okabe, A. Moriyama, M. Furutani, M. Marcus, K. Harada (Sweden)*

Psychotic disorder; Pharmacology - Intervention; Neuromodulation - Intervention

**P.613****Assessment of the role of cognitive control on monetary reward and loss anticipation: an electrophysiological study in subjects with schizophrenia**

*A. Vignapiano\*, A. Mucci, P. Bucci, G.M. Giordano, A. Amodio, S. Galderisi (Italy)*

Psychotic disorder; Neurophysiology / EEG - Method

**P.614****Inflammatory markers and cognitive performance in patients with schizophrenia treated with lurasidone**

*B.J. Miller, A. Pikalov\*, C. Siu, M. Tocco, J. Tsai, P.D. Harvey, A. Loebel (USA)*

Psychotic disorder; Neuro-inflammatory disorder

**P.615****Network meta-analysis of the efficacy and safety of antidepressants for acutely ill elderly patients with major depressive disorder**

*M. Krause\*, S. Leucht (Germany)*

Psychotic disorder; Pharmacology - Intervention

**P.616****Efficacy of cariprazine in the treatment of negative symptoms of schizophrenia: post hoc analyses versus aripiprazole**

*A. Barabassy, B. Szatmári, I. Laszlovszky\*, J. Harsányi, K. Acsai, B. Sebe, W. Earley, M. Patel, G. Németh (Hungary)*

Psychotic disorder; Pharmacology - Intervention

**P.617****Prediction of visceral obesity in schizophrenic patients under therapy with antipsychotics**

*E. Kornetova\*, A. Kornetov, V. Dubrovskaya, O. Lobacheva (Russia)*

Psychotic disorder; Pharmacology - Intervention

**P.618****Safety profile of cariprazine: post hoc analysis of safety parameters of pooled cariprazine schizophrenia studies**

*B. Szatmári, A. Barabassy, I. Laszlovszky\*, J. Harsányi, K. Acsai, A. Burján, B. Sebe, W. Earley, M. Patel, G. Németh (Hungary)*

Psychotic disorder; Pharmacology - Intervention

**P.619****Functional remission frequency in a French cohort of schizophrenia patients initiating treatment with long-acting injectable antipsychotic**

*S. Bouju\*, C. Déal, E. Bessières, S. Lancrenon, P.M. Llorca, P. Gorwood (France)*

Psychotic disorder; Pharmacology - Intervention

**P.620****Convergence eye movement deficits in bipolar disorder**

*A. Chrobak\*, J. Rybakowski, M. Abramowicz, M. Perdziak, A. Tereszko, M. Włodarczyk, S. Dziuda, M. Fąfrowicz, P. Czarnecki, Z. Sołtys, M. Siwek, J. Ober, T. Marek, D. Dudek (Poland)*

Psychotic disorder; Movement disorder; Mood and bipolar disorder

**P.621****Early response to antipsychotic medication in adolescents with first-episode psychosis predictor of ultimate response and remission**

*L. Von Hardenberg\*, C.U. Correll, B. Galling, K. Pagsberg (Germany)*

Psychotic disorder; Pharmacology - Method

**P.622****Basal cortisol concentrations and symptoms severity in patients with schizophrenia treated with atypical antipsychotics**

*K. Wilczyński\*, D. Tobolska, M. Lorek, E. Mazgaj, K. Krysta, M. Krzystanek, A. Gawlik (Poland)*

Psychotic disorder; Stress related disorder; Pharmacology - Intervention

**P.623****Selective 5-HT<sub>1A</sub> receptor agonists biased to pERK1/2 or  $\beta$ -arrestin activation show differential in vivo behavioral profiles**

*D. Wilczyńska\*, M. Jastrzębska-Więsek, A. Partyka, J. Śniecikowska, A. Wesolowska, M.A. Varney, A. Newman-Tancredi, M. Kołaczowski (Poland)*

Psychotic disorder; Animal models - Method

**P.624****Short-term efficacy of brexpiprazole in patients with schizophrenia with clinically relevant levels of negative symptoms**

*S.R. Meehan\*, P. Zhang, M. Hobart, N. Hefting, R.A. Baker, C. Weiss (Denmark)*

Psychotic disorder; Pharmacology - Intervention

**P.625****Sodium nitroprusside but not molsidomine may be used for antipsychotic augmentation in treatment resistant schizophrenia**

*J. Titulaer\*, A. Malmerfelt, M.M. Marcus, A. Perrone, G. Alken, T.H. Svensson (Sweden)*

Psychotic disorder; Pharmacology - Intervention

**P.626****Aripiprazole long-acting injection in first psychotic episode management**

*G. Giordano\*, L. Tomassini, I. Cuomo, E. Amici, F. Perrini, G. Kotzalidis, S. De Filippis (Italy)*

Psychotic disorder; Pharmacology - Intervention

**P.627****An exploratory analysis of personal and social performance (PSP) scoring issues from multiple schizophrenia clinical trials**

*A. Kott\*, D.G. Daniel (Czech Republic)*

Psychotic disorder; Biostatistics & computational method

**P.628****Long-term efficacy of brexpiprazole in patients with schizophrenia with clinically relevant levels of negative symptoms**

*C. Weiss\*, P. Zhang, R.A. Baker, M. Hobart, N. Hefting, S.R. Meehan (USA)*

Psychotic disorder; Pharmacology - Intervention

P.629

**Impact of an early psychosis unit on psychopharmacological treatment patterns and clinical outcomes – a retrospective study**

*J. Silva Ribeiro\*, M. Coroa, P. Oliveira, S. Morais, M. Bajouco, S. Caldeira, H. Costa, V. Santos, N. Madeira (Portugal)*

Psychotic disorder; Prevention / course alteration

P.630

**Neurocognition for the classification of first episode schizophrenia, unaffected family members and healthy controls: a machine learning study**

*E. Ince\*, S.V. Kalmady, R. Greiner, S. Dursun, A. Üçok (Turkey)*

Psychotic disorder; Neuropsychology - Method; Biostatistics & computational method

P.631

**Maintenance of effects after discontinuation of early intervention services for psychosis: systematic review and meta-analysis**

*M. Becker\*, C.U. Correll, B. Galling (Germany)*

Psychotic disorder; Psychotherapy - Intervention

P.632

**Longitudinal assessment of negative symptoms in early onset first episode psychosis**

*M. Garcia Traverso\*, D. Fraguas, C. Arango, J. Castro-Fornieles, A. González-Pinto, M. Parellada, M. Graell, C. Soutullo, I. Bombin, M. Rapado-Castro (Spain)*

Psychotic disorder; Neuropsychology - Method

P.633

**Regional and sociodemographic differences in duration of untreated psychosis (DUP) in first episode schizophrenia: results from a meta-analysis and exploratory meta-regression analysis**

*E. Martínez\*, D. Guinart, A. Armendariz, J. Soler, J.M. Rubio, C. Correll (Spain)*

Psychotic disorder; Epidemiology and big data - Method

P.634

**Are altered plasma vitamin D, vitamin A and one-carbon metabolism related to metabolic syndrome in patients with a severe mental disorder?**

*M. Sanchez-Autet\*, B. Arranz, G. Safont, P. Garcia-Portilla, P. Sierra, C. Hernandez, L. San (Spain)*

Psychotic disorder; Mood and bipolar disorder

P.635

**Derived domain indexes from epicog-sch brief battery to describe cognitive profile in schizophrenia stable patients**

*S. Zaragoza Domingo\* (Spain)*

Psychotic disorder; Epidemiology and big data - Method

P.636

**Lisdexamfetamine dimesylate in adult ADHD with anxiety disorder and depression comorbidity: a 17-week cross-over study**

*M. Van Ameringen\*, W. Simpson, B. Patterson, J. Turna, K. Pullia (Canada)*

ADHD - Disorder; Pharmacology - Intervention

P.637

**Impact of domestic physical violence on symptom severity in children with attention deficit hyperactivity disorder**

*S.G. Ipek\*, A. Tahiroglu (Turkey)*

ADHD - Disorder; Psychotherapy - Intervention

P.638

**A robot-assisted kinematic measurement for children with attention-deficit hyperactivity disorder**

*S.H. Kim\*, A. Min, D. Ahn (South-Korea)*

ADHD - Disorder; Biostatistics & computational method

P.639

**The course of ADHD diagnosis over a 6-year timeframe in a Romanian inpatient sample**

*L.E. Andrei\*, A.I. Cerlinca, R.D. Neacsu, A.L. Niculae, I. Mihailescu (Romania)*

ADHD - Disorder; Epidemiology and big data - Method; Prevention / course alteration

P.640

**Effect of stimulant medications on intelligence quotient scores in a Spanish sample of children and adolescents with ADHD.**

*M. Vallejo Valdivielso\*, A. Román-Jarrín, C. Vidal-Adroher, R. Gómez-Coronado, P. DeCastro-Manglano, A. Díez-Suárez, C. Soutullo (Spain)*

ADHD - Disorder; Pharmacology - Intervention; Neuropsychology - Method

P.641

**Controlling anterior cingulate cortex dopamine via the mediodorsal thalamus may regulate valuation underlying impulsive action***J. Glennon\*, M. Havenith, W. O'Connor (The Netherlands)*ADHD - Disorder; Animal models - Method;  
Pharmacology - Method

P.642

**Underlying factors of the association between cesarean section and autism spectrum disorder***I. Menashe\*, M. Huberman, A. Bashiri, I. Dinstein, G. Meiri (Israel)*

Autism / ASD - Disorder; Epidemiology and big data - Method

P.643

**Neuroigin-3 and neuroigin-4x promote nanoscopic growth cone actin reorganization in early neurodevelopment with implications for autism***N. Gafford\*, P.J. Micheal Deans, R.R. Duarte, G. Chennell, P. Raval, H. Creaney, M. Tegtmeyer, P. Gordon-Weeks, J. Price, D.P. Srivastava (United Kingdom)*Autism / ASD - Disorder; Pharmacology - Method;  
Biochemistry - Method

P.644

**Are parenteral steroids for epileptic encephalopathy with electrical status epilepticus during sleep effective for associated autistic disorder?***N. Jovic\* (Serbia)*Autism / ASD - Disorder; Epilepsy - Disorder;  
Pharmacology - Intervention

P.645

**Diffusion tensor imaging in neurodevelopmental disorders***M. Hrdlicka\*, J. Sanda, T. Urbanek, I. Dudova, S. Beranova, L. Pospisilova, M. Mohaplova, P. Krsek, M. Kudr, A. Maulisova, M. Kyncl, V. Komarek (Czech Republic)*

Autism / ASD - Disorder; Neuroimaging - Method

P.646

**Use of psychotropic medication among adolescents and adults with autism spectrum disorders***L. Fusar-Poli\*, N. Brondino, M. Rocchetti, B. Petrosino, D. Arillotta, P. Politi, E. Aguglia (Italy)*

Autism / ASD - Disorder; Pharmacology - Intervention

P.647

**Neuropsychiatric disorders in tuberous sclerosis complex: a referral center experience***I. Ivanovic\*, N. Jovic (Montenegro)*

Autism / ASD - Disorder; Epilepsy - Disorder; Intellectual disability disorder

P.648

**Autism-like behaviour of young rats prenatally exposed to valproic acid***K. Fereshetyan\*, K. Yenkovyan (Armenia, Rep. of)*Autism / ASD - Disorder; Animal models - Method;  
Neuropsychology - Method

P.649

**The impact of 1q21.1 copy number variant on brain anatomy***C. Modenato\*, A. Pain, S. Martin-Brevet, A. Maillard, B. Rodriguez-Herreros, S. Richetin, S. Jacquemont, B. Draganski (Switzerland)*Intellectual disability disorder; Neuroimaging - Method;  
Genetic & molecular approaches - Method

P.650

**Treatment with kaempferol: a possible tool to restore neurogenesis in Down syndrome?***F. Stagni\*, M.E. Salvalai, S. Guidi, A. Giacomini, M. Emili, B. Uguagliati, M. Grilli, R. Bartesaghi (Italy)*

Intellectual disability disorder; Pharmacology - Intervention

P.651

**Forensic psychiatry – scenario in the largest security ward in Portugal: intellectual disorder***P. Jorge\*, T. Carvalhão, J. Santos, P. Batalim (Portugal)*

Intellectual disability disorder; Pharmacology - Intervention; Psychotic disorder

P.652

**The factors associated with mild cognitive disorder in Behçet's disease patients***P. Ovcharov\*, T. Lisitsyna, D. Veltishchev, O. Seravina, O. Kovalevskaya, Z. Alekberova, E. Nasonov (Russia)*

Intellectual disability disorder; Neuro-inflammatory disorder; Healthy brain

UPDATED PROGRAMME:

<https://2018.ecnp.eu/> ECNP app / congress info terminals

**P.653**

**Aripiprazole-induced diurnal and nocturnal enuresis in Down's syndrome**

*S. Marini\* (Italy)*

Intellectual disability disorder; Pharmacology - Intervention

**P.654**

**Involvement of Dyrk1A, a down syndrome candidate gene, in the thalamocortical connectivity**

*M. Martinez De Lagran\*, M. Ruiz-Mejias,*

*M. Sanchez-Vives, M. Dierssen (Spain)*

Intellectual disability disorder; Autism / ASD - Disorder

**P.655**

**Neurogenesis deficits in Down syndrome: testing recovery with GABAa5 negative allosteric modulator,  $\beta$ 2 adrenergic agonist and IGF-1 in Ts65Dn mice.**

*C. Albac, F. Stagni, M. Grilli, M.E. Salvalai, R. Bartesaghi,*

*M.C. Potier\* (France)*

Intellectual disability disorder; Pharmacology - Intervention; Animal models - Method

**P.656**

**Neuroprotective and neurotrophic actions of estrogens on amyloid  $\beta$  synaptotoxicity are mediated by distinct estrogen receptors**

*I. Watson\*, K.J. Sellers, R. Killick, D.P. Srivastava (United Kingdom)*

Dementia & neuro degeneration - Disorder; Pharmacology - Method

**P.657**

**Correlation between electrophysiological test and visual dysfunction in multiple sclerosis patients**

*E. Viladés Palomar\*, E. Orduna Hospital, M.J. Rodrigo Sanjuan, J.G. Larrea Samper, E. Garcia Martin (Spain)*

Dementia & neuro degeneration - Disorder; Neurophysiology / EEG - Method

**P.658**

**Longitudinal associations between serum cytokine levels and dementia**

*J.W. Kim\* (South-Korea)*

Dementia & neuro degeneration - Disorder; Immunology - Method

**P.659**

**Alzheimer's disease and neurotransmission gene variants: focus on their effects on psychiatric comorbidities and inflammatory parameters**

*S. Porcelli\*, M. Calabrò, C. Crisafulli, A. Politis,*

*I. Liappas, D. Albani, I. Raimondi, G. Forloni,*

*F. Benedetti, G. Papadimitriou, A. Serretti (Italy)*

Dementia & neuro degeneration - Disorder; Mood and bipolar disorder; Genetic & molecular approaches - Method

**P.660**

**Functional connectivity alterations in the noradrenergic system in patients with late-life major depression**

*I. Del Cerro\*, V. Soria, I. Martinez-Zalacain,*

*A. Guinea-Izquierdo, J. Gascon-Bayarri,*

*M. Urretavizcaya, C. Aguilera, R. Reñe, J.M. Menchón,*

*C. Soriano-Mas (Spain)*

Dementia & neuro degeneration - Disorder; Mood and bipolar disorder; Neuroimaging - Method

**P.661**

**Effects of Interleukin-6 trans-signalling in a mouse model of Alzheimer's disease and high fat diet-induced obesity**

*A. Escrig\*, A. Molinero, B. Méndez, M. Giral,*

*F.M. LaFerla, L. Giménez-Llort, S. Rose-John, J. Hidalgo (Spain)*

Dementia & neuro degeneration - Disorder; Animal models - Method; Neuro-inflammatory disorder

**P.662**

**Bioelectrical impedance analysis in patients with Alzheimer's disease**

*H. Kim\*, K.J. Lee, J.H. Roh (South-Korea)*

Dementia & neuro degeneration - Disorder; Lifestyle and nutrition - Intervention

**P.663**

**Unrevealing the role of a frontotemporal dementia protein (TDP-43 protein) in bipolar disorder**

*C. Nascimento\*, P. Nunes Villela, H. Kyunghye Kim,*

*K. De Oliveira, R.E. Paraizo Leite, R.E.D.L. Ferretti-*

*Rebustini, L.T. Grinberg, C.K. Suemoto,*

*C.A. Pasqualucci, R. Nitrini, W. Jacob-Filho,*

*H.P. Brentani, B. Lafer (Brazil)*

Dementia & neuro degeneration - Disorder; Mood and bipolar disorder; Biochemistry - Method

P.664

**Mitochondrial cholesterol enrichment affects PINK1-PRKN-mediated mitophagy in Alzheimer's disease***V. Roca Agujetas\*, E. Barbero-Camps, C. De Dios, A. Colell (Spain)*

Dementia &amp; neuro degeneration - Disorder; Biochemistry - Method; Animal models - Method

P.665

**When hoofbeats are zebras: late onset niemann-pick disease type C overlapping with frontotemporal dementia***N. Balázs, D. Milanovich, C. Hornyák, D. Bereczki, T. Kovács\* (Hungary)*

Dementia &amp; neuro degeneration - Disorder; Movement disorder

P.666

**Neurocognitive disorders and language: the impact of cognitive decline and neuropsychiatric symptoms on the language performance***M. Králová\*, Ľ. Izáková, B. Mészáros Hideghéty, M. Hajdúk, J. Marková, Z. Cséfalvay (Slovak Republic)*

Dementia &amp; neuro degeneration - Disorder; Neuropsychology - Method

P.667

**The role of genetic polymorphism of cytochrome P450 family member in schizophrenia***R. Zakharyan\*, V. Hayrapetyan, L. Karapetyan, A. Chavushyan, A. Arakelyan (Armenia, Rep. of)*

Dementia &amp; neuro degeneration - Disorder; Neuro-inflammatory disorder

P.668

**Dimethyl fumarate improves adult hippocampal neurogenesis and memory impairments in aged rats in the streptozotocin model of Alzheimer's disease***E. Kurowska\*, I. Majkutewicz, M. Podlacha, D. Myslinska, B. Grembecka, J. Rucinski, E. Jurkowlanec (Poland)*

Dementia &amp; neuro degeneration - Disorder; Animal models - Method

P.669

**Positivity of Borna disease virus in patients with Alzheimer disease and its influence in cognition***S. Rackova\*, J. Racek (Czech Republic)*

Dementia &amp; neuro degeneration - Disorder; Neuro-inflammatory disorder

P.670

**Altered pupillary response during oddball detection in mild cognitive impairment and late-life major depression: neuroimaging correlates***I. Martinez-Zalacain\*, A.L. Leon, I. Del Cerro, A. Guinea-Izquierdo, J. Gascón, C. Aguilera, M. Urretavizcaya, R. Reñé, V. Soria, J.M. Menchón, C. Soriano-Mas (Spain)*

Dementia &amp; neuro degeneration - Disorder; Prevention / course alteration

P.671

**Effects of LSL 61122 and 2-BFI, two imidazoline I2 receptor ligands, on FADD and p25/p35 hippocampal protein content in aged rats***E. Hernández-Hernández\*, M.J. García-Fuster (Spain)*

Dementia &amp; neuro degeneration - Disorder; Pharmacology - Intervention

P.672

**AXS-05 (Dextromethorphan/Bupropion): psychopharmacology and the potential for therapeutic application in the treatment of neuropsychiatric symptoms***C. O'Gorman\*, A. Jones, H. Tabuteau (USA)*

Dementia &amp; neuro degeneration - Disorder; Mood and bipolar disorder

P.673

**The 14-day carbamazepine treatment increases expression of KAT1 (Ccb1l) and KAT2 (Aadat) genes in rat brain cortex***T. Kocki\*, Ł. Pyzia, K. Wicha-Komsta, I. Zakrocka, S. Pabiś, W.A. Turski (Poland)*

Epilepsy - Disorder; Genetic &amp; molecular approaches - Method

P.674

**IPR-179, a gelatinase inhibitor, is able to mitigate epileptogenesis in the rat***A. Bertran, D.W.M. Broekaart, E. Aronica, T. Tarragó, E.A. Van Vliet, R. Prades\* (Spain)*

Epilepsy - Disorder; Pharmacology - Intervention; Prevention / course alteration



P.675

**Effects of repeated Agomelatine injection in status epilepticus on epileptiform activity during acute and chronic epilepsy phases in rats***N. Ivanova\*, J. Tchekalarova, P. Marinov (Bulgaria)*

Epilepsy - Disorder; Neurophysiology / EEG - Method

P.676

**R2\* relaxometry in sclerotic hippocampi of patients with temporal lobe epilepsy***R. Horváth, G. Perlaki, S.A. Nagy, G. Orsi, E. Varga\*, O. Mákos, G. Darnai, B. Bóné, C. Gimesi, D. Tényi, J. Janszky (Hungary)*

Epilepsy - Disorder; Neuroimaging - Method

P.677

**Synergistic anticonvulsant effect of gidazepam and novel esters based on glycine and monoterpenes***M. Nesterkina\*, I. Kravchenko (Ukraine)*

Epilepsy - Disorder; Pharmacology - Method; Animal models - Method

P.678

**Increased expression of  $\alpha\beta 3$  integrin in reactive astrocytes is controlled by the Rab endocytic pathway***J. Díaz\*, A. Quest, L. Leyton (Chile)*

Neuro-inflammatory disorder; Genetic &amp; molecular approaches - Method; Biochemistry - Method

P.679

**Post-traumatic stress symptoms following childhood sepsis: the impact of inflammation and corticosteroids***G. Corbet Burcher\*, G. Caspani, M. Cooper, C. Pierce, L. Als, E. Garralda, S. Nadel (United Kingdom)*

Neuro-inflammatory disorder; Pharmacology - Intervention; Stress related disorder

P.680

**Role of tumor necrosis factor gene in acute lipopolysaccharide effect on behavior, brain expression of interleukins and brain serotonin system in mice***D. Bazovkina\*, A. Pershina, D. Fursenko, N. Khotkin, E. Kulikova, E. Bazhenova, A. Kulikov (Russia)*

Neuro-inflammatory disorder; Genetic &amp; molecular approaches - Method

P.681

**Effects of chronic ethanol abuse on endogenous retinoid homeostasis***V. Clemens\*, F. Regen, A. Quante, P. Neu, L. Gerland, I. Heuser, J. Hellmann-Regen (Germany)*

Neuro-inflammatory disorder; Addiction - Disorder; System biology - Method

P.682

**Serum osmolarity and blood viscosity in neuroleptic malignant syndrome***G. Çelikel\*, T. Kalelioglu, N. Karamustafalioglu, A. Genc, M. Emul (Turkey)*

Neuro-inflammatory disorder; Psychotic disorder

P.683

**Depression in interferon-beta treated multiple sclerosis patients***R. Guedes\*, C. Peixoto de Sousa, R. Curral, C. Silveira (Portugal)*

Neuro-inflammatory disorder; Mood and bipolar disorder

P.684

**Effect of chronic paracetamol administration on nitroglycerine-induced migraine model in rats***M.B. Bereketoğlu\*, M.K. Güçlü, A. Gökçeli, A.T. Tamer, H. Çolak, Ş. Erdoğan, F. Aksu (Turkey)*

Pain and headache; Pharmacology - Method

P.685

**The importance of spinal CC chemokine ligands 2 and 7 in neuropathic pain development and opioids effectiveness***K. Kwiatkowski\*, K. Popiolek-Barczyk, E. Rojewska, A. Piotrowska, J. Mika (Poland)*

Pain and headache; Neuro-inflammatory disorder; Immunology - Method

P.686

**Analgesic effect of a newly synthesized N-pyrrolylcarboxylic acid in experimental conditions***H. Zlatanova\*, S. Vladimirova, I. Kandilarov, I. Kostadinov, D. Delev, I. Kostadinova, A. Bijev (Bulgaria)*

Pain and headache; Animal models - Method

P.687

**Effects of pregabalin on paclitaxel-induced neuropathic pain in rats***V. Kokova\*, E. Apostolova, L. Peychev (Bulgaria)*

Pain and headache; Animal models - Method;

Pharmacology - Intervention

P.688

**Influence of acute hypobaric hypoxia on pain sensitivity in pregnant and non-pregnant rats***T. Yurakova\*, A. Maklakova, M. Maslova, Y. Krushinskaya (Russia)*

Pain and headache; Animal models - Method; Stress

related disorder

P.689

**Angiotensin (1-7) prevents streptozotocin-induced diabetic neuropathic pain in mice***W. Nemoto\*, O. Yoshiki, Y. Ryota, N. Osamu, T.N. Koichi (Japan)*

Pain and headache; Pharmacology - Intervention;

Neuromodulation - Intervention

P.690

**Tobacco smoking and psychotropic drugs***P. Barata\*, J.C. Melo, T. Maia (Portugal)*

Addiction - Disorder; Pharmacology - Intervention;

Lifestyle and nutrition - Intervention

P.691

**Psychedelic fauna for psychonaut hunters***L. Orsolini\*, M. Ciccarese, D. Papanti, D. De Berardis, A. Guiguis, J. Corkery, F. Schifano (United Kingdom)*

Addiction - Disorder; Pharmacology - Intervention

P.692

**Analysis of epidemiological characteristics of alcohol use disorders in the Nizhny Novgorod region (Russian Federation)***M. Denisenko\*, A. Blagonravova (Russia)*

Addiction - Disorder; Epidemiology and big data -

Method

P.693

**Substance use disorders and attention deficit hyperactivity disorder – what should we treat first?***R. Torpan\*, F. Ståhlfors, S. Moica, T. Moica (Sweden)*

Addiction - Disorder; ADHD - Disorder

P.694

**Analysing heroin samples as harm reduction intervention - prevalence of adulteration with fentanyl derivatives***M. Roldán Berengué\*, M. Grifell Guardia, I. Gonzalez Gil, J.J. Fuentes Valenzuela, M.P. Frings, M. Ventura, F. Fonseca, M. Torrens (Spain)*

Addiction - Disorder; Biochemistry - Method

P.695

**Influence of dietary trans fat on the amphetamine preference in rats.***F. Teixeira Kuhn\* (Brazil)*

Addiction - Disorder; Eating disorder; Anxiety - Disorder

P.696

**Responsivity of the brain reward network to the taste of beer in light, at-risk, and dependent alcohol users***M. Groefsema\*, R. Engels, V. Voon, A. Schellekens, M. Luijten, G. Sescousse (The Netherlands)*

Addiction - Disorder; Neuroimaging - Method; Prevention

/ course alteration

P.697

**Effects of maternal deprivation early in life followed by adolescent cocaine exposure on negative affect in rats: immediate and long-term effects***C. Bis-Humbert\*, R. García-Cabrerizo,**M.J. García-Fuster (Spain)*

Addiction - Disorder; Anxiety - Disorder

P.698

**Cocaine: a problem of the head and the heart***J.T.P.M. Maloney\*, C.M. McEniery, K.D. Ersche (United Kingdom)*

Addiction - Disorder; Prevention / course alteration

P.699

**A systematic review of the relationship between childhood maltreatment and risk of adolescent drug use***V. De La Peña Arteaga\*, L. Hines (Spain)*

Addiction - Disorder; Epidemiology and big data -

Method; Prevention / course alteration

UPDATED PROGRAMME:

<https://2018.ecnp.eu/> / ECNP app / congress info terminals

**P.700****Modulation of 5-HT7 receptor: a new approach to the management of alcohol abuse and its neurobiological consequences?**

*E. Paizanis\*, A. Lecomte, T. Corbett, L. Lanfumey (France)*

Addiction - Disorder; Animal models - Method

**P.701****Readiness, a key element of smoking cessation in severe mental illness: the opportunity for new technological tools and mobile computing**

*C. Gómez, N. Feu, M.J. Jaen-Moreno, G.I. Del Pozo Seseña, J.A. Alcalá-Partera\*, L. Carrion Expósito, M.D. Sanchez martinez, I. Caro martos, G.M. Chauca chauca, F. Sarramea Crespo (Spain)*

Addiction - Disorder; Mood and bipolar disorder; Psychotic disorder

**P.702****Relevance of dopamine D2-agonist cabergoline in modulation of the rewarding effects of alcohol**

*P. Anokhin\* (Russia)*

Addiction - Disorder; Animal models - Method; Biochemistry - Method

**P.703****The protection of smoking cessation program from recurrence among people with major depression**

*C. Cheng\*, C.H. Lin, T.H. Lan (Taiwan)*

Addiction - Disorder; Mood and bipolar disorder

**P.704****Personality trait may modify the people with antisocial personality disorder from prison to comorbid with substance use or not**

*M.Y. Hsiao\*, Y.H. Chang, R.B. Lu (Taiwan)*

Addiction - Disorder; Genetic & molecular approaches - Method; Personality disorder

**P.705****Problematic internet use and Facebook use among adolescents**

*J. Jovic\*, D. Ignjatović Ristić, D. Hinić, G. Trajković, I. Ristić, A. Ćorac (Serbia)*

Addiction - Disorder; Epidemiology and big data - Method; Prevention / course alteration

**P.706****GRIK1 polymorphism as predictor of benzodiazepine tranquilizer's safety in patients with alcohol withdrawal syndrome**

*A. Bryleva\*, D. Ivashchenko, M. Solov'eva, A. Kibitov, E. Bryun, D. Sychev (Russia)*

Addiction - Disorder; Pharmacology - Method; Genetic & molecular approaches - Method

**P.707****Effect of cognitive exercise on cocaine self-administration in rats**

*M. Wahab\*, V. Lardeux, M. Solinas (France)*

Addiction - Disorder; Animal models - Method; Psychotherapy - Intervention

**P.708****Immediate and prolonged behavioural effects following chronic morphine administration during adolescence: a study focused on gender-based differences**

*F. Jiménez Romero\*, C. Bis Humbert, M.J. García Fuster (Spain)*

Addiction - Disorder; Animal models - Method

**P.709****Efficacy and safety of adjunctive pharmacologic treatments for alcohol addiction in patients with schizophrenia and bipolar disorder**

*V.B. Nöhles\*, C.U. Correll, A. Roldàn, B. Galling (Germany)*

Addiction - Disorder; Pharmacology - Intervention; Psychotic disorder

**P.710****Reward processing in Attention-Deficit/Hyperactivity Disorder and healthy controls at high risk for Substance Use Disorders**

*M. Paraskevopoulou\*, D. Van Rooij, A. Batalla, A.H. Schene, J.K. Buitelaar, A.F.A. Schellekens (The Netherlands)*

Addiction - Disorder; ADHD - Disorder

**P.711****Cannabidiol-mediated regulation of spontaneous cannabinoid withdrawal**

*F. Navarrete, A. Aracil-Fernandez, A. Gasparyan\*, J. Manzanares (Spain)*

Addiction - Disorder; Animal models - Method; Pharmacology - Method

**P.712**

**Ketamine reduces alcohol consumption in hazardous drinkers by interfering with the reconsolidation of drinking memories: preliminary findings**

*R. Das\**, *G. Gale*, *K. Walsh*, *V. Hennessy*, *G. Iskandar*, *L. Mordecai*, *B. Brandner*, *M. Kindt*, *L. Otten*, *V. Curran*, *S. Kamboj* (United Kingdom)

Addiction - Disorder; Pharmacology - Intervention

**P.713**

**Fatal overdose in recently detoxified Russian HIV-positive persons with opioid use disorder: the role of naltrexone in prevention**

*V. Palatkin\**, *T. Yaroslavtseva*, *E. Blokhina*, *E. Krupitsky*, *E. Verbitskaya*, *E. Zvartau*, *N. Gnatienko*, *A. Walley*, *R. Gross*, *J. Samet*, *G. Woody* (Russia)

Addiction - Disorder; Pharmacology - Intervention; Pharmacology - Method

**P.714**

**Problem gambling connected with bipolarity, impulsiveness and anxious, cyclothymic, irritable affective temperaments**

*A. Turek\**, *K. Machalska*, *A.A. Chrobak*, *M. Siwek*, *D. Dudek* (Poland)

Addiction - Disorder; Mood and bipolar disorder

**P.715**

**Modified maternal diet alters melanocortin-4 receptor levels in the brain of male rat offspring**

*D. Gawliński\**, *K. Mudlaff*, *M. Filip* (Poland)

Addiction - Disorder; Healthy brain; Lifestyle and nutrition - Intervention

**P.716**

**Wanting food in cocaine addiction: a more complex relationship**

*J. Breedon\**, *H. Ziauddeen*, *K.D. Ersche* (United Kingdom)

Addiction - Disorder; Lifestyle and nutrition - Intervention

**P.717**

**Differences in PANSS score progression at first-episode psychosis in children and adolescents with cannabis use; a longitudinal prospective study**

*A. Trabsa\**, *M. De Dios*, *D. Sanagustin*, *N. Del Cacho*, *R. Vila-Badia*, *A. Butjosa*, *J. Usall*, *M. Kaplan*, *M. Pardo*, *D. Muñoz-Samons* (Spain)

Addiction - Disorder; Psychotic disorder

**P.718**

**The influence of GHB-use and GHB-induced coma on affect and the affective network**

*F. Raposo Pereira\**, *M. T.B. McMaster*, *N. Polderman*, *Y. D.A.T. de Vries*, *W. Van den Brink*, *G. A. van Wingen* (The Netherlands)

Addiction - Disorder; Epidemiology and big data - Method; Neuroimaging - Method

**P.719**

**Naphryone – pharmacokinetics and behavioural profile in wistar rat**

*L. Olejníková\** (Czech Republic)

Addiction - Disorder; Animal models - Method; Pharmacology - Intervention

**P.720**

**Neurobiological relationships between astroglial Cx43 and stress-related responses**

*B. Portal\**, *S. Manta*, *R. Rovera*, *N. Lorenzo*, *C. Rampon*, *N. Déglon*, *N. Haddjeri*, *B.P. Guiard* (France)

Anxiety - Disorder; Neuromodulation - Intervention

**P.721**

**Mediation model of comorbid anxiety disorders in late-life depression: findings from the DAS Study**

*C. Suradom\**, *N. Wongpakaran*, *T. Wongpakaran*, *P. Lertrakarnnon*, *S. Jiraniramai*, *U. Tameyapradit*, *S. Lertkachatarn*, *S. Arunpongpaisal* (Thailand)

Anxiety - Disorder; Mood and bipolar disorder

**P.722**

**Testing for bifactor model and differential item functioning of core symptom index: a tool for depression, anxiety, and somatisation**

*N. Wongpakaran\**, *T. Wongpakaran*, *S. Lertkachatarn*, *T. Sirirak* (Thailand)

Anxiety - Disorder; Mood and bipolar disorder

**P.723**

**Characterisation of three major functional networks using graph-analysis across internalising disorders**

*K. Hilbert\**, *U. Lueken*, *K. Beesdo-Baum* (Germany)

Anxiety - Disorder; Mood and bipolar disorder

**P.724**

**Insular cortical thickness is reduced in panic disorder**

*K.S. Lee\**, *T.K. Choi*, *L. Sang Hyuk* (South-Korea)

Anxiety - Disorder; Neuroimaging - Method

P.725

**The influence of trait anxiety and depressivity on emotional face processing***K. Kneer\*, J. Reinhard, M. Romanos, K. Domschke, S. Neufang (Germany)*

Anxiety - Disorder; Mood and bipolar disorder

P.726

**Transcranial magnetic stimulation of the supplementary motor area in the treatment of obsessive-compulsive disorder: a multi-site study***S. Simsek\*, R. Milev, D. Dilkov (Turkey)*

Anxiety - Disorder; Impulsive and compulsive disorder; Neuromodulation - Intervention

P.727

**The role of intranasal oxytocin in anxiety and depressive disorders: a systematic review of randomized controlled trials***F. De Cagna\*, L. Fusar-Poli, S. Damiani, M. Rocchetti, G. Giovanna, A. Mori, P. Politi, N. Brondino (Italy)*

Anxiety - Disorder; Mood and bipolar disorder; Pharmacology - Intervention

P.728

**Gene-environment interaction in myelin plasticity after chronic psychosocial stress***M.A. Laine, K. Trontti, Z. Misiewicz, E. Sokolowska, E. Rikandi, N. Kuleskaya, A. Heikkinen, S. Saarnio, I. Balcells, D. Greco, E. Jokitalo, O. Mantere, T. Kieseppä, J. Suvisaari, T.T. Raji, I. Hovatta\* (Finland)*

Anxiety - Disorder; Animal models - Method; Stress related disorder

P.729

**Childhood trauma and stressful life events are associated with cerebellar volumes in adults with obsessive-compulsive disorder***J. Hernández-García\*, M. Subirà, I. Martínez-Zalacain, M. Suñol, N. Cardoner, C. Segalàs, P. Alonso, J.M. Menchón, E. Real, C. Soriano-Mas (Spain)*

Anxiety - Disorder; Neuroimaging - Method

P.730

**Translocator protein 18 kDa may be responsible for anxiolytic effect modulation provoked by acute short-term stress in Balb/c mice***T. Kalinina\*, A. Shimshirt, N. Kudryashov, A. Volkova, T. Voronina (Russia)*

Anxiety - Disorder; Stress related disorder

P.731

**High anxiety in fully edited 5-HT<sub>2C</sub> receptor VGV mice in relation with plasticity impairment***C. Poilbout\*, M. Regue, M. Schamne, L. Lanfumey, R. Mongeau (France)*

Anxiety - Disorder; Stress related disorder; Animal models - Method

P.732

**Worry behaviour in generalised anxiety disorder***K. Beesdo-Baum\*, C. Voss, J. Venz, S. Poppenhäger, J. Berwanger, L. Pieper (Germany)*

Anxiety - Disorder; Epidemiology and big data - Method

P.733

**Neurocognitive markers of suicidal ideation in patients with anxiety and mood disorders***V. Liaugaudaite\*, J. Burkauskas, N.A. Fineberg, A. Podlipskyte, N. Mickuviene (Lithuania)*

Anxiety - Disorder; Mood and bipolar disorder

P.734

**Galactooligosaccharides attenuates anxiety and plasma corticosterone in rats evoked by electrical stimulation of the central nucleus of the amygdala***J. Ruciński\*, E. Kurowska, M. Podlacha, D. Myslinska, A. Stankiewicz, E. Jurkowlaniec (Poland)*

Anxiety - Disorder; Stress related disorder; Lifestyle and nutrition - Intervention

P.735

**Postpartum depression and risk of bipolar disorder: an 8-year follow-up study***A. Roca\*, A. Gonzalez, E. Gelabert, A. Torres, E. Solé, B. Sureda, P. Navarro, S. Andrés, M.L. Imaz, R. Martin-Santos, L. Garcia-Esteve (Spain)*

Anxiety - Disorder; Mood and bipolar disorder

P.736

**Pharmacologic influence on memory processes performance through 5-HT<sub>1</sub> serotonin receptors in rats***B.R. Buca\*, G. Rusu, D. Ciubotariu, G. Popa, L. Pavel, L. Mititelu-Tartau (Romania)*

Anxiety - Disorder; Animal models - Method; Neuro-inflammatory disorder

**P.737****Brain functional connectivity is associated with subclinical obsessive-compulsive symptoms in healthy children**

*C. Saiz Masvidal\*, M. Suñol, O. Contreras-Rodríguez, D. Macià, G. Martínez-Vilavella, I. Martínez-Zalacaín, M. Subirà, J.M. Menchón, J. Pujol, J. Sunyer, C. Soriano-Mas (Spain)*

Impulsive and compulsive disorder; Neuroimaging - Method; Anxiety - Disorder

**P.738****Metabolic and structural abnormalities in obsessive-compulsive disorder: a multimodal neuroimaging and clinical approach**

*J. Andrade\*, F. Meireles, C. Suo, M. Yucel, I. Frydman, L. Fontenelle, F. Tovar Moll (Brazil)*

Impulsive and compulsive disorder; Neuroimaging - Method

**P.739****Effects of genetic deficiency of tryptophan hydroxylase 2 on attentional processes in the five choice serial reaction time task in rats**

*J. Gołębiowska\*, A. Nikiforuk, N. Alenina, M. Bader, P. Popik (Poland)*

Impulsive and compulsive disorder; Neuromodulation - Intervention

**P.740****A systematic review of the utility of electroconvulsive therapy in broadly defined obsessive-compulsive related disorders**

*S. Dos Santos-Ribeiro\*, J.B. Salles Andrade, J.N. Quintas, K.B. Batista, M. Yücel, L.F. Fontenelle (Brazil)*

Impulsive and compulsive disorder; Neuromodulation - Intervention

**P.741****The role of DNA methylation of BDNF gene on clinical severity and cognitive performance in obsessive-compulsive disorder**

*A. Ferrer Alberti\*, M. Barrachina, J. Labad, N. Salvat-Pujol, J. Ansede-Bermejo, E. Real, C. Segalàs, P. Alonso, C. Soriano-Mas, A. Carracedo, J.M. Menchon, V. Soria (Spain)*

Impulsive and compulsive disorder; Genetic & molecular approaches - Method

**P.742****Are changes in the PANSS total during screening predictive of changes after randomization? An exploratory analysis**

*D. Daniel\*, A. Kott (USA)*

Impulsive and compulsive disorder; Neuropsychology - Method; Biochemistry - Method

**P.743****Genetic associations of serotonergic and GABAergic genes in an extended collection of early-onset obsessive-compulsive disorder trios**

*A.E. Ortiz Garcia\*, D. Boloc, S. Mas, N. Rodriguez, A. Morer, M.T. Plana, A. Lafuente, L. Lázaro, P. Gassó (Spain)*

Impulsive and compulsive disorder; Genetic & molecular approaches - Method

**P.744****Contribution of both CB1 receptors and TRPV1 channels in mediating cannabinoid-induced apathetic and impulsive patterns of choice**

*A. Khani\*, Z. Fatahi, Z. Reisi, G. Rainer, A. Haghparast (Switzerland)*

Impulsive and compulsive disorder; Pharmacology - Intervention; Addiction - Disorder

**P.745****Ventromedial prefrontal cortex glutamate is associated with fear extinction recall and cognitive behavior therapy outcome in OCD**

*M. Giménez, M. Subirà\*, I. Martínez-Zalacaín, M. Cano, P. Alonso, C. Segalàs, E. Real, J.M. Menchón, N. Cardoner, L.S. Kegeles, J.J. Weinstein, X. Xu, C. Soriano-Mas, M.A. Fullana (Spain)*

Impulsive and compulsive disorder; Neuroimaging - Method; Psychotherapy - Intervention

**P.746****Transcriptional regulation of BDNF and oxytocin receptor genes in Obsessive Compulsive Disorder**

*F. Bellia\*, B. Benatti, B. Grancini, V. De Carlo, M. Vismara, D. Galimberti, M. Maccarrone, B. Dell'Osso, C. D'Addario (Italy)*

Impulsive and compulsive disorder; Genetic & molecular approaches - Method

**P.747**

**Thyroid hormones and personality in coronary artery disease patients with and without sleep apnea**

*A. Juskiene\*, G. Varoneckas, A. Podlipskyte, A. Bunevicius, N. Mickuviene (Lithuania)*

Sleep disorder; Prevention / course alteration

**P.748**

**A phase 1/2 double-blind, placebo-controlled study of SAGE-217 in a phase advance model of transient insomnia**

*A. Bullock\*, H. Gunduz-Bruce, G. Zammit, A. Sankoh, H. Li, M. Qin, C. Silber, S. Kanes, J. Jonas, J. Doherty (USA)*

Sleep disorder; Pharmacology - Intervention

**P.749**

**Sleep prediction algorithm based on machine learning technology**

*K. Park\*, S. Lee, S. Lee, S. Cho, S. Wang, S. Kim, E. Lee (South-Korea)*

Sleep disorder; Biostatistics & computational method

**P.750**

**Repetitive microinjection of Orexin-A accelerates regulation of sleep homeostasis and recovery from barbiturate anesthesia-induced deep sleep**

*N. Maglakelidze\*, E. Chkhartishvili, O. Mchedlidze, M. Babilodze, V. Tsomaia, N. Rogava, S. Dzadzamia, E. Chijavadze, N. Nachkebia (Georgia)*

Sleep disorder; Neurophysiology / EEG - Method

**P.751**

**Brain-derived neurotrophic factor as a biomarker of insomnia**

*T. Mikoteit\*, S. Brand, A. Eckert, E. Holsboer-Trachsler, J. Beck (Switzerland)*

Sleep disorder; Stress related disorder

**P.752**

**The actigraphic monitoring of bipolar disorder manic episode**

*M. Yasar Kocatas\*, O. Caliyurt (Turkey)*

Sleep disorder; Mood and bipolar disorder

**P.753**

**Chronobiological rhythms dysregulation predicts suicidality in bipolar disorder**

*I. Masci\*, D. Caruso, G. Cipollone, F.L. Paolilli, B. Tripodi, M. Novi, U. Moretto, L. Palagini (Italy)*

Sleep disorder; Mood and bipolar disorder

**P.754**

**Common brain changes associated with increased activity in the forced swim test induced by drugs with different mechanisms of action**

*G.T. Shishkina\*, T.S. Kalinina, A.V. Bannova, N.P. Agarina, K.A. Ayriyants, N.N. Dygalo (Russia)*

Stress related disorder; Pharmacology - Intervention; Animal models - Method

**P.755**

**Stressful experiences elicit motivational component of prosocial behaviour**

*D. Winiewicz\*, J. Price (Poland)*

Stress related disorder; Animal models - Method

**P.756**

**Developmental trajectories of microbiome composition affected by stress during adolescence and impact on brain inflammation**

*S. Provasi\*, V. Begni, L. Borruso, M. Mazzelli, C. Ferrari, M.A. Riva, A. Cattaneo (Italy)*

Stress related disorder; Neuro-inflammatory disorder

**P.757**

**Cardiovascular reactivity to social stress is associated with health related quality of life in patients after acute coronary syndromes**

*J. Gecaite\*, J. Burkauskas, J. Brozaitiene, N. Mickuviene (Lithuania)*

Stress related disorder; Anxiety - Disorder

**P.758**

**The association of irritable bowel syndrome complaints and psychological distress**

*S. Balikji\*, M. Mackus, A.D. Kraneveld, J. Garssen, J.C. Verster (The Netherlands)*

Stress related disorder; Anxiety - Disorder

**P.759**

**Early-life stress affects microglia, possible modulation by dietary fatty acids**

*K. Reemst\*, L. Hoeijmakers, K.Y. Yam, E.M. Van der Beek, L. Schipper, A. Oosting, A. Van Dam, P.J. Lucassen, A. Korosi (The Netherlands)*

Stress related disorder; Neuro-inflammatory disorder; Lifestyle and nutrition - Intervention

P.760

**Long-lasting effects of stress in adolescence: behavioural and molecular characterization of an animal model of social isolation***V. Begni\*, L. Longo, S. Zampar, M.A. Riva (Italy)*

Stress related disorder; Animal models - Method

P.761

**Posttraumatic stress disorder in the primary care setting***N. Goldental\*, T. Greene, Y. Neria, R. Gross (Israel)*

Stress related disorder; Anxiety - Disorder

P.762

**How does early marriage affect general mental health and sexual health of women?***H. Kaya\*, D. Sahin, B.Z. Subasi (Turkey)*

Stress related disorder; Sexual disorder; Prevention / course alteration

P.763

**Programming of metabolic functions by early-life stress: relevance for vulnerability to obesity***S. Ruigrok\*, K.Y. Yam, M.R. Abbink, J. Kroon, S.E. La Fleur, P.J. Lucassen, A. Korosi (The Netherlands)*

Stress related disorder; Lifestyle and nutrition - Intervention

P.764

**Can gaze behaviour predict stress response and coping during acute psychosocial stress? A virtual-reality-based eyetracking study***T. Wechsler\*, L.M. Bahr, A. Mühlberger (Germany)*

Stress related disorder; Neurophysiology / EEG - Method

P.765

**Morning chronotype is associated with high psychological distress in prostate cancer patients***A. Turek\*, K. Machalska, A.A. Chrobak, A. Czech, Ł. Bełch, M. Siwek, P. Chłosta, D. Dudek (Poland)*

Stress related disorder; Neurophysiology / EEG - Method

P.766

**The influence of single prolonged stress on neuropeptides - substance P, galanin and enkephalin in rats' brain***M. Zivkovic\*, R. Petrovic, M. Aksic, D. Djorovic, M. Velimirovic, T. Stojkovic, L. Puskas, N. Petronijevic (Serbia)*

Stress related disorder; Animal models - Method

P.767

**Cortisol response to nocturnal psychosocial stress in dependence of CRHR1 genotype***J. Weeger\*, U. Schmidt, M. Uhr, A. Steiger (Germany)*

Stress related disorder; Sleep disorder

P.768

**Personality traits play a role in postpartum stressors perception***A. Lengvenyte\*, R. Strumila (Lithuania)*

Stress related disorder; Personality disorder; Anxiety - Disorder

P.769

**Characterization of memory, anxiety, depression and social behaviour in a rat model of irritable bowel syndrome generated by chronic stress contention***R. Lefter, A. Ciobica\*, S. Guenne, M. Compaore, M. Kiendrebeogo, C. Stanciu, A. Trifan (Romania)*

Stress related disorder; Eating disorder; Lifestyle and nutrition - Intervention

P.770

**Efficacy of dexprex, an internet-based depression treatment: a meta-analysis of ten randomized controlled trials***B. Meyer, O. Bültmann\*, G. Jacob (Germany)*

E-health - Intervention; Mood and bipolar disorder; Psychotherapy - Intervention

P.771

**A multi-modality and human-sensing platform for mental healthcare: prototype development***H. Atsumori\*, H. Nakagawa, H. Kuriyama, M. Egi, K. Muro, A. Nishimura, T. Tanaka, M. Kiguchi (Japan)*

E-health - Intervention; Biostatistics &amp; computational method; Neuroimaging - Method

P.772

**The use of smartphones in the management of bipolar disorder- mobile apps and voice analysis in monitoring of mental state and phase change detection***A.Z. Antosik-Wójcinska\*, M. Chojnacka, M. Dominiak, Ł. Świącicki (Poland)*

E-health - Intervention; Mood and bipolar disorder



**P.773****Design of a cognitive health app to support caregivers of people with agitation**

G. Estrada, G. Dulsat, A. Gracia, A. Boldeanu\*,  
F. Alcalde, J. Susilla, N. Santoyo (Spain)

E-health - Intervention; Psychotherapy - Intervention

**P.774****Applied mindfulness smartphone app helps mitigating smartphone addiction**

C.L. Ke\*, C. Shih-Tsung (Taiwan)

E-health - Intervention; Psychotherapy - Intervention

**P.775****Stress susceptibility – dependent effects of medial septal NMDA glutamate receptors on neuro-immune interactions in rats**

M. Podlacha\*, D. Myslinska, I. Majkutewicz,

A. Stankiewicz, K. Pierzynowska, G. Jerzemowska,

K. Plucinska, E. Kurowska, J. Rucinski, D. Wrona

(Poland)

Neuromodulation - Intervention; Immunology - Method;

Neuropsychology - Method

**P.776****Blockade of aversive and appetitive memory reconsolidation by systemic administration of beta-noradrenergic and NMDA-receptors antagonists**

M. Zaichenko\*, V. Markevich, G. Grigoryan (Russia)

Neuromodulation - Intervention; Pharmacology -

Intervention

**P.777****Increased perseverative errors during probabilistic reversal learning using cathodal high definition transcranial current stimulation**

N. Albein-Urios\*, H. Chase, M. Kirkovski, P. Enticott

(Australia)

Neuromodulation - Intervention; Healthy brain

**P.778****white matter tracts activated by successful subgenual cingulate deep brain stimulation**

D. Clark\*, K. Johnson, C. Butson, C. Lebel, D. Gobbi,

R. Ramasubbu, Z. Kiss (Canada)

Neuromodulation - Intervention; Mood and bipolar

disorder; Neuroimaging - Method

**P.779****(No) rTMS in non-treatment refractory patients with depression: findings from a meta-analysis**

M. Kiebs\*, R. Hurlmann, C. H.Y. Fu, J. Mutz (Germany)

Neuromodulation - Intervention; Mood and bipolar

disorder

**P.780****Factors associated with higher oral antipsychotic doses at discharge in compulsorily admitted patients**

S. Martinho\* (Portugal)

Pharmacology - Intervention; Prevention / course

alteration

**P.781****Use of palmitate of paliperidone 1-monthly in patients <40 years old: results of real clinical practice**

J.A. Campos\*, L. Docasar, A.M. Seoane (Spain)

Pharmacology - Intervention; Psychotic disorder

**P.782****Safety and pharmacokinetics study of inhaled esketamine after a single dose in healthy volunteers**

S. Janowska\*, E. Tratkiewicz, M. Matloka, P. Perko,

M. Gaciarz, A. Urban, M. Wieczorek (Poland)

Pharmacology - Intervention; Mood and bipolar disorder

**P.783****Pharmacodynamics of S-ketamine and ketamine racemate in rat PFC and HP after dry powder inhalation, intratracheal and intravenous administration**

A. Gajos-Draus\*, S. Janowska, M. Janicka,

M. Wieczorek, J. Pieczykolan, M. Matloka (Poland)

Pharmacology - Intervention; Mood and bipolar disorder;

Animal models - Method

**P.784****The antidiabetic drug rosiglitazone blocks Kv3.1 potassium channels**

H.M. Lee, S.J. Hahn, B.H. Choi\* (South-Korea)

Pharmacology - Intervention; Neuromodulation -

Intervention

**P.785****BMI evolution and impaired oGTT in a sample of psychotic resistant patients that starting clozapine**

*M. Garriga\*, A. Mallorqui, M. Brat, E. Sole, I. Grande, S. Amoretti, E. Vieta, C. García-Rizo, M. Bernardo (Spain)*  
Pharmacology - Intervention; Psychotic disorder;  
Lifestyle and nutrition - Intervention

**P.786****Does the MDR1 C34354T polymorphism influence the occurrence of nausea and sexual dysfunction after paroxetine treatment in the Slovak setting?**

*Z. Vančová, J. Dragašek\*, M. Čižmáriková (Slovak Republic)*  
Pharmacology - Intervention; Mood and bipolar disorder;  
Genetic & molecular approaches - Method

**P.787****CPL-500-036-02 – novel and highly bioavailable PDE10A inhibitor activates cyclic nucleotides depending signaling in rat striatum**

*P. Pankiewicz\*, S. Janowska, A. Gajos-Draus, P. Mozolewski, E. Drzazga, M. Janicka, J. Hucz-Kalitowska, M. Świątkiewicz, M. Wełniak-Kamińska, M. Fiedorowicz, P. Grieb, J. Pieczykolan, M. Wieczorek, M. Matkoka (Poland)*  
Pharmacology - Intervention; Psychotic disorder

**P.788****Glutamate modulation by evenamide, a Na<sup>+</sup> channel blocker, may benefit treatment resistant schizophrenic (TRS) patients not responding to clozapine**

*R. Anand\*, M. Bortolato, L. Faravelli (Switzerland)*  
Pharmacology - Intervention; Animal models - Method;  
Psychotic disorder

**P.789****Pentobarbital-induced sleep upregulates the survival p-FADD/FADD ratio in mouse brain cortex**

*G. Salort\*, M. Álvaro-Bartolomé, J.A. García-Sevilla (Spain)*  
Pharmacology - Intervention; Sleep disorder

**P.790****Innovative released-active drug for the treatment of neurological diseases: results of preclinical studies**

*G. Stepanov\*, P. Naplekova, S. Pertsov, S. Tarasov (Russia)*  
Pharmacology - Intervention; Neuromodulation - Intervention; Stroke

**P.791****Duration of illness' impact on readmission and adherence in patients discharged with newer long-acting injectable antipsychotics**

*J.M. Oliveira\*, S. Gonçalo, C. Pereira (Portugal)*  
Pharmacology - Intervention; Psychotic disorder;  
Prevention / course alteration

**P.792****Managing Huntington's disease – the neuropsychiatric approach**

*I. Coelho\*, J. Reis, M. Lázaro, F. Gonçalves, V. Passão, I. Cunha (Portugal)*  
Pharmacology - Intervention; Dementia & neuro degeneration - Disorder; Movement disorder

**P.793****Antidepressant-like activity of cyclo-l-prolyglycine**

*E. Vasileva\*, A. Abdullina, E. Kondrakhin, G. Kovalev (Russia)*  
Pharmacology - Intervention; Pharmacology - Method;  
Stress related disorder

**P.794****Clinical pharmacist interventions in elderly patients in primary care treated with polypharmacy and psychotropics: observational retrospective study**

*M. Stuhec\*, K. Gorenc (Slovenia)*  
Pharmacology - Intervention; Mood and bipolar disorder

**P.795****A comparison of two schizophrenia models induced by MK-801: Possible involvement of phosphodiesterase 4A and glycogen synthase kinase 3 beta**

*M.B. Yerer\*, G. Unal, H. Bekci, A. Cumaoglu, F. Aricioglu (Turkey)*  
Pharmacology - Intervention; Pharmacology - Method;  
Psychotherapy - Intervention

**P.796****In vitro characterization of buprenorphine, samidorphan, and combinations being developed as an adjunctive treatment for major depressive disorder**

*S. Pin\*, J. Bidlack, B. Knapp, D. Deaver, M. Plotnikava, D. Arnelle, A. Quinn, M. Toh, M. Namchuk (USA)*  
Pharmacology - Intervention; Mood and bipolar disorder

P.797

**An impact of clinical pharmacist interventions on the antipsychotic treatment guidelines adherence - an observational retrospective study***M. Stuhec\*, K. Gorenc (Slovenia)*

Pharmacology - Intervention; Psychotic disorder

P.798

**Plasma poly-unsaturated fatty acids profile in children with inattentive ADHD - preliminary results of an efficacy Italian study with omega 3/6***E. Sanna\*, R. Romaniello, C. Balia, S. Carucci, A. Zuddas (Italy)*

Pharmacology - Intervention; ADHD - Disorder; Pharmacology - Method

P.799

**The syndrome of irreversible lithium-effectuated neurotoxicity (silent): a case report***H. Becerra Darriba\*, A.I. Ojeda Martínez, M. Sánchez Enamorado, F.J. Olivera Pueyo, C.M. Pelegrín Valero (Spain)*

Pharmacology - Intervention; Mood and bipolar disorder

P.800

**Predicting planned suicide attempt with the Columbia-Suicide Severity Rating Scale***C.H.K. Park\*, H. Kim, B. Kim, E.Y. Kim, H.J. Lee, D. Kim, Y.M. Ahn (South-Korea)*

Prevention / course alteration; Epidemiology and big data - Method; Mood and bipolar disorder

P.801

**Factors influencing anticholinergic prescription in long-acting injectable paliperidone treated patients: a 6-year retrospective approach***P. Herrera-Gener\*, C. Alario Ruiz, P.A. Megía López, J.F. Verdugo Verdugo, F.C. Ruiz Sanz (Spain)*

Prevention / course alteration; Epidemiology and big data - Method; Movement disorder

P.802

**The association between duration of untreated illness and long-term outcome in psychiatric inpatients***G. Serafini\*, G. Canepa, D. Erbuto, M. Pompili, P. Girardi, M. Amore (Italy)*

Prevention / course alteration; Mood and bipolar disorder

P.803

**weight and metabolic risk associated with second-generation antipsychotics in antipsychotic-naïve children and adolescents: a 12 month follow-up study***A. Andreu\*, L. Pina-Camacho, C. Díaz-Caneja, D. Fraguas, C. Arango (Spain)*

Prevention / course alteration; Pharmacology - Method

P.804

**Are there differences in prodromal symptoms according to the age of onset of psychosis?***I. Baeza Pertegaz\*, O. Puig, E. De la Serna, M. Parellada, C. Manuel, J. Saiz, M. Bernardo, J. Castro-fornieles (Spain)*

Prevention / course alteration; Psychotic disorder

P.805

**Early-onset psychosis: clinical and psychosocial patient outcome improvements in a specialized programme compared to treatment as usual***N. Trovão\*, J. Canha, E. Ribeiro, L. Carneiro, F. Castro, A. Marques (Portugal)*

Prevention / course alteration; Psychotic disorder

P.806

**Differences by year of publication in duration of untreated psychosis in first episode schizophrenia: meta-analysis and meta-regression analysis***G. Salazar de Pablo\*, E. Martínez-Baringo, J.M. Rubio-Llorente, A. Armendariz, J. Soler, D. Guinart, C.U. Correll (Spain)*

Prevention / course alteration; Psychotic disorder

P.807

**Antiallodynic and antihyperalgesic activity of ceftriaxone in a mouse model of neuropathic pain induced by oxaliplatin***A. Furgała\*, K. Sałat (Poland)*

Animal models - Method; Pain and headache; Pharmacology - Intervention

P.808

**Derivatives of 1,3,5-triazine, a new class of 5-HT<sub>6</sub> receptor ligands, can reverse memory impairments in novel object recognition test in rats***M. Jastrzębska-Więsek\*, A. Partyka, M. Więcek, D. Łażewska, K. Kamińska, K. Kieć-Kononowicz, A. Wesolowska, J. Handzlik (Poland)*

Animal models - Method; Dementia &amp; neuro degeneration - Disorder; Pharmacology - Method

**P.810****Implication of the brain dopamine system in the regulation of genetically-defined aggressive behavior in rats**

*T. Ilchibaeva\*, D. Eremin, R. Kozhemyakina, V. Naumenko, A. Tsybko (Russia)*

Animal models - Method; Genetic & molecular approaches - Method

**P.811****Even low doses of d-serine can induce high anxiety in catatonic GC rats and in PM rats with audiogenic epilepsy**

*O. Prokudina\*, T. Alekhina (Russia)*

Animal models - Method; Pharmacology - Method; Mood and bipolar disorder

**P.812****Alteration of neurogenesis-related gene expression in the hippocampus of male mice with pathology of aggressive behavior**

*D. Smagin\*, I.L. Kovalenko, A.G. Galyamina, N.N. Kudryavtseva (Russia)*

Animal models - Method; Psychotic disorder

**P.813****Antidepressant efficacy of deep brain stimulation in Wistar Kyoto rats exposed to chronic mild stress: animal model of treatment-resistant depression**

*P. Gruca\*, M. Papp, M. Lason-Tyburkiewicz, E. Litwa, M. Niemczyk, K. Tota-Glowczyk, P. Willner (Poland)*

Animal models - Method; Mood and bipolar disorder

**P.814****Startle reflex and aggressiveness in adult male Norway rats selected for behaviour after intranasal oxytocin administration in adolescence**

*R. Kozhemyakina\*, S. Shikhevich, M. Konoshenko, R. Gulevich (Russia)*

Animal models - Method; Pharmacology - Method

**P.815****Changes in motivational-emotional behaviour and passive avoidance learning in “depressive” rats with high immobility and decreased level of monoamines**

*M. Shavgulidze\*, E. Chkhartishvili, M. Babilodze, N. Rogava, N. Nachkebia (Georgia)*

Animal models - Method; Mood and bipolar disorder

**P.816****Rat model of schizophrenia and gut microbiome**

*K. Olsa Fliegerova\*, S. Kvasnova, J. Mrazek, J. Klaschka, P. Kacer, H. Tejkalova (Czech Republic)*

Animal models - Method; Psychotic disorder

**P.817****Questioning the predictive validity of the amphetamine-induced hyperactivity model for screening mood stabilizing drugs**

*A. Lan\*, M. Alfie, M. Kazavchinsky, H. Einat (Israel)*

Animal models - Method; Mood and bipolar disorder

**P.818****Analysis of fabomotizole-induced transcriptional responses in male Maudsley reactive strain rat brain**

*Y. Vakhitova\*, L. Zainullina, S. Seredenin (Russia)*

Animal models - Method; Genetic & molecular approaches - Method; Pharmacology - Method

**P.819****Chlorogenic acid and gallic acid elevate pain sensitivity threshold in olfactory bulbectomised rats**

*S. Valcheva-Kuzmanova\*, B. Iren, S. Belcheva, M. Todorova, R. Tashev (Bulgaria)*

Animal models - Method; Pain and headache; Pharmacology - Method

**P.820****Polyphenol-rich aronia melanocarpa fruit juice antagonises behavioural changes and oxidative stress in rats exposed to disruption of circadian rhythms**

*S. Valcheva-Kuzmanova\*, M. Eftimov, K. Kuzmanov (Bulgaria)*

Animal models - Method; Pharmacology - Method; Biochemistry - Method

**P.821****Oxytocin administration normalises poor empathy-like behaviour and abnormal aggression in mice**

*F. Zoratto\*, F. Franchi, A. Martinelli, M. Sbriccoli, J. Glennon, S. Macri, G. Laviola (Italy)*

Animal models - Method; Impulsive and compulsive disorder; Pharmacology - Intervention

**P.822****Studying social withdrawal in group housed mice using semi-natural conditions**

*K. Ike\**, *M. Bove*, *B. Buwalda*, *S.F. De Boer*, *M.J.H. Kas* (The Netherlands)

Animal models - Method; Autism / ASD - Disorder

**P.823****Establishing an effective dose for chronic intracerebroventricular administration of clozapine in mice**

*D. Esen\**, *B. Santos da Silva*, *D. Slattery*, *A. Reif*, *F. Freudenberg* (Germany)

Animal models - Method; Pharmacology - Method; Psychotic disorder

**P.824****PPP1r1b gene and others in the dorsal striatum of mice with movement disturbances**

*D. Smagin\**, *A.G. Galyamina*, *I.L. Kovalenko*, *N.N. Kudryavtseva*, *V.N. Babenko* (Russia)

Animal models - Method; Genetic & molecular approaches - Method

**P.825****Involvement of GABAA receptor gamma 2 subunit in the anxiety-like behaviour and cognitive dysfunction in pentylenetetrazole-kindled rats**

*Z. Gáll\**, *K. Kelemen*, *S. Koncz*, *I.I. Toth*, *I. Mihály*, *M. Kolcsár* (Romania)

Animal models - Method; Anxiety - Disorder; Epilepsy - Disorder

**P.826****Epigenetic profiling of dynamic elements in Fkbp5 in an experimental model of stress-potentiated fear conditioning**

*S. Sharma\**, *Y. Li*, *P. Jin*, *K. Ressler* (USA)

Animal models - Method; Genetic & molecular approaches - Method; Stress related disorder

**P.827****Does physical activity associated with chronic food restriction alleviate anxiety like behavior?**

*M. Méquinion*, *S. Eddarkaoui*, *D. Blum*, *J. Vignau*, *V. Tolle*, *O. Viltart\** (France)

Animal models - Method; Eating disorder; Anxiety - Disorder

**P.828****Identification of the possible downstream pathways related to alpha7 nicotinic acetylcholine receptor in MK-801 induced schizophrenia model in rats**

*A. Cumaoğlu\**, *G. Unal*, *H. Bekci*, *M.B. Yerer*, *F. Aricioglu* (Turkey)

Animal models - Method; Biochemistry - Method

**P.829****effect of co-administration of zinc and fluoxetine in the chronic restraint stress model of depression in mice**

*P. Misztak\**, *P. Pańcyszyn-Trzewik*, *G. Nowak*, *M. Sowa-Kucma* (Poland)

Animal models - Method; Anxiety - Disorder; Stress related disorder

**P.830****Methylphenidate reduces anxiety and dose dependently affects aggression and sustained attention in BALB/cJ mice**

*F. Mogavero\**, *A. Jager*, *D. Kanters*, *F. Geers*, *J. Glennon* (The Netherlands)

Animal models - Method; ADHD - Disorder; Pharmacology - Intervention

**P.831****Bigger volume, less interneurons: are you aggressive? The role of anterior and midcingulate cortex in aggression and social withdrawal in BALB/cJ mice**

*S. Van Heukelum\**, *F. Mogavero*, *M. Van de Wal*, *L. Drost*, *B. Vivica*, *M.N. Havenith*, *J.C. Glennon* (The Netherlands)

Animal models - Method; Autism / ASD - Disorder; Genetic & molecular approaches - Method

**P.832****Exploratory behaviour and recognition memory in medial septal lesioned rats**

*L. Kruashvili\**, *G. Beselia*, *E. Kipiani* (Georgia)

Animal models - Method; Dementia & neuro degeneration - Disorder

**UPDATED PROGRAMME:**

<https://2018.ecnp.eu/> ECNP app / congress info terminals

**P.833****Identification of the agonist of trace amine-associated receptor 5 (TAAR5) and its action on brain physiology and neurochemistry**

*E. Efimova\**, *A. Gerasimov*, *I. Sukhanov*, *O. Korenkova*, *K. Antonova*, *M. Ptuha*, *A. Volnova*, *R. Gainetdinov (Russia)*  
 Animal models - Method; Pharmacology - Intervention; Biochemistry - Method

**P.834****The synthetic analog of acth4-10 improves memory retrieval under stressful conditions in barnes maze in wistar rats after acute neonatal hypoxia**

*D. Khukhareva\**, *J. Sukhanova*, *E. Sebentsova*, *N. Levitskaya (Russia)*  
 Animal models - Method; Pharmacology - Intervention; Anxiety - Disorder

**P.835****Effects of selective serotonin reuptake inhibitor fluvoxamine prenatal administration on anxiety and cognitive function of rat offspring**

*G. Gruzdev\**, *Y. Voronina*, *D. Manchenko*, *N. Glazova*, *N. Levitskaya (Russia)*  
 Animal models - Method; Pharmacology - Intervention; Intellectual disability disorder

**P.836****Alterations in dendritic spines following stress and L- $\alpha$ -aminoadipic-acid-induced astrocytic impairment are rescued by ZL006 inhibition of PSD95/NOS**

*K. O'Reilly\**, *J. David*, *G. Thuery*, *V. Kebede*, *A. Harkin (Ireland)*  
 Animal models - Method; Stress related disorder

**P.837****Chronic SSRI administration in Lsamp deficient mice**

*M.A. Philips\**, *A. Bregin*, *J. Innos*, *K. Lilleväli*, *K. Raudkivi*, *J. Harro*, *E. Vasar (Estonia)*  
 Animal models - Method; Biochemistry - Method; Pharmacology - Method

**P.838****Effects of oxytocin on early development, exploratory and social behavior of rats chronically exposed to sodium valproate**

*V. Gedzun\**, *K. Dovdnuk*, *N. Sarycheva*, *V. Dubynin (Russia)*  
 Animal models - Method; Autism / ASD - Disorder; Anxiety - Disorder

**P.839****Effect of vitamin D3 on glucocorticoid-induced impairments of rat hippocampus morphology and behavior**

*D. Labudzynski\**, *O. Lisakovska*, *R. Bogovik*, *M. Fedoriuk*, *S. Savosko*, *I. Shymanskyi*, *D. Isaev (Ukraine)*  
 Animal models - Method; Pharmacology - Intervention; System biology - Method

**P.840****The influence of single prolonged stress on interneurons in rats' brain**

*D. Djorovic\**, *R. Petrovic*, *M. Aksic*, *M. Zivkovic*, *M. Velimirovic*, *B. Filipovic*, *L. Puskas*, *M. Malis*, *N. Petronijevic (Serbia)*  
 Animal models - Method; Stress related disorder

**P.841****A novel positive modulator of  $\alpha$ 4-GABAA receptors, XHe-III-74, reduces ethanol intake in mouse „drinking in the dark“ model**

*T. Stankovic*, *B. Batinic\**, *M. Savic (Serbia)*  
 Animal models - Method; Addiction - Disorder

**P.842****Functional genetic variant in the GABRA6 gene interacts with environmental stress to increase the risk of multiple suicide risk-related phenotypes**

*X. Gonda\**, *J. Sarginson*, *N. Eslzari*, *P. Petschner*, *Z. Toth*, *D. Baksa*, *G. Hullam*, *J. Anderson*, *B. Deakin*, *G. Juhasz*, *G. Bagdy (Hungary)*  
 Genetic & molecular approaches - Method; Stress related disorder; Mood and bipolar disorder

**P.843****Lack of association of rs1437396 polymorphism and smoking in a Romanian alcohol dependent population**

*M. Bonea\**, *M. Farcas*, *C.I. Coroamă*, *I.V. Micluția (Romania)*  
 Genetic & molecular approaches - Method; Addiction - Disorder

**P.844****Investigation the effect of starch-based sugar on spatial memory and learning performance in rats**

*Y. Bayar\**, *A. Temeltas*, *H. Herdem*, *N. Dursun*, *C. Suer (Turkey)*  
 Genetic & molecular approaches - Method; Healthy brain; Lifestyle and nutrition - Intervention

**P.845**

**Distinct short and long-term effects of cortisol exposures on BDNF expression in an “in vitro” model of human hippocampal cells**

*V. Zonca\**, *C. Mora*, *N. Cattane*, *C.M. Pariante*, *M.A. Riva*, *A. Cattaneo (Italy)*

Genetic & molecular approaches - Method; Stress related disorder

**P.846**

**Parasuicidal behavior and neuroinflammation: a genetics and gene expression approach**

*B. Ludwig\**, *M.M.M. Mitschek*, *L. Carlberg*, *K. Kienesberger*, *P. Swoboda*, *A. Bernegger*, *M. Inaner*, *B. Senft*, *N. Kapusta*, *H. Haslacher*, *M. Aigner*, *S. Kasper*, *A. Schosser (Austria)*

Genetic & molecular approaches - Method; Mood and bipolar disorder; Neuro-inflammatory disorder

**P.847**

**5-HTTLPR ‘social sensitivity’ short allele may protect against depression after exposure to social network stressors in young people**

*X. Gonda\**, *N. Eszlari*, *I. Anderson*, *B. Deakin*, *G. Juhasz*, *G. Bagdy (Hungary)*

Genetic & molecular approaches - Method; Mood and bipolar disorder; Stress related disorder

**P.848**

**IL2 rs2069778 C/T single nucleotide polymorphism regulates micro-RNA expression in schizophrenia**

*H. Ghazaryan\**, *R. Zakharyan*, *S. Atshemyan (Armenia, Rep. of)*

Genetic & molecular approaches - Method; Psychotic disorder; Immunology - Method

**P.849**

**Microarray study of the effects of a chronic high-fat diet on a brain-specific interleukin-6-deficient mouse**

*O. Fernandez Gayol\**, *K. Aguilar*, *A. Navarro-Sempere*, *J. Hidalgo (Spain)*

Genetic & molecular approaches - Method; Animal models - Method; Biostatistics & computational method

**UPDATED PROGRAMME:**

<https://2018.ecnp.eu/> / ECNP app / congress info terminals

**P.850**

**LEP and LEPR as a marker of antipsychotic-induced weight gain: preliminary results of a prospective pharmacogenetic research**

*M. Tolmachev\**, *R. Nasyrova*, *K. Mironov*, *E. Ershov*, *V. Zhivotova*, *L. Akhmetova*, *E. Dunaev*, *N. Neznanov*, *G. Shipulin (Russia)*

Genetic & molecular approaches - Method; Pharmacology - Intervention

**P.851**

**Primary neuronal culture as a source for direct reprogramming of the cells**

*N. Katolikova\**, *R. Gainetdinov (Russia)*

Genetic & molecular approaches - Method; Dementia & neuro degeneration - Disorder

**P.852**

**Distribution among blood compartments of micro RNAs associated with antidepressant treatment response in major depressive disorder**

*C. Homorogan\**, *V.R. Enatescu*, *A. Marcu*, *E. Seclaman*, *C. Marian (Romania)*

Biochemistry - Method; Mood and bipolar disorder; Pharmacology - Intervention

**P.853**

**Effects of antipsychotic therapy on lipid and carbohydrate metabolism of schizophrenic patients**

*I. Mednova\**, *A. Boiko*, *V. Dubrovskaya*, *E. Kornetova (Russia)*

Biochemistry - Method; Pharmacology - Intervention; Psychotic disorder

**P.854**

**Catalytic antibodies as a new evidence of the humoral immune system dysfunction in schizophrenia**

*E. Ermakov\**, *S. Ivanova*, *A. Semke*, *P. Dmitrenok*, *V. Buneva*, *G. Nevinsky (Russia)*

Biochemistry - Method; Immunology - Method; Psychotic disorder

**P.855**

**Involvement of single-nucleotide missense variants of TAAR1 in mental disorders**

*S. Merlino\**, *G. Rutigliano*, *V. Carnicelli*, *C. Del Grande*, *I. Masci*, *L. Dell’Osso*, *R. Zucchi (Italy)*

Biochemistry - Method; Genetic & molecular approaches - Method; Mood and bipolar disorder

P.856

**Obesity: a neurobiological approach**

A.T. Carvalho\*, J. Felgueiras, O. Von Doellinger,  
J. Amaral da Silva (Portugal)

Biochemistry - Method; Eating disorder; Addiction -  
Disorder

P.857

**Prenatal alcohol exposure suppresses locomotion, social interaction behavior and decreases  $\alpha$ -synuclein mRNA level in the midbrain of adolescent rats**

M. Nizharadze\*, E. Razumkina, P. Anokhin, N. Saricheva  
(Russia)

Biochemistry - Method; Animal models - Method;  
Neurophysiology / EEG - Method

P.858

**Decreased plasma polymorphonuclear elastase (PMN) activity as a rait marker of depression**

A. Grzesińska, M. Kaluga\*, M. Just, D. Moś (Poland)

Biochemistry - Method; Mood and bipolar disorder;  
Neuro-inflammatory disorder

P.859

**Perceived stress, anxiety and depression among undergraduate students**

J. Mirón\*, D. Porta Casteràs, M. Vicent Gil, G. Navarra  
Ventura, N. Cardoner Álvarez, X. Goldberg (Spain)

Epidemiology and big data - Method; Anxiety - Disorder;  
Stress related disorder

P.860

**Agomelatine and other antidepressants and the risk of acute liver injury (ALI), a post authorisation safety study (PASS) in four European countries**

M. Pladelvall, A. Pottgard, T. Schink, J. Reutfors,  
R. Morros, B. Poblador-Plou, A. Timmer, J. Fornis,  
M. Hellfritsch, T. Reinders, D. Hagg, M. Giner-Soriano,  
A. Prados-Torres, M. Cainzos-Achirica, J. Hallas,  
B. Kollhorst, L. Brandt, J. Cortés, J. Aguado,  
G. Perlemuter, B. Falissard, J. Castellsagué, E. Jacquot\*,  
N. Deltour, S. Perez-Gutthann (France)

Epidemiology and big data - Method; Mood and bipolar  
disorder

P.861

**Prevalence and correlates of suicidal thoughts and behaviours among North Korean defectors**

J.H. An\*, K.E. Lee, H.C. Lee, H.S. Kim, J.Y. Jun,  
S.Y.T. Lee, H.I. Chang, S.S. Kim, J.P. Hong (South-Korea)

Epidemiology and big data - Method; Mood and bipolar  
disorder; Anxiety - Disorder

P.862

**A content analysis of 7 most commonly used scales testing for 71 different neurological soft signs**

A. Krupa\*, A. Chrobak, M. Siwek, D. Dudek (Poland)

Epidemiology and big data - Method; Biostatistics &  
computational method

P.864

**The relationship between psychopharmacotherapy and stigma and discrimination in persons with a diagnosis of mental disorder**

T. Gondek\*, K. Kotowicz, P. Ryta, M. Janusz, A. Kiejna  
(Poland)

Epidemiology and big data - Method; Pharmacology -  
Method; History / philosophy / ethics - Method

P.865

**Comprehensive analysis of readmissions of heavy psychiatric hospitalization users in a major Polish psychiatric hospital – ‘The Boomerang Project’**

P. Marcinowicz\*, M. Więdocha, M. Janoska-jażdżik,  
T. Koweszko, A. Mosiołek, A. Szulc (Poland)

Epidemiology and big data - Method; Prevention /  
course alteration

P.866

**Physical restraint: analysis of conditions in which occurs, the concomitant use of pharmacological restraint and patients' subjective opinion**

P. Ortega Orihuela\*, A.L. Pérez Morenilla, M. Zurita  
Carrasco (Spain)

History / philosophy / ethics - Method; Psychotic  
disorder; Addiction - Disorder

P.867

**Reducing stigmatizing attitudes towards mental illness among medical students**

H. Hernández-Évole\*, B. Atienza-Carbonell, V. Balanzá-  
Martínez (Spain)

History / philosophy / ethics - Method; Prevention /  
course alteration



P.868

**A decade of research by the European Federation of Psychiatric Trainees (EFPT) - a review.**

A. Szczegielniak\*, M. Pinto da Costa, M. Asztalos (Poland)  
History / philosophy / ethics - Method; Healthy brain

P.869

**GABA and glutamate in 22q11.2 deletion syndrome and healthy volunteers and the relation with cognition: a 7-Tesla pharmacological Magnetic Resonance Spectroscopy study**

C. Vingerhoets\*, D. Tse, M. Van Oudenaren, E. Van Duin, D. Hernaus, R. Jan, J. Jaap, G. McAlonan, O. Bloemen, T. Van Amelsvoort (The Netherlands)  
Neuroimaging - Method; Genetic & molecular approaches - Method

P.870

**Mesolimbic dopamine function and salience network connectivity: an integrative PET and MR study**

R. McCutcheon\*, M. Nour, T. Dahoun, S. Jauhar, P. Expert, M. Mehta, O. Howes (United Kingdom)  
Neuroimaging - Method; Healthy brain; Psychotic disorder

P.871

**Difference of brain surface area and cortical volume between suicide attempters and non-attempters with major depressive disorder**

S.G. Kang\*, S.E. Cho, K.S. Na, J.S. Lee, S.J. Cho, Y.D. Son, Y.J. Lee (South-Korea)  
Neuroimaging - Method; Mood and bipolar disorder

P.872

**Study of corpus callosum cellular microstructure using diffusion microscopy MRI in subjects with autism spectrum disorders**

M.A. D'Albis\*, S. Sarrazin, A. Lebois, J.F. Mangin, C. Laidi, J. Boisgontier, R. Delorme, F. Bolognani, S. Holiga, J. Dukart, C. Bouquet, M. Ly-Le Moal, A. Amestoy, I. Scheid, A. Gaman, M. Leboyer, C. Poupon, J. Houenou (France)  
Neuroimaging - Method; Autism / ASD - Disorder

P.873

**Retinal and optic nerve degeneration in patients with multiple sclerosis followed up for 10 years**

E. Viladés Palomar\*, E. Orduna Hospital, M.J. Rodrigo Sanjuan, J.G. Larrea Samper, E. Garcia Martin (Spain)  
Neuroimaging - Method; Dementia & neuro degeneration - Disorder

P.874

**Abnormal neuroradiological findings in children and adolescents with affective and non-affective psychotic disorders**

J. Pinzon Espinosa\*, A. Fortea, L. Espinosa, L. Lazaro, R. Calvo, J. Castro-Fornieles, N. Bargallo, I. Baeza, G. Sugranyes (Spain)  
Neuroimaging - Method; Psychotic disorder

P.875

**Changes of diffusion in normal appearing white matter during treatment with interferon- $\beta$  are not associated with clinical course of multiple sclerosis**

A. Zacharzewska-Gondek\*, A. Pokryszko-Dragan, T. Gondek, M. Sąsiadek, J. Bładowska (Poland)  
Neuroimaging - Method; Pharmacology - Intervention; Neuro-inflammatory disorder

P.876

**Are emotional regulation and extinction training the same in the brain? A meta-analysis of fMRI studies**

M. Alemany Navarro\* (Spain)  
Neuroimaging - Method; Healthy brain

P.877

**Cortical thickness in the anterior cingulate correlates with apoptotic markers in cultured fibroblasts in first-episode schizophrenia individuals**

A. Fortea\*, J.C. Pariente, A. Batalla, N. Bargallo, P. Gasso, S. Mas, A. Lafuente, E. Parellada (Spain)  
Neuroimaging - Method; Psychotic disorder

P.878

**Parcellation of the cortical serotonergic neurotransmitter system using positron emission tomography and FreeSurfer**

G.M. James\*, G. Gryglewski, T. Vanicek, N. Berroteran-Infante, C. Philippe, A. Kautzky, L. Nics, C. Vraka, G.M. Godbersen, J. Unterholzner, H.L. Sigurdardottir, M. Spies, R. Seiger, G.S. Kranz, A. Hahn, M. Mitterhauser, W. Wadsak, A. Bauer, M. Hacker, S. Kasper, R. Lanzenberger (Austria)  
Neuroimaging - Method; Healthy brain

UPDATED PROGRAMME:

<https://2018.ecnp.eu/> / ECNP app / congress info terminals

P.879

**The volumetric parameters of the brain in hospitalized patients with repeated suicidal attempts***J. Juškienė\*, V. Adomaitiene, M. Virsila, K. Banioniene, R. Gleizniene, V. Steibliene (Lithuania)*

Neuroimaging - Method; Biostatistics &amp; computational method

P.880

**Characterization of pharmacological response to selective serotonin reuptake inhibitors using clustering of resting-state hybrid PET/MR data***G. Gryglewski\*, M. Reed, L. Rischka, N. Berroterán-Infante, T. Balber, M. Klöbl, V. Pichler, E.M. Klebermass, M. Hienert, G.M. Godbersen, L. Silberbauer, P. Michenthaler, M. Hartenbach, M. Mitterhauser, W. Wadsak, A. Hahn, D. Winkler, M. Hacker, S. Kasper, R. Lanzenberger (Austria)*

Neuroimaging - Method; Healthy brain; Pharmacology - Intervention

P.881

**Morphometric studies on the midbrain dopamine cell groups after amphetamine microinjection to the nucleus accumbens shell in rats after novelty test***K. Plucinska\*, G. Jerzemowska, K. Ptaszek, M. Podlacha, A. Piwka (Poland)*

Neuroimaging - Method; Animal models - Method; Neuromodulation - Intervention

P.882

**Phenomenology and neurobiology of inner speech in healthy subjects and its implication in understanding of auditory verbal hallucinations***E. Simkova\*, F. Spaniel, Y. Zaytseva, D. Gregus, E. Bakstein (Czech Republic)*

Neuroimaging - Method; Psychotic disorder

P.883

**Standardized low resolution brain electromagnetic tomography during sleep and heart rate variability after olanzapine in healthy volunteers***M. Pawlowski, Y. Abshir Ahmed, P. Beitinger, A. Steiger\* (Germany)*

Neurophysiology / EEG - Method; Pharmacology - Intervention

P.884

**Investigation of pathological EEG during hyperventilation load***I. Khachidze\*, M. Gugushvili, K. Inasaridze (Georgia)*

Neurophysiology / EEG - Method; Epilepsy - Disorder; Stress related disorder

P.885

**Inhibition of c-Jun N-terminal kinase decelerates the reversal of induced long-term potentiation: implication on treatment of memory loss***M. Yousef\*, C. Suer, N. Dursun (Turkey)*

Neurophysiology / EEG - Method; Healthy brain; Pharmacology - Method

P.886

**Depotiation of long-term potentiation is associated with epitope specific tau hyper/hypo phosphorylation in the hippocampus of adult rats***S. Delibaş\*, B. Tan, C. Suer (Turkey)*

Neurophysiology / EEG - Method; Healthy brain; Genetic &amp; molecular approaches - Method

P.887

**Auditory steady state response as a translational EEG biomarker in the PCP rat model of schizophrenia***S. Loiodice\*, E. Cayre, G. Viardot, B. Rion, A.S. Denibaud, B. Méot, H. Wing Young, C. Drieu La Rochelle (France)*

Neurophysiology / EEG - Method; Psychotic disorder

P.888

**Often claimed, rarely tested: individual drug response in antipsychotic drug trials***S. Winkelbeiner\*, S. Leucht, J.M. Kane, P. Homan (Switzerland)*

Pharmacology - Method; Psychotic disorder

P.889

**Duration of antipsychotic treatment and doses/receptor profile modulate early gene expression throughout rat brain regions***C. Avagliano\*, F. Iasevoli, E.F. Buonaguro, L. Vellucci, A. De Bartolomeis (Italy)*

Pharmacology - Method; Psychotic disorder

**P.890****The effect of ketamine on psychopathology and implications for understanding schizophrenia: a meta-analysis**

*K. Beck\*, F. Borgan, R. McCutcheon, G. Hindley, M. Taylor, O. Howes (United Kingdom)*

Pharmacology - Method; Psychotic disorder

**P.891****Experimental study of the influence of atorvastatin and rosuvastatin on inflammation**

*M. Georgieva-Kotetarova\*, I. Kostadinova, M. Murdjeva, D. Delev, I. Kostadinov, H. Zlatanova, I. Kandilarov (Bulgaria)*

Pharmacology - Method; Animal models - Method; Immunology - Method

**P.892****LAI effect on management of schizophrenia spectrum disorders in community mental health services**

*V. Latorre\*, M. Lorusso, C. Schiraldi, A. Sgaramella, D. Moltalbò, A. Ferrante, G. Roselli, R. Manca, C. Castellana, A. D'ippolito, M. Gattullo, A.E. Uva, D. Semisa (Italy)*

Pharmacology - Method; Pharmacology - Intervention

**P.893****Evaluation of the contribution of anticholinergic activity to the antidepressant-like and learning and memory impairing effects of ketamine in rats**

*Enginar, N. \*Nurten, A. Midilli, B. (Turkey)*

Pharmacology - Method; Mood and bipolar disorder; Animal models - Method

**EP.1107****Cobalt chloride exposure in neonatal rats induces behavioral alterations: a new animal model of schizophrenia?**

*A. Camargo Ramos\*, M. Suiama, N. Derci, B. Muniz, T. Rosenstock, M. Calzavara (Brazil)*

Psychotic disorder; Animal models - Method

**UPDATED PROGRAMME:**

<https://2018.ecnp.eu/> / ECNP app / congress info terminals

**EP.1108****Diagnostic conversion from unipolar depression to bipolar disorder: a Korean nationwide epidemiologic study**

*M.J. Kim\*, N.W. Kim, E.Y. Kim, C.H.K. Park, H.Y. Kim, D. Shin, S.J. Lee, Y.M. Ahn (South-Korea)*

Mood and bipolar disorder; Epidemiology and big data - Method

**EP.1109****Depression cost analysis in South Korea with national insurance system**

*D. Shin\*, N. Kim, M.J. Kim, C.H.K. Park, S.J. Rhee, H. Kim, G. Choi, Y.M. Ahn (South-Korea)*

Mood and bipolar disorder; Epidemiology and big data - Method

**EP.1110****A prospective multicenter study for investigating a clinical course and the biopsychosocial factors of patients with alcohol use disorder in Korea**

*B.W. Nam\*, H.R. Song, H.J. Kim, S.B. Lee, W.M. Jung, J.S. Seo (South-Korea)*

Addiction - Disorder; Epidemiology and big data - Method; Prevention / course alteration

**EP.1111****Neutrophil-lymphocyte ratio and C-reactive protein as inflammation biomarkers for delirium**

*J. Oh\*, J.Y. Park, J.J. Kim, C.S. Shin, S.H. Na, J. Park (South-Korea)*

Neuro-inflammatory disorder; Dementia & neuro degeneration - Disorder

**EP.1112****Usefulness of neutrophil to lymphocyte ratio in neuroleptic malignant syndrome**

*N. Karamustafalioglu\*, T. Kalelioglu, G. Celikel, A. Genc, M. Emul (Turkey)*

Immunology - Method; Pharmacology - Method; Neuro-inflammatory disorder

**EP.1113****Cannabidiol as an adjunctive therapy for severe problem behaviors in autism with intellectual disability: a case report**

*N. Brondino\*, S. Damiani, U. Provenzani, M. Rocchetti, L. Fusar-Poli, M. Vercesi, E. Farinella, P. Politi (Italy)*

Autism / ASD - Disorder; Intellectual disability disorder; Pharmacology - Intervention

## EP.1114

**Gabapentin for anxiety in autism spectrum disorders: a case series**

*N. Brondino\**, *M. Rocchetti*, *S. Damiani*, *U. Provenzani*,  
*L. Fusar-Poli*, *F. Grasso*, *A. Goggi*, *F. De Cagna*, *P. Politi*  
(Italy)

Autism / ASD - Disorder; Anxiety - Disorder;  
Pharmacology - Intervention

## EP.1115

**Evolution of alcohol use treatment in a general hospital in Barcelona**

*M. De Dios\**, *A. Trabsa*, *E. Monteagudo*, *D. Sanagustin*,  
*S. Pérez*, *C. Tamarit*, *A. Garcia*, *F. Fonseca*, *M. Torrents*  
(Spain)

Addiction - Disorder; Pharmacology - Intervention

## EP.1116

**The PRISM clinical study: exploring biomarkers related to social withdrawal in patients with schizophrenia and Alzheimer's disease**

*A. Bilderbeck\**, *B.W. Penninx*, *C. Arango*, *N. Van der Wee*,  
*R. Khan*, *I. Winter-van Rossum*, *A. Hayen*, *A. Post*,  
*B. Sommer*, *H. Marston*, *M. Kas*, *G.R. Dawson* (United  
Kingdom)

Dementia & neuro degeneration - Disorder; Psychotic  
disorder; Neuroimaging - Method

## EP.1117

**Locus coeruleus signal intensity in patients with late-life depression is associated with dual-action antidepressant intake**

*A. Guinea-Izquierdo\**, *M. Giménez*, *I. Martínez-Zalacaín*,  
*I. Del Cerro*, *P. Canal*, *G. Blasco*, *J. Gascón*, *R. Reñe*,  
*C. Aguilera*, *M. Urretavizcaya*, *J.M. Menchón*, *V. Soria*,  
*C. Soriano-Mas* (Spain)

Neuroimaging - Method; Pharmacology - Method;  
Dementia & neuro degeneration - Disorder

## EP.1118

**Drug use during pregnancy - a vicious issue or a window of opportunity?**

*M. Moreno\**, *T. Filipe*, *N. Rodrigues*, *M. Mendes*,  
*D. Pereira*, *R. Fernandes*, *V. Nogueira*, *R. Costa*  
(Portugal)

Addiction - Disorder; Pharmacology - Intervention;  
Prevention / course alteration

## EP.1119

**The relationship between obesity and response inhibition in schizophrenia-bipolar continuum**

*E. Bora\**, *B. Verim*, *O. Akgul*, *D. Ceylan*, *K. Alptekin*,  
*A. Ozerdem*, *B.B. Akdede* (Turkey)

Psychotic disorder; Mood and bipolar disorder; Healthy  
brain

## EP.1120

**Work-related burn injuries and claims for post-traumatic stress disorder in Korea**

*B.C. Lee\**, *K.S. Lee*, *J.A. Yun* (South-Korea)

Anxiety - Disorder; Epidemiology and big data - Method;  
Prevention / course alteration

## EP.1121

**Stressful life events and depression, manic and psychotic symptomatology on the onset of first-episode psychosis: preliminary results**

*A. Butjosa\**, *R. Vila-Badia*, *N. Del Cacho*, *M. Kaplan*,  
*B. Colomer*, *Y. Delisau*, *P. Group*, *J. Usall* (Spain)

Psychotic disorder; Stress related disorder

## EP.1122

**Increased serum cortisol levels are associated with a poorer cognitive outcome in patients with first episode psychosis: 1 year follow-up study**

*F. Estrada Coma\**, *I. Montalvo*, *Á. Cabezas*, *M. Tost*,  
*V. Sánchez-Gistau*, *M. Ahuir*, *E. Vilella*, *J.A. Monreal*,  
*D.J. Palao*, *J. Labad* (Spain)

Psychotic disorder; Neuropsychology - Method;  
Biochemistry - Method

## EP.1123

**Biologically positive self-regulatory behaviour of rats being on different hierarchical level in chronic psychogenic stress model**

*T. Domianidze\**, *T. Matitaishvili*, *I. Labadze* (Georgia)

Stress related disorder; Animal models - Method

## EP.1124

**Clozapine: is there a link between titration rate and sinus tachycardia?**

*E. Federico\**, *I. Baldini*, *L. Del Matto*, *S. Desantis*,  
*M. Olivola*, *F. Salvaro*, *A. Goracci*, *A. Fagiolini* (Italy)

Psychotic disorder; Pharmacology - Intervention;  
Pharmacology - Method

**EP.1125**

**Perceived stress level, coping styles and temperament and character traits in patients with idiopathic sudden hearing loss**

*F. Akyuz\*, A. Karaman-koç, S. Yılmaz (Turkey)*

Stress related disorder; Anxiety - Disorder

**EP.1126**

**Rehospitalization after ECT for the treatment-resistant depression: a retrospective chart-reviewed study**

*H. Tominaga\* (Japan)*

Mood and bipolar disorder; Pharmacology - Method

**EP.1127**

**Effect of lurasidone on cognition in adolescents with schizophrenia: interim analysis of a 2-year open-label extension study**

*P.D. Harvey, R. Goldman, M. Tocco\*, L. Deng,*

*J. Cucchiari, A. Loebel (USA)*

Pharmacology - Intervention; Psychotic disorder

**EP.1128**

**Contribution of polymorphic variants of monoaminoxidase genes in the development of antipsychotic hyperprolactinemia in schizophrenia**

*V. Tiguntsev\*, A. Semke (Russia)*

Genetic & molecular approaches - Method; Psychotic disorder

**EP.1129**

**Retrospective scanning of paranoid disorders' socio-demographic characteristics treated between 2005-2016 years in a hospital and the drugs used for**

*F. Şimşek, N. Kaya, M. Ak\* (Turkey)*

Psychotic disorder; Epidemiology and big data - Method;

Pharmacology - Intervention

**EP.1130**

**Differential roles of childhood trauma severity on brain function during working memory in schizophrenia**

*M. Dauvermann\*, K. Rokita, N. Daly-Ryan, C. Cullen,*

*D. Mothersill, D. McKernan, B. Hallahan, C. McDonald,*

*M. Gill, A. Corvin, G. Donohoe (Ireland)*

Neuroimaging - Method; Psychotic disorder; Stress related disorder

**EP.1131**

**Have inflammatory markers a role in the etiology of major psychoses? A comparative study with drug-free patients**

*F. Mucci\*, A. Caldiroli, S. Grassi, G.S. Carnevali,*

*A.C. Altamura, M. Buoli (Italy)*

Immunology - Method; Mood and bipolar disorder;

Psychotic disorder

**EP.1132**

**Comparison of treatment choices between hospitalized manic patients with and without psychotic symptoms**

*B. Akitan\* (Turkey)*

Mood and bipolar disorder; Pharmacology - Method;

Psychotic disorder

**EP.1133**

**Second generation antipsychotics-induced obsessive-compulsive symptoms - pharmacological and genetic factors**

*B. Almeida\*, C. Fragoeiro, C. Machado, L. Monteiro*

*(Portugal)*

Psychotic disorder; Pharmacology - Intervention

**EP.1134**

**Violent behaviour in acute psychiatric inpatients: clinical characteristics, neuropsychological performance and therapeutic correlates**

*N. Cinzia\*, A. Talamo, S. Urso, G. Di Lorenzo,*

*G. Lombardozi, M. Coviello, R. Colasuonno,*

*C. Palazzetti, F. Di Michele, A. D'Argenio, P. Brogna,*

*A. Facchi, A. Paterniti, V. Infante, A. Amodeo, A. Riconi,*

*M. Siracusano, G. Lisi, L.T. Marsella, A. Siracusano,*

*F. Milano (Italy)*

Mood and bipolar disorder; Neuropsychology - Method;

Psychotic disorder

**EP.1135**

**Antipsychotic drugs for elderly patients with schizophrenia: a systematic review and meta-analysis**

*M. Krause\*, M. Huhn, J. Schneider-Thoma, P. Rothe,*

*S. Leucht (Germany)*

Psychotic disorder; Pharmacology - Intervention

## EP.1136

**Impairment of behavior and immune function on post-traumatic stress' mice: preliminary study**

*N. Ceprián\*, M. Hernández, A. Garrido, E. Díaz del Cerro, M. De la Fuente (Spain)*

Stress related disorder; Animal models - Method; Immunology - Method

## EP.1137

**Delirium in heart and lung transplantation: descriptive analysis from a cardiac surgical intensive care unit**

*V.A. Sicilia\*, F. Zanobini, A. Santucci, M. Chioccioli, M. Nitti, G. Giubbolini, F. Giubbolini, A. Fagiolini (Italy)*

Dementia & neuro degeneration - Disorder; Neuro-inflammatory disorder; Epidemiology and big data - Method

## EP.1138

**Discontinuation of the new injectable prolonged-release antipsychotics**

*D. Mendez\*, B. Salazar Laya, M.P. Fierro Alanis, T. Gonzalez Furelos, I. Rodriguez Penin, D. Nuñez Arias, D. Rey Souto, V. Aller Labandeira, A. Nuñez Boquete, B. Banga Gonzalez, A. Nuñez Perez (Spain)*

Psychotic disorder; Pharmacology - Intervention

## EP.1139

**Analysis of the use of paliperidone palmitate in psychiatric hospitalization unit and its relation to hospital admission time**

*P. Ortega Orihuela\*, C. Caballero de las Olivas Díaz, A.L. Pérez Morenilla (Spain)*

Pharmacology - Intervention; Psychotic disorder; Prevention / course alteration

## EP.1140

**Factors contributed to long time course of treatment of major depressive disorder: a randomized controlled trial based two-year longitudinal study.**

*Y. Koshikawa\*, A. Onohara, M. Wakeno, Y. Takekita, T. Kinoshita, M. Kato (Japan)*

Mood and bipolar disorder; Pharmacology - Method; Pharmacology - Intervention

## EP.1141

**Frequency of mental disorders among sexual crime offenders in Bulgaria**

*L. Zdravkov Tumbev\*, M. Stoimenova-Popova, P. Chumpalova-Tumbeva, I. Veleva, V. Valtchev, K. Stoychev, P. Popov (Bulgaria)*

Sexual disorder; Epidemiology and big data - Method

## EP.1142

**Use of psychostimulants in attention-deficit hyperactivity disorder and psychosis comorbidity: possible beneficial effect concerning substance abuse?**

*M. Sequeira\*, B. Trancas, T. Maia (Portugal)*

ADHD - Disorder; Pharmacology - Intervention

## EP.1143

**Impact of new monthly second generation long acting anti-psychotics on patient's adherence to care**

*G. Sobreira\*, C. Pereira, J. Oliveira (Portugal)*

Psychotic disorder; Prevention / course alteration; Pharmacology - Intervention

## EP.1144

**Functional recovery among patients with schizophrenia receiving aripiprazole once-monthly in a 52-week, open-label, maintenance study**

*J.J. Madera, S. Liu, T. Peters-Strickland, P. Such, R. Baker\* (USA)*

Mood and bipolar disorder; Pharmacology - Intervention

## EP.1145

**Treatment with antipsychotics in various psychiatric settings in Azerbaijan**

*J. Ismayilova\*, L. Mansurova (Azerbaijan)*

Pharmacology - Method; Psychotic disorder

## EP.1146

**Using the PReDicT test to guide the antidepressant treatment of depressed patients: interim result on patient compliance and acceptability**

*G.R. Dawson\*, J. Kingslake, C.T. Dourish, R. Dias, J. Simon, G.M. Goodwin, C.J. Harmer, R. Morriss, S. Brown, B. Guo, H.G. Ruhe, D. Veltman, A. Van Schaik, J. Deckert, A. Reif, M. Stäblein, A. Menke, P. Gorwood, V. Pérez, M. Browning (United Kingdom)*

E-health - Intervention; Mood and bipolar disorder

## EP.1147

**Differential diagnosis and multidisciplinary approach in childhood. a report of 3 cases**

*M. Valverde Barea\**, *S. Jiménez Fernández*, *G. Ruiz Martínez*, *M.I. Rodríguez Natal*, *I. Martínez Reyes (Spain)*  
Autism / ASD - Disorder; Intellectual disability disorder

## EP.1148

**Schizophrenia and anti-toxoplasmosis antibody carriership**

*I. Veleva\**, *M. Stoimenova*, *M. Lalev*, *N. Jordanova*, *M. Kostovska*, *I. Angelov*, *P. Chumpalova*, *L. Tumbev*, *A. Todorov (Bulgaria)*  
Psychotic disorder; System biology - Method

## EP.1149

**Effects of long-term treatment with sertindole and asenapine on mice detrusor muscle**

*P. Tanyeri\** (Turkey)  
Pharmacology - Method; Psychotic disorder

## EP.1150

**Establishment of a predictive profile of relapse in patients with major depressive disorder - a preliminary approach**

*M. Santos\**, *S. Carvalho*, *L. Lima*, *J. Mota-Pereira*, *P. Pimentel*, *D. Maia*, *D. Correia*, *S. Gomes*, *A. Cruz*, *R. Medeiros (Portugal)*  
Genetic & molecular approaches - Method; Mood and bipolar disorder; Immunology - Method

## EP.1151

**Alcohol hangover attentional bias among social drinkers: attention and reaction time after a night of heavy drinking**

*A. Merlo\**, *G. Bruce (United Kingdom)*  
Mood and bipolar disorder; Stress related disorder

## EP.1152

**Cerebrovascular disease, paget's disease of bone and late-onset mania**

*H. Simião\**, *N. Moura*, *I. Homem de Melo*, *I. Donas-Boto*, *R. Caetano Silva*, *B. Barahona-Corrêa (Portugal)*  
Mood and bipolar disorder; Stroke; Neuro-inflammatory disorder

## EP.1153

**A comparative analysis of the results of verbal fluency tests in patients with paranoid schizophrenia and first degree relatives and healthy controls**

*I. Veleva\**, *M. Stoimenova*, *P. Chumpalova*, *L. Tumbev*, *M. Valkova (Bulgaria)*  
Neuropsychology - Method; Psychotic disorder

## EP.1154

**Clozapine use among patients with co-occurring psychotic disorder and substance use disorder: clinical features of an inpatients sample**

*R.B. Sauras Quetcuti\**, *G. Mateu*, *A. Farre*, *J. Marti-Bonany*, *M.G. Hurtado-Ruiz*, *M.T. Campillo*, *R. Sanchez-Gonzalez*, *R. Martinez-Riera*, *L. Galindo*, *M. Torrens (Spain)*  
Psychotic disorder; Addiction - Disorder; Pharmacology - Intervention

## EP.1155

**Antidepressants vs. antipsychotics in the treatment of patients with high-risk for psychosis**

*A. Krogmann\**, *C.U. Correll*, *B. Gallig (Germany)*  
Psychotic disorder; Pharmacology - Intervention

## EP.1156

**Neural responses during down-regulation of negative emotion in patients with bipolar disorder and their unaffected relatives**

*H. Kjaerstad\**, *L.V. Kessing*, *K.W. Miskowiak (Denmark)*  
Mood and bipolar disorder; Neuroimaging - Method

## EP.1157

**Relationship between mechanical restraints in agitated patients, the diagnoses made and the medications used in an acute psychiatric ward**

*A. Giménez Palomo\**, *A. Pérez*, *F. Eva*, *A. Bastidas*, *G. Anmella*, *J.E. Pinzón*, *S. Gomes*, *E. Vieta*, *A. Benabarre (Spain)*  
Prevention / course alteration; Pharmacology - Intervention

## EP.1158

**Lipid indices as indicators for cardiovascular risk in mood episodes with mixed features in bipolar disorder**

*Y.H. Balcioglu\**, *S.S. Kirlioglu*, *T. Kalelioglu*, *E. Erten*, *N. Karamustafalioglu (Turkey)*  
Mood and bipolar disorder; Biochemistry - Method

**EP.1159**

**Inflammatory markers for mood episodes with mixed features in bipolar disorder**

*S.S. Kirlıoglu\*, Y.H. Balcioglu, T. Kalelioglu, E. Erten, N. Karamustafalıoglu (Turkey)*

Mood and bipolar disorder; Neuro-inflammatory disorder

**EP.1160**

**Homocysteine and lipid indices as atherogenic indicators of cardiovascular risk in bipolar patients with manic episode**

*S.S. Kirlıoglu\*, Y.H. Balcioglu, I. Balcioglu (Turkey)*

Mood and bipolar disorder; Biochemistry - Method

**EP.1161**

**Metachromatic leukodystrophy – a case report of autistic features as a possible onset presentation**

*R.D. Neacsu\*, A.I. Cerlinca, L.E. Andrei, A.L. Niculae, I. Mihailescu, M. Musetescu, D. Epure, C.G. Anghel (Romania)*

Autism / ASD - Disorder; Dementia & neuro degeneration - Disorder

**EP.1162**

**Burnout, depression and anxiety among health care providers in Romania**

*A. Cerlinca\*, R.D. Neacsu, L.E. Andrei, L.A. Niculae, I. Mihailescu (Romania)*

Stress related disorder; Anxiety - Disorder

**EP.1163**

**Family history moderates predictive effects of neutrophil-to-lymphocyte ratio on suicide attempt among adolescent inpatients with depressive symptoms**

*S. Leštarević\*, M. Pejović-Milovančević, J. Radosavljev-Kirčanski, M. Kalanj, D. Lečić-Toševski, M. Mitković-Vončina (Serbia)*

Biochemistry - Method; Mood and bipolar disorder

**EP.1164**

**Analysis of pharmacotherapy in patients with bipolar disorder I type**

*Y. Ashenbrenner\*, E. Chumakov, N. Petrova (Russia)*

Mood and bipolar disorder; Pharmacology - Intervention

**UPDATED PROGRAMME:**

<https://2018.ecnp.eu/> / ECNP app / congress info terminals

**EP.1165**

**Whole-exome sequencing in familial bipolar disorder: a twin study**

*M. Shugol\*, D. Popovic, A. Jacobs, E. Vieta, N. Shomron, N. Pillar (Israel)*

Genetic & molecular approaches - Method; Mood and bipolar disorder

**EP.1166**

**Possible predictors of bipolarity in a sample of psychiatric inpatients**

*G. Serafini\*, A. Aguglia, M. Pompili, P. Girardi, M. Amore (Italy)*

Mood and bipolar disorder; Prevention / course alteration

**EP.1167**

**The phenomenon of mother/child bonding failure in the context of postpartum depression**

*A. Ragimova\*, S. Ivanov (Russia)*

Mood and bipolar disorder; Prevention / course alteration; Stress related disorder

**EP.1168**

**Pleiotropic genes in psychiatry: calcium channels and the stress-related FKBP5 gene in antidepressant resistance**

*F. Corponi\*, C. Fabbri, D. Albani, I. Raimondi, G. Forloni, S. Kasper, A. Kautsky, J. Zohar, D. Sourey, S. Montgomery, C.P. Cristalli, V. Mantovani, J. Mendlewicz, K. Schruers, A. Serretti (Italy)*

Mood and bipolar disorder; Genetic & molecular approaches - Method

**EP.1169**

**Hypomanic and manic episodes in obsessive-compulsive disorder patients without bipolar history treated with antidepressants: a systematic review.**

*S. Bertolín Triquell\*, E. Real, M. Alemany, P. Alonso, C. Segalàs, J.M. Crespo, J.M. Menchón (Spain)*

Pharmacology - Intervention; Anxiety - Disorder

**EP.1170**

**Symptomatic remission with paliperidone palmitate 3-monthly formulation in schizophrenia patients in a clinical practice setting**

*P. García-Portilla, P.M. Llorca\*, G. Maina, V.P. Bozikas, H. Devrimci-Ozguven, S.W. Kim, P. Bergmans, I. Usankova, P. Cherubin, K. Pungor (Germany)*

Pharmacology - Intervention; Psychotic disorder



## EP.1171

**Treatment non-adherence in Bipolar Disorder in a Portuguese sample**

*C. Pereira\*, I. Caldas, J. Aguiar, M. Nascimento, S. Nascimento (Portugal)*

Mood and bipolar disorder; Epidemiology and big data - Method; Pharmacology - Intervention

## EP.1172

**Neuropsychiatric implications of non-convulsive epileptic status: how neuropathology explains psychiatric clinic presentation - about a clinical case**

*A. Samico\*, Â. Venâncio (Portugal)*

Neurophysiology / EEG - Method; Epilepsy - Disorder; Psychotic disorder

## EP.1173

**Lithium neurotoxicity: a case report**

*C. Coca Cruz\*, A. Alvarado Dafonte, P. Vargas Melero (Spain)*

Mood and bipolar disorder; Pharmacology - Intervention; Pharmacology - Method

## EP.1174

**Investigating effects of gabapentin on inflammation at small blood vessel level using an alternative method to in vivo studies**

*F. Alyu Tekeş\*, H.T. Kıyan, Y. Öztürk (Turkey)*

Epilepsy - Disorder; Pharmacology - Intervention; Pharmacology - Method

## EP.1175

**Predictive factors of aggressive behaviors in autism spectrum disorder**

*A.L. Niculae\*, R. Grozavescu, R.D. Neacsu, L.E. Andrei, A.I. Cerlinca, I. Mihailescu (Romania)*

Autism / ASD - Disorder; Biostatistics & computational method; Healthy brain

## EP.1176

**Association between serotonin transporter gene and suicide attempt in geriatric major depression**

*A. Bani-Fatemi\*, V. De Luca, J. Kennedy, E. Lenze, C.F. Reynolds, B.H. Mulsant (Canada)*

Genetic & molecular approaches - Method; Mood and bipolar disorder

## EP.1177

**Sodium-glucose co-transporter inhibitor dapagliflozin attenuates cognitive deficits in streptozotocin induced sporadic Alzheimer's rat model**

*A.N. Hazar-Yavuz\*, S. Yıldız, R. Keles, M.E. Cam, L. Kabasakal (Turkey)*

Dementia & neuro degeneration - Disorder; Animal models - Method; Pharmacology - Intervention

## EP.1178

**The role of vitamin B12 in the pathogenesis of depression and anxiety**

*A. Todorov\*, M. Stoimenova, P. Chumpalova, I. Veleva, L. Tumbev, K. Stoychev (Bulgaria)*

Mood and bipolar disorder; Anxiety - Disorder

## EP.1179

**Is early improvement a reliable predictor for treatment response to antidepressants in major depression: a naturalistic follow-up study**

*B.D. Ulug\*, O. Ozcan, K. Basar, S. Karahan (Turkey)*

Mood and bipolar disorder; Pharmacology - Intervention

## EP.1180

**Cognitive rehabilitation and chronic schizophrenia: an observational prospective study in an Italian real world setting**

*G. Baroni\*, M. Corbo, F. Di Carlo, M.C. Alessi,*

*D. Viceconte, G. Di Giulio, L. Caronti, C. Montemitro,*

*C. Vannini, A. Rucco, E. Rossi, I. Matarazzo,*

*M. Alessandrini, M. Di Giannantonio (Italy)*

Psychotic disorder; Prevention / course alteration

## EP.1181

**Myrtus communis subsp. communis improves cognitive function in postmenopausal diabetic rats: effects on acetylcholinesterase activity**

*B. Ertas\*, B. Kadioglu, O. Cevik, G. Sener (Turkey)*

Dementia & neuro degeneration - Disorder; Animal models - Method; Pharmacology - Intervention

## EP.1182

**Sleep in women across the life cycle**

*J. Isaac, P. Barbosa, S. Farinha-Silva, C. Santos,*

*A. Matos-Pires\* (Portugal)*

Sleep disorder; Neurophysiology / EEG - Method; Healthy brain

## EP.1183

**Meige syndrome during treatment with quetiapine and olanzapine: case report**

*M. Lázaro\*, L. Gil, A. Aleixo, I. Coelho, F. Bacelar, M. Almeida, A. Nobre (Portugal)*

Movement disorder; Dementia & neuro degeneration - Disorder

## EP.1184

**Influence of long-acting injectable antipsychotics on the number of hospitalizations - Replication study**

*C. Pereira\*, G. Sobreira, J. Oliveira, I. Caldas (Portugal)*

Psychotic disorder; Prevention / course alteration; Pharmacology - Intervention

## EP.1185

**Foreign accent syndrome: a case report with multiple accents**

*S. Karaman\*, F. Maner, B. Hakyemez (Turkey)*

Neuropsychology - Method; Stroke

## EP.1186

**Comparative study between methadone and buprenorphine-naloxone treatment in patients diagnosed of opioid use disorder**

*M.N. Ferrer Chinchilla\*, J. Payo Ollero, F.I. Mata Cala (Spain)*

Addiction - Disorder; Pharmacology - Intervention

## EP.1187

**Burning mouth syndrome in psychiatric patients: three challenging case-reports**

*J. Reis\*, S. Henriques, I. Coelho, A. Baptista (Portugal)*

Pain and headache; Mood and bipolar disorder

## EP.1188

**Steroid-responsive auto-immune encephalitis as a paradigm of neuropsychiatric differential diagnosis: case report and review**

*J. Felgueiras\*, V. Cabreira, R. Barranha, A.T. Carvalho, M. Pinheiro, J. Massano, O. Von Doellinger (Portugal)*

Neuro-inflammatory disorder; Psychotic disorder

## EP.1189

**Impact of anhedonia on affective and somatic symptoms and quality of life in patients with a depressive disorder**

*A.L. Perez Morenilla\*, P. Ortega Orihuela, A. Salazar Couso, I. Failde Martínez, J.A. Micó Segura (Spain)*

Mood and bipolar disorder; Pain and headache

## EP.1190

**Biochemical parameters associated with inflammation in depression and their relationship with suicidality**

*S. Arostegui\*, I. Horrillo, C. Sanz-Arzuaga, L. Intxauspe, J. Ballesteros, J.J. Meana, I. Querejeta (Spain)*

Mood and bipolar disorder; Neuro-inflammatory disorder

## EP.1191

**Clozapine in the treatment of first episode of psychosis; comparison with olanzapine**

*A. Hrnjica\*, S. Bise, R. Šetić, B. Kurtović (Bosnia and Herzegovina)*

Psychotic disorder; Pharmacology - Method; Pharmacology - Intervention

## EP.1192

**Use of long-acting injectable aripiprazole inpatients in a department of psychotic disorders in a psychiatry hospital in Turkey**

*A. Ziblak\*, A. Mert, A.N. İnci Kenar (Turkey)*

Pharmacology - Method; Pharmacology - Intervention; Psychotic disorder

## EP.1193

**Effect of the Val66Met BDNF polymorphism on cortical thickness in early stages of psychosis**

*I. Moreno\*, J. Labad, E.J. Canales-Rodríguez, L. Moreno, V. Sánchez-Gistau, E. Vilella, L. Martorell (Spain)*

Genetic & molecular approaches - Method; Neuroimaging - Method; Psychotic disorder

## EP.1194

**Early psychiatric symptoms in patients with substance use disorder**

*F. Barzagli\* (Italy)*

Addiction - Disorder; Mood and bipolar disorder; Anxiety - Disorder

## EP.1195

**Naphyrone - conditioned place preference in wistar rats**

*H. Danda\* (Czech Republic)*

Addiction - Disorder; Animal models - Method; Pharmacology - Intervention

EP.1196

**Differences in psychoactive substances use disorders between immigrants and autochthonous: a transcultural descriptive study.**

A. Trabsa\*, M. De Dios, E. Monteagudo, S. Pérez, C. Tamarit, S. Garcia, F. Fonseca, M. Torrens (Spain)  
Addiction - Disorder; History / philosophy / ethics - Method

EP.1197

**Neurological soft signs in paediatric patients with attention deficit hyperactivity disorder - review**

E. Żabińska\* (Poland)  
ADHD - Disorder; Epidemiology and big data - Method; Neurophysiology / EEG - Method

EP.1198

**Acute behavioral effects and pharmacokinetic profile of deschloroketamine, a novel psychoactive ketamine analogue, in wistar rats**

K. Štefková\*, N. Pinterová, L. Olejníková, E. Lhotková, K. Šichová, H.R. Rachel, H. Danda, T. Páleníček (Czech Republic)  
Addiction - Disorder; Animal models - Method

EP.1199

**Emotional memory in post-traumatic stress disorder: a systematic prisma review of controlled studies**

F. Durand\*, C. Isaac, D. Januel (France)  
Neuropsychology - Method; Stress related disorder

EP.1200

**Adaptive functioning changes in children diagnosed with autism spectrum disorders following behavioral therapy**

L. Kobylińska\*, M.C. Nedelcu, C.G. Anghel, F. Rad, I. Dobrescu (Romania)  
Autism / ASD - Disorder; Psychotherapy - Intervention; Prevention / course alteration

EP.1201

**Antipsychotic-induced dopamine supersensitivity psychosis**

A. Aleixo\*, L. Gil, C. Jesus, M. Lázaro (Portugal)  
Pharmacology - Intervention; Psychotic disorder

EP.1202

**Body mass index associates with white matter microstructure in schizophrenia**

E. Mazza\*, M. Spangaro, S. Poletti, R. Cavallaro, F. Benedetti (Italy)  
Neuroimaging - Method; Psychotic disorder; Lifestyle and nutrition - Intervention

EP.1203

**Neuroprotective effect of proline rich polypeptide via regulation the monoamines level on experimental model of Alzheimer's disease like pathology**

K. Yenkovyan\*, K. Fereshetyan, S. Matinyan, M. Aghajanyan (Armenia, Rep. of)  
Dementia & neuro degeneration - Disorder; Animal models - Method; Pharmacology - Intervention

EP.1204

**Marked differences in the activation levels of cytokine IL-8 and IL-18 in patients with varying levels of depression severity**

M. Kaluga\*, A. Grzesińska, M. Just, D. Moś (Poland)  
Mood and bipolar disorder; Biochemistry - Method; Neuro-inflammatory disorder

EP.1205

**Actual quality of life of anorectic patients hospitalized in department of psychiatry and psychotherapy of developmental age in 2015 and 2016**

I. Zasada\*, K. Wilczyński, M. Janas-Kozik, I. Jelonek, J. Hyrnik (Poland)  
Eating disorder; Epidemiology and big data - Method

EP.1206

**The level of addiction in interpersonal relationships in substance - dependent patients**

C. Varlık\*, S. Ekici, D. Sarıkaya Varlık (Turkey)  
Addiction - Disorder; Personality disorder

EP.1207

**Use of depot antipsychotic in patients in a psychosis clinic of a psychiatry hospital**

A. Mert\*, A. Zıblak, A.N. İnci Kenar (Turkey)  
Psychotic disorder; Pharmacology - Method; Psychotherapy - Intervention

## EP.1208

**A survey of cognitive enhancer prescribing for mild Alzheimer's dementia and mild cognitive impairment in a large NHS Trust**

*A. Byrne\**, *G. Cass*, *S. Turnbull-Johnson (United Kingdom)*  
Dementia & neuro degeneration - Disorder;  
Pharmacology - Intervention

## EP.1209

**Lamotrigine as a treatment of agitation in dementia**

*F. Godinho\**, *A. Valverde (Portugal)*  
Dementia & neuro degeneration - Disorder;  
Pharmacology - Intervention

## EP.1210

**Clozapine – worsening or improving obsessive-compulsive symptoms?**

*L. Carvalhão Gil\**, *M. Lázaro*, *A. Aleixo*, *R. Costa (Portugal)*  
Impulsive and compulsive disorder; Pharmacology - Intervention

## EP.1211

**The effect of anxiolytic medication in schizophrenia and schizoaffective disorder: a retrospective study**

*C. Spínola\**, *D. Neto*, *E. Pereira*, *J. Gago (Portugal)*  
Psychotic disorder; Pharmacology - Intervention

## EP.1212

**Frontal cognitive impairment in late-life bipolar disorder – frontotemporal dementia or phenocopy syndrome?**

*L.A. Fernandes\**, *S. Castro*, *J. Ramos*, *N. Borja-Santos*, *T. Maia (Portugal)*  
Mood and bipolar disorder; Dementia & neuro degeneration - Disorder; Psychotic disorder

## EP.1213

**Electroconvulsive therapy using ketamine anesthesia: a potential synergism**

*J. Facucho-Oliveira\**, *B. Prates*, *L. Roque*, *F. Dinis*, *R. Neves*, *P. Varandas (Portugal)*  
Mood and bipolar disorder; Pharmacology - Intervention

## UPDATED PROGRAMME:

<https://2018.ecnp.eu/> / ECNP app / congress info terminals





# Supporting European proposals

## How we can help

The College has an unparalleled range of platforms for researchers to identify collaborators, assemble consortia, test ideas, develop bids, disseminate information and results, and reach key stakeholders in the wider scientific, governmental and patient community.

### ECNP CONGRESS

- Europe's largest meeting for applied and translational neuroscience
- 5,000 researchers and clinicians from 100 countries annually

### EUROPEAN NEUROPSYCHOPHARMACOLOGY

- The latest and best research in applied and translational neuroscience
- 500,000 downloads per annum
- Impact factor 4.129



### ECNP NETWORKS

- Multicentre European research collaborations, covering 13 major disease areas and methodologies
- A critical springboard for European project bids

### ECNP THEMATIC WORKING GROUPS

- Platforms to test ideas, access expertise and develop cross-discipline proposal strategies

### ECNP NEW FRONTIERS MEETING

- High-level forum for mapping new lines of research at the frontiers of applied and translational neuroscience

### ECNP RESEARCH INTERNSHIP

- Exploratory internships at European laboratories under the guidance of an ECNP Fellow

ECNP is Europe's largest network of applied and translational neuroscience researchers, with 30 years of experience in promoting and facilitating European CNS research.

### ECNP WORKSHOPS

- Workshops for Europe's best early career scientists
- Two annually - on neuropsychopharmacology and clinical research methods

### ECNP SEMINARS

- Two-day interactive training sessions for 50 young clinicians
- Four annually in different Eastern European countries

### ECNP SCHOOLS

- Week-long training programmes for young clinicians
- Two annually - in general and child and adolescent neuropsychopharmacology

## The ECNP advantage

### DISSEMINATION

Uniquely wide range of channels and resources

### TRAINING

More than 20 scientific meetings every year, training over 300 early career scientists



## CONTACT US

[www.ecnp.eu](http://www.ecnp.eu), [secretariat@ecnp.eu](mailto:secretariat@ecnp.eu), +31 88 756 9555



**ECNP** european college of neuropsychopharmacology

**09.00-16.00 EXHIBITION****09.00-10.40 SCIENTIFIC SYMPOSIA**

- S.21 Brain vulnerability to Alzheimer's disease: why does it vary among individuals? **Room 113**
- S.22 Positive psychiatry: the psychoneurobiology of resilience **Room 112**
- S.23 From the lab to the clinic: chemogenetics as an innovative tool to develop new therapies for brain disease **Room 114**
- S.24 DEBATE – Evidence based findings in the diagnosis of paediatric mood disorders **Room 117**
- E.06 Update on the management of self-harm in psychiatric patients **Room 115**

**09.00-09.45 CAMPFIRE SESSIONS**

- CA.05 CRISPR-CAS9 technology **The Bubble**
- CA.06 Starting your own research group **The Bubble**

**10.40-11.00 COFFEE BREAK Poster area and exhibition****11.00-11.45 PLENARY LECTURE**

- PL.05 Paternal stress epigenetic germ cell programming of offspring neurodevelopment **Room 112**

**11.45-13.15 LUNCH Poster area and exhibition****11.55-12.25 CAREER DEVELOPMENT SESSION**

- CD.03 How to be a successful clinical scientist **The Bubble**

**11.55-12.25 TOP PAPER SESSIONS**

- TP.05 Highlights in mood disorders **Room 113**
- TP.06 Highlights in OCD and related disorders **Room 114**

**12.00-13.00 BRAINSTORMING SESSIONS**

- BS.07 Problematic gaming and compulsive sexual behaviours: real disorders or are we just pathologising? **Room 122**
- BS.08 Risk and prognostic imaging biomarkers for psychiatric disorders: potential and actual utility in the clinical practice **Room 123**
- BS.09 How to tackle biological heterogeneity in autism in the perspective of the Research Domain Criteria Initiative (RDoC)? **Room 124**

**13.15-14.00 PLENARY LECTURE**

- PL.06 New approaches to alcohol and drug prevention targeting neuropsychological risk profiles for addiction **Room 112**

**14.00-14.15 COFFEE BREAK Poster area and exhibition****14.15-15.55 SCIENTIFIC SYMPOSIA**

- S.25 The 'golden hours' of personalised intervention in post-traumatic stress disorder **Room 113**
- S.26 From the mother to the child: how psychopathology during pregnancy can affect mental health in the offspring **Room 114**
- S.27 Translating neuroimaging findings from research to clinical practice to improve outcomes in psychosis **Room 112**
- S.28 Regulatory spotlight session – Development of medicines in child and adolescent psychiatry **Room 117**
- E.07 New advances in the therapy of Huntington's and Parkinson's disease **Room 115**

**UPDATED PROGRAMME:**

<https://2018.ecnp.eu/> / ECNP app / congress info terminals

**S.21 | SYMPOSIUM**

09.00-10.40 | Room 113

**Brain vulnerability to Alzheimer's disease: why does it vary among individuals?**Chair: *Harmen Krugers, The Netherlands***S.21.01 | 09.00**Molecular and synaptic mechanisms underlying cognitive malfunction and cognitive enhancement  
*Shira Knafo, Spain***S.21.02 | 09.25**Epigenetic regulation of cognitive decline in Alzheimer's disease  
*Johannes Graff, Switzerland***S.21.03 | 09.50**Amyloid-beta effects on synapses and memory require AMPA-receptor subunit GluA3  
*Helmut Kessels, The Netherlands***S.21.04 | 10.15**Early life experiences, amyloid pathology and cognitive function  
*Harmen Krugers, The Netherlands***S.22 | SYMPOSIUM**

09.00-10.40 | Room 112

**Positive psychiatry: the psychoneurobiology of resilience**Chairs: *Nic J.A. van der Wee, The Netherlands*  
*Mathias V. Schmidt, Germany***S.22.01 | 09.00**Epigenetic regulation of risk and resilience to traumatic stress  
*Bart Rutten, The Netherlands***S.22.02 | 09.25**The resilient brain  
*Nic J.A. van der Wee, The Netherlands***S.22.03 | 09.50**The impact of the early life environment on stress resilience in adulthood  
*Mathias V. Schmidt, Germany***S.22.04 | 10.15**Positive psychological interventions in affective disorders  
*t.b.a.***S.23 | SYMPOSIUM**

09.00-10.40 | Room 114

**From the lab to the clinic: chemogenetics as an innovative tool to develop new therapies for brain disease**Chair: *Suzanne L. Dickson, Sweden***S.23.01 | 09.00**Chemogenetics: a research tool or a novel treatment?  
*Scott Sternson, USA***S.23.02 | 09.25**Chemogenetics as treatment for focal epilepsy  
*Dimitri Kullmann, United Kingdom***S.23.03 | 09.50**Chemogenetics targeted to the serotonin system to treat metabolic disease  
*Lora Heisler, United Kingdom***S.23.04 | 10.15**Targeting the dopamine system with chemogenetics to treat psychiatric disease  
*Roger Adan, The Netherlands*

For industry sessions, please see the 'Industry' tab in this booklet.

**S.24 | ALTERNATIVE SESSION**

09.00-10.40 | Room 117

**DEBATE – Evidence based findings in the diagnosis of paediatric mood disorders***Moderator: Andreas Reif, Germany**Team 1: Joseph Biederman, USA  
Janet Wozniak, USA**Team 2: Manon Hillegers, The Netherlands  
Anne Duffy, Canada***E.06 | EDUCATIONAL UPDATE SESSION**

09.00-10.40 | Room 115

**Update on the management of self-harm in psychiatric patients***Moderator: Romuald Brunner, Germany***E.06.01 | 09.05***New insights into self-harm and suicide risk  
Gil Zalsman, Israel***E.06.02 | 09.50***Interventions for treating self-harming behaviours  
Miri Bar-Halpern, USA***CA.05 | CAMPFIRE SESSION**

09.00-09.45 | The Bubble

**CRISPR-CAS9 technology***Experts: t.b.a.***CA.06 | CAMPFIRE SESSION**

09.00-09.45 | The Bubble

**Starting your own research group***Experts: Gitte Knudsen, Denmark  
Vibe Frøkjær, Denmark***COFFEE BREAK**

10.40-11.00 | Poster area and exhibition

**PL.05 | PLENARY LECTURE**

11.00-11.45 | Room 112

*Chair: David A. Slattery, Germany***TRACY L. BALE**

USA

**Paternal stress  
epigenetic germ cell  
programming of offspring  
neurodevelopment****LUNCH**

11.45-13.15 | Poster area and exhibition

**CD.03 | CAREER DEVELOPMENT SESSION**

11.55-12.25 | The Bubble

**How to be a successful clinical scientist***Chair: Thomas Steckler, Belgium**Presenter: Andreas Reif, Germany***TP.05 | TOP PAPER SESSION**

11.55-12.25 | Room 113

**Highlights in mood disorders***Chair: Aysegül Yildiz, Turkey**Presenter: Iria Grande, Spain*



**TP.06 | TOP PAPER SESSION**

11.55-12.25 | Room 114

**Highlights in OCD and related disorders**

Chair: Katharina Domschke, Germany

Presenter: Stefano Pallanti, Italy

**BS.07 | BRAINSTORMING SESSION**

12.00-13.00 | Room 122

**Problematic gaming and compulsive sexual behaviours: real disorders or are we just pathologising?**

Chair: Florence Thibaut, France

Experts: Marc Potenza, USA

Aviv Weinstein, Israel

**BS.08 | BRAINSTORMING SESSION**

12.00-13.00 | Room 123

**Risk and prognostic imaging biomarkers for psychiatric disorders: potential and actual utility in the clinical practice**

Chair: Ole A. Andreassen, Norway

Experts: Carles Soriano-Mas, Spain

Laura Pina-Camacho, Spain

**BS.09 | BRAINSTORMING SESSION**

12.00-13.00 | Room 124

**How to tackle biological heterogeneity in autism in the perspective of the Research Domain Criteria Initiative (RDoC)?**

Chair: Carmen Moreno, Spain

Experts: Jan K. Buitelaar, The Netherlands

Eva Loth, United Kingdom

**PL.06 | PLENARY LECTURE**

13.15-14.00 | Room 112

Chair: Wim van den Brink, The Netherlands

**PATRICIA CONROD**

CANADA

**New approaches to alcohol and drug prevention targeting neuropsychological risk profiles for addiction**

**COFFEE BREAK**

14.00-14.15 | Poster area and exhibition

**S.25 | SYMPOSIUM**

14.15-15.55 | Room 113

**The 'golden hours' of personalised intervention in post-traumatic stress disorder**

Chair: Joseph Zohar, Israel

**S.25.01 | 14.15**

Medication assisted psychotherapy for PTSD; focus on ketamine and MDMA

Eric Vermetten, The Netherlands

**S.25.02 | 14.40**

Propranolol – new treatment opportunities

Marieke Soeter, The Netherlands

**S.25.03 | 15.05**

Best practice of secondary prevention in PTSD

Jonathan Bisson, United Kingdom

**S.25.04 | 15.30**

Guideline for terror, update on NATO guideline

Iryna Frankova, Ukraine

**S.26 | SYMPOSIUM**

14.15-15.55 | Room 114

**From the mother to the child:  
how psychopathology during pregnancy  
can affect mental health in the offspring**Chair: *Laurence Lanfumey, France***S.26.01 | 14.15**

Modeling prenatal depression in mice: behavioural and molecular consequences and the impact of antidepressant treatment

*Juliet Richetto, Switzerland***S.26.02 | 14.40**

How do epigenetic changes contribute to the aetiology of psychiatric developmental disorders in the offspring of stressed mothers?

*Dennis Grayson, USA***S.26.03 | 15.05**

Depression in utero and long lasting behavioural and biological alterations in offspring: the role of epigenetics

*Annamaria Cattaneo, United Kingdom***S.26.04 | 15.30**

Imaging brain development from foetus to adulthood in the context of psychosis and mood disorders

*Paolo Brambilla, Italy***S.27 | SYMPOSIUM**

14.15-15.55 | Room 112

**Translating neuroimaging findings from  
research to clinical practice to improve  
outcomes in psychosis**Chair: *Celso Arango, Spain***S.27.01 | 14.15**

Predicting psychosis in patients with prodromal symptoms: the NAPLS study

*Tyrone D. Cannon, USA***S.27.02 | 14.40**

Applying neuroimaging and additional biological markers for patient stratification in psychosis:

the B-SNIP study

*Godfrey Pearlson, USA***S.27.03 | 15.05**

Optimising treatment outcomes in first episode schizophrenia using neuroimaging markers:

the OPTiMiSE project

*Paola Dazzan, United Kingdom***S.27.04 | 15.30**

Developing prognostic tools for early psychosis management: the PRONIA project

*Nikolaos Koutsouleris, Germany***S.28 | REGULATORY SPOTLIGHT SESSION**

14.15-15.55 | Room 117

**Development of medicines in child and  
adolescent psychiatry**

A special regulatory dialogue session with the European Medicines Agency (EMA).

Chairs: *Florence Butlen, United Kingdom*  
*Marie-Claude Potier, France***S.28.01 | 15.05**

Regulatory perspective

*Martina Riegl, United Kingdom***S.28.02 | 15.35**

Academic perspective

*Carmen Moreno, Spain***S.28.03 | 16.05**

Industry perspective

*Philippe Auby, Germany*

For industry sessions, please see the 'Industry' tab in this booklet.

**E.07 | EDUCATIONAL UPDATE SESSION**

14.15-15.55 | Room 115

**New advances in the therapy of Huntington's and Parkinson's disease**

Moderator: *t.b.a.*

**E.07.01 | 14.20**

New therapies in Huntington's disease by directly targeting the brain

*Anne Rosser, United Kingdom*

**E.07.02 | 15.05**

New strategies for therapy throughout the different stages of Parkinson's disease

*Walter Pirker, Austria*

# ECNP WORKSHOP

For early career scientists in Europe

*In applied and translational neuroscience*

7-10 March 2019, Nice, France



100 early career scientists  
16 world leaders in experimental  
and clinical neuroscience  
Three days of scientific interaction

Keynote speaker:  
John Cryan, Ireland

Topics:  
Molecular and cellular  
Behavioural and systems  
Clinical neuroscience  
Preventive intervention in brain disorders

Deadline abstract submission:  
17 October 2018

For more information:  
[nice2019@ecnp.eu](mailto:nice2019@ecnp.eu)  
[www.ecnp.eu/workshop](http://www.ecnp.eu/workshop)

For industry sessions, please see the 'Industry' tab in this booklet.

## INTRODUCTION

The inclusion of industry research, development and education is integral to the mission of the ECNP Congress, and all participants of the 31<sup>st</sup> ECNP Congress are welcome to attend the industry activities.

ECNP invites industry to participate in the congress in three ways:

- Industry sessions (satellite symposia and expert science exchange sessions)
- Exhibition
- Group registration

Programmes of the satellite symposia have been approved by the Scientific Programme Committee of the congress and granted accreditation for two European CME credits by the European Accreditation Committee in CNS (EACIC).

Abstracts from speakers of satellite symposia will be published after the congress in a supplement to the ECNP journal *European Neuropsychopharmacology*. They are also available on <https://2018.ecnp.eu>, congress information terminals at the venue, and the ECNP app.

The satellite symposia are scheduled on Saturday, Sunday and Monday. The expert science exchange sessions take place on Sunday and Monday. See page 257-259 for the detailed schedule. The programmes of these sessions can be found on pages 260-273.

The following companies and organisations have confirmed their participation in the 31<sup>st</sup> ECNP Congress (at the time of printing, September 2018).

In alphabetical order:

### ABP - BRAZILIAN PSYCHIATRIC ASSOCIATION

Stand number: 16



The Brazilian Psychiatric Association (ABP) is a non-profit organisation which acts in defence of psychiatric labour rights and development. ABP organises the Brazilian Congress of Psychiatry (CBP), the third major event in the world. ABP publishes the premier scientific journal in the medical community of Latin America, the *Revista Brasileira de Psiquiatria*.

[www.abp.org.br](http://www.abp.org.br)

### ALLERGAN PLC

*Expert science*

*Exchange session: CE.02*



Allergan Plc, headquartered in Dublin, Ireland, is a bold, global pharmaceutical company and a leader in a new industry model – Growth Pharma. Allergan is focused on developing, manufacturing and commercialising branded pharmaceutical, device, biologic, surgical and regenerative medicine products for patients around the world.

[www.allergan.com](http://www.allergan.com)

### ANGELINI

Stand number: 9

*Satellite symposia: C.09 & C.12*



Angelini is a privately held international pharmaceutical company. Founded in Italy in 1919, it has branches in 20 countries and employs 6,000 people. Angelini's research is focused on nervous system diseases and disorders, infectious diseases, pain and inflammation.

[www.angelini.it](http://www.angelini.it)

**BIOPAC SYSTEMS, INC.**

Stand number: 20



BIOPAC lets you measure physiology anywhere with innovative, compatible solutions that can be used by anyone for meaningful discovery. We make high-quality scientific tools for physiology measurement and interpretation with superior compatibility and world-class support. Empowering cutting edge tools that inspire discovery in ambulatory, MRI, lab, and real-world.

[www.biopac.com](http://www.biopac.com)

**C2CARE**

Stand number: 21



Virtual reality in the service of health  
C2care designs therapeutic software based on virtual reality for all healthcare professionals. The main goal of this new comprehensive therapeutic tool is to treat patients with depression, phobias, addictions, eating disorders and balance disorders through immersion brought by virtual reality.

[www.c2.care](http://www.c2.care)

**EBC - EUROPEAN BRAIN COUNCIL**

Stand number: 12



The European Brain Council (EBC) is a non-profit organisation gathering patient associations, major brain-related societies and companies. Its mission is to promote brain research in order to improve the quality of life of those living with brain disorders in Europe. 165 million Europeans have a brain disorder, costing more than EUR 800 billion annually.

[www.braincouncil.eu](http://www.braincouncil.eu)

**EUROPEAN PSYCHIATRIC ASSOCIATION (EPA)**

Stand number: 15



With active individual members in as many as 88 countries and 43 National Psychiatric Association Members who represent more than 80,000 European psychiatrists, the European Psychiatric Association is the main association representing psychiatry in Europe. The EPA's activities address the interests of psychiatrists in academia, research and practice throughout all stages of career development.

[www.europsy.net](http://www.europsy.net)

**EUFAMI**

Stand number: 14



EUFAMI is an international NGO based in Belgium committed to improving the care for and welfare of people with mental illness. Our mission is to represent at the European level all family members of persons that are affected by mental illness and to protect their rights and interests.

[www.eufami.org](http://www.eufami.org)

**GAMIAN-EUROPE**

Stand number: 13



GAMIAN-Europe, a patient-driven pan-European organisation, representing the interests of persons affected by mental health illness and advocates for their rights. GAMIAN-Europe was established in 1998 as a representative coalition of patient organisations putting the patient at the centre of all issues of the EU healthcare debate.

[www.gamian.eu](http://www.gamian.eu)

**GEDEON RICHTER PLC.**

Stand number: 8

Satellite symposium: C.10



GEDEON RICHTER

Headquartered in Hungary, Gedeon Richter is an innovation-driven specialty pharmaceutical company. It has manufacturing subsidiaries in five countries and markets its products in one hundred countries. Its latest achievement in R&D is the original antipsychotic compound, cariprazine, already marketed in the US for bipolar mania and schizophrenia treatment and received marketing authorization in the EU for the treatment of schizophrenia.

**www.richter.hu****GENOMIND**

Stand number: 19



Genomind is a unique personalised medicine platform that brings innovation to healthcare around the world. Genomind, comprised of pioneering scientists and thought leaders in brain health and genetics, delivers actionable insights to clinicians, healthcare partners and individuals in order to improve the quality of human life. Genomind is a CLIA certified and CAP accredited laboratory.

**www.genomind.com****GLOBAL MEDICAL EDUCATION**

Satellite symposium: C.08



Global Medical Education (GME), based in New York, is a medical education company, focusing primarily on psychiatry, that offers free, timely, unbiased, evidence-based information from the world's leading experts to clinicians around the world through a variety of formats including live meetings and online media.

**www.gmeded.com****H. LUNDBECK A/S**

Stand number: 4

Satellite symposia: C.01, C.02, C.04, C.05 and C.13



Expert science exchange sessions: CE.06 and CE.07

Lundbeck is a global pharmaceutical company specialized in psychiatric and neurological disorders. For more than 70 years, we have been at the forefront of research within neuroscience. Our key areas of focus are depression, schizophrenia, Parkinson's disease and Alzheimer's disease. An estimated 700 million people worldwide are living with psychiatric and neurological disorders and far too many suffer due to inadequate treatment, discrimination, a reduced number of working days, early retirement and other unnecessary consequences. Every day, we strive for improved treatment and a better life for people living with psychiatric and neurological disorders – we call this Progress in Mind. Read more at [www.lundbeck.com/global/about-us/progress-in-mind](http://www.lundbeck.com/global/about-us/progress-in-mind). Connect with us on Twitter at @Lundbeck and via our LinkedIn company page.

**www.lundbeck.com****JAMA NETWORK**

Stand number: 17



Building on a tradition of editorial excellence, the JAMA Network brings JAMA together with eleven specialty journals to offer enhanced access to the research, reviews, and opinions shaping the future of medicine. JAMA Network Open, a new open access, general medical journal, launched in 2018.

**www.jamanetwork.com****JANSSEN PHARMACEUTICA NV**

Stand number: 1

Satellite symposium: C.03 and C.06



At Janssen, we are working to create a world without disease. Transforming lives by finding new and better ways to prevent, intercept, treat and cure disease inspires us. We collaborate with the world for the health of everyone in it. Follow us at [www.twitter.com/janssenEMEA](http://www.twitter.com/janssenEMEA)

**www.janssen.com**

**KARGER PUBLISHERS**

Karger Publishers in Basel, Switzerland, is a globally active medical and scientific publishing company. Independent and family-run in the fourth generation by Vice Chairwoman & Publisher Gabriella Karger and Chairman Thomas Karger, the company is dedicated to serving the information needs of the scientific community with publications of high-quality content, covering all fields of medical science. Karger offers an extremely comprehensive portfolio in psychiatry and psychology, which will be of interest to both researchers in basic and clinical science and to practicing clinicians.

[www.karger.com/psychiatry](http://www.karger.com/psychiatry)

**MASSACHUSETTS GENERAL HOSPITAL**

Stand number: 18



The MGH Clinical Trial Network and Institute is setting new standards in psychiatric clinical research by implementing trial methodologies and strategies designed to reduce placebo response. Our proprietary SAFER interview, innovative rater training, SPCD study design, and access to KOLs enable us to offer sponsors an unsurpassed track record in CNS studies.

[www.mgh-Ctni.org](http://www.mgh-Ctni.org)

**LUNDBECK INSTITUTE**

Stand number: 4



Our mission is to develop and cascade unbiased, evidence-based medical education in psychiatry and neurology from leading experts to health care professionals and create a forum to facilitate knowledge-sharing. Since 1997 we have been committed to providing expert, international, interactive seminars, thereby building a valued legacy in medical education.

[www.lundbeck.com](http://www.lundbeck.com)

**NBN - NEUROSCIENCE-BASED NOMENCLATURE**

Stand number: 10

*NS.01 Nomenclature session*



The Neuroscience-based Nomenclature (NbN) is an ECNP-led international collaboration to align the nomenclature of psychotropic drugs with the underlying neuroscience, providing a rational and intelligible framework for researchers, clinicians and patients. The new nomenclature encompasses all medications with CNS indications and is now available for free download on the iOS App Store and the Google Play Store. The NbN comes in both general and child and adolescent editions. A free copy of the third edition is available to every congress delegate and can be picked up at the booth.

[www.nbn2.com](http://www.nbn2.com)

**OTSUKA PHARMACEUTICAL EUROPE LTD**

Stand number: 3

*Satellite symposia: C.01*

**OTSUKA PHARMACEUTICAL DEVELOPMENT AND COMMERCIALIZATION, INC**

*Satellite symposia C.13*

*Expert science exchange session: CE.07*

Otsuka Pharmaceutical is a global healthcare company with the corporate philosophy: 'Otsuka-people creating new products for better health worldwide.' Otsuka's 45,000 employees ensure that patients have access to innovative products and medical devices in our therapy areas of central nervous system disorders, endocrinology, nephrology, gastroenterology and oncology.

[www.otsuka-europe.com](http://www.otsuka-europe.com)

[www.otsuka-us.com](http://www.otsuka-us.com)

**PIVITAL PRODUCTS LTD**

Stand number: 23



At P1vital Products Ltd (PPL), we build on scientific research and collaborate with experts in academia and industry to develop evidence-based digital health innovations that are high quality, cost-effective, reliable and easy to use in both clinical research and healthcare settings to bring benefit to patients' lives.

<http://www.p1vitalproducts.com>

**PFIZER INC.**

*Expert science exchange session:  
CE.03  
Industry views*



At Pfizer, we apply science and our global resources to bring therapies that extend and significantly improve people's lives. Our global portfolio includes medicines and vaccines as well as many of the world's best-known consumer health care products.

[www.pfizer.com](http://www.pfizer.com)

**RECORDATI S.P.A.**

*Stand number: 8  
Satellite symposium: C.10*



Recordati is an international pharmaceutical group, listed on the Italian Stock Exchange, dedicated to the research, development, manufacturing and marketing of pharmaceuticals. Recordati is committed to the research and development of new specialties within cardiology, psychiatric and urogenital therapeutic area and of treatments for rare diseases.

[www.recordati.com](http://www.recordati.com)

**SAGE THERAPEUTICS**

*Stand number: 22*



Sage Therapeutics is committed discovering and developing life-altering therapies to treat central nervous system (CNS) disorders, and we are dedicated in our pursuit to deliver new medicines with the goal of making life better for patients and their families.

[www.sagerx.com](http://www.sagerx.com)

**SALADAX BIOMEDICAL**

*Expert science exchange  
session: CE.01*



Saladax develops rapid blood tests to measure levels of antipsychotic drug in a patient. These tests will enable psychiatrists to better assess adherence and better adjust dosing. The Saladax MyCare Psychiatry line will provide antipsychotic drug levels for greater insight into patient adherence and possible treatment failures. Saladax believes that truly personalised medicine can only exist when the right drug is taken at the right dose. Our diagnostic reagent kits are distributed worldwide and are pending approval in the United States. Saladax is ISO 13485:2003 certified.

[www.MyCareTests.com](http://www.MyCareTests.com)  
[www.saladax.com](http://www.saladax.com)

**SCHWABE GROUP**

*Stand number: 2  
Satellite symposium: C.11*



**Schwabe Group**  
From Nature. For Health.

The Schwabe Group comprises several different affiliated companies in the pharmaceutical and health industry. All of the companies within the Group focus on plants as the basis for developing pharmaceuticals and health products. The original form of the Group's parent company, which is now Dr. Willmar Schwabe GmbH & Co. KG, is one of the oldest pharmaceutical manufacturers in Europe and has a company history dating back over 150 years.

[www.schwabe-group.com](http://www.schwabe-group.com)

**SERVIER**

*Stand number: 7  
Satellite symposium: C.07*



Servier is an international independent pharmaceutical company governed by a non-profit foundation. Neuropsychiatry is one of the fifth therapeutic areas where research and development of innovative therapeutic solutions for patients are concentrated. Agomelatine was approved in 2009 for the treatment of depression. Multiple sclerosis and autism spectrum disorders are also areas of interest for Servier.

[www.servier.com](http://www.servier.com)



**SHIRE**

*Satellite symposium: C.08*  
*Expert science exchange*  
*sessions: CE.04, CE.05*



With more than 20 years of experience, Shire is a global leader in ADHD education and treatment innovation. We are committed to raising awareness of this impairing psychiatric disorder through engagement with physicians, patients and caregivers. Shire enable people with life-altering conditions in specialty and rare diseases to live their lives to the fullest. We work tirelessly to develop breakthrough medicines that have a meaningful impact on these patients and all who support them on their journey. Our diverse capabilities enable us to reach patients in over 100 countries across therapeutic areas such as neuroscience, rare diseases, haematology and immunology.

**[www.shire.com](http://www.shire.com)**

**SUMITOMO DAINIPPON  
 PHARMA CO., LTD.**

*Satellite symposium: C.09*



Sumitomo Dainippon Pharma Co., Ltd., is headquartered in Marlborough, Massachusetts, US. Sumitomo Dainippon Pharma Co., Ltd. is among the top-ten listed pharmaceutical companies in Japan operating globally.

**[www.ds-pharma.com](http://www.ds-pharma.com)**

**SUNOVION  
 PHARMACEUTICALS  
 EUROPE**

Stand number: 9

*Satellite symposium: C.09*



Sunovion Pharmaceuticals Europe, headquartered in London, is a wholly owned subsidiary of Sunovion Pharmaceuticals Inc. Sunovion Pharmaceuticals Inc., an indirect, wholly owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd., is headquartered in Marlborough, Massachusetts, US.

**[www.sunovion.eu](http://www.sunovion.eu)**

**WISEPRESS MEDICAL  
 BOOKSHOP**

Stand number: 5



Wisepress.com, Europe's leading conference bookseller, attend around 200 conferences every year. We have an extensive range of books and journals relevant to the themes of the ECNP Congress available at our booth. We also have a comprehensive range of STM titles available on our online bookshop. Follow us on Twitter @WisepressBooks.

**[www.wisepress.com](http://www.wisepress.com)**



## ECNP SCHOOLS

Week-long residential programmes providing outstanding young clinicians from across Europe with state-of-the-art training in treatment best practices.

### AGENDA FOR 2019

#### ■ 31 March - 5 April

ECNP School of Child and Adolescent  
Neuropsychopharmacology  
Venice, Italy

#### ■ 30 June - 5 July

ECNP School of Neuropsychopharmacology  
Oxford, United Kingdom

[www.ecnp.eu/school](http://www.ecnp.eu/school)

**FREE  
REGISTRATION  
AND  
ACCOMMODATION**



**ECNP**

neuroscience  
applied

### C.01 | SATELLITE SYMPOSIUM

12.30-14.00 | Room 115

Can increased focus on patient perspectives improve outcomes in the treatment of schizophrenia?

*Educational financial support provided by Otsuka Pharmaceutical Europe Ltd. and H. Lundbeck A/S*

### C.02 | SATELLITE SYMPOSIUM

12.30-14.00 | Room 117

Functional recovery in depression: are we doing the right thing for the treatment of depression?

*Educational financial support provided by H. Lundbeck A/S*

### C.03 | SATELLITE SYMPOSIUM

15.00-16.30 | Room 112

Living with schizophrenia: how to add quality and years to patients' lives

*Educational financial support provided by Janssen*

### C.04 | SATELLITE SYMPOSIUM

15.00-16.30 | Room 114

Mechanisms underlying clinical manifestations of treatment resistance in schizophrenia

*Educational financial support provided by H. Lundbeck A/S*

### C.05 | SATELLITE SYMPOSIUM

15.00-16.30 | Room 117

From conventional antidepressant efficacy to real-world effectiveness

*Educational financial support provided by H. Lundbeck A/S*

#### UPDATED PROGRAMME:

<https://2018.ecnp.eu/> / ECNP app / congress info terminals

**CE.01 | EXPERT SCIENCE EXCHANGE**

09.00-10.00 | Room 118

Nonadherence with antipsychotics: a vexing problem  
*Educational financial support provided by Saladax Biomedical*

**CE.02 | EXPERT SCIENCE EXCHANGE**

10.00-11.00 | Room 120

Glutamate and major depression  
*Educational financial support provided by Allergan plc*

**CE.06 | EXPERT SCIENCE EXCHANGE**

15.00-16.00 | Room 118

When is the right time to change to another antidepressant treatment?  
*Educational financial support provided by H. Lundbeck A/S*

**CE.07 | EXPERT SCIENCE EXCHANGE**

16.00-17.00 | Room 120

What are the clinical and functional benefits of early use of long acting injectable antipsychotics in severe mental disorders?  
*Educational financial support provided by Otsuka Pharmaceutical Development & Commercialization, Inc. and H. Lundbeck A/S*

**C.06 | SATELLITE SYMPOSIUM**

17.15-18.45 | Room 112

Current and future management of major depressive disorder: challenges and perspectives  
*Educational financial support provided by Janssen*

**C.07 | SATELLITE SYMPOSIUM**

17.15-18.45 | Room 113

Integrating patients' expectations into the management of their depression  
*Educational financial support provided by SERVIER*

**C.08 | SATELLITE SYMPOSIUM**

17.15-18.45 | Room 114

Comorbid adult ADHD in psychiatric patients: are we missing it?  
*Educational financial support provided by Shire/Global Medical Education*

**C.09 | SATELLITE SYMPOSIUM**

17.15-18.45 | Room 115

Schizophrenia in 2018: symptoms, treatments, metabolics and cognition across lifespan  
*Educational financial support provided by Sunovion, Angelini and Sumitomo Dainippon*

**CE.03 | EXPERT SCIENCE EXCHANGE**

09.00-10.00 | Room 118

Pathways to recovery: matching symptoms with brain circuits for personalised treatment of major depressive disorder  
*Educational financial support provided by Pfizer Inc.*

**CE.04 | EXPERT SCIENCE EXCHANGE**

14.45-15.45 | Room 118

Discovering ADHD in adults  
*Educational financial support provided by Shire*

**CE.05 | EXPERT SCIENCE EXCHANGE**

15.45-16.45 | Room 118

Discovering ADHD in adults  
*Educational financial support provided by Shire*

**C.10 | SATELLITE SYMPOSIUM**

17.15-18.45 | Room 112

New trends in schizophrenia research and therapeutic practices  
*Educational financial support provided by Recordati and Gedeon Richter Plc.*

**C.11 | SATELLITE SYMPOSIUM**

17.15-18.45 | Room 113

Mild cognitive impairment (MCI): age-associated burden or treatable disease?  
*Educational financial support provided by Schwabe Group*

**C.12 | SATELLITE SYMPOSIUM**

17.15-18.45 | Room 114

Functional recovery in major depressive disorder in the age of personalised medicine  
*Educational financial support provided by Angelini*

**C.13 | SATELLITE SYMPOSIUM**

17.15-18.45 | Room 115

Dopamine D2 partial agonists in the treatment of schizophrenia – finding the right balance  
*Educational financial support provided by Otsuka Pharmaceutical Development & Commercialization, Inc. and H. Lundbeck A/S*

## SATURDAY 6 OCTOBER

## C.01 | SATELLITE SYMPOSIUM

12.30-14.00 | Room 115

**Can increased focus on patient perspectives improve outcomes in the treatment of schizophrenia?**Chair: *John M. Kane, USA*

## C.01.01

Clinician and patient attitudes in the treatment of schizophrenia  
*Sofia Brissos, Portugal*

## C.01.02

Individualisation of treatment in schizophrenia  
*John M. Kane, USA*

## C.01.03

Treatment objectives and outcomes through the course of schizophrenia  
*Jose Manuel Olivares, Spain*

## C.01.04

Improving patient acceptance of maintenance treatment with long-acting injectables  
*Steven Potkin, USA*

*Educational financial support provided by Otsuka Pharmaceutical Europe Ltd. and H. Lundbeck A/S*

## UPDATED PROGRAMME:

<https://2018.ecnp.eu/> / ECNP app / congress info terminals

## C.02 | SATELLITE SYMPOSIUM

12.30-14.00 | Room 117

**Functional recovery in depression: are we doing the right thing for the treatment of depression?**Chair: *Bernhard T. Baune, Australia*

## C.02.01

Welcome and introduction  
*Bernhard T. Baune, Australia*

## C.02.02

Myth or fact: how can we achieve functional recovery in depression?  
*Yanling He, China*

## C.02.03

Two sides of the same coin: do patients and physician have the same expectation from the treatment outcome?  
*Bernhard T. Baune, Australia*

## C.02.04

Depression scales: are we asking the right questions to patients with depression?  
*Koen Demyttenaere, Belgium*

## C.02.05

Teaming up with patients: together we can do better (how can we involve patients with depression in their treatment goals?)  
*Mark Opler, USA*

## C.02.06

Q&amp;A

*Educational financial support provided by H. Lundbeck A/S*

**C.03 | SATELLITE SYMPOSIUM**

15.00-16.30 | Room 112

**Living with schizophrenia: how to add quality and years to patients' lives***Chair: Eduard Parellada, Spain***C.03.01**Welcome and introduction  
*Eduard Parellada, Spain***C.03.02**Neuroprogression and neuroprotection in schizophrenia: can we alter the trajectory of the disease?  
*Eduard Parellada, Spain***C.03.03**Adding years to patients' lives: the role of continuous treatment  
*Jari Tiihonen, Finland***C.03.04**Adding life to patients' years: from data to clinical practice  
*Rebekka Lencer, Germany***C.03.05**Closing remarks  
*Eduard Parellada, Spain**Educational financial support provided by Janssen***C.04 | SATELLITE SYMPOSIUM**

15.00-16.30 | Room 114

**Mechanisms underlying clinical manifestations of treatment resistance in schizophrenia***Chair: Oliver Howes, United Kingdom***C.04.01**When the drugs never worked  
*Oliver Howes, United Kingdom***C.04.02**When the drugs stop working  
*Anne-Noël Samaha, Canada***C.04.03**Clinical phenotypes of treatment resistance in schizophrenia  
*Ofer Agid, Canada**Educational financial support provided by  
H. Lundbeck A/S***UPDATED PROGRAMME:**<https://2018.ecnp.eu/> / ECNP app / congress info terminals

**C.05 | SATELLITE SYMPOSIUM**

15.00-16.30 | Room 117

**From conventional antidepressant efficacy to real-world effectiveness***Chair: Pratap Chokka, Canada***C.05.01**

Traditional efficacy of antidepressants: does it reflect your long-term treatment goals?

*Iria Grande, Spain***C.05.02**

Looking beyond MADRS to restore patient functioning

*Andrew Cutler, USA***C.05.03**

A case of workplace productivity in patients with depression

*Pratap Chokka, Canada**Educational financial support provided by H. Lundbeck A/S***UPDATED PROGRAMME:**<https://2018.ecnp.eu/> / ECNP app / congress info terminals**SUNDAY 7 OCTOBER****CE.01 | EXPERT SCIENCE EXCHANGE**

09.00-10.00 | Room 118

**Nonadherence with antipsychotics: a vexing problem****CE.01.01**

Understanding nonadherence with antipsychotics in clinical practice

*John M. Kane, USA***CE.01.02**

Innovative strategies to improve adherence with antipsychotics

*Ralph Aquila, USA***CE.01.03**

Q&amp;A

*Educational financial support provided by Saladax Biomedical***CE.02 | EXPERT SCIENCE EXCHANGE**

10.00-11.00 | Room 120

**Glutamate and major depression****CE.02.01**

Role of glutamate in major depression

*Eduard Vieta, Spain***CE.02.02**

Innovative major depressive disorder treatments strategies targeting glutamate receptors

*Pierre Blier, Canada***CE.02.03**

Q&amp;A

*Educational financial support provided by Allergan plc*

**CE.06 | EXPERT SCIENCE EXCHANGE**

15.00-16.00 | Room 118

**When is the right time to change to another antidepressant treatment?****CE.06.01**

Switching as early as possible and keeping serotonin effect as long as possible

*Bernhard T. Baune, Australia*

**CE.06.02**

Delaying switch as late as possible, meanwhile adding other medications to keep the patient in the same antidepressant longer

*Peter Falkai, Germany*

*Educational financial support provided by H. Lundbeck A/S*

**CE.07 | EXPERT SCIENCE EXCHANGE**

16.00-17.00 | Room 120

**What are the clinical and functional benefits of early use of long acting injectable antipsychotics in severe mental disorders?**

*Speakers: Iria Grande, Spain*

*Charlotte Emborg, Denmark*

*Educational financial support provided by Otsuka Pharmaceutical Development & Commercialization, Inc. and H. Lundbeck A/S*

**C.06 | SATELLITE SYMPOSIUM**

17.15-18.45 | Room 112

**Current and future management of major depressive disorder: challenges and perspectives**

*Chairs: Ana Gonzalez-Pinto, Spain  
Kamilla Miskowiak, Denmark*

**C.06.01**

Where are we in treating depression today?

*Ana Gonzalez-Pinto, Spain*

**C.06.02**

How many depressions are treatment-resistant?

*Eduard Vieta, Spain*

**C.06.03**

Biological and pharmacological aspects of depression: the changing landscape

*John Krystal, USA*

**C.06.04**

Suicidality in depression: the way forward

*Philippe Courtet, France*

**C.06.05**

Closing remarks

*Ana Gonzalez-Pinto, Spain*

*Educational financial support provided by Janssen*

**C.07 | SATELLITE SYMPOSIUM**

17.15-18.45 | Room 113

**Integrating patients' expectations into the management of their depression**

Chairs: *Ellen Frank, USA*  
*Koen Demyttenaere, Belgium*

**C.07.01**

What are the patients' expectations for the treatment of their depression?

*Ellen Frank, USA*

**C.07.02**

How to fulfil the patients' needs

*David Castle, Australia*

**C.07.03**

eCBT as a new additional option to involve the patient in the management of his/her depression

*Elif Cindik-Herbruggen, Germany*

*Educational financial support provided by SERVIER*

**C.08 | SATELLITE SYMPOSIUM**

17.15-18.45 | Room 114

**Comorbid adult ADHD in psychiatric patients: are we missing it?**

Chair: *Anthony Rostain, USA*

**C.08.01**

Prevalence of comorbid adult ADHD in psychiatric patients

*Sandra Kooij, The Netherlands*

**C.08.02**

Differential diagnosis of adult ADHD in comorbid psychiatric illness

*J. Antoni Ramos-Quiroga, Spain*

**C.08.03**

Managing comorbid ADHD in psychiatric patients

*Anthony Rostain, USA*

Q&A

*Educational financial support provided by Shire/Global Medical Education*

**C.09 | SATELLITE SYMPOSIUM**

17.15-18.45 | Room 115

**Schizophrenia in 2018: symptoms, treatments, metabolics and cognition across lifespan**

Chair: *Sofia Brissos, Portugal*

**C.09.01**

Symptoms and treatments evolution in schizophrenia: from childhood to adulthood

*Carmen Moreno, Spain*

**C.09.02**

Antipsychotic treatments in schizophrenia: the burden of metabolic challenges across lifespan and the impact on mortality

*John Newcomer, USA*

**C.09.03**

The role of cognitive and functional deficits in schizophrenia: from the premorbid to the advanced stage

*Philip Harvey, USA*

*Educational financial support provided by Sunovion, Angelini and Sumitomo Dainippon*



## MONDAY 8 OCTOBER

## CE.03 | EXPERT SCIENCE EXCHANGE

09.00-10.00 | Room 118

**Pathways to recovery: matching symptoms with brain circuits for personalised treatment of major depressive disorder**

Speakers: *Stephen M. Stahl, USA*  
*Mohammad Alsuwaidan, Kuwait*

*Educational financial support provided by Pfizer Inc.*

## CE.04 | EXPERT SCIENCE EXCHANGE

14.45-15.45 | Room 118

**Discovering ADHD in adults**

Speakers: *Josep Antoni Ramos-Quiroga, Spain*  
*Anthony L. Rostain, USA*  
*Susan J. Young, UK*

*Educational financial support provided by Shire*

## CE.05 | EXPERT SCIENCE EXCHANGE

15.45-16.45 | Room 118

**Discovering ADHD in adults**

Speakers: *Josep Antoni Ramos-Quiroga, Spain*  
*Anthony L. Rostain, USA*  
*Susan J. Young, UK*

*Educational financial support provided by Shire*

## C.10 | SATELLITE SYMPOSIUM

17.15-18.45 | Room 112

**New trends in schizophrenia research and therapeutic practices**

Chair: *Stefan Leucht, Germany*

## C.10.01

The newest results in schizophrenia research and treatment trends

*Pierre-Michel Llorca, France*

## C.10.02

Conceptualization and treatment of schizophrenia negative symptoms: can we do better?

*Silvana Galderisi, Italy*

## C.10.03

Dopamine antagonists or partial agonists: which to favor?

*Stephen M. Stahl, USA*

*Educational financial support provided by Recordati and Gedeon Richter Plc.*

## C.11 | SATELLITE SYMPOSIUM

17.15-18.45 | Room 113

**Mild cognitive impairment (MCI): age-associated burden or treatable disease?**

Chair: *Mercè Boada, Spain*

## C.11.01

Mild cognitive impairment (MCI) – current views and implications

*Jakub Hort, Czech Republic*

## C.11.02

The role of mitochondria in aging, MCI and dementia

*Anne Eckert, Switzerland*

## C.11.03

Are there evidence-based treatment options for MCI?

*Lutz Froelich, Germany*

*Educational financial support provided by Schwabe Group*

**C.12 | SATELLITE SYMPOSIUM**

17.15-18.45 | Room 114

**Functional recovery in major depressive disorder in the age of personalised medicine***Chair: Andrea Fagiolini, Italy***C.12.01**

The neurobiology of depression and the mechanism-based antidepressant treatment selection  
*Francesc Artigas, Spain*

**C.12.02**

The urgency for an early and optimised therapy  
*Siegfried Kasper, Austria*

**C.12.03**

Tailored to patient' treatment plan in the landscape of residual symptoms in depression  
*Eva Ceskova, Czech Republic*

*Educational financial support provided by Angelini***C.13 | SATELLITE SYMPOSIUM**

17.15-18.45 | Room 115

**Dopamine D2 partial agonists in the treatment of schizophrenia – finding the right balance***Chair: Christoph U. Correll, USA***C.13.01**

Is functioning in patients with schizophrenia still under-prioritised?  
*Diane McIntosh, Canada*

**C.13.02**

Impact of antipsychotic side effects on patient functioning: the patient's perspective  
*Rajiv Tandon, USA*

**C.13.03**

Pharmacology of the D2 partial agonists – what they bring to the table  
*David Taylor, United Kingdom*

**C.13.04**

Efficacy and safety of D2 partial agonists in the treatment of schizophrenia – the short-term perspective  
*Greg Mattingly, USA*

**C.13.05**

D2 partial agonists for relapse prevention in schizophrenia – the long-term view  
*Christoph U. Correll, USA*

*Educational financial support provided by Otsuka Pharmaceutical Development & Commercialization, Inc. and H. Lundbeck A/S*

**UPDATED PROGRAMME:**

<https://2018.ecnp.eu/> / ECNP app / congress info terminals

# THE BRAIN PRIZE

## THE WORLD'S LARGEST BRAIN RESEARCH PRIZE.

€ 1 million awarded annually by the Lundbeck Foundation of Denmark. Recognising highly original and influential advances in any area of neuroscience – from basic to clinical.

Call for nominations for the 2019 Brain Prize is open until 1 September. For the nomination form and details of the nomination procedure, please visit [www.thebrainprize.org](http://www.thebrainprize.org).

## THE 2018 BRAIN PRIZE LECTURE

This year's Brain Prize lecture will be delivered by joint 2017 winner Peter Dayan, professor of Computational Neuroscience at the Gatsby Unit at University College London, on

### 'Computational psychiatry'

Sunday 14.00-14.45, room 112

Please join us!



## INTRODUCTION


ECNP has organised an exhibition to allow companies and organisations working in the field of clinical neuroscience to educate participants about their services, products, and/or literature. You are invited to visit these stands, where a wide variety of relevant information is presented.

The exhibition can be visited on Sunday and Monday from 09.00-17.00, and on Tuesday from 09.00-16.00.

## LIST OF EXHIBITORS

COMPANY/ORGANISATION	STAND
ABP - Brazilian Psychiatric Association	16
ANGELINI	9
BIOPAC Systems, Inc.	20
C2care	21
EBC - European Brain Council	12
EPA - European Psychiatric Association	15
EUFAMI	14
GAMIAN-Europe	13
Genomind	19
Gedeon Richter Plc.	8
H. Lundbeck A/S	4
Lundbeck Institute	4
JAMA Network	17
Janssen Pharmaceutica NV	1
Massachusetts General Hospital	18
NbN - Neuroscience-based Nomenclature	10
Otsuka Pharmaceutical Europe Ltd	3
P1vital Products Ltd	23
RECORDATI spa	8
Sage Therapeutics	22
Schwabe Group	2
SERVIER	7
Sunovion Pharmaceuticals Europe	9
Wipress Medical Bookshop	5

FLOOR PLAN EXHIBITION



# ECNP-ISCTM JOINT MEETING

## on CNS Clinical Trials Methodology

**5-7 September 2019,  
Copenhagen,  
Denmark**

(just before the  
32<sup>nd</sup> ECNP Congress)

### Programme

**5 September 2019** Welcome Reception

**6 September 2019**

**Session 1: Clinical trials for treatment resistant neuropsychiatric conditions**

*Chairs: Wolfgang Fleischhacker, Philip Harvey*

Lack of adequate response to currently available treatments is common across multiple neuropsychiatric conditions. Development of treatments that work for treatment resistant patients has shared challenges across conditions. These challenges will be discussed in this symposium, which will address schizophrenia, major depression, bipolar disorder, and anxiety disorders/PTSD.

**Session 2: Neurocognitive challenges in treatment trials for epilepsy and multiple sclerosis**

*Chairs: Jill Rasmussen, Christoph Helmstaedter*

This session will discuss clinical trial design and regulatory process to determine the efficacy and safety of interventions that effect cognition in epilepsy and multiple sclerosis.

Register  
right now at the  
ECNP Plaza and  
you will receive  
**10% discount**

**Session 3: Drug development for autism spectrum disorder: challenges and opportunities**

*Chairs: Valentina Mantua, Tiffany Farchione, Celso Arango*

There is a clear unmet need in the availability of medicinal products for the treatment of Autism Spectrum Disorder (ASD). Despite the great amount of scientific investigation into the neurodevelopmental and biological causes of ASD, research has failed in delivering a therapy. The session will follow the drug development process addressing the areas of major interest from molecular targets and pathways to biomarkers for population stratification and outcome assessments. The main trial design methodology challenges will be addressed and this would feed regulatory considerations and discussion.

**Evening** ISCTM Poster Session/Reception

**7 September 2019**

*(adjourns before the start of ECNP Congress)*

**Session 4: Developing pharmacological treatments for the rapid reduction of suicidal ideation in depression**

*Chairs: Carla Canuso, Philippe Courtet, Suresh Durgam*

Several pharmaceutical companies have initiated treatment trials targeting the rapid reduction of suicidal ideation in depression, utilizing a new class of potentially rapidly acting antidepressants. This symposium will address the unique methodological and regulatory challenges that accompany this novel indication and vulnerable patient population.

This joint meeting will be offered as one day of the ISCTM Autumn Conference, 5-7 September 2019, at the AC Hotel Bella Sky Copenhagen. Registration opens October 2018.

To request an announcement, please e-mail:  
[isctm@isctm.org](mailto:isctm@isctm.org)

## OPENING HOURS

**Cash bar (Entrance hall, Level P0)**

Saturday	09.00-18.30
Sunday-Monday	08.00-18.00
Tuesday	08.30-16.30

**CME Accreditation (Exhibition, Level P0)**

Sunday-Monday	09.00-17.00
Tuesday	09.00-16.00

**Cloakroom (Entrance hall, Level P0)**

Saturday	09.00-21.30
Sunday-Monday	07.30-19.00
Tuesday	07.30-16.30

**ECNP Plaza (Entrance hall, Level P0)**

Saturday	09.00-18.30
Sunday-Monday	08.00-18.30
Tuesday	08.00-16.30

**Exhibition (Level P0)**

Sunday, Monday:	09.00-17.00
Tuesday:	09.00-16.00

**Members' & Faculty lounge (Entrance hall, Level P0)**

Saturday	09.00-18.30
Sunday-Monday	08.00-18.30
Tuesday	08.00-16.30

**Poster service desk (Poster area, Level P0)**

Sunday	09.00-17.00
Monday	09.00-19.00

**Press room (Room 127, Level P1)**

Saturday	11.00-18.00
Sunday-Monday	08.00-17.30
Tuesday	08.00-13.30

**Registration (Entrance hall, Level P0)**

Friday	08.00-18.00 <i>(only for group registrations)</i>
Saturday	08.00-20.15
Sunday	07.15-18.00
Monday	07.15-18.00
Tuesday	07.15-16.00

**Speakers' secretariat\* (Room 134, Level P1)**

Saturday	09.00-19.00
Sunday-Monday	07.15-18.00
Tuesday	08.00-14.30
Wednesday (for TNMs)	07.00-14.00

\* For speakers of the Educational update sessions  
(interactive sessions with multiple choice questions):

Saturday	13.00-16.30
Sunday-Monday	12.00-14.00 & 16.30-18.00
Tuesday	12.00-14.00

## ACCREDITATION

ECNP's independent Scientific Programme Committee (SPC) composes the programme of the 31<sup>st</sup> ECNP Congress with the intention of providing participants with high-quality, balanced and educational content across the field of applied and translational neuroscience

## SCIENTIFIC PROGRAMME

### European CME credits

ECNP has taken great care to respond to the need of physicians to participate in continuing medical education (CME) programmes recognised by the European Union and their home countries. The programme of the 31<sup>st</sup> ECNP Congress is accordingly fully accredited by the relevant accrediting agencies.

The European Accreditation Committee in CNS (EACIC) has granted a total of **27.5 CME credits** for Saturday-Tuesday:

Saturday 6 October	3 CME credits
Sunday 7 October	8.5 CME credits
Monday 8 October	9.5 CME credits
Tuesday 9 October	6.5 CME credits

### US CME credits

The CME Institute of Physicians Postgraduate Press, Inc., is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. The scientific programme of the 31<sup>st</sup> ECNP Congress is eligible for a maximum of **27.5 AMA PRA Category 1 Credits<sup>TM</sup>**.

## SATELLITE SYMPOSIA

ECNP requires that all organisers of satellite symposia at the congress obtain accreditation for European CME. Each satellite symposium has been granted accreditation for two European CME credits by EACIC.

## HOW TO APPLY

Physicians should only claim CME credit commensurate with the extent of their participation in the activity. Requesting CME credits involves verifying their identity as participant in the 31<sup>st</sup> ECNP Congress.

Participants can obtain a participation record for claiming credit free of charge by completing an evaluation form about the congress. The evaluation form will be online from the first day of the congress until 1 December 2018. Physicians can also record their participation at the CME accreditation stand at the exhibition during the congress.

## APPLY ONLINE

Participants requesting CME credits are required to complete an online evaluation form about the congress on the EACIC website: **[www.eacic.eu](http://www.eacic.eu)**.

- Click on the 31<sup>st</sup> ECNP Congress banner (on the top of the homepage).
- Choose the option 'First time user'.
- Please provide your family name and first name as printed on your badge.
- Or choose 'I am returning user' if you have already started the evaluation of the 31<sup>st</sup> ECNP Congress.
- Log on or register.
- Choose option 1 ('I want to evaluate the congress sessions') or 2 ('I want to evaluate a satellite symposium').
- Complete the online evaluation form.
- Press 'save'.

The CME certificate will be automatically e-mailed to the address provided.

### The deadline to fill in the online evaluation form is 1 December 2018.

For more information, visit the CME accreditation desk at the exhibition or contact:

European Accreditation Committee in CNS (EACIC)  
 Scientific secretariat: Dr Daniel Souery  
 47, avenue Jacques Pastur  
 1180 Brussels  
 Belgium  
 T: +32 4 79 98 74 40  
 E-mail: [eacic@ulb.ac.be](mailto:eacic@ulb.ac.be)  
**[www.eacic.eu](http://www.eacic.eu)**

## FOR MEMBERS

**ECNP**  
**MEMBER**

ECNP greatly values the engagement and contribution of its members at ECNP Congresses. Please find below, for easy reference, an overview of special privileges and 'places to be' for members during the 31<sup>st</sup> ECNP Congress.

**Members' & Faculty lounge**

Location: Level P0

**Opening hours:**

Saturday 09.00-18.30  
Sunday-Monday 08.00-18.30  
Tuesday 08.00-16.30

The Members' & Faculty lounge offers a relaxed atmosphere in which ECNP members and congress faculty can take a moment for themselves between sessions or engage in conversation with one another during the congress.

The lounge is equipped with power outlets, a computer with printer, and coffee and tea throughout the day.

**General Assembly of ECNP members**

**Monday 8 October** 12.15-13.15 | Room 115

The annual general meeting of members is ECNP's highest deliberative body and the embodiment of one of the College's most fundamental member privileges: ordinary members get the right to vote and help shape ECNP's future.

**Brainstorming sessions**

**Sunday 7 October**  
07.45 - 08.45 | Room 122, 123 and 124



**Monday 8 October**  
07.45-08.45 | Room 122, 123 and 124

**Tuesday 9 October**  
12.00-13.00 | Room 122, 123 and 124

Nine small focused sessions organised by ECNP members on a topic of their choice. The brainstorming sessions are open to all participants.

**Become a member**

If the above inspires you to become a member of ECNP please visit [www.ecnp.eu/membership](http://www.ecnp.eu/membership). Just fill in the form and pay to immediately enjoy all the member benefits.

## FOR JUNIOR SCIENTISTS



The future of neuroscience in Europe relies on the field's ability to attract and retain talented junior researchers. To underline this, ECNP has developed a range of junior scientist\* benefits at this congress, including the ability to:

- Register for the congress free of charge or at a reduced rate.
- Win a Travel Award (for the best abstracts of junior scientists in Europe).
- Learn practical skills at the Career development sessions.
- Attend the New findings symposium (incorporated in the scientific programme).
- Join us at Bar Agüelo13 for a 'science-on-the-rocks' on Monday evening (see the next page for details).

See page 229 for other benefits that we offer to junior scientists throughout the year.

**Awards**

If you have submitted an abstract, you might have won a Travel Award! After the congress, you will receive € 500 to support your travel costs to the congress.



At the congress, you will also have the chance to win a Poster Award (not exclusively for junior scientists). These awards are given on-site to the posters of the highest scientific excellence, presented in the most effective way. The award consists of € 500 and a commemorative certificate.

**Career development sessions**

Location: The Bubble  
Sunday-Monday 12.10-12.40  
Tuesday 11.55-12.25

These training sessions each feature an engaging expert in the field, specifically invited to share with you their wealth of knowledge and experience. The topics are especially interesting for junior scientists.

**New findings symposium**

As part of the programme of the congress, 8 junior scientists who participated in the 2018 ECNP Workshop in Nice have been invited to give a presentation. Don't miss the opportunity to attend this session (S.14).



### Science-on-the-rocks

This special junior scientist evening will take place on Monday 8 October from 20.30-23.00 at Bar Agüelo13, Carrer d'Avinyó, 37, Barcelona. We will start with a specially developed '**on-the-rocks pubquiz**'. After this, there will be time to network with your fellow-junior scientists.

Be there, the first two drinks will be offered by ECNP! A voucher can be picked up at the ECNP Plaza (for a maximum of 100 people on a first come, first served basis).



\* ECNP's definition of a junior scientist for the 31<sup>st</sup> ECNP Congress is:

- Not older than 40 years (on the first day of the meeting)
- Pre-doctoral or doctoral student  
or  
Post-doc (within first four years of employment after having received their PhD)  
or  
Resident (MD's in training within first five years after becoming MD)

### CONGRESS COMMITTEES

ECNP would like to thank the following people for their invaluable input in establishing the scientific programme for the congress, the review process of the abstracts for lectures and poster presentations, and other activities:

#### Executive Committee (2017-2019)

Celso Arango, Spain, *president*  
 Guy Goodwin, United Kingdom, *past-president*  
 Gitte M. Knudsen, Denmark, *president-elect*  
 Laurence Lanfumey, France, *vice-president*  
 Eduard Vieta, Spain, *treasurer*  
 Martien Kas, The Netherlands, *secretary*

#### Councillors:

Elisabeth Binder, Germany  
 Damiaan Denys, The Netherlands  
 Suzanne Dickson, Sweden  
 Catherine Harmer, United Kingdom  
 Stefano Pallanti, Italy  
 Gil Zalsman, Israel  
 Co-opt members:  
 Gerry Dawson, United Kingdom  
 Joop van Gerven, The Netherlands  
 Mark Millan, France

#### Executive Director:

Alexander Schubert, The Netherlands

#### Scientific Programme Committee (SPC)

Astrid Linthorst, United Kingdom, *chair*  
 Gil Zalsman, Israel, *chair Educational Committee*  
 Andreas Meyer-Lindenberg, Germany, *editor-in-chief*  
*European Neuropsychopharmacology*  
 Josefina Castro-Fornieles, Spain  
 Kim Do, Switzerland  
 Marion Leboyer, France  
 Paul Lucassen, The Netherlands  
 Kamilla Miskowiak, Denmark  
 Agneta Nordberg, Sweden  
 Stefano Pallanti, Italy  
 Andreas Reif, Germany  
 Marco Riva, Italy  
 Rainer Spanagel, Germany  
 Joop van Gerven, The Netherlands  
 Mark Weiser, Israel  
 Aysegül Yildiz, Turkey

**Field editor *European Neuropsychopharmacology***

Jaanus Harro, Estonia, *overall review*

**Scientific Advisory Panel members (2017-2020)**

Roger Adan, The Netherlands  
 Laura Airas, Finland  
 Pino Alonso, Spain  
 Frank Bellivier, France  
 Anton Y. Bespalov, Germany  
 István Bitter, Hungary  
 Michael Bloomfield, United Kingdom  
 Jan Booij, The Netherlands  
 Jan K. Buitelaar, The Netherlands  
 Jocelyne Caboche, France  
 Josefina Castro-Fornieles, Spain  
 Annamaria Cattaneo, United Kingdom  
 Ginetta Collo, Italy  
 Andrea Danese, United Kingdom  
 Andrea de Bartolomeis, Italy  
 Suzanne L. Dickson, Sweden  
 Katharina Domschke, Germany  
 Filippo Drago, Italy  
 Anne Eckert, Switzerland  
 Angelika Erhardt, Germany  
 Mia Ericson, Sweden  
 Karen Ersche, United Kingdom  
 David P. Finn, Ireland  
 Gabriele Fischer, Austria  
 Kevin C.F. Fone, United Kingdom  
 Barbara Franke, The Netherlands  
 Christine Freitag, Germany  
 Vibe G. Frokjaer, Denmark  
 Silvana Galderisi, Italy  
 Alexander Gerhard, United Kingdom  
 Mark A. Geyer, USA  
 Philip Gorwood, France  
 Iria Grande, Spain  
 Edna Grünblatt, Switzerland  
 Antoni Gual, Spain  
 Gregor Hasler, Switzerland  
 Martin Hatzinger, Switzerland  
 Judith Homberg, The Netherlands  
 Iiris Hovatta, Finland  
 Michal Hrdlicka, Czech Republic  
 Evgeny Krupitsky, Russia  
 Marion Leboyer, France  
 Klaus-Peter Lesch, Germany  
 Stefan Leucht, Germany  
 Paul John Lucassen, The Netherlands

Anabel Martinez-Aran, Spain  
 David Mataix-Cols, Sweden  
 Raymond Mongeau, France  
 Carmen Moreno, Spain  
 Arne Mørk, Denmark  
 Rainald Mössner, Germany  
 Dieter Naber, Germany  
 Inga Neumann, Germany  
 Florence Noble, France  
 Mariusz Papp, Poland  
 Mara Parellada, Spain  
 Walter Pirker, Austria  
 Edith Pomarol-Clotet, Spain  
 Marie-Claude Potier, France  
 Christopher Pryce, Switzerland  
 Andreas Reif, Germany  
 Emma Robinson, United Kingdom  
 Michelle Roche, Ireland  
 Henricus G. Ruhe, The Netherlands  
 Rainer Rupprecht, Germany  
 Janusz K. Rybakowski, Poland  
 David A. Slattery, Germany  
 Koen Schruers, The Netherlands  
 Iris E.C. Sommer, The Netherlands  
 Daniel Souery, Belgium  
 Florence Thibaut, France  
 Marta Torrens, Spain  
 Elizabeth Tunbridge, United Kingdom  
 Wim van den Brink, The Netherlands  
 Guido van Wingen, The Netherlands  
 Louk J. Vanderschuren, The Netherlands  
 Elisabet Vilella, Spain  
 Odile Viltart, France  
 Ina Weiner, Israel  
 Abraham Weizman, Israel  
 Sue Wilson, United Kingdom  
 Aysegül Yildiz, Turkey  
 Alessandro Zuddas, Italy

## ECNP MEETINGS AROUND THE CONGRESS

### BRAIN DAY **ECNP Brain Day**

This year's ECNP Brain Day was held on 5 October at the University of Barcelona. The goal of the Brain Day is to bring the latest developments in brain research to the general public. Leading Spanish experts gave a series of interactive presentations on ADHD, bipolar disorder, autism, food and youth, depression and anorexia.

### Targeted Network Meetings (TNMs)

The Targeted Network Meetings are small meetings of a maximum of 30 participants held just after the ECNP Congress every year.

Set up to help develop ideas as a group with the best supporting scientific advice, TNM sessions can cover topics ranging from results already obtained by an ECNP Network, strategies for future projects, potential translational developments or critical assessments of gaps and unmet needs in a specific area.

Three TNMs will be held on Wednesday 10 October at the ECNP Congress venue in Barcelona, on the following topics:

- Anxiety disorders across the life span (organised by the Anxiety Disorders Network)
- The state of the art; biomarkers for the prediction of suicidal behaviour (organised by the Suicide Network)
- Nutrition for mental health across the lifespan (organised by the Nutrition Network)

## INFO A-Z

### Accreditation

Visit the CME accreditation desk at the exhibition or look at page 282 for more details.

### App



With our specially developed ECNP app you will have the most up-to-date congress information at your digital fingertips. As well as all the details about the congress, the app will also have information about ECNP in general. The app is available for Apple and Android.

### Badges

Each registered participant will receive a name badge upon arrival. For organisational and security reasons, we request that all participants and exhibitors wear their badges at all times during the congress activities. Lost badges can be replaced at the registration desk at a cost of € 25 per badge (Spanish VAT included).

### Certificate of attendance

Certificates of attendance will be sent to you after the congress to the e-mail address provided in your registration. It is also possible to download the certificate of attendance via the ECNP website for registered participants that have attended the congress\*. A link to download the certificate will be available after the congress.

*\* The certificate of attendance is not available for group- and on-site registrations. If you would like to have a certificate of attendance and you are part of a group, or have registered on-site, please go to the ECNP Plaza (level P0) to check if you have a My ECNP account, or create one in case you are not yet in the ECNP database.*

### Certificate of poster presentation

After the congress poster presenters can obtain a certificate of poster presentation via the ECNP website. The certificate is only available for presenting authors. Co-authors can be listed on the certificate at the request of the presenting author.

### Children at the congress

Children are not permitted in the session rooms, poster area or in the exhibition area at the venue.

### Cloakroom

The cloakroom is free of charge for congress participants. It is located on Level P0, close to the main entrance.

Opening hours:

Saturday	09.00-21.30
Sunday-Monday	07.00-19.30
Tuesday	08.00-17.00

### Coffee and lunch

Coffee, tea and lunch are included in the registration fee and are available to all congress participants at the poster area on Sunday and Monday, at the exhibition on Sunday-Tuesday, and on Saturday in Foyer 1.

Saturday	16.30-16.50	Coffee break
	10.40-11.15	Coffee break
	12.00-14.00	Lunch
Monday	14.45-15.00	Coffee break
	10.40-11.15	Coffee break
	12.00-13.30	Lunch
Tuesday	14.15-14.45	Coffee break
	10.40-11.00	Coffee break
	11.45-13.15	Lunch
	14.00-14.15	Coffee break

### Congress supplement to the ECNP journal *European Neuropsychopharmacology* (ENP)

All abstracts accepted for publication are published in the congress supplement to ENP. Participants who pre-ordered the supplement will receive their copy by regular mail after the congress. A copy can also be ordered on-site at the registration desk for € 55 (Dutch VAT included).



### Disabled persons

The congress venue is equipped with facilities for the disabled. However, if you have any special needs or disabilities, please let the registration secretariat, CPO HANSER SERVICE, know. The staff will be available at the registration desk during the congress opening hours.

### ECNP Plaza



The place to be if you want to take a break between sessions or meet up with others during the congress.

The ECNP Plaza offers a variety of features and services:

- Find out all about ECNP membership.
- Learn more about current and future ECNP activities and initiatives.
- Find printed copies of our most recent publications.

Furthermore, you can simply come by to relax in our lounge area.

You can find us on Level P0 during the following opening hours:

Saturday	09.00-18.30
Sunday-Monday	08.00-18.00
Tuesday	08.00-16.30

### Electricity and power outlets

The normal electricity supply is 230 volts. Power outlets are available at several plug-and-charge areas throughout the venue for you to charge electronic devices.

### First aid



First aid service is available at level M0. Telephone number within the venue: + 34 638774735. From outside the venue: 112.

The nearest hospital is:

Hospital del Mar  
Passeig Marítim 25-29  
08003 Barcelona  
Spain  
T+34 93 248 3000  
T+34 93 248 3335/34  
[www.parcdesalutmar.cat/hospitals/hospital-del-mar/](http://www.parcdesalutmar.cat/hospitals/hospital-del-mar/)

### Insurance

The organisers will not accept liability for individual medical, travel or personal insurance. It is highly recommended that all participants carry proper health and travel insurance.

### Language

The official language of the 31<sup>st</sup> ECNP Congress is English. No translation will be provided.

### Lost and found

For lost and found items, please go to the registration desk located at Level P0.

### Meeting point

Participants can meet at the ECNP Plaza on Level P0.

### Mobile phones

Please ensure that your mobile phone is on silent when attending a session.

### Presentations online

For those who missed a session or would like to review a presentation, all symposium presentations approved for release by their presenters are posted as webcast on the ECNP website after the congress.

### Press

ECNP welcomes the press to the 31<sup>st</sup> ECNP Congress. ECNP places a high priority on informing the public about important news and developments related to the science and treatment of disorders of the brain. The college is happy to facilitate any contacts with ECNP specialists. Tom Parkhill, ECNP press officer, is available to assist, please contact him by e-mail at [press@ecnp.eu](mailto:press@ecnp.eu).

Journalists can pick up press releases and a press information pack, from the press room (Room 127). The press room is accessible for registered press only. ECNP also offers a press interview room. Further information is available at the press room.

### Printing on-site

Printing on-site is possible at the ECNP Plaza.

### Programme look up

Special congress information terminals are available for searching through the online programme, looking up speakers and abstracts, exhibition information and floor plans. The terminals are located at the ECNP Plaza, the Poster area, the exhibition and Levels P0 and P1.

### Recording, filming and photography

Audio and video/DVD recording and taking pictures with flash are prohibited during the congress sessions. The only photography allowed during sessions is photography of slides, which is permitted only for reference purposes (to respect the speaker's copyright, reproduction is strictly forbidden). Photography of posters is allowed under similar terms.

No (professional) filming crews or photographers are allowed under any circumstances in the session rooms of the ECNP scientific programme or poster area, except those hired by the 31<sup>st</sup> ECNP Congress Foundation. Persons in possession of a filming pass (press) are allowed to film and photograph at the designated filming areas (ECNP Plaza, level P0 and Foyer 2, level P1).

### Session rooms

It is not allowed to bring drinks or food inside the session rooms. When a session room is fully seated, it is not permitted to enter the room or stand at the back of the room due to security regulations. Room 113 will be available as an overflow room during the keynote session and plenary lectures.

### Smoking

The 31<sup>st</sup> ECNP Congress is a non-smoking congress.

### Taxis

Taxis are usually stationed outside the main entrance of the congress venue.



### Wifi

Free wireless internet is available throughout the congress venue.

**Network name:** ECNP2018

**Password:** ECNP2018

At the designated plug-and-charge area in the exhibition and at the ECNP Plaza you can charge your electronic devices.

## PROJECTS AND INITIATIVES



In addition to its meetings, ECNP supports variety of projects and initiatives designed to enhance the research infrastructure of neuroscience in Europe, and supporting the advancement of important objectives in this field.

**ECNP Networks** to facilitate research groups to apply for EU grants and to build common databases accessible to European researchers for conducting studies in translational neuroscience.

**New Frontiers Meeting** to tackle the challenges in translational neuroscience that are impeding the development of new treatments and discouraging investment in the field.

**ECNP Medicines Chest** to assist clinical researchers in obtaining access to pharmacological compounds.

**ECNP Junior Scientists initiative** to attract and retain junior researchers in the field.

**ECNP Research internship** to provide short-term research internship opportunities for junior researchers in applied and translational neuroscience.

**Neuroscience-based Nomenclature (Nbn)** to rationalize the naming conventions of psychotropic medications.

**CDE incentives** lower registration fees for the ECNP Congress, for people from a country with a developing economy (CDE). Also, abstract submitters from a European CDE country may receive a CDE Grant: free registration to the congress and a grant (€ 500) to cover travel expenses to the congress.

**Non-MD** lower registration fees for the ECNP Congress, specifically for those engaged in basic research. It excludes those with medical training.

## Awards



**ECNP Neuropsychopharmacology Award**  
For individual achievements in basic science and clinical research.



**ECNP Poster Award**  
For outstanding posters of the highest scientific caliber.



**ECNP Travel Award**  
To encourage the attendance of junior scientists at the ECNP Congress.

### ECNP Preclinical Network Data Prize

To encourage publication of data where the results do not confirm the expected outcome or original hypothesis.



## CONTACT

### Scientific and organising secretariat

#### 31<sup>st</sup> ECNP Congress

ECNP Office  
 Bolognalaan 28  
 3584 CJ Utrecht  
 The Netherlands  
 T: +31 88 75 69 555  
 F: +31 88 75 59 900  
 barcelona2018@ecnp.eu  
<https://2018.ecnp.eu>

### Registration and hotel

#### 31<sup>st</sup> ECNP Congress

CPO HANSE SERVICE GmbH  
 T: +49 30 300 66 90  
 F: +49 30 305 73 91  
[registrationsecretariat@ecnp-congress.eu](mailto:registrationsecretariat@ecnp-congress.eu)

### Congress venue

Centre Convencions Internacional de Barcelona (CCIB)  
 Plaça de Willy Brandt 11-14 / FORUM  
 08019 Barcelona, Spain  
[www.ccib.es](http://www.ccib.es)

© Copyright ECNP, September 2018



## FUTURE MEETINGS

### CONGRESSES

- 32<sup>nd</sup> ECNP Congress** 7-10 September 2019, Copenhagen, Denmark
- 33<sup>rd</sup> ECNP Congress** 12-15 September 2020, Vienna, Austria
- 34<sup>th</sup> ECNP Congress** 2-5 October 2021, Lisbon, Portugal
- 35<sup>th</sup> ECNP Congress** 8-11 October 2022, Munich, Germany
- 36<sup>th</sup> ECNP Congress** 7-10 October 2023, Barcelona, Spain
- 37<sup>th</sup> ECNP Congress** 21-24 September 2024, Milan, Italy

### WORKSHOPS

#### ECNP Workshop for Early Career Scientists in Europe

7-10 March 2019, Nice, France

#### ECNP Workshop on Clinical Research Methods

7-9 November 2018, Barcelona, Spain

6-8 November 2019, Barcelona, Spain

### SEMINARS

16-18 November 2018, Saint Petersburg, Russia

16-18 November 2018, Izmir, Turkey

29-31 March 2019, Palanga, Lithuania

### SCHOOLS

#### ECNP School of Child and Adolescent

##### Neuropsychopharmacology

31 March-5 April 2019, Venice, Italy

#### ECNP School of Neuropsychopharmacology

30 June-5 July 2019, Oxford, United Kingdom

### OTHER MEETINGS

#### Targeted Network Meetings

10 October 2018, Barcelona, Spain

#### ECNP New Frontiers Meeting

10-11 March 2019, Nice, France

For more information and regular updates on ECNP initiatives please visit: [www.ecnp.eu](http://www.ecnp.eu) | <https://2019.ecnp.eu>





# 32<sup>ND</sup> ECNP CONGRESS

7-10 SEPTEMBER 2019

COPENHAGEN

**REGISTER RIGHT NOW**  
at the ECNP Plaza  
and you will receive  
**20% DISCOUNT**

<https://2019.ecnp.eu>



**ECNP**

european college of  
neuropsychopharmacology